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An exaggerated blood pressure (BP) response to maximal exercise is an 
independent risk factor for cardiovascular events and mortality. In people with 
hypertension, it is unclear if treating BP to guideline levels normalises the rise in 
BP during exercise, which is mediated in part by the metaboreflex. The main aim 
of this thesis was to assess whether adequate control of BP with anti-
hypertensive medication normalises the exaggerated pressor response to 
exercise that is well established in untreated hypertension. It was hypothesised 
that treatments that reduce metaboreflex hyperreflexia would lower the BP 
response to maximal exercise. The BP response to exercise was assessed 
during an incremental exercise test to peak oxygen consumption (V̇O2 peak) on a 
cycle ergometer. To assess the BP response to metaboreflex isolation, post-
exercise ischemia following isometric handgrip exercise was used. The first main 
finding of this thesis was that patients with treated-controlled, uncontrolled and 
untreated hypertension had an exaggerated BP response to exercise and 
metaboreflex isolation compared to age matched healthy controls. Secondly, the 
metaboreflex remains predictive of the peak BP response to incremental exercise 
when accounting for other known risk factors, including measures of central and 
peripheral arterial stiffness (aortic pulse pressure & pulse wave velocity), age and 
daytime ambulatory peripheral systolic BP. Finally, because the metaboreflex 
hyperreflexia depends on normal blood flow responses to exercise, an aim of this 
thesis was to improve nitric oxide bioavailability with chronic dietary nitrates. 
Despite improved levels of plasma nitrates in patients with treated-controlled 
hypertension, dietary nitrate supplementation had no impact on the maximal BP 
response to exercise or metaboreflex isolation compared to a placebo. Future 
research will need to assess alternative therapies to reduce exercise BP in 
patients with treated-controlled hypertension. This research will hopefully reduce 
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Chapter 1 General Introduction 
1.1 List of Abbreviations 
[Ca2+]i  Calcium influx 
A   Area 
A(P)   Aortic cross-sectional area for pressure 
ABPM  Ambulatory blood pressure monitoring 
ACE   Angiotensin converting enzyme 
AIx   Aortic augmentation index 
Akt   Protein kinase B 
Amax   Maximal diameter of the aorta 
ANOVA  Analysis of variance 
ANS   Autonomic nervous system 
ASIC   Acid sensing ion channel 
AT1 receptor Angiotensin type 1 receptor 
ATP   Adenosine triphosphate 
BH4   Tetrahydrobiopterin  
BMI   Body mass index 
BP   Blood pressure 
C3   Complement factor 3 
Ca2+   Calcium 
cAMP   Cyclic adenosine monophosphate 
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cGMP   Cyclic guanosine monophosphate 
CO2   Carbon dioxide 
CO   Cardiac output 
CRiC   Clinical Research and Imaging Centre 
CV   Cardiovascular 
CVLM   Caudal ventrolateral medulla  
CVP    Central venous pressure 
CW   Windkessel (buffer) compliance 
DBP    Diastolic blood pressure 
ECG   Electrocardiogram 
EEG   Electroencephalogram 
eNOS   Endothelial nitric oxide synthase 
EPC’s   Endothelial progenitor cells 
GABA  Gamma-Aminobutric acid 
Gs   G stimulatory proteins 
GTP   Guanosine triphosphate 
H   Wall thickness 
HF   High-frequency 
HR   Heart rate 
HRV   Heart rate variability 
K    Hydraulic conductance,  
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L    Length 
LF   Low-frequency 
L-NAME  N-nitro-L-arginine methyl ester 
M2   Muscarinic 2 
MAP    Mean arterial pressure 
MAPKs  Mitogen-activated protein kinases 
MSNA  Muscle sympathetic nerve activity 
MVC   Maximal voluntary contraction 
ɳ    Viscosity  
NAD(P)H  Nicotinamide-adenine dinucleotide phosphate oxidase 
NADH   Nicotinamide-adenine dinucleotide 
NHS   National Health Service 
NICE   National Institute for Health and Care Excellence 
nNOS   Neuronal nitric oxide synthase 
NO   Nitric oxide 
NO2-   Nitrite 
NO3-   Nitrate 
NOx Total concentration of nitrate and nitrite 
NTS    Nucleus tractus solitarius 
O2   Oxygen 
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O2-   Superoxide 
P   Pressure 
P0   Position of the inflection point on the pressure axis 
P1    Inlet pressure 
P1   P1 is the steepness of the curve at 0.75 Amax 
P2    Outlet pressure. 
P2X    purinergic receptors 
P2X receptors Purinergic receptors type 2x 
P2X2/3   Purinergic receptors 2/3 subtype 
P2X3   Purinergic receptors 3 subtypes 
P2Y   Purinergic receptors type 2Y 
Pa    Mean aortic pressure 
PEI   Post-exercise ischemia 
PKA   Protein kinase A 
PKG   Protein kinase G 
PP   Pulse pressure 
PSNS   Parasympathetic nervous system 
PWV   Pulse wave velocity 
Q   Flow  
R    Radius 
R    Resistance 
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RAAS   Renin-angiotensin-aldosterone system 
RER   Respiratory exchange ratio 
RPM   Revolutions per minute 
RSNA   Renal sympathetic nerve activity 
RVLM   Rostral ventrolateral medulla 
SAD   Sinoaortic denervation 
SBP    Systolic blood pressure 
SHRs   Spontaneously hypertensive rats 
SNA   Sympathetic nerve activity 
SNS   Sympathetic nervous system 
SPRINT  Systolic blood pressure intervention trial 
SSNA   Skin sympathetic nerve activity 
SV   Stroke volume 
TPR   Total peripheral resistance 
TRPV1 Transient receptor potential cation channel subfamily V 
member 1 
UK   United Kingdom 
USA   United States of America 
V   Volume 
VE   Minute ventilation 
VE/VECO2 slope Ventilatory efficiency slope 
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VECO2  Volume of carbon dioxide expired 
V̇O2 peak   Peak volume of oxygen inspired 
V̇O2   Volume of Inspired Oxygen 
W   Watts 
WHO   World Health Organisation 
Z0   Aortic characteristic impedance 
α1-adrenoceptors Alpha-1 adrenoceptor 
α2-adrenoceptors Alpha-adrenoceptor 2 
β1 adrenergic Beta 1 adrenoreceptor 
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1.2 General overview 
Adjustments in the autonomic nervous system are critical for the correct 
cardiovascular (CV) adjustments to exercise, which are mediated by the 
sympathetic and parasympathetic nervous system (PSNS). These adjustments 
are regulated by feed-forward signals from the brain (central command), 
feedback from skeletal muscle (the metaboreflex and the mechanoreflex) and 
continuous buffering by the arterial baroreceptors. In healthy individuals 
increased sympathetic nerve activity (SNA) during exercise causes a moderate 
rise in blood pressure (BP) that is principally caused by vasoconstriction in non-
metabolically active areas (e.g. the liver). In the active muscle, SNA is offset in a 
protective process known as functional sympatholysis, where local and extrinsic 
factors cause vasodilation. The rise in systemic BP during exercise helps 
increase perfusion pressure to the active muscle. Individuals with untreated high 
BP (hypertension) have an exaggerated BP response to exercise, that is in part 
mediated by the metaboreflex. This exaggerated BP response to exercise 
increases the risk of adverse CV events. First line anti-hypertensive treatment 
reduces BP at rest, but it is unclear if adequate control of BP in people with 
hypertension decreases BP during exercise or during metaboreflex isolation 
(post-exercise ischemia (PEI)). This is important to assess because patients with 
treatment-controlled hypertension have an elevated CV risk when compared to 
normotensive controls. An exaggerated BP response to exercise may contribute 
to this elevated risk. This thesis is concerned with the role of the metaboreflex in 
the BP response to exercise in people with treated-controlled hypertension, and 
to assess whether reducing metaboreflex activity is associated with 
improvements in exercise BP in this population. 
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1.3 Basic blood pressure physiology 
1.3.1 Basic haemodynamics 
The CV system serves to provide rapid transport of oxygen (O2), glucose, amino 
acids, fatty acids, vitamins, drugs, hormones and water to tissues in the body. In 
addition, the CV system is critically important in temperature regulation and the 
washout of metabolic waste products such as carbon dioxide (CO2) (Nobrega et 
al., 2014). The heart provides the pump to force this blood around both the 
systemic and pulmonary circulation. This thesis is concerned with the systemic 
circulation. Cardiac output (CO) is defined as the amount of blood ejected by the 
right or left ventricle per minute and is derived from stroke volume (SV) (amount of 
blood per ejection) and heart rate (HR) (number of contractions per minute). At 
rest, CO is distributed relative to the metabolic rate of tissues and it increases 
rapidly in proportion to the metabolic demand within the body (Guyton, 1981). For 
example, at rest, skeletal muscle requires around 20% of O2 consumption and 
receives around 20% of CO (Figure 1.1, page 83). At maximum exercise, the O2 
demand of the skeletal muscle rises and leads to a re-distribution of CO, with up 
to 80% being sent to the active skeletal muscle (Figure 1.1, page 83).  
 
The principle driver of blood flow through the circulation is the gradient of the BP. 
BP is the force that the circulating blood exerts on the wall of the blood vessels. 
Ejection of the left ventricle raises aortic pressure to around 100 mmHg above 
atmospheric pressure, whilst pressure in the great veins is close to the 
atmospheric pressure. Therefore, there is a large BP gradient between the aorta 
and the great veins. Arterial BP is pulsatile as the left ventricle ejects blood 
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intermittently (systolic) with periods of relaxation (diastolic) between beats. 
Normal values for systemic arterial BP are ~120/80 mmHg (systolic/diastolic) 
above atmospheric pressure. Mean arterial pressure (MAP) is defined as the 
product of CO and total peripheral resistance (TPR) (Equation 1.2). BP is 
measured in mmHg above atmospheric pressure because BP was initially 
measured using a mercury column, which used atmospheric pressure as a 
reference or 0 mmHg. Much of our understanding about BP comes from 
measuring average levels of pressure using Darcys Law. Darcy’s law explains 
the basic laws of flow (volume transferred per unit of time) of water along a rigid 
tube which is driven by a constant pressure: (Mayet and Hughes, 2003): 
 
Q = K*(P1-P2) [Equation 1.0] 
 
Where Q = flow, K = hydraulic conductance, P1 = inlet pressure and P2 = 
outlet pressure. 
 
Darcys Law can also be used to quantify the resistance that flow experiences 
when passing through a rigid tube: 
 
Q = (P1-P2)/R [Equation 1.1] 
R = Resistance. 
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If we now apply Darcys Law to the systemic circulation: 
MAP = CO * TPR [Equation 1.2] 
MAP is the average BP during a cardiac cycle. In the aorta, the MAP is 
approximately half-way between systolic (maximum blood pressure during 
contraction of the vessels) and diastolic (minimum pressure between heart beats) 
blood pressure. BP is typically measured in the brachial artery and due to the 
narrowing of the systolic peak due to distal transmission the MAP is closer to 
diastolic blood pressure and is calculated as: 
 
MAP = DBP +0.33*(SBP – DBP) [Equation 1.3] 
DBP = diastolic blood pressure 
SBP = systolic blood pressure 
 
Darcy’s Law suggests that for a larger resistance there will need to be a larger 
difference in BP to drive blood flow. Resistance is minimal in vessels such as 
elastic arteries due to increased diameter, compliance, caused by elastin. The 
highest resistance in the CV system lies in the resistance vessels (arterioles) as 
these vessels contain vascular smooth muscle and are innervated by 
sympathetic nerve fibres. The most important factor regulating BP is therefore 
blood flow in the resistance vessels. Poiseuilles described the resistance to flow 
within a vessel as: 
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R = 8ɳL/πr4 [Equation 1.4] 
R = resistance 
ɳ = viscosity 
L = length 
r = the radius 
 
Poiseuille’s Law shows the importance of the radius (to the power of 4) in 
determining resistance and therefore MAP (Singh et al., 2013). Combining 
Poiseuille’s Law with Darcys Law we get: 
 
Q = (PA-PV) * πr4/8ɳL [Equation 1.5] 
 
The Windkessel effect explains the pulsatile nature of arterial BP. Large elastic 
arteries (e.g. the aorta), which contain a large amount of elastin, distend during 
systole and convert some of the pressure generated by the left ventricle into 
potential energy (Mayet and Hughes, 2003, Frank, 1990). Following left 
ventricular contraction, the aorta recoils and the stored potential energy is 
converted into pressure energy, which is the diastolic component of BP (Mayet 
and Hughes, 2003). This helps to dampen the fluctuation in pulse pressure (PP) 
(PP=SBP-DBP) during the cardiac cycle and allows continued perfusion during 
diastole when left ventricular ejection ceases (Mayet and Hughes, 2003). The 
Windkessel effect highlights the importance of arterial compliance in the 
circulation. The arterial pressure wave transmitted by the aorta undergoes 
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changes in shape throughout the circulation (Mayet and Hughes, 2003). When 
the heart contracts there is a reflected pressure wave back from the periphery 
(wave reflection) and a pressure wave that is amplified out (forward wave) 
towards the peripheral organs. The pressure wave travels rapidly though the 
circulation. The velocity of this pressure wave is increased by the stiffening of the 
blood vessels (Blacher et al., 1999). Bifurcations and high resistance arterioles 
are the major site of wave reflection in humans (Hirata et al., 2006). In healthy 
young adults, wave reflection doesn’t influence aortic pressure or the peripheral 
pressure because the reflected wave returns during late diastole. This means that 
the reflected wave does not contribute to aortic BP, and brachial BP are larger 
than central (aortic) BPs (Hirata et al., 2006). 
 
1.3.2 Control mechanisms of blood pressure 
The following section outlines the basic control mechanisms of BP regulation 
when the human body is idle, before discussing the mechanisms mediating 
changes in BP during exercise in the following section. BP is mediated by 
changes in CO and TPR [equation 1.2 and 1.3]. Due to the importance of BP for 
flow, the arterial BP in the human body is tightly regulated by several short and 
long term mechanisms (Raven and Chapleau, 2014). Indeed, reductions in BP 
(hypotension) and subsequently blood flow lead to mismatches between O2 
demand and supply (Raven and Chapleau, 2014). The following section explains 
how BP is controlled in the short- and long-term. 
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1.3.2.1 Acute control of blood pressure 
1.3.2.1.1 Cardiac output 
CO is typically 5 L/min in a resting adult human. CO is varied by alterations in SV 
and HR (CO = SV*HR). A typical resting HR is 70 beats per minute and SV 
normally equals 70 ml/min in a resting human (Joyner and Casey, 2015). 
However, this value of CO is constantly changing to match the metabolic demand 
of the body (Joyner and Casey, 2015). For example, during maximal exercise, 
HR can reach 200 bpm and SV can reach 100-150 ml/min, giving a CO of ~20 
L/min in a normally active individual. 
 
1.3.2.1.2 Stroke Volume 
SV is the amount of blood pumped out by the heart per beat and is calculated as 
end diastolic volume – end systolic volume (Guyton, 1981, Mayet and Hughes, 
2003). 
  
1.3.2.1.2.1 Preload and Afterload 
SV is affected by two opposing factors; the energy of left ventricular contraction 
(determined by preload) and the pressure in the aorta that the left ventricle has to 
overcome to eject blood (afterload). Preload is related to the volume of blood in 
the left or right ventricle prior to contraction (end-diastolic volume). Augmented 
filling pressures increase the volume of blood in the ventricles during diastole. 
This enhances the contractile force generated during ventricular contraction via 
the length-tension relationship, which is known as the Frank-Starling Law of the 
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heart in intact hearts. When a myocyte is stretched it generates a more forceful 
contraction. Maximal force of the myocardium is achieved at a sarcomere length 
of around 2.2 µm and beyond this there is a reduction in contractile force 
(Guccione et al., 1997). In the intact heart at a normal end diastolic pressure, 
sarcomere length is normally 1.8- 2 µm (Guccione et al., 1997). Increased stretch 
of the ventricles augments the sensitivity of the cardiac sarcomeres to calcium 
(Ca2+), causing increased displacement of the troponin-tropomyosin complexes 
which increases myosin head binding to actin and therefore contraction (Allen 
and Kentish, 1985). As central venous pressure increases so does preload and 
SV. Central venous pressure is influenced by several factors, including the 
skeletal muscle pump (Stewart et al., 2004), blood volume (Berger et al., 1968), 
gravity (Buckey et al., 1993), venoconstriction (constriction of the veins) by the 
sympathetic nervous system (SNS) (Martin and Charkoudian, 2005), cardiac 
pumping (Guyton et al., 1954) and respiration (Triedman and Saul, 1994). The 
increase in SV during exercise is mediated by the skeletal muscle pump 
(Notarius and Magder, 1996, Stewart et al., 2004), respiration (Miller et al., 2005) 
and venoconstriction (Martin and Charkoudian, 2005). Secondly, afterload is 
defined as the aortic pressure that the left ventricle must overcome to effectively 
eject blood (Monroe and French, 1961, Sonnenblick, 1962). More specifically, the 
pressure in the left ventricle must be higher than the pressure in the aorta to open 
the aortic valve and pump blood into the systemic circulation (aortic impedance). 
Afterload is the pressure that opposes muscle shortening. In the intact heart 
afterload is often related to the law of Laplace: 
 
S= P * radius/2w [Equation 1.6] 
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S= wall stress  
P = ventricular ejection pressure 
W= wall thickness 
 
Laplace’s law shows that afterload (S) is dependent on not only the pressure in 
the aorta, but also the radius of the ventricles and the wall thickness. There is an 
inverse relationship between afterload and instantaneous left ventricular SV. 
Elevated afterload opposes sarcomere shortening and limits ventricular SV which 
leads to an increased end-systolic volume (volume of blood left in the heart 
following contraction) (Monroe and French, 1961). Furthermore, in the healthy 
heart this increased end-systolic volume means that end-diastolic volume is 
increased. In the following beat there is an increased left ventricular contraction 
(Frank-Starling mechanism) to compensate for the reduced SV. During upright 
exercise, end-systolic volume decreases, whilst end-diastolic volume increases 
allowing SV to increase (Andersen and Vik-Mo, 1984, Poliner et al., 1980). This is 
thought to be due to an increased myocardial fibre length (Frank-Starling) as well 
as an increased contractile state of the heart. 
 
1.3.2.1.3 The autonomic nervous system and the heart 
CO is not only regulated by intrinsic factors related to contractile energy and thus 
variations in SV but is also regulated by the autonomic nervous system. Changes 
in the PSNS and SNS regulate both HR and SV. Under resting conditions, HR is 
predominantly under the control of the PSNS (Robinson et al., 1966). 
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Parasympathetic activity, via the vagus nerve releases acetylcholine which binds 
to the muscarinic 2 (M2) receptor leading to a reduction in the formation of cyclic 
adenosine monophosphate (cAMP) and reduced calcium influx [Ca2+]i through 
the cell membrane. A reduction in [Ca2+]i causes a reduction in the speed at 
which the pacemaker action potential decays and also causes membrane 
hyperpolarisation, which leads to a reduction in HR (Harvey and Belevych, 2003, 
Bolter et al., 2001). Further, this also causes the opening of the cardiac 
muscarinic inward rectifying potassium channels (Ivanova-Nikolova et al., 1998), 
these channels increase potassium efflux which similar to M2 channels leads to 
hyperpolarisation and a reduction in HR. The action of the vagus nerve is fast 
(within a beat), compared to the much slower action of the SNS. Noradrenaline 
released from the sympathetic nerve terminals bind to beta 1 (β1)  adrenergic 
receptors, which subsequently bind to the G stimulatory proteins (Gs) activating 
adenylate cyclase, causing elevations in cAMP (Madamanchi, 2007). cAMP then 
activates cAMP-dependent protein kinase A (PKA) which increases [Ca2+]i across 
the sarcolemma through the L-type Ca2+ channel in the heart (Madamanchi, 
2007). This pathway increases cardiac contractility (enhancing SV) as well as 
increasing HR (Madamanchi, 2007), therefore CO is augmented. Binding of 
noradrenaline to β1 adrenergic receptors also shortens the duration of systole, 
allowing sufficient filling time during diastole and decreases end diastolic volume 
due to increased ejection fraction (SV/end diastolic volume). 
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1.3.2.1.3.1 The baroreflex 
The aortic and carotid baroreceptors are mechanically sensitive encapsulated 
afferent free nerve endings that lie within the aortic arch and the carotid sinus 
which modulate changes in BP on a beat-to-beat basis by mediating changes in 
efferent sympathetic nerve activity (SNA), HR, SV and TPR (Dampney, 2016, 
Raven et al., 2006, Walgenbach and Donald, 1983, Walgenbach and Shepherd, 
1984). Research in canines has shown that the aortic and carotid baroreceptors 
are split into low threshold A-fibres that are myelinated, large diameter, fast 
conducting afferents with low thresholds and operate in the BP range of 30-90 
mmHg (Dean and Seagard, 1997) and higher threshold C-fibres that are 
unmyelinated that operate at higher BPs of 70-140 mmHg (Dean and Seagard, 
1997). When BP is increasing the blood vessel wall is stretched and the 
mechanically sensitive carotid sinus and aortic baroreceptors increase their firing 
rates via the glossopharyngeal nerve (cranial nerve IX) and the vagus nerve 
(cranial nerve X), respectively, that transmit to the brainstem and terminate in the 
nucleus tractus solitarius (NTS) (Dampney, 2016, Aicher and Randich, 1990, 
Berger, 1979, Davies and Kalia, 1981). The NTS operates as an integrative site 
for the control of the circulatory system from peripheral afferents (Potts et al., 
2003). The NTS then projects to cardiac vagal sites in the nucleus ambiguus and 
to the caudal ventrolateral medulla (CVLM) (Dampney, 2016, Biaggioni et al., 
1994, Suzuki et al., 1993, Kubo et al., 1991). Excitatory impulses into the nucleus 
ambiguus lead to activation of the preganglionic cardiac vagal neurones, causing 
a lowering of HR (Dampney, 2016, Housley et al., 1987). Simultaneously, the 
CVLM inhibits sympathetic premotor neurons located in the rostral ventrolateral 
medulla (RVLM) (Dampney, 2016, Pilowsky et al., 1994, Biaggioni et al., 1994, Li 
Chapter 1 General Introduction 
 18 
et al., 1991, Guyenet, 2006). RVLM neurons project directly to the cholinergic 
preganglionic neurons in the intermediolateral cell column of the spinal cord 
(thoracolumbar regions (T1-L2)). The preganglionic neurons then terminate within 
the prevertebral ganglia or paravertebral ganglia, synapsing with the cell bodies 
of the postganglionic sympathetic neurons. These postganglionic sympathetic 
nerve fibres innervate target organs and release the co-transmitters 
noradrenaline, adenosine triphosphate (ATP) and neuropeptide Y (Burnstock, 
2012, Burnstock, 1990). Noradrenaline and ATP bind to the alpha-1 adrenoceptor 
(α1-adrenoceptors) and purinergic receptors (P2X receptors) in the peripheral 
blood vessels which leads to vasoconstriction and an elevation in arterial BP. In 
the vascular smooth muscle, the effects of noradrenaline on the α1-
adrenoceptors are mediated by increased [Ca2+]i mainly through L-type Ca2+ 
channels (Guimaraes and Moura, 2001, Xiong and Sperelakis, 1995). ATP binds 
to the P2X receptors and causes vasoconstriction by increasing [Ca2+]i mainly 
through L-type Ca2+ channels (Ralevic, 2015). Neuropeptide Y has a dual effect, 
prejunctionally it inhibits the release of noradrenaline and ATP and it also 
potentiates the post-junctional effects of noradrenaline and ATP (Burnstock, 
1990). This simultaneous coupling of the SNS and PSNS allows maximal control 
over BP.  
 
1.3.2.2 Long term blood pressure control mechanisms 
1.3.2.2.1 The renin-angiotensin-aldosterone system 
Firstly, the renin-angiotensin-aldosterone system (RAAS) plays a critical role in 
the regulation of long-term BP control (several hours/days) (Seeliger et al., 2005). 
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The RAAS responds to reductions in blood volume (e.g. dehydration), BP, 
sodium chloride, filtration flow rate and activation of the SNS that cause the 
juxtaglomerular apparatus in the kidneys macula densa to release renin. Renin 
release leads to the formation of angiotensin I from angiotensinogen which is 
released from the liver. Angiotensin I is then converted to angiotensin II, which is 
dependent on an enzyme called angiotensin converting enzyme (ACE), which is 
predominantly found in the capillaries of the lungs and the endothelial cells 
(Oppong and Hooper, 1993). Angiotensin II acts as a potent vasoconstrictor by 
binding to angiotensin type 1 receptor (AT1) receptors and causes elevations in 
peripheral resistance (de Leeuw, 1999). Angiotensin II also boosts the activity of 
the sympathetic nervous by facilitating the release of noradrenaline from 
sympathetic terminals (Rajagopalan et al., 1996, Zimmerman et al., 2002). In 
addition, cardiac contractility is enhanced by the RAAS (Brasch et al., 1993). AT1 
receptor have been located in the myocardium and angiotensin II can increase 
cardiac contractility through its effects on [Ca2+]i, similar to noradrenaline (De 
Mello and Danser, 2000). 
 
The kidney itself also plays a critical role in long-term BP regulation (Guyton et 
al., 1972). An elevation in perfusion pressure in the renal artery causes an 
increased natriuresis, this is known as the pressure-natriuresis relationship 
(Aperia et al., 1971, Guyton, 1981). By lowering the concentration of sodium and 
the overall volume of fluid in the body, the pressure-natriuresis relationship helps 
to reduce CO (Frank-Starling mechanism) and BP (Guyton, 1981, Aperia et al., 
1971). Angiotensin II also leads to the release of aldosterone which increases the 
reabsorption of sodium in exchange for potassium (Mulrow, 1999). Sodium 
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reabsorption from the tubular fluid draws water with it by osmosis and the overall 
volume of fluid in the body elevates and leads to an elevation in CO (Frank-
Starling mechanism) and BP (Cowley, 1992). 
 
AT1 receptors have also been located on blood vessels and neurons in the NTS 
(Huang et al., 2003, Paton et al., 2006). An injection of angiotensin II into the 
NTS depresses the sympathoinhibition effects (Polson et al., 2007, Boscan et al., 
2001) as well as the cardiac component of the arterial baroreflex (Paton and 
Kasparov, 1999, Paton et al., 2001, Casto and Phillips, 1986). Angiotensin II is 
unable to cross the blood-brain-barrier. Paton et al. (2006) proposed vascular 
neuronal signalling, which suggests that centrally and peripherally formed 
angiotensin II can act on the endothelium in the NTS causing the formation of 
nitric oxide (NO) (Paton et al., 2008). It has been proposed that NO reduces the 
firing rates of NTS neurons which respond to input from the arterial baroreflex, via 
increased release of the inhibitory neurotransmitter gamma-aminobutyric acid 
(GABA) (Wang et al., 2006).  
 
1.3.2.3 Long term blood pressure control by the baroreflex 
It was initially believed that the baroreceptors had little role in the long-term 
control of arterial BP. Thrasher (2002) found that denervation of the aortic and 
one carotid sinus in dogs whilst chronically unloading the baroreceptors in the 
intact sinus through common carotid artery ligation caused hypertension. These 
findings have been confirmed in rats using more direct measurements of renal 
sympathetic nerve activity (RSNA) (Barrett et al., 2005, Barrett et al., 2003). 
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Further evidence for long term control of BP by the baroreflex came when it was 
shown that following sinoaortic denervation (SAD), which removes afferent 
baroreceptor input, sustained reduction in RSNA during angiotensin II infusion 
was abolished (Barrett et al., 2005). Finally, a Fos-like protein 
immunohistochemistry study found that dogs acutely and chronically infused with 
angiotensin II had increased Fos-like staining in the NTS and CVLM neurons with 
little change in the RVLM (Lohmeier et al., 2002). This result was expected as the 
sympathoinhibition of the baroreceptor in the RVLM is mediated by increased 
neuronal activity in the NTS and the CVLM (Lohmeier et al., 2002). This suggests 
that the baroreflex is important in the chronic regulation of arterial BP.  
 
1.3.3 Local regulation of flow 
Vascular tone impacts the radius of the blood vessel and therefore has a huge 
impact on blood flow (equation 1.4 and 1.5). When the vascular smooth muscle in 
the resistance vessels relaxes (vasodilation), resistance is reduced and local flow 
increases, conversely when resistance vessels tighten (vasoconstriction), local 
blood flow decreases, causing arterial BP to rise. Vascular tone is mediated by 
several intrinsic and extrinsic factors.  
 
Intrinsic mechanisms include, myogenic (Meininger and Davis, 1992), endothelial 
secretions (Moncada and Higgs, 1993, Palmer et al., 1988) and vasoactive 
metabolites (Remensnyder et al., 1962). Firstly, the myogenic response is an 
immediate control mechanism (within seconds). When intravascular pressure in 
arteries and arterioles increases, at first this causes distention of the vessel which 
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is followed by a sustained contraction (Bayliss, 1902). In contrast, when 
intravascular pressure decreases vasodilation occurs (Bayliss, 1902). The 
myogenic response is important as it modulates basal tone (Folkow, 1962), 
stabilises capillary perfusion pressure (Meininger and Davis, 1992) and protects 
the capillaries from sustained high intravascular pressures (Meininger and Davis, 
1992). Secondly, the main role of the endothelium is as a selectively permeable 
membrane to keep plasma and red blood cells within the blood vessels, whilst 
allowing the movement of different nutrients from the blood into a variety of 
tissues around the body. The endothelium is critically important in the regulation 
of basal tone. Endothelial cells express many receptors that bind vasoactive 
substances (e.g. purinergic receptors type 2Y (P2Y receptors)) and also sense 
changes in shear stress (see Figure 1.4, page 87). A healthy endothelium 
responds by actively secreting vasoactive substances, including prostacyclin, 
endothelial-derived hyperpolarisation factor and NO which relax vascular smooth 
muscle to cause vasodilation (Davies, 1995). A key role for NO has been 
demonstrated in the regulation of endothelial mediated vasodilation (Joannides et 
al., 1995) and importantly in CV disease, abnormalities in the endothelium have 
been attributed to impaired NO bioavailability (Panza et al., 1994, Panza et al., 
1993, Panza et al., 1990). 
 
1.3.3.1 Mechanism of nitric oxide mediated vasodilation 
The exact mechanism of shear stress mediated vasodilation is thought to involve 
changes in the deformation of the endothelial cells and deformation of the 
glycocalyx due to viscous drag (Heiss et al., 2015). Shear stress activates the 
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enzyme phosphatidylinositol-3 kinase, leading to the activation of protein kinase 
B (Heiss et al., 2015). Agonist binding to the endothelium cause an [Ca2+]i which 
leads to increased Ca2+ binding to calmodulin (Moncada and Higgs, 1993, 
Dimmeler et al., 1999) (Figure 1.4, page 87). Both, Ca2+-calmodulin and protein 
kinase B enhance the activity of endothelial nitric oxide synthase (eNOS). eNOS 
cleaves the nitrogen group from L-arginine which combines with molecular O2 to 
form NO and citrulline (Gao et al., 2007, Palmer et al., 1988). In addition, this 
reaction requires electrons that are released from nicotinamide-adenine 
dinucleotide phosphate oxidase (NAD(P)H), tetrahydrobioprein (BH4) and flavin 
adenine dinucleotide as cofactors. When BH4 is not present, the endothelium can 
become uncoupled and produce superoxide (O2-) instead of NO.  
 
NO rapidly causes vasodilation by two mechanisms. Upon formation, NO diffuses 
into the blood stream (where it inhibits platelet function) and out of the vessel 
lumen into nearby vascular smooth muscle cells. In the smooth muscle cells, NO 
binds to the heme group in guanylate cyclase which catalyses the synthesis of 
cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP) 
(Tousoulis et al., 2012, Rapoport et al., 1983) (see Figure 1.4, page 87). Myosin 
light-chain kinase phosphorylates myosin light chains and leads to cross-bridge 
formation between the myosin head and actin filaments, causing smooth muscle 
contraction (Tousoulis et al., 2012). NO leads to increases in protein kinase G 
(PKG) and phosphorylates K+ATP channels, large conductance Ca2+-activated K+ 
channels, inward-rectifying K+ channels, Na+-K+ pump activity and the Ca2+ 
ATPase pumps in the plasma membrane (Thomas and Segal, 2004). 
Furthermore, PKG increases the Ca2+ and K+ efflux from the vascular smooth 
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muscle cells, causing hyperpolarisation. This subsequently inhibits [Ca2+]i 
through L-type calcium channels and causes vascular smooth muscle relaxation 
through myosin light-chain phosphatase phosphorylation which dephosphorylates 
myosin light-chain kinase (see Figure 1.4, page 87) (Thomas and Segal, 2004, 
Jackson, 1993). Finally, NO is inactivated within a couple of seconds in the 
vascular smooth muscle by the presence of O2- anions, which are a by-product of 
metabolism. NO reacts with O2- anions to form peroxynitrite in the vascular 
smooth muscle and NO also binds to red blood cells due to NOs high affinity for 
haem. 
 
Another determinant of blood flow is metabolic demand. Metabolic hyperaemia is 
an increase in organ blood flow that is associated with increased metabolic 
activity. This response is largely driven by a mismatch in O2 delivery and demand 
which can be facilitated by factors such as reduced oxygenation of the blood, 
decreased perfusion to an organ or an increase in the metabolic demand of an 
organ (Reglin and Pries, 2014) (see Figure 1.4, page 87). This occurs during 
exercise and the response is known as functional hyperaemia or functional 
sympatholysis and plays a critical role in the CV adjustments to exercise 
(Remensnyder et al., 1962) (see below; section 1.4.1.2.3 Efferent, page 37).  
 
1.4 The normal cardiovascular response to exercise 
The previous section described the mechanisms that control BP at rest, this 
section moves this discussion on to mechanisms that mediate the changes in the 
CV system associated with exercise. The co-ordinated CV response to physical 
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exercise (or exertion) is probably one of the most important circulatory response 
for the survival of all animals. More is learnt about the regulation of the human 
body by studying its responses to an acute bout of stress (e.g. exercise) than 
when it is idle. If an acute bout of exercise is repeated on several occasions, 
adaptations will occur, allowing the animal to exercise for longer. This thesis is 
focused on the acute responses to exercise. 
 
Physical exercise is an extremely potent stressor for the CV system and the 
mechanism by which BP is regulated largely depends on the mode of exercise, 
that being dynamic or isometric. During dynamic exercise, SNA is diffusely 
increased to the arterioles of all organs to cause vasoconstriction (e.g., 
splanchnic region and the non-active skeletal muscle), which maintains perfusion 
pressure into the active skeletal muscle (Remensnyder et al., 1962, Amann et al., 
2011a, Amann et al., 2010, Amann et al., 2011b). A threat to perfusion pressure 
that occurs during exercise is the increased sweating rates which cause loss of 
plasma volume and sodium (Galbo, 1986). In healthy individuals alterations in 
glomerular filtration rate (Aldigier et al., 1993) and increases in SNA (Joles et al., 
1982, Ahlborg and Lundberg, 1996) directed to the kidney act via the β-
adrenoceptors to increase the release of renin and subsequently aldosterone and 
vasopressin which inhibit renal sodium and water excretion (Milledge and Catley, 
1982), blunting loss of plasma volume and helping to maintain perfusion 
pressure. The release of renin appears to be modest at lower intensities of 
exercise in healthy humans but increases linearly with exercise intensity as SNA 
increases (Staessen et al., 1987, Tidgren et al., 1991). Venous return is also 
augmented during dynamic exercise, mostly by the skeletal muscle pump, which 
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increases end-diastolic volume (Casey and Hart, 2008). Increased venous return 
and sympathetically mediated inotropic effects on the left ventricle (reduced end-
systolic volume) mediate a large change in SV (Asmussen, 1981). Vagal 
withdrawal and sympathetic activation of the heart lead to a chronotropic effect 
that together with the increased SV lead to increases in CO (Asmussen, 1981, 
Burton et al., 2004). Metabolically induced vasodilation within the active skeletal 
muscle causes a drop in TPR during exercise. The increase in CO is larger than 
the drop in TPR and during dynamic exercise there is a small increase in MAP 
(Asmussen, 1981, Burton et al., 2004) (see Figure 1.3, page 85).  
 
In contrast, during isometric exercise, the intramuscular pressure can be so high 
that it compresses the blood vessels and occludes blood flow (Alam and Smirk, 
1937). During isometric exercise arterial BP rises to a much greater degree 
compared to dynamic exercise with the aim of overcoming the compressed blood 
vessels to maintain adequate perfusion pressure (Kaur and Mann, 2016, Lind et 
al., 1964). Dynamic and static exercise are the two broad ends of the exercise 
spectrum and most physical activity is categorised as a combination of both, for 
example walking with a shopping bag or weight lifting involves both isometric and 
dynamic components. 
 
1.4.1 What initiates and controls the circulatory adjustments during exercise? 
It is well established that several neural pathways work together during both 
dynamic and isometric exercise to precisely control the CV system. More 
precisely, feed-forward signals from the higher brain, known as central command 
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(Zuntz and Geppert, 1886, Goodwin et al., 1972, Williamson et al., 2002, 
Williamson et al., 1995), feedback from the skeletal muscle, the exercise pressor 
reflex (Kaufman, 2012, Kaufman et al., 1983, Kaufman et al., 1984, Amann et al., 
2011a, Amann et al., 2010, Amann and Light, 2015, Amann et al., 2009, Amann 
et al., 2011b) and continuous buffering from the carotid baroreflex and the aortic 
baroreflex (Bevegård and Shepherd, 1966a, Melcher and Donald, 1981) mediate 
the CV responses to exercise. 
 
1.4.1.1 Central command 
As early as 1886 Zuntz and Geppert proposed a central mechanism that 
activated respiratory and voluntary locomotor pathways (Zuntz and Geppert, 
1886) and was later shown to also influence the CV response to exercise  (Krogh 
and Lindhard, 1913, Krogh and Lindhard, 1917). Central command is a feed-
forward mechanism originating in areas of the cerebral cortex and/or motor 
regions. Central command involves descending neural signals before and during 
exercise with parallel activation of both motor and CV control centres within the 
medulla (Goodwin et al., 1972). Prior to exercise, increased central command 
mediates the anticipatory rise in HR (McArdle et al., 1967). Animal studies have 
highlighted that the subthalamic locomotor region/hypothalamic motor region 
which includes the hypothalamus and the fields of Forel (Abrahams et al., 1960, 
Eldridge et al., 1981, Eldridge et al., 1985, Smith et al., 1960, Tan and Dampney, 
1983, Waldrop et al., 1988, Waldrop et al., 1986), the rostral portion of the 
periaqueductal gray (Bandler and Carrive, 1988, Smith et al., 1960, Tan and 
Dampney, 1983) and also the amygdala (Hilton and Zbrozyna, 1963, al Maskati 
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and Zbrozyna, 1989) are important in regulating both the locomotor and the CV 
changes during exercise. In animals, it has been shown that central command 
mediates changes in parasympathetic and sympathetic outflow via input to the 
RVLM (Hilton et al., 1983, Waldrop and Bauer, 1989). However, an issue with the 
studies assessing central command in animals is that exercise is simulated via 
chemical or electrical stimulation of the brain regions and it is unknown if actual 
exercise would cause activation of the same brain pathways. A further 
disadvantage of the studies assessing the brain regions responsible for central 
command is the invasive approaches used in animal studies obviously cannot be 
repeated in humans during exercise. 
 
Evidence in humans, using handgrip exercise during positron emission 
tomography scans and functional magnetic resonance imaging has also 
highlighted that the insular and anterior cingulate cortices are important in 
mediating central command during exercise (Critchley et al., 2000, King et al., 
1999, Nowak et al., 2005, Nowak et al., 1999, Williamson et al., 2003, Williamson 
et al., 2002, Williamson et al., 2001). In addition, recent studies completed during 
deep brain stimulation in patients has furthered our knowledge of brain pathways 
involved in CV regulation during exercise. More specifically, stimulation of the 
dorsal periventricular/periaqueductal gray (Basnayake et al., 2011, Green et al., 
2005, Green et al., 2007), subthalamic nucleus (Green et al., 2007), the thalamus 
and the substantia nigra (Thornton et al., 2002) have shown to elicit CV changes 
similar to exercise. Central command appears to be important in the regulation of 
HR prior to and at the onset of exercise in humans, as the increase in HR is too 
rapid to be associated with feedback from skeletal muscle (exercise pressor 
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reflex) (Muthalib et al., 2009). It was originally thought that central command 
mediates increases in HR via withdrawal of the PSNS (Mitchell et al., 1989). 
Additionally, following tubocurarine-induced neuromuscular blockade which 
reduces the contractile ability of the active skeletal muscle and increases the 
amount of central command needed to maintain a certain workload, the initial HR 
response to voluntary static exercise is maintained in humans (Iwamoto et al., 
1987). The change in BP was reduced during blockade, but not fully diminished, 
indicating that central command can also effect BP at the onset of exercise. 
Exaggerated CV responses have been found with partial neuromuscular 
blockade during prolonged isometric handgrip exercise (Leonard et al., 1985, 
Mitchell et al., 1989). The HR and BP response to imagined (hypnosis) and 
actual handgrip are identical, suggesting that central command can be influenced 
by the perception of effort of exercise (Williamson et al., 2002). Plasma 
catecholamine levels were also elevated when central command was increased 
during partial neuromuscular blockade with tubocurarine during static (Pawelczyk 
et al., 1997) and dynamic (Galbo et al., 1987) exercise.  
 
The impact of central command on muscle sympathetic nerve activity (MSNA) in 
humans has been difficult to isolate and the data is confined to handgrip exercise. 
Using microneurography, central command has been shown to have mixed 
impacts on MSNA. There is evidence to suggest no effect during low to moderate 
intensity handgrip exercise (Victor et al., 1989, Ray et al., 1994) whereas there is 
evidence to suggest that central command can increase MSNA during high-
intensity handgrip exercise (Victor et al., 1995). Central command appears to be 
most important when feedback from skeletal muscle afferents is inhibited or 
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dysfunctional. For example, using local anaesthetics which cause substantial 
muscle weakness, reduced feedback from muscle afferents and an elevated 
feed-forward central command led to exaggerated CV response to cycle 
ergometer exercise in an attempt to maintain power output (Amann and 
Dempsey, 2008). However, in the absence of muscle weakness, central 
command appears insufficient to mediate the acute CV and cardiorespiratory 
response to exercise in humans. Blockade of the muscle afferents in the lower 
limbs at the superficial dorsal root ganglion using a selective -opioid agonist 
(lumbar intrathecal fentanyl) during moderate to heavy cycle ergometer exercise 
in healthy males caused substantial reductions in circulatory responses as well 
as ventilatory responses compared to a placebo (Amann et al., 2009, Amann et 
al., 2010, Amann et al., 2011a, Amann et al., 2011b). This led to reductions in 
perfusion pressure, arterial hypoxemia and blood flow in the active skeletal 
muscle which led to a reduction in the efflux of lactate increasing locomotor 
muscle fatigue (Amann et al., 2009, Amann et al., 2010, Amann et al., 2011a, 
Amann et al., 2011b). 
 
1.4.1.2 The exercise pressor reflex 
1.4.1.2.1 Afferent 
The peripheral mechanisms mediating the CV response to exercise have been 
studied in greater depth relative to central command, perhaps because they are 
easier to assess in humans. The exercise pressor reflex is a feedback system 
from the active skeletal muscle that contributes towards CV regulation during 
exercise. As early as 1894, Johansson (Johansson, 1894) suggested that 
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feedback from the skeletal muscle was capable of causing adjustments in the CV 
system during exercise. In 1937, Alam and Smirk proved the existence of a 
peripheral mechanism from the skeletal muscle in humans (Alam and Smirk, 
1937). They found that occluding blood flow in the thighs at the onset of calf-
raising exercise for ~12 minutes following exercise led to BP remaining elevated 
compared to free flow exercise (Alam and Smirk, 1937). Similar results were 
found using forearm exercise (Alam and Smirk, 1937). The authors postulated 
that maintenance of BP following exercise with occlusion was due to metabolites 
produced during contraction that were trapped in the exercising forearm (Alam 
and Smirk, 1937). This later became known as post-exercise ischemia (PEI).  
 
Within the skeletal muscle there are four different groups of afferents, large 
diameter group I and II afferent fibres which are thickly myelinated and smaller 
diameter thinly myelinated group III (Aδ) and unmyelinated group IV (C) fibres 
(Boyd and Kalu, 1979, Hunt, 1954, McCloskey and Mitchell, 1972). An important 
study in the area came from Coote et al. (1971) when it was found that tetanic 
contraction of the hindlimb elicited by stimulating ventral roots L6-S1 in 
anaesthetised cats caused an increase in arterial BP and a smaller rise in HR 
(Coote et al., 1971). Furthermore, when the dorsal roots L6-S1 were sectioned 
ventral root stimulation (L6-S1) did not cause a pressor response (Coote et al., 
1971). Another important finding from this study was that sectioning the articular 
nerves to the knee and ankle joints had no effect on the pressor response to 
ventral root stimulation (L6-S1) (Coote et al. 1971). These results suggested that 
the pressor response originates from the skeletal muscle. Further, using anodal 
block to inhibit group I and II fibres into the dorsal root, and anaesthetic blocks to 
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abolish group III and group IV fibres into the dorsal root, McCloskey and Mitchell 
(1972) found that the larger fibres (type I and II) have little influence on the CV 
alterations during exercise (McCloskey and Mitchell, 1972). The CV reflex from 
the skeletal muscle was mediated by the group III and IV afferents (McCloskey 
and Mitchell, 1972, Coote et al., 1971). The group III receptors have a conduction 
velocity of between 2.5 and 30 m/s in cats and between 1.6 and 10 m/s in rats 
(Kaufman et al., 1983, Kaufman et al., 1984, Mense and Stahnke, 1983, Pickar et 
al., 1994, Stone and Kaufman, 2015). This large range of conduction velocities is 
due to a large proportion of the group III afferents being rapidly stimulated by 
mechanical stimuli, whereas a smaller portion of the group III afferents are 
polymodal and respond to metabolic stimuli (Kaufman et al., 1983). The majority 
of group III afferents are quickly activated at the onset of isometric contraction 
and fire at a reduced rate during continued isometric contraction (Kaufman et al., 
1983, Cui et al., 2007, Cui et al., 2008b). Using the same protocol, the group IV 
receptors have conduction velocities of less than 2.5 m/s in cats and 1.6 m/s in 
rats and respond mainly to metabolic by-products of contraction and are known 
as metaboreceptors (Kaufman et al., 1983, Kaufman et al., 1984, Mense and 
Stahnke, 1983, Stone and Kaufman, 2015). The group IV afferents begin firing 
after around 5-30 seconds of isometric contraction and their firing rate gradually 
increases with prolonged exercise, with further increments during ischemic 
exercise (Kaufman et al., 1983). PEI causes a higher percentage of group IV 
afferents to become activated compared to group III afferents (Kaufman et al., 
1984), and PEI has since been used as a marker of metaboreflex activity which is 
independent of central command and the mechanoreflex. To assess the effects 
of dynamic exercise, the posterior hypothalamus near the Fields of Forel or the 
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midbrain near the uniform nucleus in decerebrate cats were stimulated whilst 
afferents signals were recorded from group III and IV afferents (Pickar et al., 
1994, Adreani et al., 1997). These studies found that the group III 
mechanoreceptors discharge in time with the step cycle (Adreani et al., 1997, 
Pickar et al., 1994) and that the group IV metaboreceptor afferents are activated 
at very low levels of dynamic exercise (Adreani et al., 1997). The results of this 
study questioned the previous view that the metaboreflex was only stimulated by 
ischemic conditions (Kaufman et al., 1983).  
 
It is proposed that the exercise pressor reflex has two main roles during exercise. 
Firstly, it sends an error signal to the central nervous system when there is a 
mismatch between O2 supply and demand (McCloskey and Mitchell, 1972, 
Kaufman et al., 1983, Kaufman et al., 1984, Alam and Smirk, 1937). Secondly, it 
is activated during light exercise intensities and plays a key role in mediating the 
CV adaptations to an acute bout of exercise.  
 
The free endings of the group III afferents originate in the connective tissue 
(collagen), the adventitia of the arteries and veins, tendon tissue and between the 
skeletal muscle fibrocytes (Andres et al., 1985, Stacey, 1969). The free endings 
of the group IV afferents originate in the adventitia of the arterioles and capillaries 
below the muscle fascia but are also located in the adventitia of the veins/venules 
of skeletal muscle and the adventitia of lymphocytes (Andres et al., 1985, Stacey, 
1969). Thus, the metaboreceptors are in an ideal position to relay metabolic 
disturbances between the blood vessels and the surrounding tissue to the 
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brainstem during exercise (Molliver et al., 2005, Andres et al., 1985). In addition 
some of the free endings of the group IV afferents have been located in collagen 
and tendon tissue (Stacey, 1969) suggesting mechanoreceptor function. 
 
Several chemical mediators have been highlighted that activate the group IV 
metaboreceptors during exercise in animal models including endogenous ATP 
(McCord et al., 2010, Kindig et al., 2006, Kindig et al., 2007), bradykinin 
(Kaufman et al., 1983) and prostaglandins (Rotto et al., 1990). In addition, the 
exogenous substance capsaicin, which is a chemical found in chili peppers, has 
been shown to activate the group IV metaboreceptors (Kaufman et al., 1983, 
Smith et al., 2005b, Michael and Priestley, 1999). Important roles for the acid 
sensing ion channel (ASIC), in particular ASIC3, the purinergic receptors 2/3 and 
3 subtypes (P2X2/3, P2X3) and transient receptor potential cation channel 
subfamily V member 1 (TRPV1) have been reported (Light et al., 2008, Jankowski 
et al., 2013, Pollak et al., 2014, Hanna and Kaufman, 2003). It was found that all 
of the metabolites studied (protons, ATP and lactate) were more effective than 1 
or 2 metabolites in activating the afferent neurons, suggesting a synergistic effect 
of metabolites on the group IV metaboreceptors (Light et al., 2008). Light et al 
(2008) also indicated that there are potentially two populations of group III/IV 
afferents in the skeletal muscle. More specifically, one population respond to low 
levels of metabolites, likely representing non-noxious, free flow dynamic exercise, 
contributing to the autonomic responses (Light et al., 2008, Jankowski et al., 
2013). The other population are higher threshold receptors and respond to 
ischaemic and noxious stimuli, likely playing a role in pain responses during 
exercise (Light et al., 2008, Jankowski et al., 2013). Injections of a concentration 
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of the metabolite mixture (protons, lactate and ATP) into the fascia of the 
abductor pollicis brevis muscle of the thumb in humans caused feelings of 
fatigue, similar to moderate-high intensity exercise and higher metabolite 
concentrations caused feelings of pain, similar to ischaemic exercise (Pollak et 
al., 2014). 
 
Gadolinium, an antagonist of mechano-gated receptors, reduced the RSNA and 
BP response to static contraction (Kim et al., 2007) and passive tendon stretch (a 
purely mechanoreceptor stimulus) (Hayes et al., 2009), but had no effect on 
group IV afferents in decerebrated cats (Hayes et al., 2009). Gadolinium is a non-
specific antagonist of multiple mechano-gated channels and has not enabled the 
identification of proteins that enable the activation of the mechanoreceptors 
during exercise (Maingret et al., 2000, Coste et al., 2010). Recently, in 
decerebrate rats, a toxin of the tarantula spider Grammostola spatula, also known 
as GsMTx4, a specific antagonist of Piezo1 and Piezo2 mechano-gated channels 
was shown to reduce BP and RSNA during both tendon stretch and intermittent 
contractions (mechanoreflex stimuluses) of the hindlimb of decerebrated, 
unanaesthetised Sprague-Dawley rats (Copp et al., 2016). As previously 
mentioned, some of the group III mechanoreceptor afferents are polymodal, and 
respond to metabolites in their receptive field. Local cyclooxygenase inhibition by 
infusion of ketorolac reduces the BP and MSNA response to muscle stretch 
during PEI in humans (Cui et al., 2007, Cui et al., 2008b). Suggesting that 
prostaglandins may play a role in sensitizing the group III mechanoreceptors 
during exercise, especially under ischemic conditions (Cui et al., 2008b). 
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1.4.1.2.2 Central pathways 
The group III and IV afferents synapse at the superficial dorsal root, specifically 
Rexed’s laminae I, II (inner medial aspect), and V (Kalia et al., 1981, Mense and 
Craig, 1988, Wilson et al., 2002, Panneton et al., 2005). Several 
neurotransmitters and neuromodulators are involved in the synapse at the 
superficial dorsal root, including neuropeptides such as substance P (Wilson et 
al., 1993a, Wilson et al., 1993b) and somatostatin (Wilson et al., 1992), excitatory 
amino acid neurotransmitters, including glutamate (Hand et al., 1996a) and 
aspartate (Hand et al., 1996a, Hand et al., 1996b) and the neurotransmitter 
GABA (Wang et al., 2013). Several modulators have also been studied that can 
mediate the sensory transmission within the superficial dorsal root including, 
alpha-adrenoceptor 2 (α2-adrenoceptors) (Ally et al., 1994), P2X receptors (Li et 
al., 2009), the serotonergic 1A receptors (Nobrega et al., 1995), neuronal nitric 
oxide synthase (nNOS) (Li and Mitchell, 2002) and σ-opiate receptors (Hill and 
Kaufman, 1990, Amann et al., 2011a, Amann et al., 2010, Amann et al., 2009, 
Amann et al., 2011b). Anterograde tracing studies have shown that the main 
supraspinal targets for the lamina I include the CVLM, the NTS, the lateral 
parabrachial area, the periaqueductal grey matter and the thalamus (Gauriau and 
Bernard, 2004, Todd, 2010). Lamina II mainly receive information from group III 
and IV afferents and act as modulator, passing this information onto lamina III 
and IV (Lima and Coimbra, 1991). However, lamina II have also been shown to 
project to the CVLM (Lima and Coimbra, 1991). Lamina V neurones mainly 
project to the thalamus  (D'Mello and Dickenson, 2008). Key central areas 
involved in processing of the exercise pressor reflex include activation of the 
dorsal and the rostral periaqueductal gray (Basnayake et al., 2011, Li and 
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Mitchell, 2000), NTS (Potts et al., 2002, Kalia et al., 1981, Toney and Mifflin, 
1994), and the RVLM (Iwamoto and Kaufman, 1987, Iwamoto et al., 1982). 
Additionally, cells within in the nucleus ambiguus are inhibited by the exercise 
pressor reflex (Iwamoto and Kaufman, 1987). Using electrophysiological 
techniques, it has been shown that NTS neurons are directly excited by 
mechanical and metabolic stimuli within the skeletal muscle and the NTS appears 
to be a critical integration site for the exercise pressor reflex (Person, 1989, 
Toney and Mifflin, 2000). 
 
1.4.1.2.3 Efferent 
The exercise pressor reflex mediates the CV responses to exercise by increasing 
SNA whilst simultaneously causing withdrawal of PSNA (Mark et al., 1985). A 
critical physiological response during exercise is the ability of the vasculature 
perfusing the active skeletal muscle to vasodilate even when SNA is elevated 
(Remensnyder et al., 1962). Functional sympatholysis is not an all-or nothing 
phenomenon and sympathetic vasoconstriction is gradually offset as exercise 
intensity increases in humans (Tschakovsky et al., 2002). Using intravital 
microscopy it has been found that in the hamster retractor muscle functional 
sympatholysis is least apparent in feed arteries that readily constrict during 
exercise when SNA increases (VanTeeffelen and Segal, 2003). In the rat 
cremaster muscle, the proximal arterioles remain susceptible to sympathetic 
vasoconstriction, whereas in the distal arterioles functional sympatholysis occurs 
(VanTeeffelen and Segal, 2003, Anderson and Faber, 1991). In rat cremaster 
muscle (McGillivray-Anderson and Faber, 1990, Anderson and Faber, 1991, 
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Faber, 1988) there is an increased density of α1-adrenoceptors on the feed 
arteries and larger proximal arterioles; whereas, α2-adrenoceptors are more 
prominent on the distal arterioles. However, the cremaster muscle acts to 
stabilise the testes, with no skeletal attachments (Moore et al., 2010). In the 
gluteus maximus of the mouse, the α2-adrenoceptors are more reactive in the 
proximal arterioles and α1-adrenoceptors in the distal arterioles (Moore et al., 
2010). In addition, a non-selective β-agonist (isoproterenol) caused near maximal 
dilation in both proximal and distal arterioles (Moore et al., 2010). However, the 
role of the β-adrenoceptors remains unclear in the skeletal muscle. Although, not 
fully understood, the release of vasodilatory substances from the skeletal muscle 
(Tu et al., 2010), endothelial cells (Segal, 2016, Hearon et al., 2016) and/or 
release of vasodilators from erythrocytes (Mortensen et al., 2011) can attenuate 
post-junctional adrenoceptor mediated vasoconstriction during exercise causing 
sympatholysis (Anderson and Faber, 1991, Wray et al., 2004).  
 
An initial increase in SNA during exercise results in an acute vasoconstrictor 
response in the arterioles and a reduction in O2 delivery, this stimulates an 
vasodilatory signal upstream which initiates vasodilation and offsets the 
vasoconstriction (Roy and Secomb, 2014). This phenomenon is known as 
sympathetic escape (Roy and Secomb, 2014). In feed arteries, sympathetic 
vasoconstriction overcomes any metabolic vasodilation as compared to distal 
arterioles where a much larger metabolic stimulus causes upstream vasodilation 
(Roy and Secomb, 2014). 
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In healthy animal models, including rats and hamster, several candidate 
mechanisms have been studied, including, potassium ions (Jackson, 2000, 
Quayle et al., 1997), ATP-sensitive K+ channels (Jackson, 1993, Thomas et al., 
1997a), tissue hypoxia (Roy and Secomb, 2014, Granger et al., 1976), 
prostaglandins (Kilbom and Wennmalm, 1976) and NO (Thomas and Victor, 
1998, Thomas et al., 2003). To assess the metabolites responsible for functional 
sympatholysis in humans, the majority of studies have aimed to mimic the 
process by systemic sympathetic stimulation using exercise alone or blocking the 
effect of locally administered tyramine (used to increase noradrenaline release) 
during exercise (Dinenno and Joyner, 2004). Using these techniques, it has been 
shown that NO (Chavoshan et al., 2002, Mortensen et al., 2009a, Nyberg et al., 
2012), ATP (Mortensen et al., 2009a, Mortensen et al., 2009b, Rosenmeier et al., 
2004) and prostaglandins (Dinenno and Joyner, 2004, Mortensen et al., 2007, 
Schrage et al., 2004) appear to play a key role in mediating functional 
sympatholysis in healthy humans (Figure 1.4, page 87). Exactly how these 
substances mediate functional sympatholysis is unknown. One possible 
mechanism may be increased calcium and potassium efflux from the vascular 
smooth muscle, which would lead to vascular smooth muscle hyperpolarisation 
and a closure of the L-type calcium channels (Jackson, 2000) (see Figure 1.4, 
page 87). If NOS or cyclooxygenase are inhibited using N-nitro-L-arginine methyl 
ester (L-NAME) or ketorolac functional sympatholysis will still occur in healthy 
humans (Dinenno and Joyner, 2004, Mortensen et al., 2007, Schrage et al., 
2004). This suggests redundancy in the mechanisms that mediate functional 
sympatholysis in healthy humans. However, combined blockade of NOS and 
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cyclooxygenase is sufficient to diminish functional sympatholysis (Dinenno and 
Joyner, 2004). 
 
1.4.1.2.4 The arterial baroreflex during exercise 
Originally, it was thought that the arterial baroreflex was ‘shut-off’ during exercise, 
as there are simultaneous increases in BP and HR. However, Bevegård and 
Shepherd (1966b) found that the arterial baroreflex continued to operate in 
humans and is reset during supine exercise to operate at higher BPs. This was 
evidenced by the use of neck suction (which increases baroreceptor stimulation) 
during exercise which led to a reduction in HR and a drop in BP (Bevegård and 
Shepherd, 1966b). The opposite occurred with the use of neck pressure (which 
reduces baroreceptor stimulation). The arterial baroreflex is continuously reset as 
exercise intensity increases (Ogoh et al., 2007). It has also been shown that in 
humans the contribution of peripheral vascular resistance to changes in BP 
increases as exercise intensity increases and the contribution of CO is reduced 
(Ogoh et al., 2003). Although not fully understood, the arterial baroreflex appears 
to be reset by a combination of central command (Gallagher et al., 2001a, 
McIlveen et al., 2001) and the exercise pressor reflex (Iellamo et al., 1997, 
Gallagher et al., 2001b, Fisher et al., 2008, Potts et al., 2003). In addition, the 
arterial baroreflex buffers the changes in SNA and BP caused by activation of the 
exercise pressor reflex during exercise (Waldrop and Mitchell, 1985, Kim et al., 
2005, Smith et al., 2006). 
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1.5 Hypertension 
Up to this point, the CV response to exercise has been summarised in healthy 
humans and animals. The CV response to exercise is altered in CV disease and 
provides information regarding the pathophysiology of the disease. The 
remainder of this Chapter is focused on the CV response to exercise in animal 
models and humans with hypertension.  
 
Essential hypertension is defined as hypertension that does not have a known 
cause. This thesis is only concerned with essential hypertension and not 
secondary hypertension induced by endocrine disorders that cause hypertension 
or pregnancy induced hypertension. In essential hypertension, BP is chronically 
elevated at rest and is associated with abnormalities in the CV system at both 
rest and during exercise. 
 
Hypertension is the leading modifiable risk factor that contributes towards CV 
disease; it affects 31% of the global population (Mills et al., 2016) and is 
responsible for around 10.4 million deaths per year (Forouzanfar et al., 2015, 
Forouzanfar et al., 2016). Of concern, only 10% of hypertensive patients in 
England have BP under control (<140/90 mmHg) (Fuller et al., 2017). However, a 
problem with above mentioned studies is the reliance on clinic/office BP 
measurements. It has been shown that white-coat hypertension, defined as 
office/clinic BPs >140/90 mmHg with normal 24-hour ambulatory blood pressure 
monitoring (ABPM) results (<130/80 mmHg) has a high prevalence of 15-30% 
(Franklin et al., 2013, O'Brien et al., 2013). According to the European Society of 
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Hypertension, hypertension should be confirmed by the use of 24-hour ABPM 
(O'Brien et al., 2001, O'Brien et al., 2000). As the population continues to expand, 
the annual global cost of hypertension could reach £1 trillion (Gaziano et al., 
2009). The most recent Public Health England statistics suggest that 28% of 
adults have high BP and 12% of adults have untreated hypertension which costs 
the National Health Service (NHS) a staggering £2.1 billion every year (Fuller et 
al., 2017). Public Health England has calculated that if the national average for 
BP drops by 5 mmHg it will save the NHS £850 million over the next 10 years 
(Fuller et al., 2017). 
 
There is a continuous risk of mortality from stroke, ischemic heart disease and 
all-vascular causes with resting BP above 115/75 mmHg (Lewington et al., 2002). 
In-line with this data, a recent Lancet meta-analysis found that the relative risk for 
major CV events, stroke, heart failure and all-cause mortality were proportional to 
the reduction in BP through anti-hypertensive medications (Ettehad et al., 2016). 
Finally, the systolic blood pressure intervention trial (SPRINT) found that among 
patients with hypertension, treating and controlling SBP to <120mmHg, compared 
to <140mmHg resulted in fewer fatal and nonfatal major CV events and total 
mortality over a median follow-up of 3.26 years (Wright et al., 2015). These 
studies highlight the clear importance of lowering BP in hypertension. The 
SPRINT study resulted in the reclassification of stage 1 hypertension, which was 
defined as SBP between 130-139 mmHg and DBP between 80-89 mmHg being 
redefined as >120/80 mmHg in the United States of America (USA) (Whelton et 
al., 2017). 
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1.5.1 The pathophysiology of hypertension 
It is well established that large artery (aortic) stiffness increases with ageing 
(Najjar et al., 2005) and arterial stiffness is further enhanced in hypertension 
(Koivistoinen et al., 2017, Laurent et al., 2001). In hypertension, there is an 
increased wave reflection from the periphery, which occurs early in systole and 
contributes to the aortic BP and causes aortic BP to rise to a similar level as 
brachial BP (Hirata et al., 2006). This increases the load on the left ventricle, 
reduces ejection fraction and augments the myocardial O2 requirements (Laurent 
et al., 2001). Both males and females with hypertension have an increased left 
ventricular mass. However, chronic hypertension is more likely to lead to 
concentric hypertrophy (increased left ventricular wall thickness) in women and 
eccentric hypertrophy (dilation of the left ventricle) in males (Vriz et al., 1997, 
Krumholz et al., 1993). Concentric hypertrophy in females is associated with 
increased thickening of the ventricular wall, which normalises the stress on the 
cardiac myocytes without changing the left ventricular cavity size (LaPlaces Law; 
Equation 1.6) (Krumholz et al., 1993). Eventually, the increased diffusion distance 
into the myocardium (increased wall thickness) leads to hypoxia and 
subsequently necrosis and apoptosis of the cardiac myocytes. In males, eccentric 
hypertrophy is associated with normal wall thickness and an increase in the left 
ventricular diameter which can lead to an elevated wall stress and left ventricle 
failure (decompensated hypertrophy) (LaPlaces Law; Equation 1.6) (Krumholz et 
al., 1993).  
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Similarly, in the periphery, the increased load imparted on the arterial wall by 
chronic vasoconstriction and elevations in arterial BP increases wall tension 
(Mayet and Hughes, 2003). Tensile stress can be normalised by increases in wall 
thickness and/or reductions in the diameter of the arterial lumen (Mayet and 
Hughes, 2003). Increased wall thickness in hypertension is mediated by smooth 
muscle cell hyperplasia and increased collagen-to-elastin ratio, which leads to 
augmented media-to-lumen ratios (Mulvany et al., 1985). Small artery 
remodelling is the first sign of end organ damage that appears in hypertension, 
prior to endothelial dysfunction and left ventricular hypertrophy (Park and 
Schiffrin, 2001). It is well documented that the endothelium is impaired in 
individuals with hypertension, leading to reductions in NO bioavailability (Panza 
et al., 1994, Panza et al., 1990). The Framingham Heart study found that reduced 
flow-mediated dilatation (FMD, a marker of endothelial dysfunction) was 
positively related to the severity of hypertension (Benjamin et al., 2004). Two of 
the most important drivers of endothelial dysfunction in hypertension are 
oxidative stress and vascular inflammation. Oxidative stress related to endothelial 
dysfunction appears to be mediated by increases in NAD(P)H, which uses 
nicotinamide-adenine dinucleotide (NADH)/NAD(P)H as an electron donor to 
reduce O2 to O2- anions (Paravicini and Touyz, 2006). Chronic exposure of 
isolated carotid arteries (from mice) to high intraluminal pressures leads to 
elevated levels of O2- and NAD(P)H oxidase, which are related to reductions in 
endothelium-dependent vasodilation from acetylcholine (Vecchione et al., 2009). 
In addition, elevated levels of ROS (such as hydrogen peroxide, peroxynitrite and 
O2-) produced from the mitochondria can also cause endothelial dysfunction 
(Doughan et al., 2008). In regard to inflammation, a reduction in the level of 
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endothelial progenitor cells (EPC’s) is related to impaired endothelial function in 
the presence of complement factor 3 (C3) (Hill et al., 2003, Giannotti et al., 2010). 
Endothelial dysfunction and altered large and small artery function leads to 
reductions in the capabilities of the arteries and arterioles to dilate in 
hypertensives. This leads to elevated vascular resistance in nearly every organ, 
including the kidney. SV appears to be normal or slightly reduced in essential 
hypertension, due to elevated afterload (Kahan and Bergfeldt, 2005, Safar et al., 
1976). Heart rate is typically higher in patients with essential hypertension, which 
likely reflects the heightened sympathetic tone associated with essential 
hypertension (see section 1.5.1.1. The sympathetic nervous system and 
hypertension) (Morcet et al., 1999). A study of 101 patients with hypertension and 
101 normotensives found that CO remained normal in essential hypertension 
(Safar et al., 1976). 
 
1.5.1.1 The sympathetic nervous system and hypertension 
It is well established that patients with hypertension have higher levels of SNA as 
measured by microneurography and noradrenaline spillover (Judy et al., 1979, 
Abboud, 1982, Warnert et al., 2016, Grassi and Ram, 2016, Esler, 2000). In 
addition, it has been shown that the level of SNA increases with the degree of 
hypertension and end-organ damage (Grassi et al., 1998a, Smith et al., 2004). 
These findings suggest a neurogenic component to the development and 
progression of hypertension (Mancia et al., 1999). Noradrenaline spillover is 
increased in the renal, cerebral and the coronary circulation, but normal in 
splanchnic and pulmonary regions (Esler et al., 1989). Skin sympathetic nerve 
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activity (SSNA) (measured via microneurography) is normal in hypertension but 
elevated to the vascular smooth muscle beds in essential hypertension (MSNA) 
(Grassi, 2009), highlighting that SNA over activity in hypertension is nonuniformly 
distributed around the body. Elevated α1 adrenoceptor activation causes an 
increase in NAD(P)H activation (Amin et al., 2001). α1 adrenoceptor activation 
and O2- activate a cascade of signalling pathways, including mitogen-activated 
protein kinases (MAPKs), L-type Ca2+ channels, tyrosine kinases and redox 
sensitive transcription pathways which lead to vascular smooth muscle cell 
growth and an increase in extracellular proteins, including collagen and 
fibronectin (Montezano and Touyz, 2014, Amin et al., 2001, Shi et al., 2006). In 
addition, bone mineral loss is augmented in hypertension due to higher levels of 
SNA (Cappuccio et al., 1999). Therefore, excessive SNA underlies some of the 
end organ damage associated with hypertension (Grassi and Ram, 2016, Grassi 
et al., 2015), including the elevation in vascular hypertrophy and remodelling 
(Chalothorn et al., 2005), the triggering of proatherogenic vascular effects 
(Zukowska, 2005), increased wave reflection (Hart et al., 2013), elevated large 
artery stiffness (Delacretaz et al., 2001) and augmented cardiac hypertrophy 
(Strand et al., 2006, Sen et al., 1974).  
 
Exactly what stimulates heightened SNA in hypertension is still unclear. There is 
considerable evidence that afferent nerve fibre input from different organs is 
involved. It is well established that the arterial baroreflex is reset in patients with 
hypertension (Somers et al., 1991) and animal models (Minami et al., 2003) to 
operate at higher levels of BP. Furthermore, using the modified Oxford protocol, it 
has been demonstrated that in essential hypertension, the arterial baroreflex 
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partially loses its ability to control HR but maintains its ability to modulate the BP 
and MSNA relative to normotension (Grassi et al., 1998a). Similar findings have 
been found in spontaneously hypertensive rats (SHRs) (Judy and Farrell, 1979). 
Elevated SNA in hypertension is also facilitated by the peripheral chemoreceptors 
which detect hypoxia and hypercapnia, resulting in increased SNA, BP and 
hyperventilation (Trzebski, 1992, Abdala et al., 2012, McBryde et al., 2013). In 
addition, cerebral hypoperfusion may also mediate increases in SNA, the “selfish 
brain” acts to increase SNA and BP to maintain its own perfusion (Warnert et al., 
2016). A key modulator of afferent input is the NTS and the RVLM. Centrally 
derived NO, produced from endothelial, neuronal or inducible isoforms of NOS 
decreases sympathoexcitation in the NTS and the RVLM (Paton et al., 2001, 
Ruggiero et al., 1996). Elevated ROS (e.g. O2- anions) in hypertension are known 
to scavenge NO both in the brainstem, causing less inhibition of SNA in 
hypertension (Hirooka, 2008, Hirooka et al., 2006). 
 
1.5.1.2 The RAAS in hypertension 
The RAAS is overactive in SHRs (Kobori et al., 2005) and in patients with 
essential hypertension, owing to alterations in sodium reabsorption and increased 
SNA. The RAAS contributes to the development and progression of hypertension 
through an increase in circulating angiotensin II and aldosterone (Admiraal et al., 
1990, Freis et al., 1983). Similar to α1-adrenoceptor activation, elevated 
angiotensin II levels increase NAD(P)H oxidase (Paravicini and Touyz, 2006). 
NAD(P)H mediated increases in superoxide anions are known to involve 
angiotensin II binding to the AT1 receptor in both the vascular smooth muscle and 
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brainstem (Rajagopalan et al., 1996, Zimmerman et al., 2002). This mediates 
end-organ damage by activating MAPKs, tyrosine kinases and redox sensitive 
transcription pathways which lead to vascular smooth muscle cell growth and an 
increase in extracellular proteins, (collagen and fibronectin). Increased renal 
vascular resistance in hypertension is also further enhanced by angiotensin II 
elevations, along with sympathetic stimulation. In addition, an increase in renal 
resistance mediated by RSNA and elevated angiotensin II shifts the pressure-
natriuresis curve upwards in hypertension (Hall, 2003, Hall, 1986). Natriuresis 
continues at the same rate in hypertension, but a higher pressure is needed to do 
so (Hall, 2003). Interestingly, around 25% of hypertensive individuals have 
normal activity of the RAAS. This highlights that hypertension is likely a disease 
with multifactorial causes. 
 
1.5.1.3 Current antihypertensive medications 
Various treatments for hypertension have been developed, most of which target 
the peripheral vasculature with the aim of reducing vascular tone. Anti-
hypertensive medications have been developed to target the RAAS system and 
reduce resting BP, including, ACE inhibitors (e.g. ramipril) (Kumar Chhabra et al., 
2013), AT1 receptor blockers (e.g. valsartan) (Abraham et al., 2011), renin 
inhibitors (e.g. Aliskiren) (Fu et al., 2017) and aldosterone antagonists (e.g. 
spironolactone) (Chapman et al., 2007). The dihydropyridine class of L-type 
calcium channel antagonists (e.g., amlodipine) are also given to patients with 
hypertension. This class of drugs bind to L-type calcium channels in the heart, 
causing negative inotropy and on the smooth muscle, which decrease TPR and 
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BP (Hirooka et al., 2006, Verdecchia et al., 2005, Xiong and Sperelakis, 1995). In 
addition, thiazide-like diuretics, such as indapamide reduce water and sodium, 
improve vascular tone and reduce arterial pressure (Campbell, 1983, Roush et 
al., 2015). Diuretics are generally only given to hypertensive patients who cannot 
tolerate calcium channel antagonists. These treatments for hypertension are 
regarded as the first line treatments according to the National Institute for Health 
and Care Excellence (NICE) guidelines 2011 because these medications 
produce improved survival rates. β-blockers were once regarded as first-line 
treatment for hypertension. However, the use of β-blockers is associated with 
poorer outcomes (stroke) when compared to other anti-hypertensive medications 
(De Caterina and Leone, 2010). In addition, they are associated with adverse 
side effects, such as exercise intolerance (De Caterina and Leone, 2010). 
Similarly, α-blockers are effective at lowering BP in patients with hypertension but 
are not as effective as other antihypertensive medications in reducing heart 
failure and stroke (Messerli, 2000). Of concern, treatment with a single anti-
hypertensive medication only reduces BP in around 50-60% of patients, 
highlighting the heterogeneity of the development and progression of 
hypertension (Materson et al., 1993).  
 
Despite adequate control of BP, individuals with treated-controlled hypertension 
have an increased risk of CV disease, stroke and total mortality compared to 
normotensive individuals (Almgren et al., 2005, Lawlor et al., 2011, Brown et al., 
2013). The mechanisms mediating this remain unclear, but it highlights an 
underlying pathology in hypertension that is not currently being treated.  
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The effects of the first line anti-hypertensive medications on the activity of the 
SNS remain highly controversial (Del Colle et al., 2007) and not completely 
understood. Indeed, reductions in BP with chronic use of ACE inhibitors (Grassi 
et al., 1998b), AT1 receptor antagonists, (Krum et al., 2006, Fu et al., 2017, Fu et 
al., 2005), thiazide-like diuretics (Fu et al., 2005) and short and long acting L-type 
calcium channel antagonists (Noll et al., 1998, Grossman and Messerli, 1998) 
occur alongside increased SNA, possibly due to unloading of the baroreflex (Fu 
et al., 2005). In addition, Spironolactone, despite effectively lowering BP has 
been shown to have no effect on resting MSNA in previously untreated 
hypertensive patients after 3 months of use (Menon et al., 2009). It has also been 
shown that patients with treatment-controlled hypertension have a similar basal 
MSNA level when compared to patients with untreated hypertension (Materson et 
al., 1993, Warnert et al., 2016). Moxonidine and clonidine are centrally acting 
antihypertensive drugs that activate α2/imidazoline receptors in the NTS and 
RVLM and decrease MSNA (Hausberg et al., 2010). However, centrally acting 
hypertensives are associated with unfavourable side effects such as dry mouth, 
impotency and sedation and are therefore not routinely given to treat 
hypertension. Anti-hypertensive medications have been shown to have mixed 
effects on bone mineral loss in hypertension (Ghosh and Majumdar, 2014). 
Antihypertensive medication may not lower SNA, but it does reduce mortality 
compared to untreated hypertension. What is concerning is that mortality is still 
elevated when compared to normotensives. 
 
An alternative treatment strategy for hypertension is CV exercise training. 
Physical inactivity constitutes a key risk factor of developing hypertension and 
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several meta-analysis have concluded that increasing aerobic exercise frequency 
decreases resting SBP and DBP (Whelton et al., 2002) and also decreases in CV 
and all-cause mortality (Rossi et al., 2012) in patients with hypertension. The 
recent Public Health England statistics revealed that only 66% of males and 58% 
of females meet the aerobic activity guidelines set by the World Health 
Organisation (WHO) (Fuller et al., 2017) which currently suggest 150 minutes of 
moderate activity or 75 minutes of high intensity exercise each week (Kikuchi et 
al., 2018, Fagard, 2012). Importantly, a prospective cohort study showed that 
meeting these guidelines was associated with reduced all-cause mortality 
(Kikuchi et al., 2018). In addition, objective measurements of fitness (e.g., peak 
volume of O2 uptake test (V̇O2 peak)) are inversely related to CV events/mortality 
and all-cause mortality in observational studies, even after adjusting for resting 
SBP (Pardaens et al., 1996, McAuley et al., 2009). Physical exercise has been 
shown to improve several markers involved in the pathophysiology of 
hypertension, including lowering MSNA (Sinoway et al., 1996, Laterza et al., 
2007), enhancing endothelial function (Di Francescomarino et al., 2009), 
increasing baroreflex sensitivity (Somers et al., 1991), improving insulin 
sensitivity (Stewart, 2002) and a reduction in body fat mass (Palatini et al., 1994). 
 
While consistent evidence suggests that aerobic fitness and dynamic exercise 
reduce resting BP in patients with hypertension, there is a cause for concern due 
to stroke events. Untreated sedentary hypertensive individuals have an 
exaggerated rise in SBP during acute exercise. Studies show that BP rises 
excessively during low-intensity isometric handgrip at 30-50% maximal voluntary 
contraction (MVC) (Greaney et al., 2015a, Greaney et al., 2014, Aoki et al., 1983, 
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Delaney et al., 2010, Choi et al., 2013, Brorson et al., 1978), during low-intensity 
dynamic exercise (Seguro et al., 1991, Barbosa et al., 2016, Brorson et al., 1978) 
and maximal dynamic exercise (Kokkinos et al., 2002) testing. 
 
An exaggerated BP response to exercise represents an important marker for 
future development of essential hypertension in both young and older 
normotensives (Berger et al., 2015, Holmqvist et al., 2012) and pre-hypertensive 
individuals (Manolio et al., 1994, Tsumura et al., 2002, Singh et al., 1999, Miyai et 
al., 2000). The exact mechanism hasn’t been clarified and it is unclear whether 
the structure of the resistance vessels and/or the activation of the SNS or RAAS 
during exercise is changed before the development of hypertension. In addition, 
family history of hypertension is associated with an increased risk of developing 
hypertension as well as an exaggerated BP and MSNA response to exercise 
(Greaney et al., 2015b, Hunt et al., 1986, Molineux and Steptoe, 1988). Although 
only speculative, it could be predicted that hypertensive responses to exercise 
lead to excessive endothelial damage, increased arterial stiffness and 
acceleration of end-organ damage which would lead to the development of 
hypertension. 
 
Using telephone interviews in the weeks following a myocardial infarction, it was 
suggested that myocardial infarctions were more likely to proceed heavy bouts of 
physical activity compared to periods of little or no physical activity (Mittleman 
and Siscovick, 1996, Willich  et al., 1993). Interviews with patients or close family 
members following a non-fatal or fatal subarachnoid haemorrhage have also 
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highlighted that this condition is more likely to happen two hours following 
moderate to heavy physical exertion compared to rest or light exercise (Anderson 
et al., 2003, Schievink et al., 1989). Older patients were at increased risk of 
subarachnoid haemorrhage following moderate to heavy physical exertion with a 
history of hypertension, treated or untreated (Anderson et al., 2003). The authors 
postulated that sharp rises in BP in these individuals during the physical activity 
may predispose to MIs and/or subarachnoid haemorrhage. An obvious limitation 
to telephone interviews and face-to-face interviews is recall bias from participants 
and therefore may have limited the findings from these studies. Nevertheless, 
these studies did indicate that the sharp BP responses to exercise in 
hypertension predispose them to adverse CV and cerebrovascular events. This is 
concerning as clinicians are increasingly advising their patients with hypertension 
to take part in more physical exercise to lower resting BP. 
 
Available evidence suggests that individuals from the general population, free 
from anti-hypertensive medication, with an exaggerated BP response to exercise 
are at increased risk of left ventricular hypertrophy (Ren et al., 1985, 
Papademetriou et al., 1989, Mizuno et al., 2016b), myocardial infarction 
(Laukkanen et al., 2006, Kjeldsen et al., 1997, Mundal et al., 1996, Kjeldsen et 
al., 2001, Filipovsky et al., 1992, Kohl et al., 1996), any type of stroke (Laukkanen 
et al., 2006, Kurl et al., 2001) and total mortality (Filipovsky et al., 1992, Fagard et 
al., 1996, Kohl et al., 1996) independent of resting BPs. These findings have 
been confirmed using both submaximal (Mundal et al., 1996, Filipovsky et al., 
1992, Kjeldsen et al., 1997, Tzemos et al., 2015) and maximal exercise (Kurl et 
al., 2001, Laukkanen et al., 2006, Fagard et al., 1996, Ren et al., 1985, Kohl et 
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al., 1996). A recent meta-analysis of 46,314 individuals from the general 
population, including normotensives and untreated hypertensives concluded that 
an excessive rise in SBP during submaximal, but not maximal exercise were 
predictive of CV outcomes (Schultz et al., 2013b). The authors stated that the 
pooled hazard ratio for the studies included was 1.36 for submaximal exercise 
and 1.49 for maximal exercise SBP, which could indicate a trend towards 
biological significance (Schultz et al., 2013b). For every 10 mmHg increases in 
SBP during submaximal exercise, there was a 10% increase in the risk of an 
adverse CV event (Schultz et al., 2013b). Additionally, a low number of studies 
that have assessed the significance of maximal exercise SBP limited the 
statistical power for this analysis. It is interesting to note that the most consistent 
findings regarding the BP response to submaximal and maximal exercise have 
come from studies using cycle ergometer testing (Kurl et al., 2001, Laukkanen et 
al., 2006, Mundal et al., 1996, Filipovsky et al., 1992, Hietanen et al., 2010, 
Fagard et al., 1996, Kjeldsen et al., 2001), compared to studies using treadmill 
testing (Lewis et al., 2008, Ren et al., 1985, Weiss et al., 2010, Kohl et al., 1996, 
Shalnova et al., 1996). Measuring BP during treadmill testing is likely to be 
influenced by movement artefact more than during cycle ergometer testing and 
therefore BPs may not be as accurate (Laukkanen et al., 2006). 
 
There is a lack of research assessing whether having hypertension and an 
exaggerated BP response to exercise places these individuals at increased CV 
and/or cerebrovascular risk compared to normotension or even compared to 
hypertensives with a more normal rise in BP. In addition, a large proportion of the 
studies assessing the prognostic value of exaggerated SBPs have relied on clinic 
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BP assessment to assess baseline BPs. (Franklin et al., 2013, O'Brien et al., 
2013). Future studies will need to include 24-hour ABPM, and then participants 
will be properly defined as normotensive or hypertensive. The conflicting data 
that has arisen between cycle ergometer and treadmill exercise testing for the 
prognostic significance of moderate and maximal exercise BPs has led to the 
American college of cardiology/American Heart association (Gibbons et al., 2002) 
and the European Society of Hypertension/European Society of Cardiology 
(Mancia et al., 2007, Mancia et al., 2013) to include exaggerated BP responses 
to exercise being linked to future risk of hypertension but not CV disease, stroke 
or total mortality within their guidelines. Although more research in the area is 
needed, it does appear that an exaggerated SBP response to exercise does 
carry extra prognostic value independent of baseline BP values when measured 
during cycle ergometer exercise at both moderate and at maximal exercise. A 
large amount of evidence suggests that the autonomic response to exercise is 
exaggerated in patients with untreated hypertension. The research suggests that 
the exercise pressor reflex appears to be a key mediator of this exaggerated 
autonomic response to exercise in this disease. 
 
1.6 The pathophysiology of exercise hypertension 
1.6.1 The exercise pressor reflex in hypertension 
1.6.1.1 Animal models 
Both components of the exercise pressor reflex, the mechanoreflex and the 
metaboreflex are over-active in animal models of hypertension (Leal et al., 2008). 
In decerebrated SHR, activation of the metaboreflex via injections of capsaicin 
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directly into the hindlimb, which act on TPRv1 receptors, lead to exaggerated 
changes in BP and RSNA when compared to Wistar-Kyoto rats (WKY) (Leal et 
al., 2008, Mizuno et al., 2011b, Mizuno et al., 2011a, Mizuno et al., 2015b). 
Similar findings of metaboreflex oversensitivity were found when using 
aldosterone and salt-loaded hypertensive rats (Mizuno et al., 2013, Mizuno et al., 
2014b, Mizuno et al., 2015a). Importantly the BP response to acute treadmill 
exercise testing is also exaggerated in SHR compared to WKY, which would 
suggest exaggerated metaboreflex activation is related to impaired dynamic BP 
control (Kashimura and Igawa, 1996). In contrast, in canines made hypertensive 
by a reduction in renal blood flow via unilateral partial occlusion of the left kidney, 
activation of the metaboreflex via reductions in hindlimb blood flow during 
submaximal treadmill running following the induction of hypertension led to 
attenuated changes in BP, HR and CO (Spranger et al., 2017, Sala-Mercado et 
al., 2013). Several interpretations are possible 1) species variations in the 
metaboreflex 2) isometric vs dynamic exercise 3) decerebration of the rats vs 
conscious dogs and 4) the mechanisms mediating the rise in BP in order to 
develop hypertension. In the decerebrated rats the BP response to metaboreflex 
activation was primarily mediated by increased renal vasculature resistance 
(Smith et al., 2010, Smith et al., 2006, Leal et al., 2008). In contrast, in dogs the 
rise in BP during metaboreflex activation is primarily due to changes in CO (Sala-
Mercado et al., 2013, Spranger et al., 2017). Following the induction of 
hypertension in the dogs, peripheral vasoconstriction increased but the 
attenuation of the CO caused reductions in BP during metaboreflex activation 
(Sala-Mercado et al., 2013, Spranger et al., 2017). The contribution of CO 
compared to peripheral vasoconstriction to the rise in BP during metaboreflex 
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activation is also likely mediated by isometric vs. dynamic exercise and also 
whether the metaboreflex is activated during or following exercise (Crisafulli et 
al., 2011). It was later shown that the impaired CO during metaboreflex activation 
in the dogs was due to sympathetic vasoconstriction of the coronary vasculature, 
which led to decrements in left ventricular performance (Spranger et al., 2017). 
 
The mechanically sensitive afferents in decerebrated SHR using 30 seconds of 
passive stretching of the hindlimb also lead to exaggerated changes in BP, HR 
and RSNA when compared to WKY (Leal et al., 2008, Leal et al., 2013, Mizuno et 
al., 2011b).   
 
Importantly, these results in SHR for both the metaboreflex and mechanoreflex 
remain the same after decerebration, which removes the influences of central 
command, and also following baro-denervation, which removes the influences of 
the baroreflex, highlighting the importance of the exercise pressor reflex in the 
SHR model of hypertension (Smith et al., 2010, Leal et al., 2008, Mizuno et al., 
2011b). The exercise pressor reflex appears critical in mediating the abnormal 
sympathetic nervous system activity and BP response to exercise seen in animal 
models of hypertension. 
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1.6.1.1.1 Mechanisms for metaboreflex oversensitivity in animal models of 
hypertension 
The exact mechanism driving the dysfunctional metaboreflex in animal models of 
hypertension is still unclear. Alterations in the metaboreflex could occur at any 
point in the reflex arc. Capsazepine, which antagonises the TRPV1 receptors, 
reduced the MAP and RSNA response to capsaicin and ischaemic muscle 
contraction in SHR more than in WKY (Mizuno et al., 2011a). Interestingly, 
Western blot analysis revealed the density of the TRPV1 receptors was elevated 
in SHR only in the dorsal root ganglion, but not in the skeletal muscle where the 
afferent nerve endings lie (Mizuno et al., 2011a). The authors speculated that 
enhanced phosphorylation of the TRPV1 receptors in the skeletal muscle could 
lead to increased metaboreflex activity in SHR. Local administration of a non-
specific antagonist of the purinergic receptors (P2) receptors (pyridoxial-5-
phosphate (PLP)) in to the antecubital vein, had a moderate effect on the BP and 
MSNA responses to isometric handgrip exercise and PEI in patients with 
untreated hypertension (Greaney et al., 2014). This finding highlights the 
documented synergy of the metaboreflex where all the metabolites together are 
more effective than one or two (Light et al., 2008, Jankowski et al., 2013). 
However, it also demonstrates the redundancy of the metaboreflex, by abolishing 
one of the metabolites that effects the metaboreflex, it will still remain sensitised 
during exercise in hypertension due to the presence of the other metabolites 
(Joyner, 2013, Stone et al., 2015). One of the issues with targeting the skeletal 
muscle receptors for the treatment of metaboreflex hyperreflexia is that we still do 
not fully understand the exact metabolites that increase its sensitivity in 
hypertension. Interestingly, a study in mice found that µ-opioid receptor 
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expression is higher on group IV afferents, whereas δ-opioid receptor expression 
is increased on group III afferents (Scherrer et al., 2009). Therefore, the use of 
fentanyl, which is an agonist for µ-opioid receptor may highlight alterations at the 
spinal cord in the processing of the metaboreflex (Barbosa et al., 2016). 
 
Alterations in central processing of afferent signals from the skeletal muscle may 
also contribute to an exaggerated metaboreflex sensitivity. The same level of 
electrical stimulation to activate the afferent nerve fibres in decerebrated SHR 
and WKY led to exaggerated BP increases in the SHR (Smith et al., 2006). This 
suggested that the same level of group III and IV afferent information is 
interpreted differently within the dorsal horn and/or within the brain stem in 
hypertension. Increasing central NO bioavailability within the NTS decreases the 
sympathetically mediated changes in MAP associated with activation of the 
exercise pressor reflex (Smith et al., 2005a). In SHR there are fewer neurons that 
express nNOS when compared to WKY in areas of the NTS that are excited by 
the group III and IV afferents (Murphy et al., 2013). Dialysis of L-arginine in the 
NTS reduced the exaggerated increase in BP in decerebrated SHR to levels 
seen in WKY (Leal et al., 2013). Similarly, inhibiting the endogenous production 
of NO via dialysis of L-NAME into the NTS led to exaggerated BP responses to 
contraction in WKY which were similar to SHR (Leal et al., 2012). In addition, 
angiotensin II production is exaggerated in individuals with an exaggerated BP 
response to exercise (Shim et al., 2008, Williams et al., 2013). A recent study 
suggested that, in healthy people, a centrally acting ACE inhibitor (perindopril) 
was more effective at lowering MSNA and BP during exercise than a peripherally 
acting ACE inhibitor (captopril) (Moralez et al., 2018). Centrally elevated levels of 
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angiotensin II may reduce the capacity of the NTS to buffer the elevated afferent 
activity of the group III and IV afferents in hypertension, leading to excessive 
efferent MSNA. 
 
A recent study found that 3-weeks of spironolactone or eplerenone, both 
mineralocorticoid receptor antagonists, attenuated the exaggerated BP response 
to electrical stimulation of the hindlimb muscles in SHR but had no effect on WKY 
(Downey et al., 2017). Unfortunately, the oral administration of spironolactone or 
eplerenone limited the group’s ability to identify which part of the reflex arc the 
antagonists were blocking. Research has shown that there are high levels of 
mineralocorticoid receptors at the level of the dorsal horn (González et al., 1992) 
and within the NTS (Sequeira et al., 2006). Future studies will need to confirm the 
targets of mineralocorticoid receptor antagonists and further the research to 
exercise pressor reflex in human hypertension. 
 
1.6.1.2 Human hypertension 
In older human hypertensives (mean age > 60 years) withdrawn from their anti-
hypertensive medications 48-hours prior to participation, isolation of the 
metabolic component of the exercise pressor reflex using PEI leads to 
exaggerated increases in both MSNA (Delaney et al., 2010, Greaney et al., 2014) 
and SBP (Sausen et al., 2009, Delaney et al., 2010, Greaney et al., 2014) when 
compared to age-matched normotensive individuals. Metaboreflex sensitivity is 
also increased in younger never-treated prehypertensive individuals (mean age: 
35±3 years old) compared to age-matched normotensives (mean age: 33±3 
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years old)  (Choi et al., 2013). To assess whether generalised 
sympathoexcitability was the cause of the differences between hypertension and 
normotension in these studies, several used a cold pressor test (Sausen et al., 
2009, Delaney et al., 2010, Choi et al., 2013) and in response to the cold pressor 
test, MSNA and BP were similar in both groups (Choi et al., 2013, Delaney et al., 
2010, Sausen et al., 2009). In contrast, it was found that BP and MSNA were 
blunted during PEI in middle-aged never-treated hypertensive individuals (mean 
age: 42±1 years old) (Rondon et al., 2006). Although the disparity in results 
remains unclear, it could be due to the method chosen for assessment of BP 
(beat-to-beat assessment using photoplethysmography (Delaney et al., 2010, 
Sausen et al., 2009, Greaney et al., 2014, Choi et al., 2013) vs. BP 
measurements once per minute from the ankle used by Rondon et al. (2006). 
 
Owing to difficulties in assessing the mechanical component of the exercise 
pressor reflex, very little research has assessed the mechanoreflex in humans 
with hypertension. Two different methods of mechanoreflex activation have been 
assessed. Firstly, based on Kaufman et al. (1983) finding that the 
mechanoreceptors fire rapidly at the onset of isometrically induced contraction in 
cats, the SBP and MSNA responses to the first 10-30s seconds of isometric 
handgrip exercise have been assessed in untreated hypertension (Greaney et al., 
2015a). They found that even within 10s of isometric handgrip exercise at 30 and 
40% maximal voluntary contraction (MVC) that SBP and MSNA were elevated in 
older untreated individuals with hypertension (mean age: 62±1 years old), 
withdrawn from their anti-hypertensive medications 48-hours prior to 
investigation, when compared to age-matched normotensive controls (mean age: 
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60 ±1 years old) (Greaney et al., 2015a). This result was taken to suggest 
increased mechanoreflex sensitivity in human hypertension. However, it is known 
that at the onset of isometric handgrip the autonomic response is also mediated 
by central command (Goodwin et al., 1972). Therefore, it is very difficult to draw 
specific conclusions regarding the mechanoreflex from this study. A more specific 
method to assess mechanoreflex sensitivity in humans is passive cycling using 
motorised pedals (Williamson et al., 1995). Passive arm cycling in untreated 
hypertension leads to exaggerated MSNA and BP when compared to age-
matched normotensives (Velasco et al., 2015). It is clear that both the 
metaboreflex and mechanoreflex sensitivity both appear to be elevated in 
patients with untreated hypertension when compared to age-matched individuals.  
 
In patients with untreated hypertension no differences in the control of HR are 
seen during PEI following isometric and dynamic handgrip exercise (Rondon et 
al., 2006, Sausen et al., 2009, Delaney et al., 2010, Choi et al., 2013, Greaney et 
al., 2014). During PEI following arm exercise, sympathetically mediated increases 
in HR are buffered by a synchronous increase in cardiac parasympathetic tone 
(Fisher et al., 2013, Fisher et al., 2010). This increased parasympathetic tone 
occurs due to withdrawal of mechanoreflex activity (Gladwell et al., 2005) and 
central command (Krogh and Lindhard, 1917, Goodwin et al., 1972). However, 
following exercise using a large muscle mass (e.g dynamic cycle ergometer), HR 
is increased or maintained during PEI (e.g., cycle ergometer) which invokes a 
larger metaboreflex mediated increase in SNA and withdrawal of vagal tone that 
is maintained during PEI (Fisher et al., 2013). Whether differences in HR would 
be found between hypertension and normotension during PEI following cycle 
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ergometer testing remains to be seen. On the contrary, the mechanoreflex 
appears to mediate exaggerated increases in HR in untreated hypertension 
relative to age matched normotensives (Greaney et al., 2015a, Velasco et al., 
2015). Lumbar intrathecal fentanyl (µ-opioid receptor agonist) normalised the 
SBP response to low intensity (40 watts) cycle ergometer exercise in untreated 
hypertensive (mean age: 49±2 years old) individuals relative to normotensives 
(mean age: 47±5 years old), highlighting a critical role for the exercise pressor 
reflex in untreated hypertension (Barbosa et al., 2016). Unlike the other studies in 
hypertension, this study classified untreated hypertension and normotensives 
using 24-hour ABPM.  
 
A final possible mechanism mediating enhanced metaboreflex sensitivity in 
hypertension is impaired functional sympatholysis. This would lead to a supra-
physiological rise in metabolites that activate the metaboreflex and lead to an 
exaggerated sympathetic and BP response during exercise (Mizuno et al., 2014a, 
Choi et al., 2013, Saltin and Mortensen, 2012). 
 
1.6.1.3 Functional sympatholysis in hypertension: insights from animal models 
Research in hypertensive animals assessing functional sympatholysis has shown 
that rats made hypertensive by angiotensin II infusion (Zhao et al., 2006), SHR 
(Mizuno et al., 2014a) and dogs with renovascular hypertension (Sala-Mercado et 
al., 2013, Spranger et al., 2017) have impaired functional sympatholysis 
compared to normotensive animals. The nNOS splice variant sarcolemmal 
nNOSµ is particularly abundant in skeletal muscle, and in combination with eNOS 
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in the blood vessels, enables matching of O2 supply and demand (Thomas et al., 
1998, Thomas et al., 2003). In mice, NO produced from nNOSµ has been shown 
to be able to diffuse from local skeletal sarcolemma in to resistance vessel 
vascular smooth muscle where it attenuates post-junctional α1- and α2- 
adrenoceptors (Thomas et al., 1998, Thomas et al., 2003). During exercise, 
skeletal muscle NO levels are diminished in rats made hypertensive by infusion 
of angiotensin II compared to control animals (Zhao et al., 2006). Similar to the 
brainstem, decreased NO bioavailability is partially mediated by increased levels 
of angiotensin II, noradrenaline and ROS (Zhao et al., 2006). The levels of 
NAD(P)H and O2- were elevated during exercise in the active skeletal muscle in 
anaesthetized hypertensive rats compared to control anaesthetized animals 
(Minuz et al., 2002, Zhao et al., 2006). Importantly, increased levels of O2- in 
hypertensive rats were normalised when the rats were given tempol and 
functional sympatholysis was restored (Zhao et al., 2006). However, when these 
animals received the non-specific NOS inhibitor L-NAME, the normalisation of 
functional sympatholysis was reversed, highlighting a key role for NO in 
hypertensive rats (Zhao et al., 2006). Additionally, functional sympatholysis is 
normalised in endurance trained SHR relative to WKY (Mizuno et al., 2014a). 
When the endurance trained SHR were given L-NAME, the improvements in 
functional sympatholysis were diminished (Mizuno et al., 2014a). Suggesting a 
key role of NO in mediating improvements in functional sympatholysis seen with 
endurance training. Recent studies have attempted to move these studies from 
animals with experimentally induced hypertension in to humans with essential 
hypertension. 
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1.6.1.3.1 Humans 
In humans, functional sympatholysis is assessed using vascular ultrasound (to 
measure forearm/femoral blood flow) and forearm muscle oxygenation levels 
using near infrared spectroscopy (NIRS). Firstly, forearm blood flow and forearm 
vascular conductance increased similarly in middle aged patients with untreated 
essential hypertension and normotensives during dynamic handgrip exercise at 
30% MVC for 6 minutes (Vongpatanasin et al., 2011). At rest, lower body 
negative pressure at -20 mmHg induced similar decreases in forearm blood flow, 
forearm vascular conductance and forearm muscle oxygenation levels in 
untreated hypertensives and normotensives (Vongpatanasin et al., 2011). 
Interestingly, there was an attenuated decrease (compared to rest) in forearm 
blood flow, forearm vascular conductance and muscle oxygenation levels when 
an additional sympathetic stimulus (lower body negative pressure at -20 mmHg) 
was applied during minutes 3-5 of the dynamic handgrip exercise at 30% MVC in 
normotensive participants, indicating functional sympatholysis (Vongpatanasin et 
al., 2011). However, in the untreated hypertensive patients, forearm blood flow, 
forearm vascular conductance and muscle oxygenation levels were reduced to a 
similar level as rest when lower body negative pressure at -20 mmHg was 
applied during minutes 3-5 of the dynamic handgrip exercise, indicating impaired 
functional sympatholysis (Vongpatanasin et al., 2011). In contrast, infusion of 
adenosine (which stimulates the formation of NO and prostacyclin) into the 
femoral artery of untreated hypertensive and normotensive participants led to a 
similar increase in leg blood flow and vascular conductance (Hellsten et al., 
2012). However, exercise induced changes in interstitial adenosine were reduced 
in untreated hypertensives compared to normotensives (Hellsten et al., 2012). 
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Furthermore, during one-legged knee extensor exercise at 20 watts, femoral 
blood flow and femoral vascular conductance were lower in untreated 
hypertensives compared to normotensives (Hellsten et al., 2012). Similar findings 
were found when measuring femoral blood flow and femoral vascular 
conductance in the last 30 seconds of one-legged knee extensor exercise (30 
watts) in patients with untreated hypertension (Mortensen et al., 2014). However, 
tyramine infusion into the femoral artery during one-legged knee extensor 
exercise (30 watts) caused a similar reduction in femoral blood flow and vascular 
conductance in untreated hypertensives and normotensives (Mortensen et al., 
2014). Leg V̇O2 was reduced in untreated hypertensives compared to 
normotensives with tyramine infusion during one-legged knee extensor exercise 
at 30 watts which may suggest impaired perfusion during leg exercise 
(Mortensen et al., 2014). Interestingly, previous literature has highlighted 
differences in vascular function between the arms and the legs (Pawelczyk and 
Levine, 2002). For example, infusion of phenylephrine into the brachial and 
femoral artery led to greater reductions in vascular conductance in the calf 
compared to the forearm in healthy individuals (Pawelczyk and Levine, 2002). 
Furthermore, due to the inconsistencies in the literature more research is needed 
to assess differences in functional sympatholysis in the leg and arms in untreated 
hypertension when compared to normotension. 
 
Chapter 1 General Introduction 
 67 
1.6.2 Link between metaboreflex over-sensitivity and impaired functional 
sympatholysis 
In patients with untreated hypertension, impaired functional sympatholysis 
augments a mismatch between O2 supply and demand, which facilitates an 
increase in metabolites that sensitise the metaboreflex. An exaggerated increase 
in SNA, mediated by the metaboreflex would likely lead to further 
vasoconstriction, consequently stimulating the metaboreflex further in a viscous 
cycle (Figure 1.5, page 89). In untreated hypertension, it could be speculated that 
as exercise intensity increases, CO rises alongside an excessive rise in TPR. 
This leads to abnormally large increases in BP. A recent study suggested that 
increased metaboreflex sensitivity in prehypertension is associated with 
exaggerated increases in TPR (Choi et al., 2013). Additionally, functional 
sympatholysis was improved in patients with untreated hypertension with 
irbesartan (Vongpatanasin et al., 2011) and nebivolol (Price et al., 2013) and both 
were associated with a lower BP response to exercise, but not improvements in 
MSNA when compared to pre-treatment measurements. No studies have directly 
established whether increases in metaboreflex sensitivity are associated with 
impaired functional sympatholysis in hypertension. However, some indirect 
evidence comes from peripheral artery disease (PAD), which is characterised by 
impaired perfusion during exercise (Bakke et al., 2007). An animal model of PAD 
in rats is initiated by ligating the femoral artery that simulates the impaired 
functional sympatholysis during exercise but maintains normal blood flow to 
resting skeletal muscle (Stone and Kaufman, 2015). Femoral artery ligation in 
rats leads to increased expression of ASIC3 (Liu et al., 2010, Xing et al., 2012), 
P2X3 (Xing et al., 2013), bradykinin B2 (Lu et al., 2013), endoperoxide 4 
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(Yamauchi et al., 2013) receptor proteins on the peripheral endings of the group 
IV afferents. Importantly, these changes lead to exaggerated RSNA and BP 
during static contraction when compared to freely perfused rats (Liu et al., 2010, 
Xing et al., 2012, Xing et al., 2013, Lu et al., 2013, Yamauchi et al., 2013). 
Although these studies were not conducted in hypertension, blood flow, vascular 
conductance and V̇O2 in the active skeletal muscle have been shown to be 
impaired in untreated hypertension, which would suggest under-perfusion to the 
active skeletal muscle (Mortensen et al., 2014, Vongpatanasin et al., 2011). In 
addition, Mortensen et al. (2014) found that resting blood flow and vascular 
conductance were also impaired in the resting skeletal muscle. It could be 
speculated that impaired functional sympatholysis during exercise in 
hypertension leads to an increased expression of receptors that activate the 
metaboreflex. Metaboreflex hyperreflexia would lead to exaggerated increases in 
SNA, which would cause further vasoconstriction and perhaps further increase 
the expression of the receptors. 
 
1.6.3 Why focus on the metaboreflex? 
Although both the mechanoreflex and metaboreflex appear critical in mediating 
the abnormal CV response to exercise in hypertension, in this thesis I have 
focused on the metaboreflex. Firstly, assessing the metaboreflex in humans 
using PEI is much easier to assess independent of central command and 
mechanoreflex activity when compared to measuring the mechanoreflex 
sensitivity via passive cycling (Velasco et al., 2015), immediate CV responses to 
isometric handgrip exercise (Greaney et al., 2015a) and passive stretch (Choi et 
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al., 2013). After several attempts to perform passive cycling to isolate the 
mechanoreflex I stopped as without electromyography (EMG) to confirm the 
absence of active muscle movement I could not be confident of mechanoreflex 
isolation. Additionally, more is known about the mechanisms that mediate the 
metaboreflex in human hypertension and pharmacological options exist that 
could be used to dampen down its sensitivity. Little is known about the specific 
mechano-gated receptors that mediate the mechanoreflex component of the 
exercise pressor reflex in human hypertension. Therefore, at this moment, 
potential treatment for mechanoreflex oversensitivity in human hypertension is 
very limited. 
 
1.6.4 How do antihypertensive medications influence the BP response to 
exercise? 
There is a lack of studies investigating the effects of anti-hypertensive 
medications on the BP response to exercise. This is important to assess because 
of the relationship between exaggerated BP responses to exercise and CV 
events. The long term haemodynamic effects of anti-hypertensive medications on 
mild intensity cycling exercise at 100 watts in middle aged patients with 
hypertension were assessed by Omvik and Lund-Johansen (1993), they found 
similar reductions in BP at rest and during exercise regardless of drug class. A 
different study found that only β-adrenoceptor antagonists, long-acting calcium 
channel blockers and ACEi were effective at lowering exercise BP at submaximal 
cycling exercise (Arita et al., 2001) compared to α1-adrenoceptor antagonists, 
thiazide like diuretics or short-acting calcium channel blockers. Alternatively, 
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other studies have found that only chronic use of β-adrenoceptor antagonists are 
effective at lowering BP during moderate and maximal treadmill exercise 
compared to an ACEi, calcium channel blocker or diuretic (Kokkinos et al., 2006). 
All of these studies lacked healthy controls, so we do not know if antihypertensive 
medications lower BP to normal levels during exercise. The inconsistency from 
these studies could be due to differences in drugs, such as half-life and exercise 
pharmacokinetics, different exercise intensities (submaximal vs. maximal) and 
exercise modes used (treadmill vs. cycling exercise). One study assessed the 
prognostic value of exaggerated BP response to exercise in 300 patients with 
hypertension withdrawn from their anti-hypertensive medication or who were 
untreated, confirmed by 24-hour ABPM, free from CV disease (except 
hypertension) (Cho et al., 2012). 87.1% of these individuals were taking anti-
hypertensive medication prior to withdrawal and these individuals had their BP 
response to a submaximal Naughton/Balke treadmill test measured. The 
individuals with the largest BP response to exercise had an increased risk of 
mortality, ischemic heart disease and stroke, independent of resting BP (Cho et 
al., 2012). An exaggerated BP response to exercise following 12 months of anti-
hypertensive was associated with depressed anti-hypertensive treatment-induced 
regression of left ventricular hypertrophy (Mizuno et al., 2016b). Unfortunately, 
this study lacked a control group of normotensives. Additionally, the study 
assessing left ventricular hypertrophy did not follow up individuals long term to 
see if these individuals were at increased risk of CV disease and/or mortality 
(Mizuno et al., 2016b). 
 
These studies have left two important questions unanswered:  
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1) Does adequately controlling BP based on 24-hour ABPM normalise the BP 
response to exercise? 
2) If adequate control of resting BP doesn’t normalise the BP response to 
exercise, is this group at increased risk of adverse events compared to 
normotensive controls? The main aim of this thesis is to answer question 
one. 
 
We currently do not know if anti-hypertensive medication that normalises 
baseline BP restores metaboreflex sensitivity to normotensive levels (Figure 1.5, 
page 89). The current anti-hypertensive treatments do not act on the known 
receptors that activate the skeletal muscle metaboreflex (Figure 1.5, page 89). 
Two important pathways have been targeted in human hypertension for the 
treatment of insufficient functional sympatholysis, ATP (Mortensen et al., 2014) 
and NO (Price et al., 2013, Vongpatanasin et al., 2011). Interestingly, anti-
hypertensives that have similar effects on lowering BP at rest have differential 
effects on functional sympatholysis (Price et al., 2013, Vongpatanasin et al., 
2011). Four weeks of ibersartan, an AT1 receptor antagonist, or a thiazide-like 
diuretic (chlortalidone), caused similar reductions in resting BP but only the AT1 
receptor antagonist caused improvements in functional sympatholysis 
(Vongpatanasin et al., 2011). This supports a key role of angiotensin II in 
mediating excessive vasoconstriction in the active skeletal muscle (Zhao et al., 
2006, Rajagopalan et al., 1996). In a follow-up to this study it was shown that 12 
weeks of nebivolol, a selective β-adrenoceptor 1 antagonist with both antioxidant 
and NO potentiating properties, improved functional sympatholysis during 
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handgrip in patients with untreated hypertension compared to a conventional β1 
adrenergic antagonist (metoprolol) (Price et al., 2013). 
 
Interestingly, in both of these studies, the anti-hypertensive drugs had no effect 
on the level of SNA during handgrip or handgrip with lower body negative 
pressure (Price et al., 2013, Vongpatanasin et al., 2011). The antioxidant 
properties of nebivolol may have caused a reduction in ROS decreasing O2- 
production, thereby increasing the bioavailability of NO (Zhao et al., 2006). The 
vasodilatory effect of nebivolol in the renal vasculature is mediated by an 
increased P2Y receptor activation via augmented ATP efflux from the endothelial 
cells, which leads to a calcium-dependent activation of eNOS (Kalinowski et al., 
2003). Although this has not been assessed in skeletal muscle, it does suggest a 
possible interaction between ATP and NO in the human skeletal muscle during 
exercise. However, Mortensen et al. (2014) found no difference in the 
vasodilatory response to femoral arterial ATP infusion in patients with untreated 
hypertension compared to healthy controls. 
  
Further work is needed to establish the mechanism underlying impaired 
functional sympatholysis in human hypertension. Therefore, increased sensitivity 
of the metaboreflex in treated-controlled hypertension could lead to exaggerated 
rises in MSNA that will not be correctly offset by functional sympatholysis during 
exercise which would be expected to lead to an elevated BP response and place 
these individuals at increased CV risk. 
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Increasing NO bioavailability in patients with hypertension may therefore be a 
therapeutic avenue to explore to decrease metaboreflex hyperreflexia during 
exercise. However, the replacement of substrates and co-factors (such as L-
arginine) in hypertension have not been successful in improving vascular function 
(Boger, 2007, Schulman et al., 2006, Wilson et al., 2007), perhaps because they 
rely on a healthy endothelium. Furthermore, NO donors such as nitroglycerin lead 
to endothelial dysfunction (Fadel et al., 2012) and are prone to tachyphylaxis 
(Fadel et al., 2012). Nebivolol may improve functional sympatholysis during 
rhythmic handgrip exercise in untreated hypertension (Price et al., 2013), but β-
adrenoceptor antagonists are known to impair the CV response to exercise at 
submaximal and maximal intensities (Van Baak, 1988). Therefore, therapeutics 
could be investigated that aim to improve metaboreflex hyperreflexia and 
functional sympatholysis (but do not limit the CV response to exercise). 
 
1.7 Dietary Nitrates 
It was originally thought that NO was generated solely by the oxidation of L-
arginine, which results in the oxidation of NO to nitrite (NO2-) and nitrate (NO3-) 
(Moncada and Higgs, 1993). NO3- and NO2- were thought to be inert end 
products of the oxidation of NO (Mensinga et al., 2003). However, since 2001 it 
has been discovered that dietary sources of inorganic NO3- can be reduced to 
NO2- and NO in various tissues and represent an alternative NO pathway (NO3-- 
NO2- - NO pathway) (Webb et al., 2008b, Demoncheaux et al., 2002). The NO3-- 
NO2- - NO pathway appears to complement the classical L-arginine pathway 
(Kapil et al., 2010). The greatest source of dietary inorganic NO3- comes from 
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leafy green vegetables such as beetroot, rocket and spinach which contain > 250 
mg (> 4mmol) of dietary NO3- per 100 g. To put this into context, the typical intake 
of dietary NO3- in the non-vegetarian United Kingdom population is around 90 
mg/day (Ysart et al., 1999). 
 
In humans, upon swallowing dietary NO3-, ~25% enters the enterosalivary 
circulation where NO3- is concentrated within the salivary glands (Duncan et al., 
1995). It is at this site where NO3- is reduced to NO2- by a 2-electron reduction by 
symbiotic bacterial NO3- reductases on the lingual portion of the tongue (Duncan 
et al., 1995). Using gene sequencing techniques, the specific species that reduce 
NO3-  have been identified as the Veillonella, Prevotella, Neisseria, Haemophilus 
and Actinomyces (Hyde et al., 2014). The importance the oral microflora was 
demonstrated by studies using antibacterial mouthwash, which effectively 
diminished the normal rise in plasma NO2- following NO3- ingestion (Woessner et 
al., 2016, Kapil et al., 2013). A portion of the swallowed NO2- is reduced to NO 
due to the acidity within the stomach, however, NO2- also enters the circulation 
and leads to a substantial rise in plasma NO2- levels (Webb et al., 2008b). 
Following ingestion, plasma NO3- levels rise sharply (within ~30 minutes), peak at 
around 2-3 hours and remain elevated when compared to basal levels for 24-
hours post-ingestion (Kapil et al., 2010). Plasma NO2- levels rise slowly and are 
noticeable within 1.5 - 2 hours following ingestion and plateau at around 2.5 
hours, similar to NO3-, NO2- levels remain elevated 24-hours following ingestion 
(Kapil et al., 2010). Importantly, the one electron reduction of NO2- to NO occurs 
particularly when the partial pressure of O2 is reduced or in conditions of low pH 
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(Modin et al., 2001), conditions that are likely to occur in the skeletal muscle 
during exercise (Richardson et al., 1995). 
 
The reduction of NO2- to NO is endothelial independent and is carried out in the 
plasma and in various bodily tissues by a variety of NO2- reductases including 
deoxygenated haemoglobin (see Figure 1.4, page 87) (Cosby et al., 2003, 
Gladwin and Kim-Shapiro, 2008), deoxygenated myoglobin (Shiva et al., 2007), 
neuroglobin (Tiso et al., 2011, Petersen et al., 2008), xanthine oxidoreductase 
(Ghosh et al., 2013, Webb et al., 2004, Webb et al., 2008a, Li et al., 2008, Badejo 
et al., 2010), aldehyde oxidase (Li et al., 2008), the electron transport chain 
(Kozlov et al., 1999), cytochrome p450 reductase (Li et al., 2006), mitochondrial 
aldehyde dehydrogenase (Badejo et al., 2010) and carbonic anhydrase (Aamand 
et al., 2009). Under physiological conditions, where partial pressure of O2 and pH 
are not extremely low, the main mechanism mediating NO2- to NO is 
deoxygenated haemoglobin (Cosby et al., 2003) (see Figure 1.4, page 87). 
Importantly there is a temporal pattern of increased plasma nitrite and cGMP 
levels, indicating that plasma nitrites lead to increased NO activity (Kapil et al., 
2010). Additionally, unlike other NO donors (e.g., nitroglycerin), dietary NO3- do 
not suffer from tachyphylaxis (Kapil et al., 2015, Vanhatalo et al., 2010).  
 
Short term (2-6 days) dietary NO3- can reduce the O2 cost (V̇O2) of exercise at a 
fixed power output (Larsen et al., 2007, Bailey et al., 2009), improve exercise 
efficiency (Larsen et al., 2007, Bailey et al., 2009), increase time to exhaustion 
(Bailey et al., 2010, Larsen et al., 2010, Thompson et al., 2014) and improve 
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‘real-world’ performance (Lansley et al., 2011a, Wilkerson et al., 2012) in healthy 
athletic populations. These effects are maintained following 15 days of dietary 
NO3- supplementation (Vanhatalo et al., 2010) and importantly when compared to 
a placebo (NO3--depleted) (Lansley et al., 2011b, Lansley et al., 2011a). 
Physiologically, these changes in exercise performance are in part mediated by 
improvements in mitochondrial respiration (decreases in ATP turnover) (Bailey et 
al., 2010), oxidative phosphorylation (Larsen et al., 2011) and the contractile 
function of fast twitch skeletal muscle fibres (Hernandez et al., 2012). 
 
Interest in dietary NO3- for CV protection has increased in recent years, partly 
because leafy green vegetables confer the largest benefit to CV health compared 
to other vegetables (Joshipura et al., 2001). The Japanese diet, which is 
traditionally very high in dietary NO3- is associated with lower resting SBP and 
DBP when compared to the Western diet in the Japanese population (Sobko et 
al., 2010, Sadakane et al., 2008). Acute (Kapil et al., 2010, Bondonno et al., 
2012, Liu et al., 2013, Bahra et al., 2012, Lansley et al., 2011a, Webb et al., 
2008b) and chronic (Larsen et al., 2007, Bailey et al., 2009, Ashworth et al., 
2015, Jovanovski et al., 2015, Lansley et al., 2011a, Bailey et al., 2010, 
Vanhatalo et al., 2010) use of dietary NO3- has been shown to lower resting clinic 
SBP and DBP in healthy individuals in a dose-dependent manner, with at least a 
dose of 2-3 mmol/day of dietary NO3- (~200 g of spinach) needed to confer this 
CV benefit (Hobbs et al., 2012, Bondonno et al., 2012, Sobko et al., 2010). Doses 
of up to 24 mmol have been shown to lower BP in healthy individuals, however, 
this dosage may be very hard to achieve through a normal diet (Kapil et al., 
2010). These finds have also been replicated when using 24-hour ABPM in 
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healthy volunteers following acute dietary NO3- intervention but not chronic 
interventions (Hobbs et al., 2012, Coles and Clifton, 2012).  
 
Importantly, in SHR, there is a dose-dependent decrease in resting BP from NO2-
, that is not apparent in Wystar-Kyoto rats (Beier et al., 1995, Classen et al., 
1990, Haas et al., 1999). Similar findings have been found in salt-induced 
hypertension (Carlstrom et al., 2011). Mechanistically, expression of the NO2- 
reductase xanthine oxidoreductase was increased in the liver (a major site for 
xanthine oxidoreductase synthesis) and erythrocytes in SHR compared to the 
Wystar-Kyoto rats (Ghosh et al., 2013). Furthermore, this suggests that dietary 
NO3- may be more effective in hypertension than in those with normal BP. In the 
same study the BP lowering effect of dietary NO3- was blocked by allopurinol (a 
xanthine oxidoreductase antagonist) (Ghosh et al., 2013). Secondly, dietary NO3- 
decreased vascular NAD(P)H oxidative stress in two-kidney one clip hypertensive 
rats (Montenegro et al., 2011). 
 
Dietary NO3- have also been shown to lower resting BP in humans with 
hypertension. Ghosh et al. (2013) showed that 3.3 mmol of dietary NO3- (beetroot 
juice) acutely decreased clinic SBP in treatment naïve males and females with 
hypertension. The same group then did a larger 4-week randomised, double-
blinded, placebo-controlled, crossover (2-week run-in) study and found that 
treated middle-aged males and females with elevated resting BP had a reduction 
in clinic, 24-hour ABPM and home BP monitoring following 6.4 mmol/day dietary 
NO3- compared to the placebo (Figure 1.6, page 90). (Kapil et al., 2015). This 
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study also found that pulse wave velocity, augmentation index and flow mediated 
dilatation were improved in the dietary NO3- group (Kapil et al., 2015). Most 
importantly, unlike the endothelium, which is dysfunctional in hypertension, this 
study suggested that the entero-salivary circulation is intact and that a diversity of 
oral bacteria exist in patients with hypertension which is able to perform the 
critical reduction of NO3- to NO2-. In contrast, similar studies have found short 
term dietary NO3- for 1-week have no effect on ambulatory BP or home BP 
monitoring in treated (Bondonno et al., 2015) and pre (Bondonno et al., 2014) 
hypertensives compared to a placebo. Reasons for this discrepancy remain 
unclear, however, dietary NO3- may be more effective in individuals with higher 
BP at rest. For example, the BP lowering effect of anti-hypertensive medications 
is enhanced with increasing resting BP (Law et al., 2003). Additionally, a 
substantial drop in resting BP may not be expected in individuals who already 
have treated-controlled hypertension at rest (Bondonno et al., 2015). The final 
possibility is the length of intervention with dietary NO3- (Kapil et al., 2015). Kapil 
et al. (2015) used 4-weeks of treatment compared to the 1-week of dietary NO3- 
used by Bondonno et al. (2015). It may be possible that longer treatment is 
needed for dietary NO3- to be efficacious at lowering resting BP.  
 
1.7.1 Dietary nitrates, functional sympatholysis and the metaboreflex 
Very little is known about dietary NO3-, functional sympatholysis and the 
metaboreflex. Sprague-Dawley rats fed beetroot juice for 5 consecutive days had 
improved functional sympatholysis in blood vessels suppling fast-twitch muscle 
fibres (type IIb) and reduced exercising BP during treadmill exercise when 
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compared to NO3--free water fed rats (Ferguson et al., 2013). Similar results have 
been found in healthy humans; it was shown that a NO2- infusion reduced 
vasoconstrictor tone at rest and improved functional sympatholysis during 
rhythmic handgrip exercise and reduced MAP as compared to a saline (placebo) 
infusion (Cosby et al., 2003).  
 
Acute ingestion of dietary NO3- (in the form of beetroot juice) has also recently 
been shown to improve forearm blood flow and forearm vascular conductance 
during rhythmic handgrip exercise at 15 and 25% of MVC when compared to a 
placebo in healthy young individuals (Richards et al., 2018). In pre-hypertensive 
males, a dietary NO3- intervention improves endothelial function (as measured by 
flow-mediated dilatation), improves functional sympatholysis and decreases SBP 
at rest and during cycle ergometer exercise (Choi et al., 2016). In addition to its 
effects on peripheral vasodilation, dietary NO3- and NO2- are also able to cross 
the brain-blood barrier and lead to improvements in brain perfusion (Presley et 
al., 2011), cerebrovascular resistance (Bond et al., 2013) and decrease central 
sympathetic outflow (Notay et al., 2017) at rest and during isometric plus dynamic 
exercise. Acute dietary NO3- supplementation was shown to decrease MSNA at 
rest and during isometric handgrip exercise in young healthy individuals 
compared to a placebo (Notay et al., 2017). NO is also known to act as an 
inhibitory neuronal messenger within the carotid body (Wang et al., 1994). The 
effect of dietary NO3- on the carotid body is unknown but increasing NO 
bioavailability may decrease the activity of the carotid body. Finally, a recent 
study found that metaboreflex sensitivity, assessed by the change in SBP was 
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reduced in older adults by four weeks of dietary NO3- supplementation compared 
to a placebo (Schneider et al., 2018). 
Currently, whether dietary NO3- intervention will decrease the sensitivity of the 
metaboreflex and reduce exercise BP in hypertension is unknown. It could 
therefore be speculated that by improving functional sympatholysis, and therefore 
lowering the level of metabolites that sensitise the metaboreflex, the exaggerated 
SNA response seen during exercise will be attenuated in hypertension. This 
could explain why the BP response to exercise was attenuated during exercise 
following a dietary NO3- intervention in pre-hypertensive males (Choi et al., 2016). 
Additionally, as dietary NO3- and NO2- are able to cross the blood-brain-barrier 
they could also improve the central processing of the metaboreflex. It is currently 
unclear what effect dietary NO3- will have on the BP response to exercise in 
individuals with hypertension who are currently treated and controlled by anti-
hypertensive medication.  
 
The current literature suggests that the first-line treatment for hypertension has 
mixed effects on functional sympatholysis, it could be suggested that dietary NO3- 
could improve the underlying physiological abnormalities that contribute to an 
exaggerated BP response to exercise in individuals with hypertension as well as 
improving exercise performance. Most importantly, dietary NO3- could be a low-
cost method for making exercise safer in the hypertensive population. 
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1.8 Aims and hypotheses 
The overall aim of this thesis is to assess whether adequate control of BP with 
anti-hypertensive medication normalises the exaggerated pressor response to 
exercise that is associated with untreated hypertension. It is hypothesised that 
anti-hypertensive medication will have no effect on the CV response to exercise 
in hypertension and that treatments that reduce metaboreflex hyperreflexia in 
hypertension will prove more beneficial.  
 
The primary aim of Chapter three of this thesis is to assess the difference in 
SBP response to dynamic exercise (V̇O2 peak test) and metaboreflex isolation 
(using post-exercise ischemia) between untreated hypertension, treated-
uncontrolled hypertension and treated-controlled hypertension compared to 
normotensive controls. Based on previous research, the hypothesis was that 
there would be a difference in the BP response to incremental cycle ergometer 
exercise and metaboreflex isolation between normotensive controls versus 
treated-controlled, treated-uncontrolled and untreated patients with hypertension.   
 
In Chapter four, the primary aim is to assess whether elevated arterial stiffness 
(carotid-femoral pulse wave velocity) and increased central aortic SBP (arterial 
tonometry) at rest are associated with an elevated SBP response to V̇O2 peak 
testing in untreated hypertension, treated-uncontrolled hypertension and treated-
controlled hypertension compared to normotensive controls. It is hypothesised 
that elevated arterial stiffness and central aortic SBP at rest will be associated 
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with an exaggerated SBP response to V̇O2 peak testing in normotensives, 
treatment controlled, uncontrolled and untreated hypertensive individuals.  
 
The main aim of Chapter five is to assess whether dietary NO3- supplementation 
for 4 weeks can reduce metaboreflex hyperreflexia and therefore the SBP 
response to V̇O2 peak testing in patients with treated-controlled hypertension 
compared to a placebo. It is hypothesised that there will be a change in the 
SBP response to V̇O2 peak testing and metaboreflex isolation following dietary 
NO3- supplementation for 4 weeks when compared to a placebo. 
  




At rest, with a normal CO of 5 L/min the distribution of blood is relative to oxygen 
demand. As exercise intensity increases and CO and the demand for oxygen is 
increased in the skeletal muscle, skeletal muscle blood flow increases to match 
the oxygen demand [from Joyner and Casey (2015)]. 
  
Figure 1-1 Total blood flow at rest and during exercise in a nonathlete and athlete. 
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At rest, carotid chemoreflex, arterial baroreceptors and cardiopulmonary 
baroreceptors send feedback signals to the cardiovascular control centres in the 
brainstem that mediate efferent SNS and PSNS activity. During exercise, feed-
forward signals (central command), feedback from the carotid chemoreflex, 
arterial baroreceptors, metabolically and mechanically sensitive afferents in the 
skeletal muscle (exercise pressor reflex) and cardiopulmonary baroreceptors 
send neural signals to the brain altering the outflow of sympathetic and 
parasympathetic nerve activity to the periphery [from Fisher, Young and Fadel 
(2016)]. PSNA, parasympathetic nervous system; SNA, sympathetic nerve 
activity; norepi, noradrenaline; Ach, achetlycholine. 
  
Figure 1-2 The regulation of the autonomic nervous system during exercise 
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Illustration demonstrating the difference between a normotensive response to 
exercise (black solid line) and a blood pressure response to exercise typical of a 
patient with hypertension (exercise hypertension) (dotted blue line). In 
normotensive individuals, systolic blood pressure increases gradually during 
increasing exercise intensities whilst diastolic blood pressure remains similar or 
drops below resting values. In contrast, in a typical patient with hypertension, 
systolic and diastolic blood pressure rise dramatically during increasing exercise 





Figure 1-3 The normotensive and hypertensive response to exercise. 
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Nitric oxide is important in the regulation of blood flow 
during exercise and is regulated by increases in shear stress, agonist binding to the endothelium, nitrite reduction to nitric oxide 
and release from the skeletal muscle sarcolemma. In patients with hypertension, production of nitric oxide by the endothelium is 
impaired. Increasing nitrate bioavailability using beetroot juice increases nitrate-nitrite-nitric oxide reduction and may improve 
blood flow during exercise in patients with hypertension. NO3-; nitrate, NO2-; nitrite; oxyHb; oxygenated haemoglobin, metHb; 
methemoglobin, deoxyHb; deoxygenated haemoglobin, N2O3; dinitrogen trioxide, ATP; adenosine triphosphate, IP3; inositol 
triphosphate, ER; endoplasmic reticulum, DAG; Diacylglycerol, ROC; receptor operated channels, SOC; store operated 
channels, Ca2+; calcium, PKB; protein kinase B, eNOS; endothelial nitric oxide synthase, NO; nitric oxide, nNOSµ; sarcolemmal 
neuronal nitric oxide synthase, GTP; guanosine triphosphate, cGMP; cyclic guanosine monophosphate, PKG; protein kinase G, 
K+; potassium, KATP; ATP-sensitive potassium channels, Na+-K+ pump; sodium-potassium pump, Kir; inward rectifying potassium 
channels, Ca2+ ATPase pump;  calcium ATPase pump, [Ca2+]I; intracellular calcium, MLCK; myosin light chain.
Figure 1-4 A schematic of the regulation of nitric oxide during exercise. 
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Increased oxidative stress (red boxes) in the skeletal muscle leads to impaired functional sympatholysis in hypertension and this 
increases the level of metabolites (blue boxes) in the skeletal muscle which leads to increased metaboreflex hyperreflexia. The 
metaboreflex afferents are modulated at the dorsal root and further modulated supraspinally in the brainstem. Altered processing of 
the metaboreflex in the nucleus of solitary tract and rostral ventrolateral medulla leads to increased sympathetic nerve activity 
during exercise. Sympathetic nerve activity is normally offset in the skeletal muscle in healthy individuals, in patients with 
hypertension impaired functional sympatholysis causes a reduction in skeletal muscle blood flow. The exact location that mediates 
metaboreflex hyperreflexia in patients with hypertension is unclear but is likely multifactorial. The effect of first line treatment for 
hypertension on the metaboreflex and functional sympatholysis is unclear. DRG; dorsal root ganglion, NTN; nucleus of solitary 
tract, RVLM; rostral ventrolateral medulla, IML; intermediolateral cell column, NAD(P)H; nicotinamide-adenine dinucleotide 
phosphate oxidase, O2-; superoxide anions, NO; nitric oxide, MSNA; muscle sympathetic nerve activity, and ATP; adenosine 
triphosphate. 
 
Figure 1-5 A schematic illustrating the potential mechanism for metaboreflex hyperreflexia in patients with hypertension. 




Dietary nitrate intervention (red bars) for 4-weeks lowers 24-hour ambulatory 
SBP (SBP) in middle-aged male and female individuals with hypertension 





Figure 1-6 Dietary nitrate and ambulatory blood pressure in hypertension. 
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Chapter 2 General Methods 
2.1 Participants 
All of the studies in this thesis conformed to the Declaration of Helsinki 
(https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-
for-medical-research-involving-human-subjects/). The procedures used were 
granted ethical approval by the Research Ethics Committee (REC) and the Health 
Research Authority (HRA). Ethical approval for the study in Chapter 3 and 4 was 
granted by the Southwest-Exeter NHS REC (16/SW/0004). The study in Chapter 
5 was given ethical approval through the Northern-Ireland proportionate review 
NHS REC (17/NI/0097). As defined by the National Institute for Health and Care 
Excellence (NICE guidelines, 2011) normotension was defined as clinic blood 
pressure (BP) <140 mmHg and day-time ambulatory blood pressure (ABPM) 
<135/85 mmHg with the absence of anti-hypertensive medication. Treated-
uncontrolled hypertension was defined as daytime ABPM 135/85 mmHg despite 
the use of at least one anti-hypertensive medication. Treated-controlled 
hypertension was defined as previous diagnosis of hypertension, but BP currently 
controlled with at least one anti-hypertensive therapy and daytime ABPM <135 
mmHg. Finally, untreated hypertension was defined as daytime ambulatory BP 
135 mmHg with the absence of anti-hypertensive medication.  
General exclusion criteria for all studies included: 
i) diagnosed major respiratory-cardiovascular (CV) disorders (i.e., severe 
cardiac electrical conduction abnormalities, angina, chronic heart failure, 
and respiratory diseases, such as chronic obstructive pulmonary 
disease).  
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ii) metabolic and endocrine disorders such as thyroid 
underactivity/overactivity, diabetes mellitus (type I and II), 
hyperlipidaemia and osteoporosis.  
iii) major illness such as cancer, inflammatory disease including vasculitis, 
rheumatoid arthritis etc.  
iv) pregnancy in women of child bearing age. 
v) intravenous drug use and/or alcohol intake >28 units per week. 
vi) taking nitrates/steroids/immunosuppressants. 
vii) febrile illness within one week of participation. 
viii) currently enrolled in a clinical trial of a medicinal product 
ix)  body mass index (BMI) >= 35 kg/m2.  
 
More specific exclusion criteria for each study can be seen in the respective 
Chapters. All participants attended the laboratory situated in the Clinical Research 
and Imaging Centre (CRiC)-Bristol at a similar time of day and lab conditions were 
controlled to a set temperature (22C). Participants were asked to refrain from 
alcohol/caffeine consumption and strenuous exercise for 12 hours before the study 
visits. Participants were advised to have a small meal 2 or 3 hours prior to arrival 
at the laboratory. Participants were also asked to avoid the use of painkillers such 
as aspirin, paracetamol or anti-inflammatory drugs (e.g., ibuprofen) for 24-hours 
prior to the study visits. Participants were asked to refrain from these medications 
due to their known inhibitory effects on exercise BP (Drew et al., 2013, Cui et al., 
2007, Cui et al., 2008b). 





Prior to all studies, participants were given a screening phone call to ensure that 
they met the specific inclusion criteria for the study and did not meet any of the 
exclusion criteria. Specific inclusion criteria for each study can be found in their 
respective Chapters. All participants gave written consent during the initial 
screening visit at the CRiC-Bristol. Participants also completed a screening 
questionnaire during the initial visit to rule out any of the exclusion criteria. 
Participants were then asked to rest for 10 minutes before resting clinical BP was 
taken using an automatic oscillometric monitor according to the European Society 
of Hypertension guidelines (Omron, 705IT, Omron Healthcare Europe) (O'Brien et 
al., 2001). The first reading was ignored and then a BP was taken on the left and 
right arm, with two further readings being taken on the arm where BP was highest 
(O'Brien et al., 2001). The average of these final two readings was taken as clinic 
BP. The participant also carried out a urine dipstick test (Siemens Multistix) to 
assess evidence of kidney damage and diabetes. Specifically, leukocytes, nitrite, 
urobilinogen, protein, pH, haemoglobin, specific gravity, ketone and glucose 
(Siemens Multistix) were measured. For females of a child bearing age, a human 
chorionic gonadotropin (hCG) hormone sensitive test was used for pregnancy 
screening. A 12-lead electrocardiogram (ECG) was completed by a research nurse 
and checked over by a Cardiologist to assess for any abnormalities. Any adverse 
incidents or events that occurred during the studies in this thesis were recorded in 
the study site files. Any serious adverse events were recorded and reported to the 
University of Bristol research and development governance team department and 
the UH Bristol research and development team. 
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2.3 Experimental Measures 
2.3.1 Cardiopulmonary exercise testing  
The peak volume of oxygen (O2) that a participant could consume and use (V̇O2 
peak) was assessed during all studies by an incremental exercise test on an 
upright cycle ergometer (Ergoselect 100, Love Medical, Manchester, UK). Prior to 
the V̇O2 peak test, a 12-lead ECG was fitted by a research nurse for continuous 
monitoring of heart rate (HR) and heart rhythm monitoring. V̇O2 peak was 
calculated by plotting workload (watts (W)) vs. O2 uptake (V̇O2) and was 
expressed as mL/min/kg. The test began with a 5-minute baseline period while 
the participant was sat upright on the cycle ergometer and resting 
haemodynamics and respiratory values were assessed. The participants began 
cycling at 0 watts for 3 minutes. V̇O2 peak was assessed by using a ramp 
protocol of 25 watts per minute (25 watts/min) until volitional fatigue. Participants 
were asked to maintain a constant cadence of 60-80 revolutions per minute 
(RPM). V̇O2 max is defined as “the O2 uptake during an exercise intensity at 
which actual O2 intake reaches a maximum beyond which no increase in effort 
can raise it” (Hill et al., 1923). A plateau in V̇O2 is often not observed during 
maximal upright cycle ergometer exercise, as the addition of arm exercise at 
maximum cycle ergometer exercise increases V̇O2 (Taylor et al., 1955). V̇O2 peak 
is defined as the mean V̇O2 attained during the final 30 seconds of the exercise 
test and is used as a measure of peak exercise capacity from cycle ergometer 
testing (Wylie et al., 2016).  
 
Prior to each V̇O2 peak test, the flow sensor (spirometry) used for gas and 
respiratory analysis (Ergostik CPET system, Love Medical, Manchester, UK) was 
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calibrated with high-precision calibration gases (5.13% carbon dioxide (CO2), 
15.15% O2 and balance nitrogen) and a 3-litre calibration syringe. A facemask 
was fitted to each participant and checked for leaks prior to any testing. The 
facemask was fitted to a non-rebreathing valve. The V̇O2 was measured breath 
by breath which was determined by a flow sensor. The % O2 inspired and expired 
was assessed by an electrochemical cell. More specifically, O2 enters the flow 
sensor and comes into a contact with a cathode. O2 then gets reduced to 
hydroxyl ions, which react with a lead anode and oxidise to lead oxide. These 
reactions cause the generation of a current which is proportional to the % of O2 
(Love Medical, Manchester, UK). The % CO2 was determined by the flow sensor 
via infrared spectroscopy (Love Medical, Manchester, UK). Flow was measured 
by the flow sensor using the differential pressure principle (Love Medical, 
Manchester, UK). Tidal volume, breathing frequency, minute ventilation (VE), 
tidal volume, breaths per minute) were also measured using the Ergoflow flow 
sensor for spirometry (Ergostik CPET system, Love Medical, Manchester, UK). 
The VO2 and VECO2 were then calculated using the following equations: 
 
VO2 = (Inspired volume * Fraction of inspired O2) - (Expired volume * 
Fraction of expired O2) [equation 2.1] 
 
VECO2 = (Expired volume * Fraction of expired CO2) - (Inspired volume * 
Fraction of inspired CO2) [equation 2.2] 
 
To ensure that participants had reached their V̇O2 peak the respiratory exchange 
ratio (RER) (VECO2/V̇O2) was calculated. RER is used as an indicator of what the 
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body is using as its main energy source (fat or carbohydrate), at rest it is 0.7-0.8 
where V̇O2 is higher than VECO2 expired, indicating predominant fatty acid 
oxidation. However, during intense exercise VECO2 increases due to increased 
CO2 production from the active muscle and more O2 is extracted by the working 
muscle, meaning that RER will increase to above 1. The criteria used for V̇O2 
peak were: 1) An RER of >1.15 (Issekutz et al., 1962), 2) HR >85% of maximal 
HR, defined as 220-age, was used as another criteria to indicate maximal 
exercise (Brown et al., 2002) and 3) a rating of perceived exertion >17 on the 6-
20 Borg scale (Church et al., 2008). The anaerobic threshold is defined as an 
intensity of exercise at which uptake of O2 uptake cannot account for the majority 
of energy production (Wasserman, 1986). Exercise above the anaerobic 
threshold is associated with exponential increases in blood lactate (Wasserman, 
1986). The anaerobic threshold was calculated by plotting a moving average of 
VECO2 (L/min) against V̇O2 (L/min) to smooth out any random breath by breath 
fluctuations (Beaver et al., 1986). The intersection point for the VECO2 and V̇O2 
was regarded as the anaerobic threshold and is given as a percentage of V̇O2 
peak (V-slope method) (Svedahl and MacIntosh, 2003, Sue et al., 1988, 
Schneider et al., 1993). Importantly, the V-slope method has been shown to 
correspond with increases in lactate above the lactate threshold and also the 
estimated bicarbonate threshold (Beaver et al., 1986).  
 
In addition, the ventilatory efficiency slopes (VE/VECO2 slope), defined as the 
relationship between minute ventilation and carbon dioxide production were 
measured (Rausch et al., 2013). A VECO2 slope >34 has been shown to highlight 
high risk pulmonary hypertension and heart failure patients (Rausch et al., 2013, 
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Bard et al., 2006). However, little is known about the VE/VECO2 slope in patients 
with essential hypertension, treated or untreated. The VE/VECO2 slope is 
assessed by plotting VE against VECO2 from the onset of exercise to peak 
exercise or baseline to the anaerobic threshold (Bard et al., 2006). One study 
found that there was a significant correlation between the VE/VECO2 slope 
measured from baseline to peak and to anaerobic threshold (r=0.83) (Metra et al., 
1992). However, for the studies in this thesis the peak VE/VECO2 slope was used 
as this has increased prognostic value when compared to the VE/VECO2 slope up 
to the anaerobic threshold (Bard et al., 2006). In addition, the peak VE/VECO2 
slope remained predictive of mortality in this large group of heart failure patients 
when V̇O2 peak was added to a cox regression model (Bard et al., 2006). 
 
2.3.2 Assessment of the BP response to incremental exercise 
Prior to V̇O2 peak testing the participants arm size was measured to ensure the 
correct cuff size was fitted to the participant. During the V̇O2 peak testing the 
participant was asked to drop their arm by their side as this helped increase the 
number of BP readings attained. The rise in BP during the V̇O2 peak test was 
assessed using an automated sphygmomanometer specific for exercise every 
1.5 minutes (Love Medical, Manchester, UK). BP was measured every 1.5 
minutes so that enough readings could be taken to assess the BP rise during 
each predefined percentage of V̇O2 peak testing (Baseline, 0-25%, 26-50%, 51-
75%, 76-100% and peak V̇O2 peak testing) (Love Medical, Manchester, UK). 
During pilot testing, BP readings every 1 minute were attempted but participants 
found it uncomfortable to do this at this frequency. For isometric handgrip testing, 
beat-to-beat BP was measured using the Finapres (Finometer, FMS, 
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Netherlands; see section 2.6, page 108). The Finapres was not used to measure 
the BP response to peak exercise testing (V̇O2 peak test) as the Finapres is not 
validated for exercise, especially at high intensity (Finometer, FMS, Netherlands; 
see section 2.6) (Parati et al., 1989). Additionally, the Finapres measures BP 
from the finger and the hand needs to be very still for the Finapres to get a 
successful reading (Finometer, FMS, Netherlands; see section 2.6, page 108). 
This makes using the Finapres difficult during exercise. A 12-lead ECG (Love 
Medical, Manchester, UK) was used to measure HR during the V̇O2 peak test. 
 
2.3.3 Repeatability of peak exercise blood pressure (within subjects) 
A mixture of 9 treated controlled (n=5), uncontrolled (n=3) and untreated (n=1) 
individuals with hypertension from the study detailed in Chapter 3 came back and 
repeated a V̇O2 peak test. The participants returned to the laboratory between 2 
weeks and 1 year following the study visit V̇O2 peak test. All patients with treated 
hypertension that came back remained on the same anti-hypertensive 
medications as they did when they came in for the study in Chapter 3. The repeat 
test results for absolute SBP and the change in absolute SBP can be found in 
Table 2.1 and 2.2 (page 125 and 126) and Figure 2.1 and 2.2 (page 134 and 
135). From this small repeatability test it was found that the coefficient of variation 
for the absolute SBP during two V̇O2 peak tests is low (2.45%) (Table 2.1, page 
125). There was a strong positive correlation found for the absolute SBP during 
V̇O2 peak testing (Pearson’s r = 0.82; Figure 2.1, page 134). In addition, for the 
absolute change in SBP from baseline the coefficient of variation was 6.98% 
between two V̇O2 peak tests (Table 2.2, page 126). A strong positive correlation 
was found for the absolute change in SBP during V̇O2 peak testing (Pearson’s r = 
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0.89; Figure 2.2, page 135). This suggests that the BP response to V̇O2 peak 
testing is reliable. These variations in SBP between tests will need to be 
considered in studies that are aiming to lower exercise SBP. For example, the 
change in absolute SBP during V̇O2 peak testing varies by about 6.98% and 
therefore effects of interventions looking to lower exercise SBP will have to have 
a larger effect than 6.98%. In addition, the V̇O2 peak score (ml/min/kg) remained 
similar between the two visits, a coefficient of variation of 6.07% was found 
(Table 2.3, page 127 and Figure 2.3, page 136). The coefficient of variation for 
V̇O2 peak scores was performed as changes in CV fitness between tests is likely 
to influence the BP response to exercise. 
 
2.4 Arterial tonometry (Chapter 4) 
Aortic BP and central (aortic) stiffness were measured using non-invasive pulse 
wave analysis and pulse wave velocity in participants with hypertension and 
normotension in the study detailed in Chapter 4. 
 
2.4.1 Introduction to the arterial pulse pressure 
 The left ventricle ejects blood into the elastic aorta at a faster velocity than blood 
can drain away and the resulting increase of the volume of blood into the aorta 
leads to a steep increase in BP during systole. Only 20-30% of the blood ejected 
by the left ventricle goes to the peripheral vessels, while 70-80% is stored as 
mechanical energy in the elastic vessels. When the vessels recoil this mechanical 
energy is converted into pressure energy during diastole and helps to maintain 
perfusion (Windkessel effect). In young healthy individuals the Windkessel effect 
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helps the dampening of the PP (SBP-DBP) over the cardiac cycle whilst 
maintaining perfusion following left ventricular ejection. If the arteries had 
completely stiff walls the BP would be instantly increased throughout the whole 
arterial bed during systole due to a rapid pulse transmission velocity. Pulse wave 
transmission velocity travels at around 4-5 m/s in young healthy individuals and 
travels faster than the blood velocity which travels only at around 0.2 m/s in the 
ascending aorta. As the pulse wave transmission is dependent on arterial wall 
deformation, increased stiffness of the arteries increases transmission velocity of 
the pulse. Central (aortic) stiffness can be measured non-invasively using pulse 
wave analysis and pulse wave velocity. Both of these methods are discussed 
below. Central (aortic) stiffness was measured for the study detailed in Chapter 4 
as elevated aortic stiffness has been shown to be related to an exaggerated 
peripheral BP response to exercise  (Tsioufis et al., 2008, Thanassoulis et al., 
2012). 
 
2.4.1.1 Pulse wave velocity 
The SphygmoCor System (AtCor Medical, Sydney SpA) was used as a non-
invasive method for assessing pulse wave velocity as a marker of central (aortic) 
stiffness in participants for the study in Chapter 4. Pulse wave velocity is measured 
by assessing the transmission time of the R wave (as measured by a 3-lead ECG) 
to the onset of the pulse pressure wave in the 2 sites measured (see Figure 2.4, 
page 137). Further, this is then divided by the difference in the distance between 
the suprasternal notch and the 2 sites assessed (see Figure 2.4, page 137): 
 
PWV = dsa-dsb/tta-ttb [equation 2.3] 
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d = distance 
tt = pulse transmit time 
s = suprasternal notch 
 
The concept of pulse wave velocity is based on the Moens Korteweg equation 
(Bramwell and Hill, 1922). Velocity of the pulse wave is influenced by the radius, 
wall thickness, density of fluid and the elastic properties of the arteries (Messas et 
al., 2013): 
 
PWV = √Youngs modulus ∗ h/2Rρ [equation 2.4] 
PWV = pulse wave velocity  
Youngs modulus represents the elastic properties of the artery for lateral 
expansion 
h = wall thickness  
R = radius 
 𝜌 = density of fluid 
 
For thick walled tubes with flow the Moens Korteweg equation has been adapted 
to account for the assumption that pulse wave convection changes with the cross-
sectional averaged velocity of the blood (Khir et al., 2001): 
 






) + 𝑈 [equation 2.5] 
 
ri = internal radius of the artery. 
U = cross-sectional averaged velocity 
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It has been documented that decreases in the Youngs modulus, the elasticity of 
the artery, will cause an elevated pulse wave velocity (Khir et al., 2001). Carotid-
femoral pulse wave velocity was assessed as this is the most established method 
for assessing aortic pulse wave velocity and arterial stiffness over carotid-brachial 
arteries (Tillin et al., 2007, Boutouyrie et al., 2002). In addition, the major advantage 
of using carotid-femoral pulse wave velocity as compared to the femoral-tibial or 
carotid-radial pulse is that propagation time is assessed along the aortic and aortio-
iliac pathway (Laurent et al., 2006). This makes the assessment of the carotid-
femoral pulse wave velocity the most clinically relevant as the ascending aorta and 
the common iliac artery are where the left ventricle first ejects blood into and are 
the most pathophysiological areas for the blood vessels to stiffen (Laurent et al., 
2006). Pulse wave velocity has been shown to predict adverse CV events in the 
general population (Willum-Hansen et al., 2006, Mattace-Raso et al., 2006) and is 
elevated in hypertensive individuals and remains predictive of adverse CV 
outcomes (Blacher et al., 1999, Boutouyrie et al., 2002, Laurent et al., 2001, 
Laurent et al., 2003, Hua et al., 2005). The Framingham Heart Study found that in 
2232 individuals, a carotid-femoral pulse wave velocity score of more than 11.8 
m/s was an independent risk factor of adverse CV events (Mitchell et al., 2010). 
Importantly, central (aortic) pulse wave velocity as measured by the SpygmoCor 
(SpygmoCor System, AtCor Medical, Sydney) system has been validated, by 
comparing assessment of aortic pulse wave velocity during cardiac catherization 
(Weber et al., 2009) and via phase contrast magnetic resonance imaging (Hickson 
et al., 2010). This suggests that pulse wave velocity as measured by the 
SpygmoCor is an accurate measurement of central (aortic) pulse wave velocity. 
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Pulse wave velocity was calculated automatically by the SpygmoCor 
(SpygmoCor System, AtCor Medical, Sydney) using the equation (Laurent et al., 
2006, Thanassoulis et al., 2012): 
 
Pulse Wave Velocity = dPWV/∆t [equation 2.6] 
 
where dPWV = distance between sternal notch to femoral artery (cm) – 
distance between sternal notch carotid artery (cm) and ∆t = the change in 
time. 
 
2.5 Pulse wave analysis 
2.5.1 Wave reflection and central blood pressures 
Pulse wave analysis was also used as an estimate of central (aortic) BP using 
arterial tonometry. Higher central (aortic) BP is a marker of elevated central (aortic) 
stiffness (Pereira et al., 2013, Laurent et al., 2001, Laurent et al., 2006, Laurent et 
al., 2003). 
 
SBP is typically measured in the brachial artery in clinical practice, however SBP 
is typically 40 mmHg higher in the brachial artery as compared to the aorta (Kroeker 
and Wood, 1955). This amplification of SBP towards the periphery arises mostly 
due to elevated arterial stiffness in the peripheral arteries as compared to the 
elastic aorta (McEniery et al., 2014) (Figure 2.5, page 138). 
 
Two main models have been described to explain the SBP amplification towards 
the peripheral arteries. Firstly, the pressure wave transmitted by the central aorta 
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consists of a reflected wave back from the periphery (wave reflection) and a 
forward wave that is amplified out towards the peripheral organs. The forward wave 
is generated by the contraction of left ventricle during systole (Westerhof et al., 
1972). Wave reflection is mediated by sites of impedance mismatch (e.g. 
bifurcations and high resistance arterioles are the major site of wave reflection in 
humans) (Hirata et al., 2006, Westerhof et al., 1972). The sites of impedance 
mismatch generate several wavelets during one cardiac cycle that summate into 
one reflected wave (McEniery et al., 2014). In healthy young and normotensive 
adults, the summed wave reflection doesn’t influence aortic systolic pressure 
because the reflected wave returns during late diastole, there is high amplification 
of the pressure wave between the aorta and periphery, resulting in larger peripheral 
BPs compared to aortic (or central) BPs (Hirata et al., 2006). However, ageing is 
associated with an increased reflection of the pressure wave from the periphery, 
which occurs early in systole due to increased peripheral arterial stiffening which 
contributes to the aortic SBP and causes central BP to rise to a similar level as 
peripheral BP (Figure 2.4, 2.5, 2.6 and 2.7, pages 137-140) (Hirata et al., 2006, 
McEniery et al., 2014). This increases the load on the left ventricle and negatively 
effects ejection fraction and augments the myocardial O2 requirements (Laurent et 
al., 2001). The presence of hypertension increases the reflection wave, compared 
to age matched normotensives, which raises aortic BP compared to age matched 
normotensives (Fantin et al., 2007). 
 
A second paradigm that has been assessed to explain SBP amplification is an 
adaptation of the Windkessel model. The original two-element Windkessel model 
shows that during systole there is an ejection of blood from the left ventricle into a 
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compliant aorta. In the elastic arteries some of this energy is stored as potential 
energy and during diastole where the vessels this potential energy is converted 
into pressure energy. However this model fails to allow the investigation of the 
pulse wave transmission and SBP amplification in the periphery (McEniery et al., 
2014). The adaptation of the Windkessel approach is a time-based model which 
accounts for both the central reservoir and the wave transmission functions of the 
CV system. The central reservoir is the potential energy stored following systole, 
before recoil during diastole (Wang et al., 2003). The model consists of the central 
reservoir pressure and an excess pressure: 
 
Excess pressure = aortic pressure – Windkessel pressure (reservoir 
pressure) [equation 2.7] 
 
Excess pressure is defined as the pressure difference driving flow into the 
ascending aorta (Windkessel) (Wang et al., 2003). Aortic flow into the Windkessel 
is proportional to excess pressure under normal conditions, which suggests that 
the reflected wave contributes very little to the augmentation of peripheral SBP and 
central SBP under normal conditions (Wang et al., 2003). This model further 
describes how aortic flow, aortic pressure and peripheral SBP augmentation under 
normal conditions is mediated mostly by a forward wave (aortic outflow) and a 
reservoir pressure (Windkessel pressure) (Wang et al., 2003). Aortic BP was used 
for the study in Chapter 4 as an indication of central (aortic) stiffness.  
 
Higher aortic BP is an indicator of elevated Windkessel stiffness in the aorta (Wang 
et al., 2003). Elevated aortic BP at rest, similar to elevated central (aortic) PWV 
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has been shown to be predictive of an exaggerated peripheral BP response to 
exercise (Thanassoulis et al., 2012).  
 
To perform applanation tonometry using SphygomoCor (SpygmoCor System, 
AtCor Medical, Sydney) the participant was first asked to lay supine for 10 minutes 
of quiet rest. The participants resting BP was measured in the supine position from 
the brachial artery. In accordance with the European Society of Hypertension 
guidelines resting BP was assessed using an automatic oscillometric monitor 
(Omron, 705IT, Omron Healthcare Europe). The first reading was ignored and then 
a BP was taken on the left and right arm, with two further readings being taken on 
the arm where BP was highest (O'Brien et al., 2001). The average of these final 
two readings was taken as BP (O'Brien et al., 2001). This reading was then entered 
into the SpygmoCor System (AtCor Medical, Sydney). The system uses a BP 
reading from the periphery (brachial artery) to calibrate to aortic BP. To perform 
this analysis, a tonometer was placed over the radial artery for a sufficient period 
of time so that a radial pulse trace could be recorded. The SphygomoCor 
(SpygmoCor System, AtCor Medical, Sydney) system has an inbuilt calculation 
that assesses the variability of the recording, this is called the operator index and 
is a scale of 0-100 (100 being the best quality). If the operator index was <= 95 a 
repeat reading was done until the score was > 95. The SpygmoCor (SpygmoCor 
System, AtCor Medical, Sydney) systems assessment of central BPs is built on a 
general transfer function (Karamanoglu et al., 1993). The general transfer function 
is based on common frequency components of the peripheral pressure waveforms 
and the aortic pressure waveforms (Butlin and Qasem, 2017, Karamanoglu et al., 
1993). The transfer function uses discrete Fourier transformation which is a 
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mathematical algorithm that creates a aortic BP waveform based on the extraction 
of simple sine waves of varying frequency and amplitude from the peripheral pulse 
in the time domain to harmonics in the frequency domain (Olafiranye et al., 2011). 
Several factors can influence the recreation of the aortic BP waveform, including, 
HR, blood volume, viscosity, vascular impedance and arterial compliance which 
the transfer function considers (Olafiranye et al., 2011, Karamanoglu et al., 1993). 
Importantly, the transfer function has been well validated against invasive aortic 
BP measurement by micromanometer (Chen et al., 1997, Pauca et al., 2001). 
Suggesting that the recreation of the central (aortic) BP wave from the radial artery 
is an accurate measurement of central (aortic) BP and aortic stiffness. From the 
recreated central pressure waveform, the software calculates aortic augmentation 
pressure (which is defined as the difference between the peak 1 and peak 2 wave 
in the central pressure waveform), aortic SBP, aortic PP and augmentation index 
(AIx %) (aortic augmentation pressure/aortic PP * 100) (Figure 2.7, page 140). The 
AIx was calculated as follows: 
Aortic AIx (%) = aortic augmentation pressure/aortic pulse pressure*100 
[equation 2.8] 
 
where augmentation pressure is the magnitude of wave reflection which increases 
with reduced compliance of the elastic arteries seen in hypertension and aortic 
pulse pressure = aortic SBP – aortic DBP. The AIx % is taken as a marker of wave 
reflection (Hirata et al., 2006). AIx is also reported as AIx 75 which is normalised 
to a HR of 75, which allows the comparison between individuals with different 
resting HR. Pulse wave analysis was performed two times in each participant and 
the mean value is presented in Chapter 4. 
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2.5.2 Repeatability of carotid-femoral pulse wave velocity (within subjects) 
A mixture of 7 normotensive (n=2), controlled (n=1), uncontrolled (n=2) and 
untreated (n=2) hypertensive individuals had their pulse wave velocity (carotid-
femoral) measured on two separate occasions. The pulse wave velocity 
assessment was at least 2 weeks apart and no longer than a month was left 
between readings. All patients with treated hypertension that came back 
remained on the same anti-hypertensive medications as they did when they 
came in for the first assessment. The repeat rest results for pulse wave velocity 
can be found in Table 2.4 (page 128) and Figure 2.8 (page 141). From this small 
repeatability test it was found that the coefficient of variation for pulse wave 
velocity was 3.2% (Table 2.4, page 128). There was a significant strong positive 
correlation for pulse wave velocity (Pearson’s r = 0.99, P=<0.0001; Figure 2.8, 
page 141). This suggests that my assessment of pulse wave velocity within 
individuals over 2 weeks to a month is reliable.  
 
2.6 Handgrip exercise and metaboreflex assessment 
In the relevant studies in this body of work, the sensitivity of the metaboreflex was 
assessed using circulatory occlusion following isometric handgrip exercise 
(Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014). This is called post 
exercise ischemia (PEI) and is routinely used to assess the contribution of the 
metaboreflex to exercise BP and SNA (Delaney et al., 2010, Greaney et al., 2014, 
Sausen et al., 2009). PEI has been used extensively in the literature to isolate the 
metaboreflex since Alam and Smirk (1937) found that circulatory occlusion 
following forearm exercise causes SBP to be maintained at exercise levels when 
compared to no circulatory occlusion following the cessation of exercise. 
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Subsequent research by Kaufman et al. (1984) found that PEI in cats caused a 
higher percentage of group IV afferents to be activated compared to the group III 
afferents. Importantly, this PEI period appears to selectively isolate the 
metaboreflex, independent of the mechanoreflex and feed-forward central 
command (Kaufman et al., 1983, Kaufman et al., 1984).  
 
Prior to isometric handgrip exercise, participants maximal voluntary contraction 
(MVC) was measured. Participants performed three maximal contractions of the 
handgrip dynamometer with the dominant arm with one minute between each 
attempt. The MVC was taken as the highest score achieved from the three 
measurements (Delaney et al., 2010). For the studies in Chapter 3 and 4, 
participants first performed isometric handgrip exercise at 30% of MVC for 1 
minute. At 1-minute, isometric handgrip ended and an occlusion cuff was pumped 
up to 240 mmHg in all participants and this cuff remained pumped up for 1 minute 
30 seconds (Delaney et al., 2010). This 1 minute 30 seconds of occlusion following 
isometric handgrip exercise was the PEI period (Figure 3.4, page 199). For the 
study in Chapter 5, the intensity of isometric handgrip was increased to 40% MVC 
for 1 minute and PEI was increased to 2 minutes. The rationale for this was that at 
an increased % of MVC more metabolites in the forearm will increase the activation 
of the metaboreflex (Crisafulli et al., 2006). Typical CV responses to activation of 
the metaboreflex include increases in muscle sympathetic nerve activity (MSNA), 
BP, HR, stroke volume (SV), CO and increased respiration (Amann et al., 2011a, 
Amann et al., 2010, Delaney et al., 2010). An important component of activation of 
the metaboreflex is an increased BP to perfuse active skeletal muscle (Amann et 
al., 2011a, Amann et al., 2010). However, the technique chosen to activate the 
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metaboreflex (exercise ischemia vs. PEI) appears to determine how the 
metaboreflex increase BP (Crisafulli et al., 2011). In a recent study, Crisafulli et al. 
(2011) showed that in healthy volunteers, activation of the metaboreflex increased 
BP via increasing CO. When the metaboreflex was isolated during PEI the increase 
in CO was driven by an increase in SV (Crisafulli et al., 2011). Interestingly, HR 
returned to resting levels during PEI following dynamic and static exercise with a 
small muscle mass (e.g., forearms) (Crisafulli et al., 2011, Watanabe et al., 2010, 
Fisher et al., 2013). 
  
2.6.1 Haemodynamic measurements during baseline, isometric handgrip 
exercise and metaboreflex isolation 
Participants rested for at least 15 minutes before a baseline period of 10 minutes 
was commenced. BP was measured from the opposite (non-exercising) arm 
during isometric handgrip exercise and PEI from the baseline period on a beat-to-
beat basis using finger photo-plethysmography (Finometer, FMS, Netherlands; 
see section 2.6, page 108). A beat-to-beat estimate of SV was measured by the 
Finapres (see section 2.6, page 108). HR was recorded using a 3-lead ECG. To 
ensure that participants maintained normal breathing rates (eupnoea) during 
baseline, isometric handgrip exercise and PEI, a respiratory belt was used to 
measure respiratory rate. If the participant temporarily ceased breathing (apnoea) 
during isometric handgrip exercise the isometric handgrip test was repeated after 
a 10-minute recovery period.  
 




The Finapres system was used to measure beat-to-beat SBP and DBP during 
baseline, isometric handgrip exercise and PEI. The Finapres system uses the 
volume clamp protocol of Penaz (1973). Using infrared photoplethysmography 
(light) from an inflatable finger cuff (Figure 2.9, page 124) the volume of blood 
and artery size is continuously measured. Owing to the non-linear relationship 
between transmural pressure and volume, the diameter of the artery is clamped 
to a ‘setpoint’ which occurs despite changes in arterial pressure during the 
cardiac cycle (Boehmer, 1987). This ‘setpoint is accomplished via a counter 
pressure from an inflatable finger cuff that applies an external pressure to the 
finger equal to the pressure inside of the arterial wall (Boehmer, 1987). This 
keeps transmural pressure (transmural pressure = arterial pressure – external 
pressure) at zero (Boehmer, 1987). As the blood volume in the finger is 
determined by light intensity, an increase in light intensity indicates a drop-in 
blood volume and the cuff pressure is reduced by a rapid servo-controller system 
to allow blood volume to increase which allows light intensity to return to the set 
point. The opposite occurs when light intensity declines. At zero transmural 
pressure the external counter pressure by the finger cuff is equal to intra-arterial 
pressure in the finger (Imholz et al., 1988). At zero transmural pressure the veins 
in the finger are fully collapsed, but the arteries maintain a third of their cross-
sectional area and volume, the arteries are said to be ‘unloaded’ and are 
maintained at zero transmural pressure (unstressed diameter) (Imholz et al., 
1988). Therefore, during systole blood flow continues to flow out of the finger and 
during diastole flow continues to flow into the finger, maintaining oxygenation 
levels to an normal level in the finger (Gravenstein et al., 1985). Once per minute 
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(up to 70 seconds) the Finapres calibration system (PhysioCal) automatically 
checks for any changes in the unloaded artery size induced by smooth muscle 
vasoconstriction or vasodilation and rapidly adjusts the finger cuff pressure 
accordingly by altering the set point (Wesseling et al., 1995). The measurement 
of beat-to-beat SBP and DBP is temporarily interrupted during PhysioCal. 
 
This technique produces a finger pressure waveform; however, finger artery 
pressure pulsations vary in shape and amplitude than pressures recorded from 
the clinical site of BP measurement in the brachial artery. The Finometer has built 
in software to account for these differences. Firstly, the Finometer Pro 
reconstructs the brachial artery pressure from the finger BP waveform using 
waveform filtering via an inbuilt transfer function (Guelen et al., 2003). The 
reconstructed waveform is similar in shape but not in magnitude (Bos et al., 
1996). From the reconstructed waveform the pressure level differences between 
the finger and brachial arteries can be calculated using a level correction 
equation (Gizdulich et al., 1997, Bos et al., 1996). Finally, a return-to-flow systolic 
pressure was assessed via a standard Riva-Rocci cuff around the upper arm of 
the participant and is used to calibrate the waveform and level corrected 
pressures (Guelen et al., 2003). This is only performed once and is completed 
prior to any baseline recordings.  
 
The Finometer Pro (Finometer, FMS, Netherlands) when measuring absolute 
SBP fails to meet the guidelines of the Advancement of Medical Instrumentation 
(AAMI) of a standard deviation of < 8 mmHg between intra-arterial BPs and the 
device being tested (Imholz et al., 1998). However, the change in SBP or DBP 
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using the Finometer Pro is reliable when measured at rest when compared to 
intra-arterial BP (Parati et al., 1989) and during tests that induce a pressor 
response, including handgrip exercise (Parati et al., 1989). Importantly, tracking 
the change in BP has been shown to be reliable in patients with hypertension 
compared to intra-arterial BP (Bos et al., 1992). 
 
2.6.2.1 Modelflow method 
The Modelflow method non-invasively assesses left ventricular SV by computing 
an aortic waveform using a three-component model of aortic input impedance 
(Wesseling et al., 1993). This model of aortic input impedance (Westerhof et al., 
1971) describes the relationship between the aortic inflow and pressure by 
assessing the aortas opposition to left ventricular ejection (Westerhof et al., 
1971). This model describes the relationship between aortic pressure and flow to 
give readings of cardiac SV and therefore enables the calculation of beat-to-beat 
CO (SV * HR) (Wesseling et al., 1993). The three components of the model flow 
method (Figure 2.10, page 143) are: 
1. Aortic characteristic impedance (Z0): Upon left ventricular contraction, 
blood is forced into the aorta but the aorta already contains a certain 
amount of blood and this existing pressure apposes left ventricular 
ejection. Z0 is the resistance of the aorta to pulsatile inflow from the 
contracting left ventricle (Wesseling et al., 1993, Bogert and van Lieshout, 
2005). Increases in pressure lead to minimal changes in Z0. 
2. Windkessel (buffer) compliance (CW): This is the ability of the aorta to 
expand upon receiving blood during left ventricular contraction during 
systole. A highly compliant aorta will expand leading to minimal increase in 
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aortic pressure (Bogert and van Lieshout, 2005). An increase in pressure 
leads to a non-linear reduction in compliance. In a stiffer aorta a given 
increase in volume will lead to a larger increase in pressure.  
3. TPR (Rp): overall resistance of the vascular bed which is influenced by a 
diverse range of factors, such as sympathetic activity, certain medications 
and metabolism (Wesseling et al., 1993). 
 
The aortic impedance and Windkessel compliance are the two major 
determinants of systolic aortic inflow and are dependent on the elasticity of the 
aorta (Wesseling et al., 1993). The time course of changes in cross-sectional 
area of the aorta varies with pressure in a non-linear fashion. At low pressures, 
the cross-sectional area increases rapidly, whereas at higher pressures, the 
cross-sectional area changes slowly, as compliance is reduced (van Lieshout et 
al., 2003). The aortic cross-sectional area for pressure (A(P)) has been described 
as a mathematical equation: 
A(P) = Amax [0.5+1/ arctan (P - P0/P1)] [equation 2.9] 
 
where Amax is the maximal diameter of the aorta during ejection, P is pressure, P0 
is the position of the inflection point on the pressure axis at 0.5 Amax, and P1 is 
the steepness of the curve at 0.75 Amax. As it is assumed that the aortic length (L) 
remains constant, the change in volume (V) (as assessed by V = r2L or V=AL, A 
being area and r being radius) is proportional to changes in the cross-sectional 
area of the aorta (Wesseling et al., 1993). Therefore, the two main components of 
systolic inflow are calculated as follows: 
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Windkessel compliance (Cw): the change in area (dA)/ the change in 
pressure (dP) [equation 2.10]  
 
The aortic impedence (Z0):  √density of blood (p)/(Area (A) * Compliance 
(C)) [equation 2.11] 
 
The values of Cw and Z0 are computed once per beat. However, the values of P0, 
P1 and Amax during measurement are taken from an inbuilt database from a study 
that found that the values of aortic impedance and Windkessel compliance were 
related to age, gender, height and weight (Langewouters et al., 1984). The model 
parameters are simulated during recording which outputs a continuous aortic 
waveform (Figure 2.10, page 143). The waveforms are produced on a beat-to-
beat basis and it is integrated during systole to give a measurement of SV (Figure 
2.10, page 143).  
 
A problem with the Modelflow method is that the Amax component has been 
shown to be variable between individuals, and the system assumes set values 
(Langewouters et al., 1984). This has caused considerable variation in the 
calculation of absolute SVs from model flow when compared to other methods 
such as Doppler Ultrasound (van Lieshout et al., 2003, Dyson et al., 2010) and 
thermodilution (Jansen et al., 2001). However, tracking the change in SV using 
the Finapres model flow method is tied to Doppler Ultrasound changes (van 
Lieshout et al., 2003) and thermodilution (Wesseling et al., 1993), although this 
finding isn’t always consistent (Dyson et al., 2010). Indeed, initial calibrations of 
the model flow method to a gold standard method such as thermodilution is 
Chapter 2 General Methods 
116 
 
needed for accurate measurements of absolute SV and CO (Bogert and van 
Lieshout, 2005). Nevertheless, changes in SV and CO have been reported as 
accurate compared to echocardiography during isometric exercise (van Dijk et 
al., 2005). For the studies in this thesis there was no capability to calibrate the 
Modelflow technique to a gold standard method and therefore changes in beat-to-
beat SV are reported relative to a baseline period. 
 
2.6.3 Reliability of the BP response to metaboreflex isolation measured via the 
Finapres 
To assess the reliability of the BP response to metaboreflex isolation, test re-test 
data were collected from 8 people normotensive (n=1), treated controlled (n=5) 
and uncontrolled (n=2) hypertensives. More specifically, participants performed 
isometric handgrip exercise for 1 minute at 30% MVC and an occlusion cuff was 
pumped up to 240 mmHg for 1 minute 30 seconds (PEI). The time between 
repeat metaboreflex assessment was at least 2 weeks apart and no longer than a 
month was left between readings. All patients with treated hypertension that 
came back remained on the same anti-hypertensive medications as they did 
when they came in for the first assessment. The repeat rest results for 
metaboreflex can be found in Table 2.5 (page 129) and Figure 2.11 (page 144). 
From this small repeatability test it was found that the coefficient of variation for 
absolute change in SBP from baseline during PEI was 13% (Table 2.4, page 
128). There was a significant strong positive correlation for the absolute change 
in SBP during PEI (Pearson’s r = 0.90, P=<0.0021; Figure 2.11, page 144). Any 
interventions aiming to lower SBP during PEI will need to find a larger decrease 
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in SBP than 13% for it to be meaningful for a study with a similar number of 
participants. 
 
2.7 Microneurography (Chapter 5) 
Microneurography was used to measure acute and temporal changes in multi-
unit MSNA in the peroneal nerve. Microneurography was measured to assess the 
level of MSNA at rest. The resting level of MSNA was used to compare to the 
level of MSNA during isometric handgrip exercise and during PEI. 
Microneurography was originally developed in Sweden by clinical 
neurophysiologists Karl-Erik Hagbarth and Ake Valbo between 1965-1966 and 
data from microneurography was first presented at a Scandinavian 
electrophalography (EEG) meeting in Copenhagen in 1966 (Vallbo and Hagbarth, 
1967). Gunnar Wallin led the development of studying the measurement of 
sympathetic bursts to skin and muscle and it was first measured successfully in 
1972 (Delius et al., 1972a, Delius et al., 1972b). 
 
2.7.1 Methodology of microneurography 
Microneurography measures changes in the post-ganglionic efferent 
unmyelinated C- fibres of the sympathetic nervous system. Efferent sympathetic 
nerve activity (SNA) can be measured from any peripheral nerve. However, the 
peroneal nerve in the leg, proximal to the fibular head is the most commonly used 
nerve to measure efferent SNA. Proximal to the fibula head, the peroneal nerve 
bifurcates into the deep and superficial portions. An obvious limitation to 
performing microneurography in the peroneal nerve is not being able to assess 
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MSNA during dynamic leg exercise, but it does allow measurement of MSNA 
during upper body exercise, such as isometric handgrip testing. Advantages are 
that it is easily identifiable, it is a peripheral nerve, the leg can be held still for a 
long time, and can be performed whilst the participant is supine, semi-supine or 
seated upright. 
 
Participants were asked to position themselves semi-supine on the bed and the 
leg and foot were partially elevated and supported. The participant was then 
encouraged to fully relax their leg throughout the test to avoid activation of motor 
units. Next, cutaneous electrical stimulation was used to locate the position of the 
peroneal nerve. To stimulate the nerve, a blunt tipped stimulator, which applies a 
small electrical current ranging from 1-3 mAs for short durations (1 ms) was 
applied to the area surrounding the peroneal nerve. More specifically, electrical 
stimulation of the deep peroneal nerve leads to dorsiflexion and stimulation of the 
superficial portion leads to lateral movements of the foot (Vallbo et al., 1979). 
Where electrical stimulation lead to dorsiflexion, the stimulator was moved 
laterally and/or vertically to assess where the dorsiflexion was strongest. As this 
is an indicator of the position of the deep peroneal nerve (Vallbo et al., 1979), a 
small red dot was marked on the participants leg (Figure 2.12, page 145). At least 
3 or 4 good sites with dorsiflexion are located before moving on to the next step 
(Figure 2.12, page 145). 
 
The tip of a 35 mm un-insulated tungsten reference micro-electrode was then 
inserted into the participants skin around 1-2 cm from the expected site of the 
deep peroneal nerve. This acts as an electrical reference that allows changes in 
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electrical activity to be detected by the active micro-electrode. The reference 
micro-electrode is not normally moved until the end of recording. An un-insulated 
active tungsten micro-electrode (5μM tip diameter, shaft diameter of ~100-200 
μM and impedance 2 MΩ at 1 kHz) was then inserted through the skin and into 
the nerve. Higher electrode impedances can also be used when the aim is to 
assess a smaller area of the nerve (e.g., single-fibre recording) (Macefield et al., 
1994). Tungsten is used for microneurography as its electrical (conduction) and 
mechanical (non-brittle, thin and stiff) properties make it suitable for the 
percutaneous insertion into the nerve. The position of this active micro-electrode 
is moved until it is in a satisfactory position within the deep portion of the 
peroneal nerve that indicates MSNA. 
 
Several criteria were used to assess whether a satisfactory MSNA signal had 
been obtained. Firstly, efferent sympathetic outflow in humans consists of either 
MSNA or skin sympathetic nerve activity (SSNA) (Delius et al., 1972a, Delius et 
al., 1972b). Multiunit MSNA is characterised by cardiac synchronicity and an 
increase in frequency of bursts during breath hold at the end of normal expiration 
(Wallin et al., 1973, Delius et al., 1972a, Delius et al., 1972b, Hagbarth et al., 
1972). Another method for assessing whether MSNA was found was by 
assessing afferent activity. Nerve discharge when tapping the muscle belly of the 
anterior tibialis, activating the toe extensors and applying pressure to the tendon 
of the foot was also used as another indication of MSNA. In contrast to muscle 
nerves, changes in multiunit records of SSNA are evoked by alterations in 
arousal, environmental temperature, emotional status and by light stroking of the 
skin (Delius et al., 1972a, Delius et al., 1972b). Multiunit SSNA have no cardiac 
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rhythmicity (Hagbarth et al., 1972) (Figure 2.13, page 146). Increases in efferent 
SSNA are independent of changes in BP, unlike MSNA, suggesting a lack of 
baroreflex control over nerve activity to the skin (Hagbarth et al., 1972) (Figure 
2.13, page 146). It is highly important to consider these classification factors 
when measuring MSNA as afferent and efferent nerves from the skin and muscle 
transverse within the same nerve. Having mixed MSNA and SSNA can lead to 
difficulties in detecting MSNA bursts during analysis (White et al., 2015). Once a 
successful site was obtained, participants were asked to lie quietly for a 10-
minute baseline period prior to metaboreflex testing (see section 2.5, page 103). 
 
The active and reference electrode were attached to a pre-amplifier that amplifies 
the signal before the signal reaches a main amplifier (80,000-fold amplification). 
The raw signal was band-pass filtered between 700 and 5000 Hz) (White et al., 
2015). The amplified and band-pass filtered signal was then full-wave rectified 
and integrated (time constant 0.1s) using computer-based algorithms (Absolute 
Design and Manufacturing Services, Iowa). The raw and integrated signal were 
then displayed on a data acquisition software on a laptop (AD Instruments, 
LabChart Pro version 7). A 3:1 signal to noise ratio was used to assess whether 
the signal obtained was of good enough quality for analysis (Hart et al., 2017). To 
identify MSNA during baseline, isometric handgrip exercise and PEI a script 
written in a data analysis program was used (Spike 2, Cambridge Electronic 
Designs). MSNA is most commonly quantified as bursts per minute (burst 
frequency), which shows the amount of MSNA that the vascular smooth muscle 
is exposed to in a period of time, and also bursts per 100 heartbeats (burst 
incidence), which accounts for an individual’s HR. Both methods for quantifying 
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MSNA are normally reported, MSNA bursts per 100 heartbeats should be 
interpreted with some degree of caution as if there are large increases in HR 
during a stressor (e.g., exercise) without a change in MSNA this would suggest a 
decrease in the level of MSNA (White et al., 2015). 
 
Figure 2.14 (page 147) illustrates how challenging it is to attain a high quality 
MSNA signal in every individual (Tompkins et al., 2013). Figure 2.14 (page 147) 
also demonstrates that certain parts of the peroneal nerve contain larger 
concentrations of active recording sites for MSNA than others and how subtle 
adjustments in the position of the electrode can lead to larger or smaller burst 
size (Tompkins et al., 2013). In the peroneal nerve postganglionic sympathetic C-
fibre fascicles, axons can exist singularly or in bundles, they are more commonly 
found in bundles of 2-42 (up to 44) axons (Tompkins et al., 2013, Macefield et al., 
1994). Using a signal-to-noise ratio of >3 the smallest detectable action potential 
in the integrated trace is when four or more axons are firing (Salmanpour et al., 
2011, Steinback et al., 2010). Some individuals have an increased number of 
large bundles of axons when compared to others and this enhances the ability to 
get a good quality recording in some individuals compared to others (Tompkins et 
al., 2013).   
 
2.7.2 Identifying and quantifying MSNA (bursts/min, bursts/100Hb, MSNA area 
and total MSNA) 
MSNA burst identification was completed using a script written in a data analysis 
program (Spike 2, Cambridge Electronic Designs). Firstly, a minimum amplitude 
was set for the detection of MSNA bursts, which was set for ~2 standard 
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deviations above the level of noise (Hart et al., 2017). The program then moves 
through the file and automatically determine bursts that are above the level of 
noise. The electrocardiogram signal is then marked (to calculate latency between 
R wave and the next burst). Next, the whole signal was manually assessed to 
ensure that the bursts were correctly identified by the program. The bursts are 
checked for their latency from the previous R wave, multiunit MSNA bursts 
typically have a latency of ~1.3s (Hart et al., 2017, Salmanpour et al., 2011). The 
latency of a multiunit MSNA is mediated by the size of the burst, with larger 
bursts having increased latency (Salmanpour et al., 2011). The latency was then 
plotted against burst amplitude to check that bursts have been marked correctly. 
If any bursts were identified as outliers the burst was identified and reviewed 
accordingly. Following this, the script automatically calculates burst frequency 
(bursts/min) and burst incidence (bursts/100Hb).  
 
This analysis was completed for 10 minutes of baseline, isometric handgrip 
exercise, PEI and during 5 minutes of recovery for the study in Chapter 5. In 
addition, MSNA burst strength was assessed, this involves measuring MSNA 
burst area which was assessed by the same data analysis program (Spike 2, 
Cambridge Electronic Designs). Burst area was calculated by firstly assigning the 
largest spontaneous burst in the signal as 100 arbitrary units (AU) and a period of 
no bursts was marked as 0 AU (Hart et al., 2017). The start and end of each 
multiunit MSNA burst were then marked and the integral was then assessed 
between ‘start’ and ‘end’ (Hart et al., 2017). However, an issue with using this 
technique for analysis is that in one visit the needle may be close to the muscle 
sympathetic nerve, showing a large voltage on the trace, whereas in the next visit 
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the electrode could be further away from the nerve producing a smaller voltage. 
Baseline MSNA burst strength should therefore not be compared between two 
visits. Changes in MSNA burst strength will be reported as an absolute and 
percentage change (Fonkoue and Carter, 2015). Measuring MSNA area allows 
the total area to be calculated as the sum of burst area/time and the sum of burst 
area/HR to account for differences in HR (White et al., 2015). 
 
2.7.3 Reliability of repeat microneurography assessments 
2.7.3.1 Intra-observer reliability 
Neurograms recorded from people with normotension (n=2) and treated 
controlled hypertension (n=4) were used to assess intra-observer reliability. 
Resting MSNA (bursts/min) and MSNA (bursts/100Hb) were analysed on 3 
separate occasions with at least 24 hours between the analysis. The intra-
observer reliability are shown in Table 2.6. and Table 2.7. (pages 130 and 131). 
The coefficient of variation for MSNA (burst/min) was 4% and MSNA 
(burst/100Hb) was 4% (Table 2.6 and 2.7, page 130 and 131). 
 
2.7.3.2 Inter-observer reliability  
To assess inter-observer reliability, neurograms from 4 different patients with 
treated-controlled hypertension were analysed on 3 separate occasions by two 
different observers. The files were analysed on 3 separate days with at least 24 
hours between the analysis. The inter-observer reliability for the 4 treated 
controlled hypertensives results during baseline are in Table 2.8. and Table 2.9. 
(pages 132 to 133). From this small interobserver repeatability test it was found 
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that the coefficient of variation for MSNA (burst/min) was 4% and MSNA 
(burst/100Hb) was 4% between two observers (Table 2.8 and 2.9, pages 132 to 
133). 
 
2.8 General data analysis 
All data was collected using a data acquisition system (LabChart 7 or 8, AD 
Instruments). Data were analysed using Spike 2 (Cambridge Electronic Designs), 
R studio version 3.4.1 (RStudio: Integrated Development Environment for R, 
Boston, MA) and LabChart 7 (AD Instruments). Analysed data were stored using 
Microsoft Excel (Microsoft Corp Redmond, WA). Statistical analysis was 
completed in IBM SPSS Statistics 24 (IBM Corp, Armonk, New York) and 
GraphPad version 7 (GraphPad Software, La Jolla California USA). Specific data 
analysis techniques will be discussed in more detail in the relevant Chapters. 
 
2.9 Statistics 
Power calculations for each study are provided in the relevant Chapter. Specific 
statistical tests performed will be discussed in detail in the relevant Chapters. 
Where relevant, averaged data are presented as mean ± standard deviation. 
Data were tested for normal distribution using a D’Agostino-Pearson omnibus K2 
normality test. α was set at 0.05.  




Table 2-1 Repeat assessments of peak absolute systolic blood pressure (SBP) 
during V̇O2 peak testing on two different test days with no intervention.  
The coefficient of variation indicates that the measurement of peak SBP during 




Test one Peak 
absolute SBP 
(mmHg) 





HP 206 212 2.02 
KP 212 212 0 
AH 183 185 0.77 
EA 207 194 4.58 
GW 227 194 11.09 
NH 155 153 0.98 
JM 208 207 0.34 
KM 209 208 0.34 
GS 213 219 1.96 
Average 202±21 198±20 2.45±3.53 
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Table 2-2 Repeat assessments of the absolute change in peak systolic blood 
pressure (SBP) V̇O2 peak testing on two different test days with no intervention.  
The coefficient of variation indicates that the measurement of peak absolute 




Test one peak 
absolute change 
in SBP (mmHg) 
Test two peak 
absolute change 
in SBP (mmHg) 
Coefficient of 
Variation (%) 
HP 81 92 8.99 
KP 79 80 0.89 
AH 65 57 9.27 
EA 45 43 3.21 
GW 85 68 15.71 
NH 41 43 3.37 
JM 91 82 7.36 
KM 92 83 7.27 
GS 80 88 6.73 
Average 73±19 71±19 6.98±4.33 
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Table 2-3 Repeat assessments of V̇O2 peak scores (ml/min/kg) on two days 
(mean ± standard deviation). 
Participant 
initials 
Test one V̇O2 
peak scores 
(ml/min/kg) 





HP 30 32.20 5 
KP 23.03 23.80 5.46 
AH 18 17.90 0.39 
EA 10.40 10.20 1.37 
GW 27.50 22.30 14.77 
NH 22.80 25.60 8.18 
JM 28.50 33.30 10.98 
KM 20.20 21.25 3.58 
GS 45 42 4.88 
Average 25.05±9.6 25.39±9.36 6.07±4.58 
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Table 2-4 Repeat assessments of carotid-femoral pulse wave velocity (m/s) on 
two different test days with no intervention (mean ± standard deviation). 
Participant 
initials 
Test one PWV 
(m/s) 




AW 6.7 7.4 7 
SBN 6.1 5.9 2.4 
CW 7.9 7.6 2.7 
MS 13.9 13.4 2.6 
BT 16.5 15.6 4 
ET 10.3 10.4 0.7 
RG 11.4 10.9 3.2 
Average 10.4±3.8 10.2±3.5 3.2±1.9 
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Table 2-5 Repeat assessments of the absolute change in SBP (mmHg) during 






in SBP (mmHg) 
Test two 
absolute change 
in SBP (mmHg) 
Coefficient of 
Variation (%) 
JR 35 40 9.43 
KP 24 20 12.86 
AH 26 31 12.40 
GW 34 32 4.29 
CJ 32 46 25.38 
SHY 6 8 20.20 
HP 26 31 12.40 
DL 41 43 3.37 
Average 28±11 31±13 13±7 
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Table 2-6 Repeat intra-observer analysis of bursts of muscle sympathetic nerve 














CC 45 42 45 4 
JP 32 34 33 3 
KP 42 42 43 1 
AM 59 60 61 2 
PR 36 35 33 4 
GS 35 30 32 7 
Average 39±10 39±10 39±9 4±2 
 
  
Chapter 2 General Methods 
131 
 
Table 2-7 Repeat intra-observer analysis of bursts muscle sympathetic nerve 
















CC 78 72 78 4 
JP 58 61 59 3 
KP 79 79 80 1 
AM 70 70 71 1 
PR 76 74 78 4 
GS 56 51 54 5 
Average 67±14 67±12 67±12 4±2 
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Table 2-8 Repeat interobserver analysis of bursts of muscle sympathetic nerve 













KP 42±1 46±1 5 
AM 60±1 60±1 0 
PR 35±2 38±1 5 
GS 32±3 32±2 6 
Average 42±13 44±12 4±3 
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Table 2-9 Repeat interobserver analysis of bursts muscle sympathetic nerve 














KP 79±1 85±2 4 
AM 71±1 76±2 4 
PR 76±2 81±0.2 4 
GS 54±3 55±3 5 
Average 70±11 74±13 4±1 
  




Figure 2-1 Repeatability of systolic blood pressure (SBP) during incremental 
cycle ergometer exercise test (V̇O2 peak test) on two separate days. 
Linear regression of peak SBP assessment during an V̇O2 peak test on two 
separate days, without an intervention (n = 9). There was a positive correlation 
between the peak SBP measured on two separate days (Pearson’s r = 0.82, 
P=0.006). 
  




Figure 2-2 Repeatability of the change in systolic blood pressure (SBP) during 
incremental cycle ergometer exercise test (V̇O2 peak test) on two separate days.  
Linear regression of change in absolute peak SBP assessment during an V̇O2 
peak test on two separate days without an intervention (n = 9). There was a 
positive correlation between the peak SBP measured on two separate days 
(Pearson’s r = 0.89, P=0.001). 
  




Figure 2-3 Repeatability of V̇O2 peak scores (ml/min/kg) during incremental cycle 
ergometer exercise test (V̇O2 peak test) on two separate days without intervention. 
Linear regression of V̇O2 peak scores (ml/min/kg) measured from an incremental 
cycle ergometer exercise test (V̇O2 peak test) on two separate days without an 
intervention (n = 9). There was a positive correlation between the peak SBP 
measured on two separate days (Pearson’s r = 0.95, P=<0.0001). 
  




Figure 2-4 A schematic of the measurement of pulse wave velocity. 
Measurement of pulse wave velocity using the SphygmoCor System (AtCor 
Medical, Sydney SpA). Pulse transmit times are calculated from the R wave of 
the electrocardiogram (ECG) to the onset of the pulse pressure wave. The 
difference in the pulse transmit time is then calculated for the 2 sites being 
assessed. Further, the difference in the distance between the two sites and the 
suprasternal notch is then calculated. To assess pulse wave velocity (PWV) the 
difference in the pulse transmission time is divided by the distance between the 
carotid and femoral pulse (image from Laurent et al. (2006)). 
  




Figure 2-5 Systolic blood pressure amplification from the aorta to the radial artery.  
Two models have been described to explain this systolic blood pressure 
augmentation, wave reflection model and the adapted Windkessel approach. 
  




Figure 2-6 Pulse wave analysis in a patient with untreated hypertension. 
A peripheral arterial waveform from the radial pulse (left), SBP (Sp), DBP (Dp), 
MAP (Mp) and pulse pressure (PP) are all calculated automatically from the 
SpygmoCor system. On the right is a reconstructed aortic pressure waveform 
from the radial pulse via a transfer function. 
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AP = aortic augmentation pressure, Aortic SBP = Aortic SBP and Aortic PP = 
Aortic Pulse Pressure. AIx (%) is the augmentation index and is calculated from 
Aortic Arterial Pressure/Aortic Pulse pressure*100. 
  
Aortic AP 
Aortic SBP  
Aortic PP 
AIx (%) = Aortic AP/Aortic PP*100 
Figure 2-7 An aortic pressure waveform from an untreated hypertensive human. 




Figure 2-8 Repeatability of pulse wave velocity (m/s) (PWV) at rest. 
Linear regression of PWV measured from the carotid-femoral pulse on two 
separate days without an intervention (n = 7). There was a positive correlation 
between the PWV (carotid-femoral) measured on two separate days (Pearson’s r 
= 0.99, P=<0.0001). 
  




Figure 2-9 An illustration of the experimental set up used for the Finometer Pro 
system (Finometer, FMS, Netherlands). 
  




Figure 2-10 Schematic illustration of the 3-element model used for model flow. 
The left side shows the simulated aortic flow pulse and the right side shows the 
self-adapting 3- element model. Arterial pressure (p) is inputted into the model. 
Z0, characteristic impedance of the aorta; CW, Windkessel compliance’ RP, total 
peripheral resistance. The arrow through RP shows that it changes during 
changes in arterial pressure and the line through CW and Z0 indicates a non-linear 
relationship with changes in pressure. This model is simulated beat-to-beat and 
produces a flow curve (left side) labelled q. The area under the curve (q) is taken 
as the stroke volume. Image taken from Jansen et al. (2001). 
  




Figure 2-11 Correlation of the change in systolic blood pressure (SBP) from a 
baseline period during post-exercise ischemia (PEI) on two separate days.  




Figure 2-12 Set up for peroneal nerve microneurography in the right leg. 
Cutaneous electrical stimulation was used to locate the position of the peroneal 
nerve. When the electrical stimulation led to dorsiflexion a small red dot was 
marked. As this is an indicator of the position of the deep peroneal nerve. A 35 
mm tungsten reference electrode (blue flag) was then inserted into the 
participants skin around 2-3 cm away from the deep peroneal nerve. A 35 mm 
active tungsten electrode (white flag) was then inserted through the skin into the 
peroneal nerve. The active and reference electrode were attached to a pre-
amplifier on the left of the image attached just above the knee.  




Figure 2-13 Resting muscle (MSA) and skin (SSA) sympathetic nerve activity.  
The example MSA and SSA shown here are integrated neural outputs from a raw 
trace, time constant, 0.1s). It is clearly demonstrated that when BP dips (black 
arrows) it leads to increases in MSA (cardiac rhythmicity) but not changes in 
SSA. (Image from Delius et al., 1972a, Delius et al., 1972b). 
  




Figure 2-14 The common peroneal nerves surgically excised from a human 
cadaver. 
Tyrosine hydroxylase containing axons were assessed in the common peroneal 
nerve. This figure shows a magnification of a tungsten needle (top left) and of 
one fascicle within the common peroneal nerve, the brown staining indicates 
tyrosine hydroxylase containing sympathetic nerve fibres. Some of these 
fascicles contain no sympathetic nerve fibres. Image from Tompkins et al. (2013). 
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Chapter 3 The Exercise Pressor Reflex in Humans with Hypertension 
Part of this study has been published in Hypertension (see appendix 2, 
page 377) (Chant et al., 2018). 
3.1 Introduction 
It is well established that a sedentary lifestyle is a key risk factor for the 
development of hypertension, and that chronic aerobic endurance training can 
lower resting blood pressure (BP) and mortality rates in these individuals 
(Whelton et al., 2002, Rossi et al., 2012). However, during an acute bout of 
dynamic or isometric exercise, individuals with untreated hypertension have an 
exaggerated increase in BP compared to normotensive controls (Delaney et al., 
2010, Greaney et al., 2015a, Greaney et al., 2014, Aoki et al., 1983, Choi et al., 
2013, Brorson et al., 1978, Seguro et al., 1991, Barbosa et al., 2016). Worryingly, 
an exaggerated increase in BP during an acute bout of dynamic exercise is an 
independent risk for adverse cardiovascular (CV) events (Kjeldsen et al., 1997, 
Kjeldsen et al., 2001) any type of stroke (Kurl et al., 2001, Laukkanen et al., 
2006), left-ventricular hypertrophy (Ren et al., 1985, Papademetriou et al., 1989), 
myocardial infarction (Laukkanen et al., 2006, Kjeldsen et al., 1997, Kjeldsen et 
al., 2001, Mundal et al., 1996, Filipovsky et al., 1992, Kohl et al., 1996) and total 
mortality (Filipovsky et al., 1992, Kohl et al., 1996, Fagard et al., 1996) 
independent of resting BP. 
 
Adjustments in the autonomic nervous system during exercise are mediated by 
central command (feed-forward signals from higher brain centres) (Zuntz and 
Geppert, 1886, Goodwin et al., 1972), mechanically sensitive afferents (group III) 
and metabolically sensitive afferents (group IV) from the skeletal muscle 
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(collectively known as the exercise pressor reflex) (Alam and Smirk, 1937, Mense 
and Stahnke, 1983, Kaufman et al., 1983). In addition, a proportion of the group 
III afferents are polymodal and are stimulated by metabolic stimuli (Kaufman et 
al., 1983). The exercise pressor reflex is critical in regulating the normal CV 
response to exercise, including the maintenance of perfusion pressure to the 
active skeletal muscle (Amann et al., 2011a, Amann et al., 2010, Amann and 
Dempsey, 2008, Amann et al., 2011b). Individuals with untreated hypertension 
have a higher level of sympathetic nerve activity (SNA) at rest (Warnert et al., 
2016) and an exaggerated rise in SNA during dynamic (Sausen et al., 2009, 
Vongpatanasin et al., 2011) and isometric exercise (Delaney et al., 2010) when 
compared to age-matched normotensive individuals. An intrathecal opioid agonist 
(fentanyl), which inhibits the exercise pressor reflex at the dorsal horn, 
normalised the exaggerated BP rise observed in patients with untreated 
hypertension compared to healthy age-matched individuals (Barbosa et al., 
2016). This study highlights the importance of the exercise pressor reflex in 
mediating the abnormal CV response to exercise in hypertension. In animal 
models of hypertension, activation of the metaboreflex leads to exaggerated 
increases in mean arterial pressure (MAP), heart rate (HR) and renal sympathetic 
nerve activity (RSNA) when compared to normotensive animals (Mizuno et al., 
2014b, Mizuno et al., 2013). Additionally, work in humans has also highlighted a 
key role of the metaboreflex (Delaney et al., 2010, Sausen et al., 2009, Greaney 
et al., 2014) in driving an abnormal elevation in MSNA and BP during exercise in 
patients with untreated hypertension.  
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Currently, our understanding of the BP response to exercise and isolation of the 
metaboreflex in patients with treated hypertension is limited. Research in human 
hypertension has focused on patients with untreated hypertension or withdrawn 
from their medication 48-hours prior to participation. It is important to establish 
whether individuals with untreated hypertension who have their BP controlled by 
anti-hypertensive medication still have an exaggerated BP response to 
metaboreflex isolation. Exaggerated BP responses to exercise in patients with 
hypertension are associated with blunted reductions in left ventricular 
hypertrophy during anti-hypertensive therapy (Mizuno et al., 2016b). Worryingly, 
despite adequate BP control, patients with treated-controlled hypertension have 
an increased risk of stroke, CV disease and total mortality when compared to 
normotensive individuals (Lawlor et al., 2011, Brown et al., 2013, Almgren et al., 
2005). Although the exact mechanism for this is unknown, first-line treatment for 
hypertension (including angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, calcium channel blockers and diuretics) does not antagonise 
any of the known receptors that sensitize the metaboreflex in hypertension (acid 
sensing ion channels (ASIC3), purinergic receptors (P2X2/3 and, P2X3 subtypes) 
and transient receptor potential cation channel subfamily V member 1 (TRPv1) 
(Light et al., 2008, Pollak et al., 2014, Stone et al., 2015). The aim of this study 
was to assess whether patients with treated-controlled, treated-uncontrolled and 
untreated hypertension will have an excessive rise in BP during 1) an incremental 
exercise test to peak oxygen consumption (V̇O2 peak test) and 2) isolation of the 
metaboreflex (post-exercise ischemia; PEI). Based on previous research, the 
hypothesis was that there would be a difference in the BP response to 
incremental cycle ergometer exercise and metaboreflex isolation between 
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normotensive controls versus treated-controlled, treated-uncontrolled and 




69 participants were screened for this study and 10 were excluded due to 
screening failure (Figure 3.1, page 196). 16 normotensives, 16 treated-controlled, 
16 treated-uncontrolled and 11 untreated hypertensives (N=59) were matched for 
age, body mass index (BMI), and for CV fitness (V̇O2 peak) (Table 3.1, page 
190). Ethical approval for this study was granted by the Southwest-Exeter NHS 
REC (16/SW/0004). Volunteers were recruited from our groups’ specialist 
hypertension clinic at University Hospitals Bristol Trust and Foundation, Bristol. 
The remaining participants with hypertension were recruited from the surrounding 
area. Normotensive control participants were recruited from our existing database 
of willing participants and from advertising locally. Participants gave informed 
consent during an initial screening visit prior to participation. Table 3.1 (page 190) 
shows participant demographics. Overall, 29 females (49%) were recruited to this 
study and 27 of which were postmenopausal (93%). The remaining 7% were 
perimenopausal. The study was conducted at the Clinical Research and Imaging 
Centre (CRiC), Bristol. All participants attended the CRiC Bristol at a similar time 
of day and all lab conditions were controlled to a set temperature (22C). 
Participants were asked to refrain from alcohol and caffeine for 12 hours before 
the study visits. In addition, participants were asked to abstain from high-intensity 
exercise for at least 24-hours prior to participation. Participants in the treated-
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hypertensive group were asked to take their anti-hypertensive medication as 
normal. 
 
In accordance with the National Institute for Health and Care Excellence (NICE)  
guidelines (NICE, 2011), normotension was defined as clinic BP <140/90 mmHg 
and daytime ambulatory blood pressure monitoring (ABPM) =<135/85 mmHg and 
free from anti-hypertensive medication(s). Untreated hypertension was defined as 
daytime ABPM =>135/85mmHg and not currently taking any anti-hypertensive 
medication (s). Treated-controlled hypertension was defined as daytime ABPM 
(<135/85 mmHg) and the use of one or more anti-hypertensive medications. 
Treated-uncontrolled hypertension was defined as poor BP control on daytime 
ABPM (=>135/85 mmHg) whilst taking one or more anti-hypertensive 
medications. Exclusion criteria included; diabetes mellitus (urine dipstick test and 
self-reported), BMI (>30 kg/m2), pregnancy, major illness (such as cancer), overt 
respiratory-CV disease (other than hypertension), V̇O2 peak > 40 ml/min/kg and 
febrile illness with 2 weeks of the study. Participants were excluded if V̇O2 peak > 
40 ml/min/kg because the BP response to exercise may be modulated by CV 
fitness levels (Kokkinos, 2014). In a group of pre-hypertensive hypertensive 
individuals (average age 52±10), high-fit individuals had a reduced BP during 
moderate and maximal treadmill exercise when compared to unfit individuals 
(Kokkinos et al., 2007). Furthermore, for the average age of the participants in 
this study a V̇O2 peak > 40 ml/min/kg is extreme and way above the average for 
both males (29.4±7.9 ml/min/kg) and females (20.7±5 ml/min/kg) (Kaminsky et 
al., 2015). Participants were excluded from the study if V̇O2 peak > 40 ml/min/kg 
following the screening visit. Participants were also asked to avoid the use of 
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painkillers such as aspirin, paracetamol or anti-inflammatory drugs (e.g., 
ibuprofen) for 24 hours prior to the study visits. Participants were asked to refrain 
from these medications due to their known inhibitory effects on exercise BP 
(Drew et al., 2013, Cui et al., 2007, Cui et al., 2008b). 
 
3.2.2 Study Design 
This was a case-control study. The researcher was blinded to the data analysis 
until all data was analysed. 
 
3.2.3 Screening procedures 
Participants attended an initial screening visit where resting clinic BP was 
measured using an automated cuff (Omron, The Netherlands). In line with the 
European Society of Hypertension (O'Brien et al., 2000, O'Brien et al., 2001, 
O'Brien et al., 2013), the first BP measurement was ignored which was followed 
by a BP reading on both the left and right arm and a final reading was then taken 
on the arm where BP was highest. A research nurse then fitted participants with a 
12-lead electrocardiogram (ECG) prior to a maximal exercise test (V̇O2 peak test) 
on a cycle ergometer to rule out any CV abnormalities. The ECG was checked by 
a cardiologist. Participants were fitted with a 24-hour ABPM to classify 
participants to their respected groups (Spacelabs, OSI Systems Company, USA). 
The 24-hour ABPM assessed BP every 30 minutes during the daytime and once 
per hour throughout sleeping hours. Participants also completed a 24-hour BP 
diary. The ABPM was delayed for 24-hours following the V̇O2 peak to avoid post-
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exercise hypotension (Brito et al., 2014). A flow diagram for the initial screening 
can be seen below (Figure 3.2, page 197). 
 
3.2.3.1 V̇O2 peak assessment 
V̇O2 peak was assessed using a 25 watts/min ramp protocol on a cycle 
ergometer, which started at 0 watts (Love Medical, Manchester, United 
Kingdom). The test began with a 5-minute baseline period which was used to 
compare all haemodynamic variables measured during the V̇O2 peak test. 
Participants were instructed to maintain a cadence during the test of between 60-
80 revolutions per minute. V̇O2 peak (mL/min/kg) was defined as the mean value 
of V̇O2 attained during the final 30 seconds of exercise (Wylie et al., 2016). V̇O2 
peak was defined by the following criteria: an respiratory exchange ratio (RER) of 
>1.15 (Issekutz et al., 1962), HR of 85% maximum (220-age) (Brown et al., 2002) 
and a rating of perceived exertion of > 17 on the 20 point Borg Scale (rating 
perceived exertion) (Church et al., 2008). For more detailed information see 
Chapter 2 (section 2.3.1, page 94). 
 
3.2.4 Study Visit design  
Participants returned at a similar time of day for a follow up visit to the screening 
visit with at least 48 hours between. The study day involved the assessment of 
clinic BP using the same protocol from the initial screening visit. The maximal 
voluntary contraction (MVC) was then assessed using a handgrip dynamometer 
on the dominant hand. To assess the MVC, participants performed a maximal 
contraction of the handgrip dynamometer three times with at least 30 seconds 
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between each attempt. The highest value of the three attempts was regarded as 
the MVC (Delaney et al., 2010). An outline of the study visit design can be seen 
in Figure 3.3 (page 198). 
 
3.2.4.1 Handgrip and Metaboreflex testing 
Prior to handgrip testing the participant was asked to relax for 10 minutes before 
the onset of a baseline period of 10 minutes. Following the baseline assessment, 
the participant performed 1 minute of isometric handgrip exercise at 30% MVC 
(Figure 3.4, page 199). An occlusion cuff was inflated to suprasystolic pressure 
(240 mmHg) over the brachial artery on the exercising arm at 1 minute and 
remained inflated for a further 1 minute 30 seconds and was regarded as PEI 
(Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014, Alam and Smirk, 
1937) (Figure 3.4, page 199). PEI represents isolation of the metaboreflex, 
independent of the mechanoreflex and central command (Kaufman et al., 1983, 
Kaufman et al., 1984). The change in systolic blood pressure (SBP) from 
baseline during the final minute of the PEI period was used as an assessment of 
the sensitivity of the metaboreflex (Figure 3.4, page 199). 
 
3.2.5 Physiological Monitoring During V̇O2 Peak and Metaboreflex Testing 
3.2.5.1 V̇O2 peak test 
BP was measured every 1.5 minutes during the V̇O2 peak testing on the left arm 
of the participant using an automated sphygmomanometer which had not been 
validated for use during exercise (Love Medical, Manchester, UK). To measure 
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HR a 12-lead ECG (Love Medical, Manchester, UK) was used during the V̇O2 
peak test. Breathing frequency, tidal volume, minute ventilation (breathing 
frequency * tidal volume), V̇O2 and volume of carbon dioxide expired (V̇ECO2) 
were assessed using an Ergoflow flow sensor for spirometry (Ergostik CPET 
system, Love Medical, Manchester, UK). For more detailed information see 
Chapter 2 (section 2.3.1, page 94). 
 
3.2.5.2 Metaboreflex testing 
During isometric handgrip exercise and PEI, the change in BP was assessed on 
a beat-to-beat basis using finger plethysmography (Finometer; Finapres Medical 
Systems, The Netherlands). The change in HR was measured using a 3-lead 
ECG. The change in BP and HR were compared to a baseline period of 10 
minutes. Data was collected during baseline, isometric handgrip exercise and PEI 
using a data acquisition system (LabChart 7; AD Instruments). 
 
3.2.6 Power calculations 
To find a significant difference (P=<0.05) in peak SBP during maximal exercise 
testing (V̇O2 peak test), 60 participants will provide the power >80%. A previous 
study (Mizuno et al., 2016b) found that an exaggerated SBP during exercise 
testing was 214±12 mm Hg (n=40) and a normal SBP response to exercise was 
172±8 mm Hg (n=63). A large effect size was calculated from these results (f = 
2.04). It was assumed that there would be more variance in our data because this 
previous study grouped participants into subgroups based on their SBP response 
to exercise (e.g. low-medium-high) and was therefore left with a small standard 
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deviation and very large effect size, therefore a smaller effect size was used for 
this study (d = 0.45). 
 
3.2.7 Data analysis 
3.2.7.1 V̇O2 peak test 
The previous literature that has assessed BP responses to maximal exercise 
testing (V̇O2 peak testing) has focused on peak BP. It is currently unclear at what 
% of V̇O2 peak testing the exaggerated BP rise occurs in patients with 
hypertension (Kjeldsen et al., 2001, Kjeldsen et al., 1997, Mundal et al., 1996, 
Kurl et al., 2001, Fagard et al., 1996). Therefore, to assess at what % of V̇O2 
peak testing that the rise in BP is different between normotensives, untreated 
hypertensives, treated-controlled hypertensives and treated-uncontrolled 
hypertensives two methods of analysis were used: 
1. The absolute change (Δ), percentage change (%) and absolute BP during 
the V̇O2 peak test was assessed in five different epochs of: 0-25, 26-50, 
51-75, 76-100% and the peak BP attained during the V̇O2 peak test. 
2. The peak absolute change in SBP attained during the test was divided by 
the peak exercise time to calculate the rise in SBP per minute (SBP/min). 
This analysis was completed during V̇O2 peak testing for SBP, diastolic blood 
pressure (DBP), MAP, pulse pressure (PP), HR, tidal volume, breathing 
frequency and minute ventilation. The anaerobic threshold was calculated using 
the V-slope method, briefly, a moving average of VECO2 (L/min)  was plotted 
against a moving average of V̇O2 (L/min), the intercept at which  VECO2 (L/min) 
crosses V̇O2 (L/min) was regarded at the anaerobic threshold (Svedahl and 
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MacIntosh, 2003, Sue et al., 1988, Schneider et al., 1993). The anaerobic 
threshold is reported as a percentage value of V̇O2 peak. Additionally, the 
ventilatory efficiency slopes (VE/VECO2 slope), defined as the relationship 
between minute ventilation and carbon dioxide production were assessed 
(Rausch et al., 2013). A VE/VECO2 slope >34 has been shown to highlight high 
risk pulmonary hypertension and heart failure patients (Rausch et al., 2013, Bard 
et al., 2006). However, little is known about the VE/VECO2 slope in patients with 
essential hypertension, treated or untreated. The VE/VECO2 slope is assessed by 
plotting VE against VECO2 from the onset of exercise to peak exercise or 
baseline to the anaerobic threshold (Bard et al., 2006). The VE/VECO2 slope has 
increased prognostic value when measured from the onset of exercise to peak 
exercise in heart failure (Bard et al., 2006). 
 
3.2.7.2 Metaboreflex testing 
The absolute change in SBP, DBP, MAP, PP and HR during isometric handgrip 
exercise and PEI were measured over 30 second epochs (Delaney et al., 2010). 
The change in SBP, DBP, MAP, PP and HR were assessed by comparing to a 
10-minute baseline prior to the onset of isometric handgrip exercise. PEI was split 
into 3 epochs, PEI 1, PEI 2 and PEI 3 which accounted for the initial drop in BP 
following the withdrawal of isometric handgrip exercise expected in PEI 1 
(Delaney et al., 2010). A 5-minute recovery period following metaboreflex testing 
was split into 5 1-minute epochs (R1, R2, R3, R4, R5). The analysis was 
completed using LabChart 7 (AD Instruments), Spike 2 (Cambridge Electronic 
Designs) and Microsoft Excel (Microsoft Corp., Redmond, WA). 
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3.2.8 Additional physiological measurements 
3.2.8.1 Heart Rate Variability 
Heart rate variability (HRV) (LabChart 8; AD Instruments) was calculated using 
the Lomb Periodogram nonparametric method for spectral analysis from the 10 
minute baseline period and the 5 minute recovery period following PEI (Krafty et 
al., 2014). The software used for analysis (LabChart 7, AD Instruments) 
automatically removes any abnormal R-R intervals for analysis (e.g. ectopics). 
The following parameters were used for the HRV analysis: low-frequency (LF) 
power = 0.04-0.15 Hz and high-frequency (HF) power =0.15-0.40 Hz (Billman, 
2013). HF represents a parasympathetic component related to HR changes 
mediated by respiration and LF represents baroreceptor modulation (Miranda 
Dantas et al., 2012, Akselrod et al., 1981, Pomeranz et al., 1985). Patients with 
baroreflex failure have a reduced LF power during tyramine administration when 
compared to individuals with a normally functioning baroreflex (Moak et al., 
2007). The European Society of Cardiology guidelines for HRV state that at least 
60 seconds of ECG recording is needed for LF and 120 seconds for HF, 
therefore HRV analysis was analysed at rest and recovery but not during 
isometric handgrip or PEI (Force, 1996). The very low-frequency (VLF) (0.0033 – 
0.04 Hz) power for this study is not reported as longer time periods (24-hours) 
are needed for analysis of this component of HRV (Kleiger et al., 2005, Force, 
1996). For HRV, the LF/HF ratio, the LF and HF are reported as normalised to 
total power (HF nu and LF nu) and as total power (ms2). 
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In addition, HRV was assessed using the time-domain method using LabChart 
version 8 (AD Instruments). The following parameters are reported from the time-
domain analysis. Firstly, the standard deviation of the RR interval (SDRR). As the 
SDRR is equal mathematically to the total power of the spectral analysis, the 
SDRR is a reflection of the combination of the cyclic components of the variability 
from the recording period (Force, 1996). The ESC guidelines suggest that a 
minimum period of 5 minutes should be used to assess SDRR (Force, 1996). 
However, with longer periods of analysis (e.g. 24 hours) the variability of the RR 
interval is larger and when using shorter analysis time lengths (e.g. 5 minutes) 
the SDRR may only represent the high frequency component of HRV. Other 
methods, such as the standard deviation of the average RR interval (SDARR) 
and standard deviation of the RR interval require longer periods of recording for 
accurate assessment (e.g. 24 hours). In addition, the square root of the mean 
standard differences (RMSSD) of successive RR intervals and the pRR50 
represent the high frequency component of the HRV (Force, 1996, Hartwich et 
al., 2013, Hartwich et al., 2011) and can be assessed accurately over short 
periods of time (e.g. 5 minutes) (Force, 1996). The pRR50 is the RR50, the 
amount of RR intervals above 50 ms divided by the total number of RR intervals 
(Force, 1996).  
 
3.2.8.2 Spontaneous Cardiac Baroreflex Sensitivity 
 The spontaneous cardiac baroreflex sensitivity was assessed using the 
sequence method in all of the participants from the 10-minute baseline period 
prior to metaboreflex testing and during the 5-minute recovery period. The up and 
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down sequences of SBP and the R-R interval were used for this analysis (Parati 
et al., 1988). More specifically, up sequences require at least 3 or more cardiac 
cycles where there is an increase in SBP and the R-R interval (Parati et al., 
1988). Similarly, down sequences require at least 3 or more cardiac cycles where 
there is a decrease in SBP and the R-R interval (Parati et al., 1988). Any points 
at which one parameter was increasing and the other decreasing were not 
included in the analysis (Parlow et al., 1995). The thresholds for cardiac 
baroreflex sensitivity are a minimum change in SBP of 1 mmHg and a change in 
the R-R interval of 6 msec (Parati et al., 1988, Taylor et al., 2015). The change in 
R-R interval to a given change in SBP was chosen as there is evidence that this 
related to vagal tone at the level of the heart (Parker et al., 1984). The sensitivity 
of the cardiac baroreflex was assessed by plotting the change in the R-R interval 
against the absolute change in the SBP, the accepted r value was set at =>0.80 
(Parati et al., 1988). A minimum number of 3 sequences was required to perform 
analysis of the cardiac baroreflex sensitivity (Parati et al., 1988). LabChart 7 (AD 
Instruments), Spike 2 (Cambridge Electronic Designs), Microsoft Excel (Microsoft 
Corp., Redmond, WA) and CardioSeries v2.4 (http://www.danielpenteado.com) 
were used to assess cardiac baroreflex sensitivity. An issue with the sequencing 
method is that over short periods of time increases in SBP are not always 
coupled to changes in the R-R interval (Di Rienzo et al., 2001). Whereas over a 
24-hour period typically 80 sequences are found per hour in healthy individuals 
(Di Rienzo et al., 2001, Parati et al., 1988). The baroreflex effectiveness index 
was also assessed which uses the same 3 or more cardiac cycles where there is 
an increase in SBP and the R-R interval (Di Rienzo et al., 2001). In addition, this 
method also uses a minimum change in SBP of 1 mmHg and a change in the R-
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R interval of 6 msec (Di Rienzo et al., 2001). Unlike the cardiac baroreflex 
sensitivity analysis the baroreflex effectiveness index considers SBP and R-R 
interval ramps from 0, 1 and 2 beat lags. This inclusion criteria were based on 
previous research that found SBP and R-R interval ramps with 0,1 and 2 beat 
delays are under baroreflex control (Blaber et al., 1995). The baroreflex efficiency 
index was calculated as the total number of SBP ramps divided by the number of 
R-R interval/SBP sequences (Di Rienzo et al., 2001). The average of the 
baroreflex efficiency index was taken from 0,1 and 2 beat delays to give an 
overall baroreflex efficiency index (Di Rienzo et al., 2001). 
 
3.2.9 Statistical Analysis  
Baseline characteristics were compared using an ordinary 1-way analysis of 
variance (ANOVA) with a Tukey test for multiple comparisons if a significant 
interaction effect was found. Data were tested for normal distribution and 
homogeneity of variance using a D’Agostino-Pearson omnibus K2 normality test 
and Levine’s test for homogeneity of variances respectively. The α level was set 
at 0.05. 
 
The group averages (normotensives, untreated hypertensives, treated-controlled 
hypertensives and treated-uncontrolled hypertensives) for the absolute change 
(Δ), percentage change (%) and absolute SBP, DBP, MAP, PP, HR, tidal volume, 
breathing frequency and minute ventilation during the V̇O2 peak test were 
compared using an ordinary 2-way ANOVA. A Tukey test for multiple 
comparisons was used if a significant interaction effect was found with the 
Chapter 3 The Exercise Pressor Reflex in Humans with Hypertension 
163 
 
ordinary 2-way ANOVA. The group averages for the absolute change (Δ) in SBP, 
DBP, MAP, PP and HR during isometric handgrip and PEI were compared using 
an ordinary 2-way ANOVA. A Tukey test for multiple comparisons was used if a 
significant interaction effect was found with the ordinary 2-way ANOVA. A 
Pearson’s correlation coefficient was performed to assess whether the was a 
relationship between the change in absolute SBP during PEI and the absolute 
change in SBP at peak exercise during the V̇O2 peak test. All data from the V̇O2 




3.3.1 Participant demographics 
All of the groups were matched for age (P=0.73; Table 3.1. page 190), BMI 
(P=0.25; Table 3.1, page 190), V̇O2 peak scores (P=0.97; Table 3.1, page 190) 
and anaerobic threshold (P=0.75; Table 3.1. page 190). As predicted, daytime 
ambulatory SBPs were different between groups (F=26.57; P=<0.0001; Table 
3.1, page 190). Most importantly, the treated-controlled hypertension group had a 
similar daytime systolic ABPM result compared to normotension (125±7 mm Hg 
vs. 120±9 mmHg; P=0.37). Additionally, treated-uncontrolled hypertensive 
individuals (145±12 mm Hg) had higher daytime ambulatory SBP when 
compared to normotensive (120±9 mmHg; P=<0.0001) and treated-controlled 
hypertensives (125±7 mmHg; P=<0.0001). Similarly, untreated hypertensives 
(145±10 mmHg) had a higher daytime ambulatory SBP when compared to 
normotensive (120±9 mmHg; P=<0.0001) and treated-controlled hypertensives 
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(125±7 mmHg; P=<0.0001). Treated-uncontrolled (145±12 mmHg) and untreated 
hypertensive (145±10 mmHg) individuals had a similar daytime ambulatory SBP 
(P=0.99). Daytime DBP (F=8.89; P=<0.0001), MAP (F=17.53; P=<0.0001) and 
PP (F=9.13, P=<0.0001) showed a similar pattern between groups (see Table 
3.1, page 190). There were no group differences in daytime ambulatory HR 
(F=1.2; P=0.32). Similar to daytime systolic ABPM there was also a difference in 
night-time ambulatory SBP monitoring (F=15.35; P=<0.0001; Table 3.1, page 
190). A Tukey post hoc test showed that night-time ambulatory SBP was similar 
between normotension and treated-controlled hypertension (108±10 vs. 112±10 
mmHg respectively; P=0.68). Treated-uncontrolled hypertensives (130±12 mm 
Hg) had a higher night-time ambulatory SBP when compared to normotensive 
(108±10 mm Hg; P=<0.0001) and treated-controlled hypertensive (112±10 
mmHg; P=0.002) individuals. Untreated hypertensives (129±12 mmHg) had a 
higher night-time ambulatory SBP when compared to normotensive (108±10 
mmHg; P=<0.0001) and treated-controlled hypertensives (112±10 mmHg; 
P=0.001). Treated-uncontrolled (130±12 mmHg) and untreated hypertensives 
(129±12 mmHg) had a similar night-time ambulatory SBP (P=0.99). Similar 
results were found for MAP (F=12.39;P=<0.0001;Table 3.1, page 190) and PP 
(F=5.56;P=0.002;Table 3.1, page 190) but there were no group differences for 
night-time ambulatory DBP (F=1.82 P=0.15; Table 3.1, page 190) or HR 
(F=1.13;P=0.35; Table 3.1, page 190). Group averages for clinic BP 
measurements are shown Table 3.1 (page 190). The antihypertensive 
medications that participants were taking are shown in Table 3.1 (page 190) and 
Table 3.2 (page 192). 
 
Chapter 3 The Exercise Pressor Reflex in Humans with Hypertension 
165 
 
3.3.2 V̇O2 Peak Test 
A significant interaction effect was found between the percentage of V̇O2 peak 
and the absolute change in SBP (F (15, 275) = 4.937; P=<0.0001; Figure 3.5, 
page 200). The Tukey post hoc test revealed that that absolute increase in SBP 
was similar between all groups at 0-25 and 26-50% V̇O2 peak testing (P=>0.05). 
However, at 51-75% V̇O2 peak testing, treated-uncontrolled (45±14 mmHg) and 
treated-controlled hypertensives (42±13 mmHg) had a similar change in absolute 
SBP (P=0.9) that was elevated compared to normotensive individuals (29±17 
mmHg; P=0.009 and P=0.048). Untreated hypertensive (42±16 mmHg) and 
normotensive (29±17 mmHg) individuals had a similar absolute increase in SBP 
at 51-75% V̇O2 peak (P=0.09). Similarly, at 76-100% V̇O2 peak the treated-
uncontrolled (74±22 mmHg), treated-controlled (65±12 mmHg) and untreated 
hypertensives (68±20 mmHg) had a similar absolute change in SBP (P=>0.05) 
which was elevated compared to the normotensive group (46±17 mmHg; 
P=<0.0001, P=0.0007, and P=0.0003 respectively). Similar results were found for 
peak exercise (Figure 3.5, page 200). The results were similar when assessing 
the absolute SBP and percentage change in SBP (Figure 3.6 and 3.7, pages 
202-204). However, the absolute resting SBP prior to the V̇O2 peak test was not 
different between the groups (P=>0.05; Figure 3.6, page 202). The SBP/min was 
different between groups (F=5.762, P=0.002). The Tukey post hoc test showed 
that the SBP/min was similar between treated-uncontrolled, controlled and 
untreated hypertensives but was elevated when compared to the normotensive 
group (8±2,8±1, 8±3 vs. 5±2 mmHg respectively; P=0.02, P=0.002 and P=0.02 
respectively).  
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The absolute change in DBP during exercise was different between groups (F 
(15,275) =3.082, P=0.001). The Tukey post hoc test found that the absolute 
change in DBP was similar between the groups during 0-25 and 26-50% V̇O2 
peak (P=>0.05; Figure 3.5, page 200). However, at 51-75% V̇O2 peak the 
treated-controlled hypertensive group (10±19 mmHg) had an increased absolute 
change in DBP when compared to normotensives (1±7 mmHg; P=0.02). In 
addition, the absolute change in DBP was similar between treated-uncontrolled 
(7±9 mmHg) and treated-controlled (10±19 mmHg) hypertension (P=0.89) but 
was elevated when compared to untreated hypertension (-2±8 mmHg; P=0.027 
and P= 0.004 respectively). Normotensive (1±7 mmHg) and untreated 
hypertensive (-2±8 mmHg) individuals had a similar absolute change in DBP at 
51-75% V̇O2 peak (P=0.83). At 76-100% V̇O2 peak the treated-uncontrolled 
hypertension (18±14 mmHg) group had a larger increase in absolute change in 
DBP when compared to normotensives (5±8 mmHg; P=0.0005). Treated-
uncontrolled (18±14 mm Hg) and treated-controlled (12±12 mmHg) hypertension 
had a similar change in absolute DBP (P=0.29), but both were exaggerated when 
compared to untreated hypertension (2±10 mm Hg; P=<0.0001 and P=0.02 
respectively). Again, the absolute change in DBP was similar between 
normotensives (5±8 mmHg) and untreated hypertensives (2±10 mmHg) at 76-
100% V̇O2 peak (P=0.78). Similar results were attained at peak exercise (Figure 
3.5, page 200). In addition, similar results were found for the absolute change in 
MAP and PP during the V̇O2 peak (F (15,275) = 4.807; P=<0.0001 and (F 
(15,275) = 3.132; P=<0.0001 respectively; Figure 3.5, page 200). 
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The absolute change in HR during the V̇O2 peak test was different between the 
groups (F (15,275) = 2.032, P=0.01; Figure 3.5, page 200). The Tukey post hoc 
test revealed that there was no difference between the groups up to 76-100% 
V̇O2 peak, where untreated hypertensives (72±19 beats/min) had an exaggerated 
rise in absolute HR compared to treated-uncontrolled hypertension (61±14 
beats/min; P=0.047). At peak exercise, both treated-controlled (80±13 beats/min) 
and untreated hypertension (83±19 beats/min) had a similar rise in absolute HR 
(P=0.91) that was exaggerated when compared to normotension (70±14 
beats/min; P= 0.04 and P= 0.01). In addition, at peak exercise, both treated-
controlled (80±13 beats/min) and untreated hypertension (83±19 beats/min) had 
an exaggerated change in absolute HR when compared to treated-uncontrolled 
hypertension (67±16 beats/min; P=0.003 and P=0.001). Normotensive (70±14 
beats/min) and treated-uncontrolled (67±16 beats/min) hypertensives had a 
similar change in absolute HR at peak exercise (P=0.86). 
 
Tidal volume and breathing frequency were similar between all groups during 
baseline and during the V̇O2 peak test (F(15,330)=0.218, P=0.99 and F(15,330) = 
0.88, P=0.59 respectively; Figure 3.8, page 206). Similarly, minute ventilation was 
also similar between the groups during baseline and the V̇O2 peak test (F 
(15,330) = 0.29, P=0.99; Figure 3.8, page 206). RER was similar between 
normotensives (1.21±0.16), treated uncontrolled (1.16±0.12), treated controlled 
(1.21±0.14) and untreated hypertensives (1.22±0.13) (F(15,330)=0.91; P=0.55) at 
peak exercise ( Figure 3.8, page 206). 
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The VE/VECO2 slope was different between the groups (F=2.97; P=0.04). A 
Tukey multiple comparison post-hoc test found that untreated hypertensives 
(33±4) had an elevated VE/VECO2 slope when compared to normotensive 
individuals (29±4; P=0.04). However, the VE/VECO2 slope was similar between 
treated controlled hypertension (32±4) and normotensive individuals (29±4; 
P=0.12). The VE/VECO2 slope was also similar between treated uncontrolled 
hypertension (30±4) and normotension (29±4; P=0.93). There was no correlation 
between the VE/VECO2 slope and the change in SBP (mmHg) at moderate (51-
75% V̇O2 peak testing) (r=0.19; P=0.41; Figure 3.9, page 209) or at peak 
exercise (r=-0.06; P=0.66; Figure 3.9, page 209). 
 
3.3.3 Metaboreflex testing 
Two of the 16 treated-controlled hypertensives withdrew between visit one and 




The absolute SBP as measured by the Finapres was similar between 
normotensive (129±19 mmHg), treated uncontrolled (140±13 mmHg), treated 
controlled (123±25) and untreated hypertensives (130±26 mmHg) 
(F(15,265)=1.858; P = 0.15). Similar results were found for baseline absolute 
DBP between normotensives (57±12 mmHg) treated uncontrolled (58±9 mmHg), 
treated controlled (56±15) and untreated hypertensives (60±17 mmHg) 
(F(15,265)= 0.2547; P = 0.86). Similar results were found for MAP and PP. In 
Chapter 3 The Exercise Pressor Reflex in Humans with Hypertension 
169 
 
addition, there were no differences between normotensives (61±9 beats/min), 
treated uncontrolled (62±13 beats/min), treated controlled (60±10 beats/min) and 
untreated hypertension (58±9 beats/min) in baseline absolute HR 
(F(15,265)=0.2482; P=0.86). Breathing frequency was also comparable among 
normotensives (13±3 breaths/min), treated uncontrolled (14±2 breaths/min), 
treated controlled (13±2 breaths/min) and untreated hypertensives (13±3 
breaths/min) (F(15,265)=0.68; P= 0.57).  
 
3.3.3.2 HRV 
3.3.3.2.1 Spectral analysis 
No differences were found for either the LF/HF ratio, LF (nu), HF (nu), LF (ms2) or 
HF (ms2) between normotensive, treated controlled, treated uncontrolled or 
untreated hypertension during the baseline period (P=>0.05; Table 3.3, page 
193). 
 
3.3.3.2.2 Time-domain analysis 
No differences were found for either the SDDR (ms), RMSDD (ms) or the pRR50 
(%) between normotensive, treated controlled, treated uncontrolled or untreated 
hypertension during baseline (P=>0.05; Table 3.3, page 193). 
 
3.3.3.3 Spontaneous cardiac baroreflex sensitivity 
There were no differences in the gain of the cardiac baroreflex sensitivity at 
baseline between the groups (P=>0.05; Table 3.4, page 194). However, during 
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baseline only 64% of untreated hypertensives, 69% of treated uncontrolled, 86% 
of treated controlled and 94% of normotensives had 3 or more baroreflex 
mediated ramps (Table 3.4, page 194). Untreated hypertensives had significantly 
more baroreflex sequence ramps (total) when compared to normotensives 
(P=0.035), treated controlled (P=0.02) and treated uncontrolled (P=0.049) (Table 
3.4, page 194). The total ramps (baroreflex and non-baroreflex ramps) were not 
different between groups and can be found in Table 3.4 (page 194). In addition, 
untreated hypertensives had a higher baroreflex effectiveness index when 
compared to normotension (P=0.0004), treated uncontrolled (P=0.007) and 
treated controlled (P=0.0004) (Table 3.4, page 194). However, during baseline 
the baroreflex effectiveness index could only be assessed in 64% of untreated 
hypertensives, 69% of treated uncontrolled, 86% of treated controlled and all 
(100%) of the normotensives (Table 3.4, page 194). 
 
3.3.3.4 Isometric handgrip 
The absolute change in SBP, DBP, MAP, PP and HR during isometric handgrip 
exercise and PEI can be seen in Figure 3.10 (page 210). Figure 3.11 (page 212) 
shows a typical absolute change in SBP during isometric handgrip and during 
PEI from one individual from each group. There was a significant interaction 
effect during isometric handgrip for the absolute change in SBP (F (15,265) = 
4.222; P = <0.0001). A post-hoc Tukey test revealed that during 0-30s and 30-
60s of isometric handgrip exercise testing, treated controlled and treated 
uncontrolled hypertensives had a similar absolute change in SBP (P=0.83 and 
P=0.14 respectively). Treated-controlled hypertensives had an exaggerated 
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change in absolute SBP compared to normotensives during 0-30s and 30-60s of 
isometric handgrip (P=0.006 and P=0.02 respectively). Treated-uncontrolled 
hypertensives also had an exaggerated change in absolute SBP compared to 
normotensives (P=0.0001 and P=<0.0001 respectively). Untreated hypertensives 
had a similar change in absolute SBP when compared to normotensives during 
both 0-30 and 30-60s of isometric handgrip (P=0.41 and P=0.24 respectively). 
There was no significant interaction effect for the groups for the absolute increase 
in DBP during isometric handgrip (F (15,265) = 1.701; P = 0.051). A significant 
interaction effect was noted for the absolute change in MAP and PP during 
isometric handgrip (F (15,265) = 3.021, P=0.0002 and F (15,265) = 2.665, 
P=0.0009). Tukey post-hoc tests revealed similar results compared to the 
absolute change in SBP for MAP and PP (Figure 3.10, page 210). There was 
also no significant difference noted for the absolute increase in HR during 
isometric handgrip (F (15,265) = 1.478, P=0.11). 
 
There was a significant interaction effect for the absolute SBP during isometric 
handgrip exercise (F(15,265) = 4.16; P=<0.0001). A Tukey post test revealed that 
treated uncontrolled hypertensives had a higher absolute SBP compared to 
normotensives (P=0.01) and treated controlled hypertension (P=0.048) during 0-
30s of isometric handgrip. Similar results were found during 30-60s of isometric 
handgrip exercise. No other significant differences were found between groups 
(P=>0.05). No significant differences were found for absolute DBP (P=>0.05) and 
MAP (P=>0.05) during 0-30 or 30-60s of isometric handgrip exercise. However, a 
significant interaction effect was found for absolute PP (F(15,265) = 2.589; 
P=0.001). Similar to SBP, treated uncontrolled hypertensives had a higher 
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absolute PP compared to normotensives (P=0.03) and treated controlled 
hypertension (P=0.04) during 0-30s and 0-60s of isometric handgrip. No 
differences were found for absolute HR during isometric handgrip exercise at 0-
30s or 30-60s of isometric handgrip exercise (P=>0.05). Finally, there were no 
significant differences for absolute breathing frequency between groups during 0-
30 or 30-60s of isometric handgrip exercise (P=>0.05), indicating that participants 
continued a normal breathing pattern during isometric handgrip exercise. 
 
3.3.3.5 Post-exercise ischemia 
A significant interaction effect was found the absolute change in SBP during PEI 
(F (15,265) = 4.222; P = <0.0001). A Tukey post-hoc test revealed that during the 
first epoch of PEI treated controlled, treated uncontrolled and untreated 
hypertension had an exaggerated absolute change in SBP compared to 
normotension (P=<0.0001, P=0.0142 and P=0.0009). Similar results were seen 
for the second and third epoch of PEI (see Figure 3.10, page 210). There was not 
a significant interaction effect for the absolute increase in DBP during the three 
epochs of PEI (F (15,265) = 1.701; P = 0.051). A significant interaction effect was 
noted for the absolute change in MAP and PP during the three epochs of PEI (F 
(15,265) = 3.021, P=0.0002 and F (15,265) = 2.665, P=0.0009). A Tukey post-
hoc test revealed comparable results for MAP and PP compared to SBP (see 
Figure 3.10, page 210). Similar to isometric handgrip no difference was observed 
for the absolute change in HR during any of the three epochs of PEI (F (15,265) = 
1.478, P=0.11). 
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There was a positive correlation between the change in SBP (mmHg) during 
metaboreflex isolation and the peak change in SBP (mmHg) during V̇O2 peak 
testing (r = 0.36; R2 = 0.13; P=0.007; see Figure 3.12, page 213). There was no 
correlation between spontaneous cardiac baroreflex sensitivity and the rise in 
SBP during PEI (r=-0.1887; P=0.29). 
 
There was also a significant interaction effect for the absolute SBP during all 
epochs of PEI (F(15,265) = 4.16); P=<0.0001). A Tukey post test revealed that 
during PEI1, PEI2 and PEI3 treated uncontrolled hypertensives had a higher 
absolute SBP compared to normotensives (P=<0.05) and treated controlled 
hypertension (P=<0.05). No other significant differences were found between 
groups (P=>0.05). There were no significant differences for absolute DBP or 
MAP (P=>0.05) during PEI1, PEI2 or PEI3. However, a significant interaction 
effect was found for absolute PP during PEI (F(15,265) = 2.589); P=0.001). 
Treated uncontrolled hypertensives had a higher absolute PP during PEI1, PEI2 
and PEI3 compared to normotensives (P=<0.05) and treated controlled 
hypertensives (P<0.05). No other differences were found for PP during PEI1, 
PEI2 or PEI3 (P=>0.05). No differences were found for absolute HR during PEI 
(P=>0.05). Similar to isometric handgrip exercise there were no significant 
differences for absolute breathing frequency between groups during PEI1, PEI2 
and PEI3 (P=>0.05). 
 




There were no differences between normotension, treated uncontrolled, treated 
controlled or untreated hypertension for the change in SBP, DBP, MAP, PP or 
HR from baseline during R1, R2, R3, R4 or R5 following metaboreflex testing 
(P=>0.05; Figure 3.13, page 214). Similarly, no differences were found for 
absolute SBP, DBP, MAP or HR during R1, R2, R3, R4 or R5 following 
metaboreflex testing (P=>0.05). However, absolute PP was significantly elevated 
in treated uncontrolled hypertensives when compared to normotensives, treated 
controlled and untreated hypertensives during R1, R2, R3, R4 and R5 (P=<0.05). 
 
3.3.3.7 HRV during recovery 
3.3.3.7.1 Spectral analysis 
No differences were found for either the LF/HF ratio, LF (nu), HF (nu), LF (ms2), 
HF (ms2) between normotensive, treated controlled, treated uncontrolled or 
untreated hypertension during recovery (P=>0.05; Table 3.3, page 193). In 
addition, no differences were found when comparing baseline to recovery for 
LF/HF ratio, LF (nu), HF (nu), LF (ms2), HF (ms2) to recovery (P=>0.05; Table 
3.3, page 193). 
 
3.3.3.7.2 Time-domain analysis 
No differences were found for either the SDDR (ms), RMSDD (ms) or the pRR50 
(%) between normotensive, treated controlled, treated uncontrolled or untreated 
hypertension during recovery (P=>0.05; Table 3.3, page 193). In addition, no 
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differences were found when comparing baseline to recovery for time-domain 
HRV analysis (SDDR (ms), RMSDD (ms) or the pRR50 (%) (P=>0.05; Table 3.3, 
page 193). 
 
3.3.3.7.3 Spontaneous cardiac baroreflex sensitivity 
There were no differences in the gain of the cardiac baroreflex sensitivity during 
recovery between the groups (P=>0.05; Table 3.3, page 193). However, during 
recovery only 64% of untreated hypertensives, 75% of treated uncontrolled, 71% 
of treated controlled and 94% of normotensives had 3 or more baroreflex 
mediated ramps (P=>0.05; Table 3.3, page 193). There were no differences in 
the baroreflex sequences ramps (total) between groups (P=>0.05; Table 3.3, 
page 193). The total ramps (baroreflex and non-baroreflex ramps) were not 
different between groups (P=>0.05) and can be found in Table 3.3 (page 193). In 
addition, there were no differences in the baroreflex effectiveness index between 
groups during recovery (P=>0.05; Table 3.3, page 193). However, during 
recovery the baroreflex effectiveness index could only be assessed in 64% of 
untreated hypertensives, 75% of treated uncontrolled, 71% of treated controlled 
and 94% of normotensives (Table 3.3, page 193). 
 
3.4 Discussion 
The main finding of this study is that individuals with treated controlled 
hypertension have an excessive rise in absolute SBP during moderate and peak 
dynamic exercise compared to normotensive individuals, despite having similar 
resting BP. In addition, individuals with treated controlled hypertension had a 
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disproportionate change in BP during isolation of the metaboreflex, which was 
higher than normotensives. This suggests that the metaboreflex plays a part in 
mediating this abnormal BP response to exercise in treated and untreated 
hypertension. Most concerning is that this occurs regardless of antihypertensive 
treatment and adequate control of resting BP. 
 
3.4.1 Blood pressure during dynamic exercise and cardiovascular risk 
The current goal of the clinician is to normalise resting BP to guidelines targets 
and lower the risk of CV events in patients. The results of this study and other 
studies suggest that this routine clinical practice needs to be reassessed. This is 
especially concerning as the BP response to exercise has been associated with 
acute myocardial infarction (Mittleman and Siscovick, 1996, Willich  et al., 1993) 
and subarachnoid haemorrhage (Anderson et al., 2003, Schievink et al., 1989). 
Additionally, it is an independent risk factor for long term risk of adverse CV 
events (Kjeldsen et al., 1997, Kjeldsen et al., 2001), any type of stroke (Kurl et 
al., 2001, Laukkanen et al., 2006), left-ventricular hypertrophy (Ren et al., 1985, 
Papademetriou et al., 1989), myocardial infarction (Laukkanen et al., 2006, 
Kjeldsen et al., 1997, Kjeldsen et al., 2001, Mundal et al., 1996, Filipovsky et al., 
1992, Kohl et al., 1996) and total mortality (Filipovsky et al., 1992, Kohl et al., 
1996, Fagard et al., 1996). This study highlights that an exaggerated rise in BP 
during dynamic and isometric exercise may be a factor contributing to the 
increased CV risk in treated controlled hypertension when compared to 
normotensives (Lawlor et al., 2011, Almgren et al., 2005, Brown et al., 2013). 
Clinicians may need to consider exercise testing as part of the screening protocol 
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when diagnosing and treating patients with hypertension. This may help to fully 
highlight the CV risk of the patient.  
 
The VE/VEVCO2 slope was increased in patients with untreated hypertension 
when compared to normotensives. The peripheral chemoreceptors which are 
located in the aortic and carotid bodies senses changes in body partial pressure 
of oxygen (PO2), partial pressure of carbon dioxide (PCO2) and pH and relay 
afferent information to the nucleus tractus solitarius via the carotid sinus and 
vagus nerve (Guyenet, 2014). Stimulation of the peripheral chemoreceptors leads 
to increased respiratory drive and efferent SNA (Sinski et al., 2012, Stickland et 
al., 2008). Increased ventilation during exercise is tightly related to increases in 
CO2 production and peripheral chemosensitivity has been associated with an 
exaggerated VE/VEVCO2 slope during exercise in chronic heart failure (Chua et 
al., 1997, Tomita et al., 2003). Although this has not directly been assessed in 
hypertension, the results from this study suggest increased peripheral 
chemoreceptor activity in untreated hypertension (Ponikowski et al., 2001). The 
VE/VEVCO2 slope has added prognostic value during exercise. For example, 
Arena et al. (2008) reported that in heart failure, an VE/VEVCO2 slope >35 is 
associated with increased risk of an adverse cardiac event. In contrast, Buys et 
al. (2013) found that a VE/VEVCO2 slope >27 was associated with increased risk 
for the future development of hypertension following surgery for aortic 
coarctation. The individuals with untreated hypertension in this study had a 
VE/VEVCO2 slope of 33±4 compared to 29±4 in normotension. Similar to this 
study, a previous study found a VE/VEVCO2 slope of 29±4 in healthy control 
patients (Shen et al., 2015). There is a paucity of research around the 
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VE/VEVCO2 slopes in essential hypertension and more research is needed to 
understand whether these values are prognostically important. In addition, both 
treated hypertension groups had similar VE/VEVCO2 slopes compared to 
normotension. Although this is suggestive that antihypertensive medication can 
influence the sensitivity of the peripheral chemoreceptors during exercise, more 
research is needed to confirm this. 
 
3.4.2 The Metaboreflex 
Interestingly, there was no difference in baseline absolute BPs between the 
groups prior to metaboreflex testing. It is unclear why there was no difference in 
baseline BP, especially as there were differences between the groups using clinic 
and daytime ABPM. However, The Finometer Pro (Finometer, FMS,  
Netherlands) when measuring absolute SBP fails to meet the guidelines of the  
Advancement of Medical Instrumentation (AAMI) of a standard deviation of < 8 
mmHg between intra-arterial BPs and the device being tested. Indeed, the 
Finapres may under or over predict BP by as much as ± 4 for SBP. However, the 
change in SBP using the Finometer Pro has been shown to be more accurate 
(Parati et al., 1989). The remainder of this Chapter will be focused on the 
absolute change in SBP from the Finometer Pro.  
 
There was no difference in LF/HF, LF (nu), HF (nu), LF (ms2), HF (ms2), pRR50, 
SDDR or RMSSD components of HRV among the groups at rest or during 
recovery from metaboreflex testing. Previous research has suggested that the HF 
(nu) and the RMSSD HRV components are predominantly linked to the PSNS 
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(Akselrod et al., 1981, Pomeranz et al., 1985). The utility of the LF (nu) and the 
LF/HF ratio has been questioned because both components are not eliminated 
following parasympathetic denervation and β-adrenergic receptor blockade 
(Randall et al., 1991). In addition, there is reported disparity in the literature 
between the LF component of HRV and the gold standard measurement of SNA, 
microneurography (Notarius et al., 1999). Previous research in small groups of 
patents with hypertension has found mixed results regarding the sequence and 
time-domain measures of HRV relative to normotension (Dassi et al., 1991, 
Radaelli et al., 1994). However, studies with larger numbers of participants have 
found that HRV is impaired in hypertension (Singh et al., 1998, Huikuri et al., 
1996). Therefore, a larger cohort may have been needed in this study to show 
differences in HRV among the groups. 
 
Cardiac baroreflex sensitivity has previously been demonstrated to be impaired in 
patients with hypertension (Zuern et al., 2013, Bristow et al., 1969, Gribbin et al., 
1971, Pikkujamsa et al., 1998). However, there was no differences noted in this 
study. A limitation of the sequencing method to establish cardiac baroreflex 
sensitivity is that the original research to develop the technique was based on 24-
hour readings. A typical 24-hour period typically produces around 80 sequences 
per hour (Parati et al., 1988). A 10-minute baseline period was used for this study 
and 94% (15 out of 16) of normotensives, 86% (12 out of 14) of treated 
uncontrolled, 69% (11 out of 16) of treated controlled and 64% (7 out of 11) of 
untreated hypertensives had 3 or more baroreflex linked sequences during 
baseline to assess resting cardiac baroreflex sensitivity (Table 3.3, page 193). 
This lack of data limits the ability to compare to the previous literature. Potentially, 
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longer periods of time (e.g. 24 hours) are needed to truly establish differences in 
cardiac baroreflex sensitivity between groups (Parati et al., 1988). There 
remained no significant differences in cardiac baroreflex sensitivity during 
recovery from metaboreflex testing between groups. A similar number of 
participants had 3 or more baroreflex related sequences following exercise when 
compared to baseline (Table 3.3, page 193).  
 
3.4.2.1 Metaboreflex testing 
It is well established that the metaboreflex is abnormal in animal models of 
hypertension (Mizuno et al., 2011a, Mizuno et al., 2011b, Mizuno et al., 2013, 
Sala-Mercado et al., 2013) as well as in older patients with untreated 
hypertension (Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014). 
This study has extended these findings to older patients with treated controlled 
and treated uncontrolled hypertension. This heightened metaboreflex sensitivity 
contributes to the exaggerated BP response to dynamic and isometric exercise in 
treated hypertension, regardless of BP control. A recent study found that 
heightened metaboreflex sensitivity in a canine model of hypertension (via partial 
unilateral renal artery occlusion), led to coronary vasoconstriction that limited the 
exercise induced rise in CO and augmented peripheral vasoconstriction (Sala-
Mercado et al., 2013). Coronary vasoconstriction during exercise may limit O2 
delivery to the myocardium and limit ventricular performance. This would also 
contribute to the elevated CV risk associated with exercise in hypertension. 
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In accordance with previous studies, a similar HR response during metaboreflex 
isolation among the individuals with hypertension and normotension was seen 
(Delaney et al., 2010, Sausen et al., 2009). During metaboreflex isolation (PEI) 
where isometric exercise has stopped, it is well documented that despite 
continued BP elevation, HR returns to baseline values (Crisafulli et al., 2003). 
Withdrawal of the mechanoreceptors and central command plus intense 
baroreflex stimulation leads to an increase in parasympathetic activity and a 
decrease in HR towards baseline levels, despite heightened SNA maintained by 
the metaboreflex (Crisafulli et al., 2003, O'Leary, 1993). This phenomenon is 
known as accentuated antagonism (Uijtdehaage and Thayer, 2000). 
 
The metaboreflex mediated increases in SNA, as measured by 
microneurography is exaggerated in patients with untreated hypertension 
(Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014). This has also 
been confirmed during metaboreflex activation in spontaneously hypertensive 
rats (SHR’s) by measuring RSNA (Mizuno et al., 2011b, Mizuno et al., 2011a). 
Although, microneurography was not done in this study, evidence from previous 
literature (Delaney et al., 2010, Sausen et al., 2009) would suggest that 
exaggerated MSNA during metaboreflex activation mediates the BP response to 
exercise in treated controlled and uncontrolled hypertension. 
 
The findings reported in this study are consistent with some (Greaney et al., 
2014, Delaney et al., 2010, Sausen et al., 2009) but not all studies (Rondon et al., 
2006) in individuals with untreated hypertension. Interestingly, the mean age of 
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the participants was above 60 years of age in the studies finding that 
metaboreflex activity was elevated in untreated hypertension (Greaney et al., 
2014, Delaney et al., 2010, Sausen et al., 2009). In contrast, in the study by 
Rondon et al. (2006), the average age of normotensives and untreated 
hypertensives was 38±1 and 42±1 years of age respectively. The current 
consensus is that with increasing age there is a shift towards more oxidative 
skeletal muscle phenotype leading to a reduction in the metabolic disturbance 
that occurs with exercise and therefore a reduction in metaboreflex activity 
(Markel et al., 2003). Interestingly, hypertension is associated with a lower 
proportion of oxidative muscle fibres in the vastus lateralis when compared to 
normotension (Hernelahti et al., 2005). In addition, arterial stiffness (Parikh et al., 
2016) and MSNA (Hart et al., 2009a, Hart et al., 2009b) increase with age and 
are both exaggerated further in patients with hypertension (Warnert et al., 2016). 
These factors may explain why metaboreflex activity is maintained or elevated in 
older untreated hypertensive individuals. 
 
Activation of the mechanoreflex, using passive hindlimb stretch in SHR’s also 
leads to exaggerated BP and RSNA when compared to Wistar-Kyoto rats (Leal et 
al., 2008, Mizuno et al., 2011b, Leal et al., 2013). Moreover, BP and MSNA are 
higher during passive cycling (Velasco et al., 2015) and the first 10 seconds of 
handgrip exercise (Greaney et al., 2015a) in patients with untreated 
hypertension. However, the metaboreflex component of the exercise pressor 
reflex was the sole focus of this Chapter due to the wealth of previous literature in 
untreated hypertension (Delaney et al., 2010, Sausen et al., 2009, Bruce et al., 
1945, Rondon et al., 2006, Greaney et al., 2014). In addition, during exercise of 
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increasing intensity where the metabolism changes primarily from oxidative 
metabolism to glycolysis the changes in the concentration of metabolites (e.g. 
lactate) are likely to augment metaboreflex activity as compared to 
mechanoreflex activity. Indeed, Kaufman et al. (1983) found that the 
metaboreflex increases its firing rates with prolonged exercise. In contrast, the 
mechanoreceptors fire at the onset of exercise but then fire at a reduced rate with 
continued exercise (Kaufman et al., 1983). The previous literature has shown that 
PEI isolates the metaboreflex component of the exercise pressor reflex (Kaufman 
et al., 1984, Alam and Smirk, 1937), whereas it is more difficult to truly isolate the 




The exact mechanisms that mediate altered metaboreflex activity in hypertension 
are unclear. Increased SNA during exercise is directed to all vascular beds during 
exercise, including the active skeletal muscle. However, in normotensive 
individuals the increased SNA is offset in the active skeletal muscle by vasoactive 
metabolites (Thomas et al., 1997a, Thomas et al., 1994, Thomas et al., 1997b, 
Thomas and Segal, 2004, Thomas et al., 2003, Thomas and Victor, 1998). This 
protective mechanism ensures O2 demand is met with adequate supply during 
exercise and is known as functional sympatholysis (Thomas et al., 1997a, 
Thomas et al., 1994, Thomas et al., 1997b, Thomas and Segal, 2004, Thomas et 
al., 2003, Thomas and Victor, 1998). Animals with experimentally induced 
hypertension and humans with untreated hypertension exhibit impaired functional 
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sympatholysis during exercise and this has been shown to be mediated, in part, 
by a reduced nitric oxide (NO) bioavailability, which is caused by a damaged 
endothelium and/or increased oxidative stress within the skeletal muscle itself 
(Zhao et al., 2006, Price et al., 2013, Vongpatanasin et al., 2011). Impaired 
functional sympatholysis leads to a blunted increase in blood flow to the active 
skeletal muscle, which may cause larger accumulations in the metabolites that 
activate the metaboreflex in hypertension (Price et al., 2013, Vongpatanasin et 
al., 2011, Zhao et al., 2006). It could be speculated that the current first line 
treatment for hypertension (calcium channel blockers, thiazide-like diuretics and 
angiotensin-converting enzyme inhibitors (Ahluwalia and Bangalore, 2017) do 
not: A) selectively inhibit the receptors known to activate the metaboreflex or B) 
normalise functional sympatholysis/improve blood flow during exercise. This 
requires future investigation to assess specific effects of individual anti-
hypertensive therapies. A recent series of studies found that nebivolol, a β1-
adrenoceptor antagonist with NO potentiating effects improves functional 
sympatholysis during dynamic handgrip exercise (Price et al., 2013) whereas 
irbesartan, a angiotensin II receptor antagonist failed to cause any improvements 
(Vongpatanasin et al., 2011). Novel anti-hypertensive medications need to 
reduce BP at rest and also dynamic BP control during dynamic and isometric 
exercise, as well as during other stressors (e.g. mental stress and pregnancy). 
Although, recent evidence has highlighted key receptors that activate the 
metaboreflex (Pollak et al., 2014, Light et al., 2008), it is likely that the 
metaboreflex is more complex and much redundancy has been shown by studies 
blocking the receptors (Stone et al., 2015). Improving functional sympatholysis 
and increasing the washout of metabolites that activate the metaboreflex may 
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provide the best option for the pharmacological treatment of exaggerated BP 
responses to exercise. 
 
Despite the clear importance of the metaboreflex in untreated hypertension 
(Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014) very little 
research has assessed the sensitivity/density of the receptors within the skeletal 
muscle that are known to activate the metaboreflex in hypertension. The only 
study that has directly looked at this so far was by Mizuno et al. (2011a), they 
found that expression of TRPV1 was upregulated in the dorsal horn of the spinal 
cord in SHR’s but not in the skeletal muscle where the afferent nerve endings lie. 
It was speculated that enhanced phosphorylation of the TRPV1 receptors on the 
afferent nerve endings could mediate enhanced metaboreflex activity during 
exercise in SHR’s (Mizuno et al., 2011a). 
 
The V̇O2 peak scores of the participants were within the normal range for their 
age group (Kaminsky et al., 2015) and all the groups were matched for V̇O2 peak 
scores. Increasing CV fitness after 8 weeks of aerobic training has been shown to 
improve functional sympatholysis and BP during one-legged knee extensor 
exercise (Mortensen et al., 2014). Similarly, in SHR’s 12 months of wheel running 
has been shown to decrease the pressor response and RSNA during activation 
of the metaboreflex similar to levels seen in Wistar-Kyoto rats (Mizuno et al., 
2014a). Therefore, increasing CV fitness could also improve the autonomic 
response to exercise in hypertension. However, poor adherence to exercise 
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programs is well reported and therefore methods to improve adherence need to 
be emphasised (Brand et al., 2014). 
 
Far more attention has been given to SBP during exercise in the literature and it 
remains unclear as to why the DBP was higher during both moderate (51-75% 
V̇O2 peak) and peak exercise in both the treated controlled and treated 
uncontrolled hypertensive group when compared to patients with untreated 
hypertension and normotension. Normally, DBP remains the same or decreases 
slightly during exercise, indicative of a decline in vascular resistance (Schultz and 
Sharman, 2014). In contrast, an exaggerated increase in DBP during exercise 
highlights an impaired vasodilation of resistance vessels within the skeletal 
muscle vasculature (Brett et al., 2000) and increased risk of CV events 
(Chatterjee et al., 1995, Brett et al., 2000). In addition, increased aortic stiffness 
has been shown to increase SBP and decrease DBP, resulting in elevated PP 
(Laurent et al., 2001, Laurent et al., 2003). Aortic stiffness has previously been 
shown to be elevated in untreated hypertension and could be related to the 
reduction in DBP during exercise (Laurent et al., 2001, Laurent et al., 2003). 
Furthermore, different antihypertensive medications have different effects on 
aortic stiffness with ACEi’s and ARB’s being most effective (Blacher et al., 2005, 
Boutouyrie et al., 2011, Protogerou et al., 2009). Further research is needed to 
fully understand these results. 
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3.4.4 Study limitations 
Firstly, adherence to anti-hypertensive medication is typically poor (Herttua et al., 
2013, Ong et al., 2007) and it was not assessed whether patients with treated 
controlled or treated uncontrolled hypertension were taking their medication(s). 
However, the individuals with treated controlled hypertension had BP under 
control during daytime ABPM and this would suggest that this group were 
adherent to their anti-hypertensive medication(s). In addition, participants were 
asked to record a 24-hour diary during ABPM monitoring and to take note of the 
time that they took their anti-hypertensive medication(s). Second, the treated 
controlled and treated uncontrolled hypertension group both started the study 
taking anti-hypertensive medication, future research will need to assess whether 
different types of anti-hypertensive medications have a different effect on the BP 
response to dynamic and isometric exercise. For example, a recent study found 
that perindopril, a centrally acting angiotensin converting enzyme inhibitor was 
more effective at lowering SBP and MSNA than a peripherally acting angiotensin 
converting enzyme inhibitor (captopril) during dynamic exercise (Moralez et al., 
2018). Future research will need to confirm whether centrally acting anti-
hypertensives are more effective in normalising exercise BP and metaboreflex 
activity in treated controlled and treated uncontrolled hypertension. Thirdly, PEI 
may activate a subtype of the group IV afferents that respond to high levels of 
metabolites that mediate pain (Light et al., 2008, Pollak et al., 2014, Kaufman et 
al., 1984, Amann and Light, 2015). An increased perception of pain during PEI 
may have caused an elevated BP response (Sacco et al., 2013). Although the 
differences in pain perception between the groups during PEI were not assessed 
in this study, individuals with hypertension have a reduced sensitivity to painful 
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stimuli (Ring et al., 2008) and all participants received the same occlusion 
pressure of 240 mmHg. 
 
The metaboreflex was assessed following isometric handgrip exercise with a 
small muscle mass (forearm) and compared to the BP response to dynamic 
exercise with a large muscle mass (legs, V̇O2 peak test). The CV response to 
metaboreflex isolation is different following forearm and leg exercise (Fisher et 
al., 2013) and although the exact mechanism is not understood, it could be 
related to differences in skeletal muscle fibre type, sympathetic vasoconstrictor 
tone and the regulation of functional sympatholysis (Fisher et al., 2013).  
 
3.4.5 Clinical perspectives 
A change in SBP of more than 64 mmHg at peak exercise in the general 
population has been shown to place individuals at increased CV risk (Laukkanen 
et al., 2006). In our treated controlled group, there was a similar change in SBP 
of 72 mmHg. Mizuno et al. (2016b) found that patients with treated hypertension 
who still presented with an exaggerated BP response to exercise had an 
impaired regression of left ventricular hypertrophy compared to patients with 
treated hypertension who had a normalised BP response to exercise. Based on 
this data, future longitudinal studies will need to assess whether exaggerated BP 
response to exercise in patients with treated-controlled hypertension have an 
increased CV risk. In terms of the management of hypertension, these results 
suggest that BP testing should be included in routine clinical practice for treated 
controlled, uncontrolled and untreated hypertension and this will highlight 
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individuals at increased CV risk. This study has highlighted that despite BP 
control at rest, treated controlled hypertensives remain hypertensive during CV 
stress. This suggests an underlying pathology that is currently not being treated 
in hypertension with the currently given anti-hypertensive medications. The 
SPRINT (Systolic Blood Pressure Intervention Trial) found that intensive anti-
hypertensive treatment to lower SBP below 120 mmHg conferred greater CV 
benefits (Wright et al., 2015). The treated controlled hypertensive group in this 
study had a daytime ambulatory SBP of 125±7, it remains to be seen whether 
further lowering of SBP along with the SPRINT guidelines would normalise the 
BP response to exercise and metaboreflex isolation. 
 
3.5 Conclusions 
This is the first study to show that adequate control of BP, classified by 24-hour 
ABPM, fails to normalise the BP response to moderate and peak exercise testing 
when compared to normotensives. An exaggerated change in SBP during 
exercise may explain why treated controlled hypertensives are at increased CV 
risk, despite a similar resting BP, compared to normotensives. In addition, it has 
been shown that the metaboreflex partially mediates this abnormal response to 
exercise in treated controlled, uncontrolled and untreated hypertension. 
  















N 16 11 16 16 
M/F 8/8 6/5 9/7 7/9 
Age (Years) 65±5 65±7 66±6 67±6 
Height (cm) 172±11 173±12 170±9 167±9 
Weight (kg) 70±14 72±14 74±12 72±12 







































































































N/A N/A 1 (IQR=1-
1.75) 
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N; number, M; male, F; female, BMI; body mass index, V̇O2 peak; peak volume of 
oxygen inspired, AT; anaerobic threshold (%), ABPM; ambulatory blood pressure 
monitoring, SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; 
mean arterial pressure, PP; pulse pressure, HR; heart rate, ACEi; angiotensin 
converting enzyme inhibitor, ARB; angiotensin receptor blocker, CCB; calcium 
channel blocker, IQR; inter-quartile range. * P=<0.05 vs. normotension; †P=<0.05 
vs. controlled hypertension (all one-way ANOVA with a Tukey post-hoc test). 
  






Specific drug taken % taking drug 
ARB Candesartan 8 
 Losartan 12 
ACEi Perindopril 4 
 Ramipril 20 
 Lisinopril 4 
CCB Amlodipine 40 
α-blocker Doxazosin 4 
β-blocker Bisoprolol 4 
Diuretics Bendroflumethiazide 4 
Treated-uncontrolled hypertension 
ARB Candesartan 10 
 Losartan 5 
ACEi Ramipril 28 
 Enalapril 5 
CCB Amlodipine 18 
 Felodipine 10 
α-blocker Doxazosin 5 
β-blocker Bisoprolol 5 
Diuretics Bendroflumethiazide 14 
ACEi; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor 
blocker, CCB; calcium channel blocker.
Table 3-2 Anti-hypertensive drug classification. 
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Table 3-3 Heart rate variability (HRV). 
Heart rate variability (HRV) 
Spectral analysis 
 Baseline Recovery 









LF/HF ratio 1.30±2.5 1.89±2.89 1.67±1.55 3.37±5.91 1.22±1.23 1.63±1.79 1.26±1.52 2.73±4.79 
LF (nu) 38±20 45±25 50±24 50±30 44±22 47±21 40±24 51±22 
HF (nu) 56±19 49±22 47±22 44±28 52±20 46±18 51±21 45±21 
LF (ms2) 505±739 437±458 520±635 654±529 627±777 474±541 548±355 1100±622 
HF (ms2) 848±1678 695±961 744±1062 646±631 649±582 452±698 673±685 452±698 
Time domain 
SDRR (ms) 42±19 47±33 43±21 59±32 53±22 43±19 60±37 67±29 
RMSSD (ms) 33±19 44±41 40±26 56±50 35±17 33±21 56±52 58±46 
pRR50 (%) 17±15 24±23 35±31 18±22 14±16 10±16 14±17 28±20 
LF/HF ratio; low frequency/high frequency ratio, LF; low frequency, HF; high frequency, SDRR; standard deviation of the RR 
interval, RMSSD; root mean square of successive RR interval differences, pRR50; percentage of successive RR intervals that differ 
by more than 50 ms. 
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Table 3-4 Spontaneous cardiac baroreflex sensitivity. 
Spontaneous cardiac baroreflex sensitivity 
Sequence technique 
 Baseline Recovery 












15/16 (94%) 12/14(86%) 11/16 (69%) 7/11(64%) 15/16 (94%) 10/14(71%) 12/16(75%) 7/11(64%) 
Up ramps (n) 33±16 34±18 36±11 38±14 40±12 39±17 41±12 40±22 
Down ramps 
(n) 
35±16 34±12 34±12 37±16 42±11 40±13 44±16 40±22 
All ramps (n) 69±31 67±28 70±21 75±29 83±22 79±29 85±32 80±43 
Sequence 
ramps up (n) 




4±3 4±4 5±6 10±8 7±6 5±4 8±7 8±4 
Sequence 
ramps all (n) 
9±8 6±8 9±11 22±16 || ** $ 15±12 10±9 16±13 17±9 





12±9 11±8 11±7 10±3 13±10 11±10 11±7 10±2 
Down ramps 
(gain) 
11±6 12±6 11±7 10±3 13±7 9±4 10±7 10±4 
All ramps 
(gain) 
12±7 12±7 11±7 10±3 13±8 10±6 10±7 11±3 




for BEI (n) 
16/16 (100%) 12/14(86%) 11/16 (69%) 7/11(64%) 15/16 (94%) 10/14(71%) 12/16(75%) 7/11(64%) 
BEI (up) 0.17±0.12 0.12±0.07 0.18±0.11 0.35±0.17 
|| ** $ 
0.2±0.11 0.130.27±0.10 0.27±0.09 0.21±0.06 
BEI (down) 0.16±0.09 0.19±0.12 0.22±0.15 0.42±0.23 
|| ** $ 
0.23±0.04 # 0.16±0.09 0.24±0.14 0.27±0.13 
BEI (all) 0.15±0.1 0.13±0.09 0.2±0.11 0.38±0.19 
|| ** $ 
0.2±0.11 0.14±0.08 0.24±0.11 0.23±0.07 
││ P=<0.05 untreated hypertension vs. normotension, ** P=<0.05 treated-uncontrolled hypertension vs. untreated hypertension, $ 
treated-controlled hypertension vs. untreated hypertension and # P=<0.05 treated-controlled hypertension vs. treated-uncontrolled 
hypertension. 




Figure 3-1 Participant recruitment information.  
Participants recruited for study (n=59) 
• Normotension (n=16) 
• Treated-controlled hypertension (n=16) 
• Treated-uncontrolled hypertension (n=16) 
• Untreated hypertension (n=11) 
 
Participants completed screening visit (n=59) 
• Normotension (n=16) 
• Treated-controlled hypertension (n=16) 
• Treated-uncontrolled hypertension (n=16) 
• Untreated hypertension (n=11) 
 
Participants completed second visit (n=57) 
• Normotension (n=16) 
• Treated-controlled hypertension (n=16) 
• Treated-uncontrolled hypertension (n=14) 
• Untreated hypertension (n=11) 
2 participants chose to withdraw from the study. 
Assessed for eligibility (n = 69) 
Excluded (n=10) 
Did not meet exclusion criteria: 
• Too high fitness level (V̇O2 peak > 40 ml/min/kg) (n=4) 
• Obesity (BMI > 35 kg/m2) (n=1) 
• White-coat hypertension (n=1) 
• Low age (n=2) 
• Cancer diagnosis (n=1) 
• Use of nitrates (n=1) 




Figure 3-2 Flow chart for visit one to the CRiC. 
  
1. Consent Obtained 
 
2. Medical history taken 
 
3. Screening 
• Height, weight, and non-invasive oxygen saturations taken. 
 
4. Screening 
• Clinical blood pressure 
• 12 lead-ECG taken 






5. V̇O2 peak test on upright cycle ergometer 
 
30 minutes 
6. Ambulatory Blood Pressure Monitor fitted 
 
5 minutes 




Figure 3-3 Flow chart for visit two to the CRiC. 
 
1. Arrival  
• Participant arrives at the Clinical Research and Imaging 
Centre-Bristol 
2. Resting clinic blood pressure then maximal voluntary 
contraction recorded on handgrip dynamometer. 
 
 
3. Prior to protocol 1: 
• Finapres fitted to monitor beat-to-beat blood pressure. 
• 3-lead ECG fitted to monitor heart rate. 
• Metabolic cart system mask fitted. 
4. Metaboreflex protocol 
• Isometric handgrip (30% MVC) for one minute, at one minute 
the occlusion cuff is inflated (240 mmHg) to initiate exercise 
ischemia. The occlusion cuff then remained at 240 mmHg for 





























Figure 3-4 A schematic outlining the protocol used to isolate the metaboreflex. 




Figure 3-5 The change in haemodynamics from baseline during V̇O2 peak 
testing. 
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Absolute change from baseline A) systolic blood pressure (SBP), B) diastolic 
blood pressure (DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) 
and E) Heart rate (HR). Changes in haemodynamics were calculated at different 
percentages of V̇O2 peak so that comparisons could be made between the 
participants. * P=<0.05 all groups vs. normotension. † P=<0.05 treated-
uncontrolled hypertension vs. normotension. ‡ P=<0.05 treated-controlled 
hypertension vs. normotension. § P=<0.05 treated-controlled and treated-
uncontrolled hypertension vs. untreated hypertension. ^ P=<0.05 untreated 
hypertension vs. normotension. # P=<0.05 treated-controlled hypertension vs. 
treated-uncontrolled hypertension. + P=<0.05 treated-uncontrolled hypertension 
vs. untreated hypertension. $ treated-controlled hypertension vs. untreated 
hypertension. 
  




Figure 3-6 Absolute haemodynamics during V̇O2 peak testing. 
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A) systolic blood pressure (SBP), B) Diastolic blood pressure (DBP), C) Mean 
arterial pressure (MAP), D) Pulse pressure (PP) and E) Heart rate (HR). The 
cardiovascular response to exercise was split up into differences percentages of 
V̇O2 peak. * P=<0.05 for all groups for normotension. † P=<0.05 treated-
uncontrolled hypertension vs. normotension. ‡ P=<0.05 treated-controlled 
hypertension vs. normotension. § P=<0.05 treated-controlled and treated-
uncontrolled hypertension vs. untreated hypertension. ^ P=<0.05 untreated 
hypertension vs. normotension. # P=<0.05 treated-controlled hypertension vs. 
treated-uncontrolled hypertension. + P=<0.05 treated-uncontrolled hypertension 
vs. untreated hypertension. Normotension (blue line), untreated hypertension 
(black line), treated-uncontrolled hypertension (red line) and treated-controlled 
hypertension (green line). 
  




Figure 3-7 The % change in haemodynamics during V̇O2 peak testing. 
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A) systolic blood pressure (SBP), B) Diastolic blood pressure (DBP), C) Mean 
arterial pressure (MAP), D) Pulse pressure (PP) and E) Heart rate (HR). The data 
are presented as different percentages of V̇O2 peak. * P=<0.05 for all groups for 
normotension. † P=<0.05 treated-uncontrolled hypertension vs. normotension. ‡ 
P=<0.05 treated-controlled hypertension vs. normotension. § P=<0.05 treated-
controlled and treated-uncontrolled hypertension vs. untreated hypertension. # 
P=<0.05 treated-controlled hypertension vs. treated-uncontrolled hypertension. + 
P=<0.05 treated-uncontrolled hypertension vs. untreated hypertension. £ 
P=<0.05 treated-controlled hypertension vs. untreated hypertension. ^ P=<0.05 
untreated hypertension vs. normotension. Normotension (blue line), untreated 
hypertension (black line), treated-uncontrolled hypertension (red line) and 
treated-controlled hypertension (green line). 
  




Figure 3-8 The absolute respiratory responses to V̇O2 peak test  
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A) minute ventilation (VE), B) breathing frequency and C) tidal volume D) volume 
of expired carbon dioxide (VCO2) and E) the respiratory exchange ratio (RER) 
during V̇O2 peak testing. 
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Figure 3-9 Relationship between VE/VEVCO2 slope and systolic blood pressure 
during submaximal (51-75 % V̇O2 peak testing) and at peak exercise. 
The data show that there is no correlation between the VE/VEVCO2 slope and the 
∆SBP during moderate intensity (51-75% V̇O2 peak testing) or peak exercise. 
Blue dots, normotension; green dots, treated-controlled hypertension; red dots, 
treated-uncontrolled hypertension and black dots, untreated hypertension. 
  




Figure 3-10 The change in haemodynamics from baseline during handgrip 
testing.  
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The absolute change from baseline in A) systolic blood pressure (SBP), B) 
diastolic blood pressure (DBP), C) mean arterial pressure (MAP), D) Pulse 
pressure, and heart rate (HR) during 0-30 and 30-60s isometric handgrip 
exercise (30% maximal voluntary contraction) and during post-exercise ischemia 
(PEI) (30 second ± periods PEI1, 2 and 3). * P=<0.05 for all groups for 
normotension. † P=<0.05 treated-uncontrolled hypertension vs. normotension. ‡ 
P=<0.05 treated-controlled hypertension vs. normotension. § P=<0.05 treated-
controlled and treated-uncontrolled hypertension vs. untreated hypertension. # 
P=<0.05 treated-controlled hypertension vs. treated-uncontrolled hypertension. + 
P=<0.05 treated-uncontrolled hypertension vs. untreated hypertension. £ 
P=<0.05 treated-controlled hypertension vs. untreated hypertension. ^ P=<0.05 
untreated hypertension vs. normotension. Normotension (blue line), untreated 
hypertension (black line), treated-uncontrolled hypertension (red line) and 
treated-controlled hypertension (green line). 
  




Figure 3-11 Example systolic blood pressure (SBP) responses to isometric 
handgrip exercise and all of post-exercise ischemia (PEI) in one patient with 
treated-controlled hypertension (green line), treated-uncontrolled hypertension 
(red line), untreated hypertension (black line) and normotension (blue line).  
  




Figure 3-12 Relationship between the change in systolic blood pressure (∆SBP) 
at peak V̇O2 and the change in SBP during post-exercise ischemia (PEI).  
The data show that increased ∆SBP during the 1 minute 30 seconds of 
metaboreflex isolation (PEI) is linked to an exaggerated ∆SBP during V̇O2 peak 
testing. Blue dots, normotension; green dots, treated-controlled hypertension; red 
dots, treated-uncontrolled hypertension and black dots, untreated hypertension. 
  




Figure 3-13 The change in haemodynamics during recovery from metaboreflex.  
The absolute change from baseline in A) systolic blood pressure (SBP), B) 
diastolic blood pressure (DBP), C) mean arterial pressure (MAP), D) Pulse 
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pressure, and heart rate (HR) during 5 epochs of recovery from metaboreflex 
testing (R1,R2,R3,R4 and R5). * P=<0.05 for all groups for normotension. † 
P=<0.05 treated-uncontrolled hypertension vs. normotension. ‡ P=<0.05 treated-
controlled hypertension vs. normotension. § P=<0.05 treated-controlled and 
treated-uncontrolled hypertension vs. untreated hypertension. # P=<0.05 treated-
controlled hypertension vs. treated-uncontrolled hypertension. + P=<0.05 treated-
uncontrolled hypertension vs. untreated hypertension. £ P=<0.05 treated-
controlled hypertension vs. untreated hypertension. ^ P=<0.05 untreated 
hypertension vs. normotension. Normotension (blue line), untreated hypertension 
(black line), treated-uncontrolled hypertension (red line) and treated-controlled 
hypertension (green line). 
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Chapter 4 Arterial stiffness and exaggerated blood pressure responses 
to exercise in humans with hypertension 
4.1 Introduction 
During an acute bout of dynamic or isometric exercise, untreated hypertensive 
individuals have an exaggerated rise in systolic blood pressure (SBP) when 
compared to normotensive individuals (Delaney et al., 2010, Sausen et al., 2009, 
Aoki et al., 1983, Chant et al., 2018). The cardiovascular (CV) response to 
isolation of the metaboreflex component of the exercise pressor reflex is also 
overactive patients with untreated hypertension (Chant et al., 2018, Delaney et 
al., 2010, Sausen et al., 2009, Greaney et al., 2014). The excessive CV response 
to metaboreflex isolation is partially mediated by the sympathetic nervous system 
(SNS), as assessed by microneurography (Delaney et al., 2010). Worryingly, an 
exaggerated increase in blood pressure (BP) (measured in the brachial artery) 
during an acute bout of dynamic exercise is an independent risk for any type of 
CV event, end organ damage and mortality (Kurl et al., 2001, Laukkanen et al., 
2006), In the study in Chapter 3, the findings indicated that despite adequate 
control of resting SBP, a group with treated controlled hypertension had an 
augmented BP response to incremental exercise testing to peak oxygen 
consumption (V̇O2 peak) as well as isolation of the metaboreflex (post-exercise 
ischemia (PEI)) compared to normotensive individuals. However, it is unlikely that 
the metaboreflex alone mediates the exaggerated BP response to exercise in 
patients with hypertension. Other potential candidates for an exaggerated rise in 
BP during exercise in patients with treated controlled hypertension include 
increased large artery (e.g. aorta, brachial, carotid artery) stiffness and abnormal 
central haemodynamics. 
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Pulse wave velocity is the gold standard measurement of aortic stiffness (Weber 
et al., 2015, Van Bortel et al., 2012). Resting pulse wave velocity predicts 
adverse CV events in the general population (Willum-Hansen et al., 2006, 
Mattace-Raso et al., 2006). Pulse wave velocity is elevated and remains 
predictive in treated and untreated hypertensive patients (Pereira et al., 2013, 
Laurent et al., 2001, Laurent et al., 2006, Laurent et al., 2003) independent of 
other risk factors such as previous CV disease, resting SBP, diabetes and age. 
Elevated large artery stiffness in patients with essential hypertension may 
decrease the ability of the blood vessels to distend when they face exercise 
induced elevations in CO (Schultz and Sharman, 2014). Tsioufis et al. (2008) 
found that untreated hypertensives with an exaggerated rise in peripheral SBP 
during maximal treadmill testing had higher resting carotid-femoral pulse wave 
velocity when compared to untreated hypertensives with a normal peripheral BP 
response to exercise. An elevated carotid-femoral pulse wave velocity has also 
been shown to be positively related to SBP during submaximal treadmill exercise 
testing in treated and untreated hypertensive individuals (Thanassoulis et al., 
2012). This study included patients with diabetes and high cholesterol 
(hypercholesterolemia), as well as obese individuals (Thanassoulis et al., 2012). 
All of these CV risk factors are known to alter the CV response to exercise and 
therefore the effects of arterial stiffness on the BP response to exercise remains 
unclear (Thanassoulis et al., 2012, Sharman et al., 2007).  
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Pulse wave velocity is the speed at which a pressure wave is transmitted down 
the arterial tree. Upon leaving the left ventricle blood generates a forward 
pressure wave that expands the aorta and shunts blood forward. The forward 
wave generated by the left ventricle is returned (via a process called reflection) 
late during diastole in young healthy individuals due to compliant large arteries 
(Hirata et al., 2006). Wave reflection does not influence aortic BP in young 
healthy individuals and the brachial artery BP is higher than aortic BP (Hirata et 
al., 2006). This leads to elevated brachial BP when compared to aortic BP in 
young individuals (Schultz et al., 2012). However, ageing is associated with 
increased large artery stiffness and the pressure wave is returned during systole 
(McEniery et al., 2014, Lee and Oh, 2010, McEniery et al., 2005). In the elderly, 
wave reflection early in systole causes aortic BP to rise to a similar extent as 
peripheral BP. Of concern, in older hypertensive individuals’ arterial stiffness is 
further increased and the wave reflection augments aortic BP higher (Hirata et 
al., 2006, McEniery et al., 2014, Fantin et al., 2007). This causes aortic BP to rise 
to a similar level as peripheral brachial BP, with brachial SBP being similar to 
aortic SBP (Hirata et al., 2006, Fantin et al., 2007). The heart, brain and the 
kidney are exposed to the BP generated by the left ventricle, rather than the 
brachial artery. Importantly, resting aortic BP is an independent risk factor for 
end-organ damage, adverse CV events and total mortality when compared to 
BP’s measured in the brachial artery (Vlachopoulos et al., 2010, Kostapanos et 
al., 2016). An adaptation of the Windkessel model (Wang et al., 2003) has also 
been used in an attempt to describe differences in aortic and brachial artery BPs. 
A portion of the stroke volume (~40%) generated during systole is stored in the 
vessel wall as blood moves into the aorta quicker than it can leave. The 
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distention of the aorta by a rise in volume of blood causes an increase in 
pressure (Windkessel pressure). This Windkessel function acts as a reservoir for 
blood during systole (Davies et al., 2010). In addition, loss of compliance of the 
aorta has been shown to cause an elevated aortic pressure for a given volume of 
blood (Davies et al., 2010). The adapted Windkessel model account for both the 
Windkessel reservoir function and wave reflection (Wang et al., 2003). This 
model has shown that forward waves are more important than reflected waves at 
rest and during exercise (Wang et al., 2003, Davies et al., 2010, Schultz et al., 
2013a). An interpretation could be that increased resting aortic BP in 
hypertensive individuals, associated with elevated aortic stiffness (Pereira et al., 
2013, Laurent et al., 2001, Laurent et al., 2006, Laurent et al., 2003) would lead 
to a reduced capacity of the aorta to store potential energy during exercise 
induced increases in stroke volume. This would lead to an elevated forward 
pressure from the left ventricle and an increase in peripheral (brachial) BP. 
Importantly, resting aortic BP is related to submaximal intensity treadmill exercise 
brachial SBP in male and female hypertensive patients (Thanassoulis et al., 
2012). 
 
Different antihypertensive medications that cause a similar lowering of brachial 
artery BP have markedly different effects on pulse wave velocity and aortic BP 
(Blacher et al., 2005, Boutouyrie et al., 2011, Protogerou et al., 2009). In patients 
with hypertension, treated or untreated, it is unknown whether increased aortic 
BP and increased pulse wave velocity increase the brachial artery BP response 
to submaximal and peak dynamic exercise. This is important because adequately 
reducing aortic BP and pulse wave velocity in patients with hypertension could be 
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an effective way of controlling BP in the brachial artery during exercise. This 
would have a therapeutic benefit to the hypertensive patient and reduce the CV 
risks associated with exercise in this group.  
 
The aims of this study were too firstly assess whether resting aortic BP and pulse 
wave velocity are related a change in peripheral SBP during submaximal and 
maximal exercise testing (V̇O2 peak test). The secondary aim was to assess what 
variable was the leading predictor (e.g. age, arterial stiffness and metaboreflex 
hyperreflexia) of submaximal and peak exercise peripheral SBP. This was 
completed using multiple linear regression. It was hypothesised that aortic BP 
and pulse wave velocity would be different among treated controlled, treated 
uncontrolled, untreated hypertensive and normotensive participants. Secondly, it 
was hypothesised that aortic BP and pulse wave velocity would be related to the 
peripheral SBP during submaximal and peak exercise testing. Finally, it was 
hypothesised that the leading predictors of an exaggerated peripheral SBP 
response to submaximal and peak exercise will have a different influence on the 




The same group of participants were used in this study as the study in Chapter 3. 
16 normotensives, 14 treated-controlled, 16 treated-uncontrolled and 11 
untreated hypertensives who were matched for age, body mass index (BMI), and 
for CV fitness (V̇O2 peak) were used for the study in this Chapter (Chapter 3, 
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Table 3.1 and Table 3.2, pages 190 to 192). All individuals were free from 
diabetes mellitus (urine dipstick test and self-reported), and were non-obese 
(Chapter 3, Table 3.1 and Table 3.2, pages 190 to 192). Ethical approval for this 
study was granted by the Southwest-Exeter NHS REC (16/SW/0004). The 
information regarding recruitment and inclusion/exclusion criteria for this study 
can be found in Chapter 3 (Chapter 3; section 3.2, page 151). 
 
4.2.2 Study Design 
This study was a case-control study and the researcher was blinded to the 
participant BP classification until the data analysis was complete. Participants 
visited the laboratory on 2 separate occasions. 
 
4.2.3 Screening procedures 
The screening procedures used for Chapter 4 were the same as Chapter 3 
(Chapter 3; section 3.2.3 Screening procedures, page 153). A flow diagram for 
the initial screening can be seen in Figure 3.2. (Chapter 3, page 197). At the end 
of the initial screening visit, the participants performed a V̇O2 peak test on a cycle 
ergometer (Chapter 2; section 2.3.1, page 94 and Chapter 3; section 3.2.1, page 
151). See Chapter 3 (section 3.2.1, page 151) for the criteria used to define V̇O2 
peak. 
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4.2.4 Study visit design 
Participants returned at a similar time of day for a follow up visit to the screening 
visit with at least 48 hours between. Firstly, the participants clinic BP was 
assessed using the same protocol outlined in Chapter 3 (section 3.2.3, page 
153). Following this, participants were asked to rest for 10 minutes prior to the 
measurement of pulse wave analysis and pulse wave velocity. 
 
4.2.5 Arterial Stiffness 
4.2.5.1 Pulse Wave Analysis 
Pulse wave analysis was used to measure aortic BP. For a more detailed 
description of pulse wave analysis, please see Chapter 2, section 2.4. (page 99). 
Applanation tonometry was performed using SphygomoCor (SpygmoCor System, 
AtCor Medical, Sydney) on the right radial artery whilst the participant lay supine. 
Firstly, the participants resting BP was measured in the supine position from the 
brachial artery. In accordance with the European Society of Hypertension 
guidelines resting BP was assessed using an automatic oscillometric monitor 
(Omron, 705IT, Omron Healthcare Europe) (Chapter 2, section 2.4, page 99). 
These readings were then entered into the SpygmoCor System (AtCor Medical, 
Sydney). To perform this analysis, a tonometer was placed over the radial artery 
for a sufficient period of time so that a radial pulse trace could be recorded. The 
SphygomoCor (SpygmoCor System, AtCor Medical, Sydney) system has an 
inbuilt calculation that assesses the variability of the recording, this is called the 
operator index and is a scale of 0-100 (100 being the best quality). If the operator 
index was <= 95 a repeat reading was done until the score was > 95. Central 
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pressures were estimated using an inbuilt transfer function in the SphygmoCor 
system, which estimates the central BP waveforms from the radial pulse 
waveform (SpygmoCor System, AtCor Medical, Sydney) (Karamanoglu et al., 
1993, Chen et al., 1997). From the recreated central pressure waveform, the 
software calculates aortic augmentation pressure (which is defined as the 
difference between the peak 1 and peak 2 wave in the central pressure 
waveform), aortic SBP, aortic PP and augmentation index (AIx %) (aortic 
augmentation pressure/aortic PP * 100) (Figure 4.1, page 249). The AIx % is 
taken as a marker of wave reflection (Hirata et al., 2006) (Figure 4.1, page 249). 
AIx is also reported as AIx 75 which is normalised to a heart rate (HR) of 75, 
which allows the comparison between individuals with different resting HR. Pulse 
wave analysis was performed two times in each participant and the mean value is 
presented in the study in this Chapter. Following the measurement of pulse wave 
analysis, the participant was asked to rest for 5 minutes prior to the assessment 
of pulse wave velocity. 
 
4.2.5.2 Pulse Wave Velocity 
Aortic stiffness was assessed non-invasively using pulse wave velocity in both 
hypertensives and normotensive participants (see Chapter 2, section 2.4.1.1, page 
100). See Chapter 2 for repeatability data for pulse wave velocity (section 2.5.2. 
Table 2.4, page 128 and Figure 2.8, page 141). Pulse wave velocity was measured 
via arterial tonometry (SpygmoCor System, AtCor Medical, Sydney) between the 
carotid-femoral arteries as this is the most valid method for assessing large arterial 
stiffness over carotid-brachial arteries (Tillin et al., 2007) (see Chapter 2, section 
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2.4.1, page 99). The distance between the sternal notch and the carotid and 
femoral artery was carefully measured and entered into the SpygmoCor System 
(AtCor Medical, Sydney) in mm. Following this the carotid and the femoral 
waveform were captured respectively. Pulse wave velocity was calculated 
automatically by the SpygmoCor (SpygmoCor System, AtCor Medical, Sydney) 
using the equation: 
Pulse Wave Velocity = dPWV/∆t [equation 4.1] 
dPWV = distance between sternal notch to femoral artery (cm) – distance between 
sternal notch carotid artery (cm) 
∆t = the change in time 
 
4.2.6 Handgrip and Metaboreflex testing 
See Chapters 2 and 3 for the protocol used for isometric handgrip exercise and 
isolation of the metaboreflex (section 2.6, page 108 and section 3.2.4.1, page 155). 
 
4.2.7 Physiological Monitoring During V̇O2 Peak and Metaboreflex Testing 
4.2.7.1 V̇O2 peak test 
The methods used for physiological assessment during the V̇O2 peak test can be 
found in Chapter 3 (section 3.2.3.1, page 154). 
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4.2.7.2 Handgrip and Metaboreflex isolation 
The methods used for physiological assessment during handgrip, exercise 
ischemia and metaboreflex isolation (post-exercise ischemia (PEI)) can be found 
in Chapter 3 (section 3.2.4.1, page 155). 
 
4.2.8 Power calculations 
This Chapter was part of a larger study (Chapter 3) and the power calculations 
were based on the SBP response to a maximal exercise test (this was the primary 
outcome) rather than resting aortic BPs and pulse wave velocity. The power 
calculations can be found in Chapter 3 (section 3.2.6, page 156).  
 
4.2.9 Data analysis 
4.2.9.1 V̇O2 peak test 
The methods used to analyse the V̇O2 peak test are described in Chapter 3 (section 
3.2.7.1, page 157). 
 
4.2.9.2 Metaboreflex testing 
The methods used to analyse isometric handgrip exercise, exercise ischemia and 
PEI are described in Chapter 3 (section 3.2.7.2, page 158). 
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4.2.10 Statistical analysis 
To avoid repetition the statistical analysis performed to assess for differences in 
the baseline, V̇O2 peak test, isometric handgrip exercise, exercise ischemia and 
PEI are not described again here and can be found in Chapter 3 (section 3.2.9, 
page 162). 
 
The group averages (normotensives, untreated hypertensives, treated-controlled 
hypertensives and treated-uncontrolled hypertensives) for differences in resting 
aortic augmentation pressure, aortic SBP, aortic PP, AIx, AIx 75 and pulse wave 
velocity were compared using an ordinary 1-way analysis of variance (ANOVA), 
with a Tukey test for multiple comparisons. Data were checked for normality using 
a D’Agostino-Pearson normality test. To examine whether there was a relationship 
between pulse wave velocity, aortic SBP, AIx, AIx 75 and the absolute change in 
SBP metaboreflex isolation (PEI) and the absolute change in SBP during VO2 peak 
testing, a Pearson’s correlation coefficient was also performed to assess 
relationships with the change in peripheral SBP during submaximal intensity (51-
75% of V̇O2 peak) and peak exercise. Forced entry multiple linear regression was 
then performed (SPSS Statistics 24; IBM Corp, Armonk, New York) to make a 
model which predicts the individual contribution of the independent variables to the 
change in SBP during submaximal intensity (51-75% of V̇O2 peak) and peak 
exercise.  
 
Data analysis and statistical analysis were completed using LabChart 7 (AD 
Instruments), Spike 2 (Cambridge Electronic Designs), Microsoft Excel (Microsoft 
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Corp., Redmond, WA), IBM SPSS Statistics 24 (IBM Corp, Armonk, New York), R 
studio version 3.4.1 (RStudio: Integrated Development Environment for R, Boston, 
MA) and GraphPad version 7 (GraphPad Software, La Jolla California USA). Data 
are reported as mean ± standard deviation (SD) The α-level was set at 0.05. 
 
4.3 Results 
4.3.1 Participant demographics 
The baseline participant demographics for normotensive, treated uncontrolled, 
treated controlled and untreated hypertensive participants can be found in Table 
4.1 (page 243). 
 
4.3.2 V̇O2 Peak Test and Metaboreflex testing 
The changes in haemodynamics during V̇O2 peak testing, isometric handgrip, 
exercise ischemia and PEI can be found in Chapter 3 (section 3.3.2 and 3.3.3 and 
Figure 3.5-3.13). 
 
4.3.3 Pulse wave analysis 
All measures that were assessed from arterial tonometry can be found in Figure 
4.2 (page 250) and Table 4.1 (page 243). There was a difference between 
groups for aortic SBP (F(3,53) = 7.603; P=0.0003; ɳ2 = 0.3). Treated-uncontrolled 
(138±17 mmHg) and untreated hypertensive participants (134±20 mmHg) had 
elevated aortic SBP when compared to normotensive (113±10 mmHg) 
participants (P=0.0002 and P=0.007 respectively; Tukey test). There were no 
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differences in aortic SBP between treated controlled (127±17 mmHg) and 
normotensive (113±10 mmHg) (P=0.09) participants. No differences were found 
between treated controlled and treated uncontrolled (P=0.20) or untreated 
hypertensive (P=0.66) participants in aortic SBP. In addition, there were no 
differences in aortic SBP between patients with treated uncontrolled and 
untreated hypertension (P=0.91). A difference was found between groups for 
aortic DBP (F(3,53) = 5.091; P=0.004; ɳ2 = 0.22). More specifically, untreated 
(88±11) and treated uncontrolled (88±11) hypertensive groups had a larger aortic 
DBP compared to normotensives (77±6) (P=0.03 and P=0.01 respectively). 
Treated controlled hypertensives (79±10) had a similar aortic DBP when 
compared to normotensives (77±6) (P=0.89). Treated controlled hypertensive 
participants had a comparable aortic DBP compared to patients with treated 
uncontrolled and untreated hypertension (P=0.08 and P=0.16 respectively, Tukey 
test). Finally, no difference was found for aortic DBP between participants with 
treated uncontrolled hypertension and untreated hypertension (P=0.99). There 
was also a difference in aortic PP between groups (F(3,53)=4.743; P=0.005; ɳ2 = 
0.21). Interestingly treated controlled (48±9 mmHg) and treated uncontrolled 
hypertensives (50±13 mmHg) had an elevated aortic PP compared to 
normotensives (36±8 mmHg) (P=0.04 and P=0.004 respectively). There was no 
difference in aortic PP between untreated hypertensives (46±15) compared to 
normotensives (36±8) (P=0.10). Again, no differences were found between 
treated and untreated hypertensive individuals (P=>0.05). 
 
There were no differences in the aortic augmentation pressure (F(3,53) = 2,284; 
P=0.09, ɳ2 = 0.11), AIx (%) (F(3,51)=0.2501; P=0.86, ɳ2 = 0.001) or the AIx 75 
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(F(3,50)=0.028;P=0.99, ɳ2 = 0.001) between the groups (Figure 4.2, page 250 
and Table 4.1, page 243). No differences were found for the amplification 
between aortic SBP and the brachial SBP between the groups (F(3,53) = 0.61; 
P=0.61; ɳ2 = 0.11). In addition there was no difference for the amplification of the 
aortic DBP and brachial DBP between the groups (F(3,53) = 0.61; P=0.61; ɳ2 = 
0.03). Finally, no difference was found for the PP amplification (brachial PP – 
aortic PP) between the groups (F(3,53) = 2.16; P=0.10; ɳ2 = 0.11). There was a 
positive correlation between aortic SBP and daytime ambulatory SBP (r = 0.53; 
R2 = 0.27; P=<0.0001; Figure 4.3 for linear regressions, page 251). Similarly, a 
positive correlation was also found between aortic DBP and daytime ambulatory 
DBP (r = 0.64; R2 = 0.42; P=<0.0001; Figure 4.3 for linear regressions, page 
251). A comparable positive correlation was found for aortic PP and brachial PP 
(r = 0.49; R2 = 0.21; P=0.0001; Figure 4.3 for linear regressions, page 251). 
 
4.3.4 Pulse wave velocity 
There was a difference found between the groups for pulse wave velocity (m/s) 
(F(3,53)=3.062; P=0.04, ɳ2 = 0.13). Untreated hypertensives (11.2±2 m/s) had an 
expected elevated pulse wave velocity score when compared to normotensives 
(8.8±1.5 m/s) (P=0.048). There were no differences in pulse wave velocity between 
participants with treated controlled (10.6±2.3 m/s) or treated uncontrolled (10.6±2.5 
m/s) hypertension when compared to individuals with normotension (8.8±1.5 m/s; 
P=0.14 and P=0.11 respectively). In addition, there were no difference between 
treated uncontrolled, treated controlled and untreated groups with hypertension (all 
P=>0.05). 
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4.3.5 The effect of arterial stiffness on the change in SBP during submaximal 
and peak V̇O2 peak testing 
4.3.5.1 Submaximal intensity (50-75% V̇O2 peak testing) 
There was a positive correlation for both aortic PP and SBP against the change 
in brachial SBP during submaximal intensity exercise (50-75% V̇O2 peak testing) 
(r = 0.28; R2 = 0.08; P=0.03 and r = 0.27; R2 = 0.08; P=0.04 respectively; Figure 
4.4 for linear regressions, page 253).  
 
There was no correlation between augmentation pressure (mmHg), AIx (%) or 
the AIx 75 and the change in brachial SBP that occurred during submaximal 
intensity (50-75%) V̇O2 peak testing (Figure 4.4, page 253). There was no 
correlation between pulse wave velocity (m/s) at rest and the change in brachial 
SBP during submaximal intensity (50-75%) dynamic exercise (r = 0.19; R2 = 0.04; 
P=0.10; Figure 4.4 for linear regressions, page 253). 
 
4.3.5.2 Peak V̇O2 peak testing 
Unlike submaximal exercise (50-75% V̇O2 peak), there was a positive correlation 
between resting pulse wave velocity and the peak change in brachial SBP 
(mmHg) during V̇O2 peak testing (r = 0.29; R2 = 0.08; P=0.03; Figure 4.5, page 
254). In addition, aortic PP (mmHg) and aortic SBP (mmHg) were also both 
positively correlated to the maximal change in brachial SBP during V̇O2 peak 
testing (r = 0.37; R2 = 0.14; P=0.004 and r = 0.43; R2 = 0.18; P=0.0009 
respectively). There was no correlation between augmentation pressure (mmHg), 
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AIx (%) and AIx 75 and the change in brachial SBP at maximal V̇O2 peak testing 
(Figure 4.5, page 254). 
 
4.3.6 Multiple regression analysis 
The study in Chapter 3 showed that there was a positive correlation between the 
change in brachial SBP measured during metaboreflex isolation (PEI) and the 
change in brachial SBP at peak exercise (V̇O2 peak testing) (r = 0.36; R2 = 0.13; 
P=0.007; section 3.3.3.6; Figure 3,12, page 213). To assess whether metaboreflex 
hyperreflexia or increased arterial stiffness was a larger contributor towards an 
exaggerated change in SBP during peak and submaximal V̇O2 peak testing a 
forced entry multiple linear regression test was performed. The independent 
variables chosen (aortic PP, pulse wave velocity, age, daytime ambulatory SBP 
and the change in SBP during PEI (metaboreflex isolation) (Delaney et al., 2010, 
Sausen et al., 2009, Tsioufis et al., 2008, Thanassoulis et al., 2012) were based 
on previous research that has suggested that these variables increase the risk of 
having an exaggerated rise in brachial SBP during submaximal and peak exercise. 
 
4.3.6.1 Submaximal intensity (50-75% V̇O2 peak testing) 
No multicollinearity was found between independent variables (Table 4.2 and 4.3, 
page 245 and 246). More specifically, all of the calculated variance inflation factors 
were below 10 and the tolerance levels were all above 0.2 (Table 4.2 and 4.3, page 
245 and 246). A significant regression equation was found (F(5,46)=2.859; 
P=0.025), R2 = 0.237). The change in brachial SBP during submaximal intensity 
(50-75%) V̇O2 peak testing was predicted only by the change in brachial SBP 
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during PEI (37.363+0.409; P=0.005, Table 4.3, page 246). None of the other 
independent variables were significantly related to the change in SBP during 
submaximal exercise (50-75% V̇O2 peak, Table 4.3, page 246). The augmentation 
in SBP during submaximal intensity (50-75%) V̇O2 peak testing increased 0.409 
mmHg per 1 mmHg change in peripheral SBP during PEI (metaboreflex isolation).  
 
4.3.6.2 Peak V̇O2 peak testing 
A second forced entry multiple linear regression was also performed to predict 
the change in brachial SBP during peak exercise using the same independent 
variables. No multicollinearity was found between independent variables (Table 
4.4 and 4.5, pages 247 and 248). More precisely, all of the calculated variance 
inflation factors were below 10 and the tolerance levels were all above 0.2 for all 
of the independent variable interactions (Table 4.4 and 4.5, page 247 and 248). A 
significant regression was found (F(5,46) = 4.332, P=0.003), with an R2 = 0.246. 
The predicted change in peak brachial SBP during a V̇O2 peak test was equal to 
45.017 + 0.594 (PEI; P=0.047) + 0.578 (aortic PP; P=0.048) (Table 4.5, page 
248). Participants peak change in brachial SBP during a V̇O2 peak test increased 
by 0.594 mmHg for each mmHg increase in brachial SBP during PEI 
(metaboreflex isolation) and 0.578 mmHg for each mmHg increase in aortic PP at 
baseline. Both the change in brachial SBP (mmHg) during PEI (P=0.047) and the 
resting aortic PP (mmHg) (P=0.048) were significant predictors of the peak 
change in SBP during a V̇O2 peak test. The remaining independent variables 
were not significant predictors of the absolute change in SBP during peak 
exercise (Table 4.4, page 247). 
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The main finding of this study was that elevated aortic PP and metaboreflex 
hyperreflexia were the most powerful predictors of an exaggerated rise in SBP 
during maximal exercise (V̇O2 peak test), even when accounting for other factors 
that are known to mediate an exaggerated peripheral BP response to exercise. In 
addition, metaboreflex hyperreflexia was the only significant predictor of the 
augmentation of SBP during submaximal exercise (50-75%) during V̇O2 peak 
testing. Finally, the study indicates that aortic PP remains elevated in patients with 
treated controlled hypertension. However, pulse wave velocity was only elevated 
in untreated hypertensive individuals. 
 
4.4.1 Pulse wave analysis and pulse wave velocity 
Current clinical guidelines do not aim at lowering aortic BP alongside brachial BP, 
perhaps due to difficulties with its measurement during a patient visit to their 
clinician or general practitioner. This is concerning considering aortic BP is the 
pressure that the heart, the kidney and the arteries supplying the brain are exposed 
to (Hirata et al., 2006). Indeed, elevated aortic PP and aortic SBP are stronger 
predictors of adverse CV events when compared to brachial PPs and SBPs (Safar 
et al., 2002, Roman et al., 2007, Pini et al., 2008, Roman et al., 2009, Wang et al., 
2009). Although aortic BP has been shown to be a useful marker for adverse CV 
events, a large-scale randomised trial has not yet been commenced with the end 
goal of lowering central BP or arterial stiffness. However, a randomised controlled 
trial found that using aortic BP as a marker of the effectiveness of antihypertensive 
therapy led to the use of less medications to achieve adequate BP control when 
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compared to using brachial artery BP measurements in 286 hypertensive patients 
(Sharman et al., 2013). Most concerning is that both treated controlled and treated 
uncontrolled hypertensives had elevated aortic PP in this study when compared to 
normotensive participants. The current view is that drugs that interfere with the 
renin-angiotensin-aldosterone system (RAAS), such as angiotensin converting 
enzyme inhibitors (ACEi) are more effective at lowering aortic pressures when 
compared to other anti-hypertensive medications (Boutouyrie et al., 2011). This 
may be due to the profibrotic effect of angiotensin II on the arterial wall (Laurent et 
al., 2005). It is interesting to note that in the present study a large proportion of the 
treated hypertensives were taking ACEi (44% of treated uncontrolled hypertension 
and 88% of treated controlled hypertension; Chapter 3; Table 3.1, page 190) and 
angiotensin receptor blockers (25% of treated uncontrolled hypertension and 31% 
of treated controlled hypertension (Chapter 3; Table 3.1, page 190) yet still had 
elevated aortic PP. Therefore, general practitioners and clinicians may consider 
measurements of aortic PP when seeing hypertensive patients. 
 
It remains to be seen why aortic SBP and DBP were not elevated in treated 
controlled hypertensives compared to normotensive participants, whereas central 
PP was different. However, there was a large effect size (ɳ = 0.3) calculated for 
aortic SBP. This would suggest that with a larger sample size differences between 
treated controlled hypertension (127±17) and normotension (113±10) may have 
been found. Similarly, a large effect size was also calculated for the effect of group 
on aortic DBP (ɳ = 0.22). 
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Only untreated hypertensive individuals had elevated pulse wave velocity in this 
study when compared to normotensive individuals. It is unclear why the arterial 
tonometry used to calculate aortic PP and pulse wave velocity measurement was 
inconsistent with each other as they both indirectly measure arterial stiffness. One 
study found that reductions in pulse wave velocity were associated also with 
reductions in aortic SBP and PP (Ait-Oufella et al., 2010). This study was powered 
to assess the differences in SBP during maximal exercise, and more participants 
are likely to be needed to see differences in pulse wave velocity. Similar to aortic 
SBP and DBP a large effect size was calculated for pulse wave velocity (ɳ = 0.22). 
This may suggest differences may have been found between the groups if this 
study had been powered to find differences in pulse wave velocity. 
 
4.4.2 Identifying the cause of an exaggerated SBP response to V̇O2 peak testing 
The exact mechanism that mediates exaggerated changes in SBP during exercise 
is unknown. In the study in Chapter 3 it was shown that metaboreflex hyperreflexia 
in treated and untreated hypertension partially mediates an exaggerated change 
in SBP during submaximal intensity (51-75% V̇O2 peak) and peak exercise testing 
(V̇O2 peak test). It is well documented that metaboreflex hyperreflexia is present in 
people with untreated hypertension (Delaney et al., 2010, Sausen et al., 2009, 
Greaney et al., 2014, Chant et al., 2018). An additional mechanism that mediates 
an exaggerated rise in peripheral SBP during exercise in individuals with essential 
hypertension is increased pulse wave velocity (Tsioufis et al., 2008). In the 
Framingham study it was shown that both pulse wave velocity and aortic PP were 
positively associated with an increased brachial SBP during a sub-maximal 
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exercise test on a treadmill (Thanassoulis et al., 2012). In the current study, prior 
to adjustment for known mediators of an exaggerated brachial SBP response to 
exercise pulse wave velocity, aortic PP and the change in peripheral SBP during 
PEI (metaboreflex isolation) were positively correlated to an exaggerated change 
in brachial SBP at peak exercise, which would support the Framingham study 
(Tsioufis et al., 2008). However, after accounting for age, daytime ambulatory SBP, 
pulse wave velocity, the change in brachial SBP during PEI (metaboreflex isolation) 
and aortic PP (independent variables), the strongest predictors of an exaggerated 
change in absolute SBP during maximal exercise were both central aortic PP and 
the change in SBP during PEI (metaboreflex isolation). Together, aortic PP and the 
absolute change in SBP during PEI accounted for 25% (R2=0.25) of the change in 
SBP at peak exercise. In addition, the change in SBP during sub-maximal exercise 
was found to be predicted only by the change in SBP during PEI. Metaboreflex 
hyperreflexia accounted for 18% (R2=0.15) of the change in SBP during sub-
maximal exercise. It is clear that other mechanisms are contributing substantially 
to the exaggerated SBP response to submaximal and peak exercise in these 
groups, as only 15% of the submaximal and 25% of the peak change in absolute 
SBP can be explained by this study. It is likely that other neural mechanisms, such 
as the mechanoreflex (Velasco et al., 2015, Greaney et al., 2015a), central 
command (Liang et al., 2016), peripheral chemoreceptors (Pijacka et al., 2018) and 
impaired aortic and carotid baroceptor function (Brum et al., 2000) are also 
contributing to the SBP response to exercise. Metabolic irregularities have also 
been highlighted in mediating an exaggerated SBP response to exercise, such as 
hypercholesterolemia (Thanassoulis et al., 2012, Sharman et al., 2007) and insulin 
resistance (Park et al., 2006). 
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The focus of this Chapter was on the SBP response to exercise due to the well 
documented relationship between an exaggerated SBP and elevated CV risk (Kurl 
et al., 2001, Laukkanen et al., 2006). In addition, there is very limited data available 
regarding the DBP during exercise and CV risk. MSNA is closer related to DBP 
than SBP (Sundlöf and Wallin, 1978) and MSNA contributes to the exaggerated 
pressor response to exercise in hypertension (Delaney et al., 2010). Future 
research will need to assess the DBP response to exercise and elevated CV risk 
in hypertension. This Chapter supports previous research that highlights that aortic 
PPs are importantly linked to SBP during dynamic exercise and helps further 
explain the abnormal pathophysiology during exercise in treated controlled 
hypertension highlighted in the study in Chapter 3. 
 
4.4.3 Mechanisms 
In the simplest form the two-element Windkessel model describes the circulation 
as a function of resistance and capacitance (total peripheral resistance (TPR) and 
compliance respectively) (Dart and Kingwell, 2001). Compliance is defined as the 
capacity of a large artery to accommodate increases in the volume of blood 
(change in volume/change in pressure) (Dart and Kingwell, 2001). The majority of 
systemic arterial compliance is determined by the branches of the aorta and the 
aorta itself (Liu et al., 1986). Aortic compliance decreases at higher pressures and 
is dependent on the initial volume conditions (Liu et al., 1986). However, an issue 
with the two-element Windkessel model is that it assumes that all pressure 
changes occur instantly upon left ventricular contraction and that it does not 
account for wave reflection (Dart and Kingwell, 2001).  In hypertensive patients, 
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peripheral arterial stiffness is elevated, and the wave reflection occurs earlier in 
systole and contributes to the aortic BP (Fantin et al., 2007). Another mechanism 
to explain heightened aortic PP at rest in treated controlled and treated 
uncontrolled hypertension is the alternative Windkessel model (Wang et al., 2003, 
Davies et al., 2010). This model focuses on an excess pressure that is calculated 
from aortic pressure and Windkessel pressure (reservoir pressure = aortic outflow 
– Windkessel pressure) (Wang et al., 2003). This model states that a forward wave 
generated by the left ventricle and the Windkessel reservoir function are more 
important when describing aortic outflow from the windkessel, aortic PP and 
peripheral PP when compared to wave reflection (AIx) (Wang et al., 2003, Davies 
et al., 2010). The excess pressure has is the minimum amount of work that the left 
ventricle has to perform to eject blood into the aorta. The Windkessel reservoir is 
important in dampening the aortic PP and brachial PP. The elevated aortic PP in 
the treated controlled and uncontrolled hypertensive groups may have caused an 
increased Windkessel pressure in the aorta during left ventricular contraction 
(Wang et al., 2003, Davies et al., 2010, Heffernan et al., 2013). This would cause 
the aorta to lose its ability to act as a reservoir during systole and a faster forward 
wave would occur (Wang et al., 2003). Moreover, during diastole there would be 
less potential energy stored in the aorta and a reduced recoil of the vessel, which 
would lead to a widening of the aortic PP (Wang et al., 2003). Antihypertensive 
medications have a mixed effect on aortic BP (Williams et al., 2006) and a less 
compliant aorta would be less able to expand under increasing volumes of blood 
(Schultz et al., 2013a, Heffernan et al., 2013). This would have the effect of causing 
exaggerated increases in brachial artery SBP due to augmented forward waves 
from the left ventricle and a reduced Windkessel reservoir effect (Schultz et al., 
Chapter 4 Arterial stiffness and exaggerated blood pressure responses to exercise in 
humans with hypertension 
239 
 
2013a). In addition, aortic impedance (Zo) is the resistance of the aorta to the left 
ventricular stroke volume (Wesseling et al., 1993). Upon left ventricular contraction 
blood is forced into the aorta but the aorta already contains a certain volume of 
blood and this opposes left ventricular stroke volume (Wesseling et al., 1993). This 
would contribute to aortic BP because a heightened Zo would mean the left 
ventricle has to work harder to pump blood into the aorta. Interestingly, Zo has 
been shown to be elevated in hypertension (Li and Ahn, 2012, Bollache et al., 
2015). These factors may help to explain why treated controlled hypertensives 
have an exaggerated rise in brachial BP during exercise. A less compliant aorta 
and elevated Zo would likely expand less during exercise induced increases in 
stroke volume and this would augment forward waves from the left ventricle and 
brachial BP (Schultz et al., 2013a).  
 
Pulse wave velocity, especially when measured from the carotid-femoral pulse has 
been shown to be strongly correlated with aortic stiffness when measured during 
phase contrast magnetic resonance imaging (Hickson et al., 2010). Recent 
evidence in 1599 patients found that aortic PP was related to CV events whereas 
carotid-femoral pulse wave velocity was related more to chronic kidney disease, 
peripheral artery disease, arterial plaques and microalbuminuria (Bai et al., 2018). 
This suggests that aortic PP may reflect issues with the myocardium whereas 
carotid-femoral pulse wave velocity may more accurately predict peripheral 
diseases. However, it is unclear why aortic PP predicted exaggerated changes in 
absolute SBP during peak exercise in this study and not pulse wave velocity. 
Further research is needed to assess how aortic PP and pulse wave velocity 
change during exercise in a larger group of treated and untreated hypertensives 
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when compared to normotensive controls. Furthermore, the specific contributions 
of the forward and backward wave have not been established at rest or during 
exercise in hypertension (Schultz et al., 2013a). 
 
These alterations in central haemodynamics and metaboreflex hyperreflexia help 
to explain why treated controlled hypertensives remain at increased risk of CV 
disease, stroke and total mortality compared to normotensive individuals (Almgren 
et al., 2005, Lawlor et al., 2011, Brown et al., 2013). It could be speculated that 
drugs that target metaboreflex hyperreflexia whilst also reducing aortic PP would 
be effective in lowering exercise BP and reducing the CV risk of treated and 
untreated hypertensive patients. 
 
4.4.4 Study limitations 
General study limitations can be found in Chapter 3 (section 3.4.4, page 187). More 
specifically, we only measured aortic PP at rest and did not measure what would 
happen to aortic PPs during exercise. Intra-arterial measurements during exercise 
have shown that in healthy young individuals that PP amplification is further 
augmented during dynamic exercise (increased brachial artery PP compared to 
aortic PP) (Rowell et al., 1968, Kroeker and Wood, 1955). Using arterial tonometry, 
Sharman et al. (2005) confirmed these results non-invasively during upright cycle 
ergometer exercise. Sharman et al. (2005) found that AIx (a marker of wave 
reflection) was reduced during exercise in healthy individuals and this was likely 
mediated by the exercise induced rise in HR and peripheral vasodilation of the 
arterioles in the active skeletal muscle (functional sympatholysis) (Sharman et al., 
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2005). However, aortic PP still increased but significantly less than brachial artery 
PP (Sharman et al., 2005). Schultz et al. (2013a) found that aortic PP during 
exercise in healthy adults was mediated by the forward wave and aortic compliance 
as compared to the reflected wave. In healthy individuals, functional sympatholysis 
in the active skeletal muscle ensures that wave reflection is minimal (reduced AIx). 
This serves to protect the aorta from reflected waves and central BP rises during 
exercise exclusively by pressure waves generated by the left ventricle (Schultz et 
al., 2013a). In addition, exaggerated increases in SNA during exercise, coupled 
with impaired functional sympatholysis in the active skeletal muscle would be 
expected to increase the contribution of the reflected wave leading to elevated 
aortic PP. This has not directly been assessed in treated or untreated hypertension. 
Nevertheless, it is known that SNA is exaggerated during exercise in untreated 
hypertension and that functional sympatholysis is impaired in these individuals 
(Vongpatanasin et al., 2011, Price et al., 2013, Delaney et al., 2010). Additionally, 
the data from Chapter 3 suggest that metaboreflex hyperreflexia is augmented in 
treated hypertensives compared to normotensive controls, which is known to be 
mediated by the SNS (Delaney et al., 2010). Based on the results of this study and 
of Chapter 3, future studies should use arterial tonometry during exercise to assess 
central haemodynamics in treated and untreated hypertension. This could 
potentially highlight treated controlled hypertensives who are at especially high risk 
for adverse CV events. This study also only included a small number of participants 
(n=59), future studies will need to include a larger number of participants to 
reconfirm these findings in a larger population. Furthermore, due to the low number 
of participants in each group we were unable to assess the effect of different anti-
hypertensive medications on aortic PP at rest and its relationship with exercise 
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SBP. This is important to assess because studies have shown mixed effects of 
different anti-hypertensive medications on aortic PP and pulse wave velocity 
(Blacher et al., 2005, Boutouyrie et al., 2011, Protogerou et al., 2009). Larger multi 
centre studies will need to assess aortic BP and brachial artery BP during exercise 
in treated hypertension to assess the variety of different anti-hypertensive 
medications available.  
 
4.5 Conclusions 
This study has highlighted that despite adequate control of baseline brachial artery 
SBP, treated controlled hypertensives have heightened resting aortic PP. 
Importantly, this contributes to the exaggerated rise in brachial artery SBP seen in 
treated controlled hypertension discussed in Chapter 3. Even after adjustment for 
other known risk factors for an exaggerated SBP response to exercise, aortic PP 
and metaboreflex hyperreflexia remained positively associated with an 
exaggerated peripheral SBP response to exercise. This research suggests that 
central haemodynamic and metaboreflex hyperreflexia should be targeted for 
optimal control of BP during exercise. Targeting these mechanisms successfully 
would reduce the associated CV risk of exercise in the hypertensive population. 
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N 16 11 16 16 
M/F 8/8 6/5 9/7 7/9 
Age (Years) 65±5 65±7 66±6 67±6 
Height (cm) 172±11 173±12 170±9 167±9 
Weight (kg) 70±14 72±14 74±12 72±12 
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Pulse wave velocity 
PWV (m/s) 8.8±1.5 11.2±2* 10.6±2.5 10.6±2.3 
N; number, M; male, F; female, BMI; body mass index, V̇O2 peak; peak volume of 
oxygen inspired, AT; anaerobic threshold (%), ABPM; ambulatory blood pressure 
monitoring, SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; 
mean arterial pressure, PP; pulse pressure, HR; heart rate, AIx; augmentation 
index, PWV; pulse wave velocity. * P=<0.05 vs. normotension; †P=<0.05 vs. 
controlled hypertension (all one-way ANOVA with Tukey post-hoc test). 
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Table 4-2 Assessment of multicollinearity between independent variables from a forced entry multiple linear regression test.  
Assessment of multicollinearity between independent variables from a forced entry multiple linear regression test assessing the 
influence of the change in systolic blood pressure during metaboreflex isolation (PEIO), aortic pulse pressure (aorticPP), pulse 
wave velocity (PWV), age and daytime ambulatory systolic blood pressure on the change in absolute systolic blood pressure during 
submaximal (modSBP) exercise testing (51-75% V̇O2 peak testing). The correlation values between independent variables were 
checked for large positive correlations (>0.7) before checking the tolerance statistic and variance inflation factor in Table 4.3. 
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Table 4-3 Assessment of multicollinearity between independent variables from a forced entry multiple linear regression test. 
Multiple regression assessing the influence of the change in systolic blood pressure during metaboreflex isolation (PEIO), aortic 
pulse pressure (aorticPP), pulse wave velocity (PWV), age and daytime ambulatory systolic blood pressure on the change in 
absolute systolic blood pressure during submaximal (modSBP) exercise testing (51-75% V̇O2 peak testing). To assess 
multicollinearity, the tolerance statistic should be above 0.2 and the variance should be below 10 for each independent variable. 
The forced entry multiple linear regression found that only the change in systolic blood pressure during metaboreflex isolation 
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Multiple regression assessing the influence of the change in systolic blood pressure during metaboreflex isolation (PEIO), aortic pulse 
pressure (aorticPP), pulse wave velocity (PWV), age and daytime ambulatory systolic blood pressure on the change in absolute 
systolic blood pressure during peak exercise testing (V̇O2 peak testing). The correlation values between independent variables were 












Table 4-4 Assessment of multicollinearity between independent variables from a forced entry multiple linear regression test.  
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Table 4-5 Assessment of multicollinearity between independent variables from a forced entry multiple linear regression test. 
Multiple regression assessing the influence of the change in systolic blood pressure during metaboreflex isolation (PEIO), aortic 
pulse pressure (aorticPP), pulse wave velocity (PWV), age and daytime ambulatory systolic blood pressure on the change in 
absolute systolic blood pressure during peak exercise testing (V̇O2 peak testing). To assess multicollinearity, the tolerance statistic 
should be above 0.2 and the variance should be below 10 for each independent variable. The forced entry multiple linear 
regression found that the change in systolic blood pressure during metaboreflex isolation (PEIO) and aortic PP predicted the 
change in absolute systolic blood pressure during peak exercise testing (V̇O2 peak testing). 
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Figure 4-1 A typical central blood pressure waveform recreated from the radial pulse 
from an inbuilt transfer function (SphygmoCor). 
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Figure 4-2 Aortic measurements from pulse wave analysis and pulse wave 
velocity. PWV; pulse wave velocity, Aortic PP; aortic pulse pressure, Aortic SBP; 
aortic systolic blood pressure, AP; augmentation pressure, AIx; augmentation 
index, AIx 75; augmentation index referenced to 75 beats (beats/min). 
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Figure 4-3 Relationship between baseline aortic haemodynamics and daytime 
systolic, diastolic and pulse pressure from ambulatory blood pressure monitoring. 
The data show that there is a positive correlation between the aortic systolic 
pressure (SBP) and daytime ambulatory systolic blood pressure (A). In addition, 
there is positive relationship between aortic DBP, aortic PP and daytime 
ambulatory DBP and PP respectively (B and C). Blue dots, normotensives; green 
dots, treated-controlled hypertensives; red dots, treated-uncontrolled 
hypertensives and black dots, untreated hypertensive participants. 
Chapter 4 Arterial stiffness and exaggerated blood pressure responses to exercise in 




Chapter 4 Arterial stiffness and exaggerated blood pressure responses to exercise in 
humans with hypertension 
253 
 
Figure 4-4 Relationship between baseline central haemodynamics and the 
change in peripheral SBP during submaximal dynamic exercise (51-75% V̇O2 
peak testing).  
The data show that there is a positive correlation between the aortic pulse 
pressure (PP) and aortic systolic blood pressure (SBP) and the change in 
peripheral SBP during submaximal dynamic exercise (51-75% V̇O2 peak testing). 
Blue dots, normotensives; green dots, treated-controlled hypertensives; red dots, 
treated-uncontrolled hypertensives and black dots, untreated hypertensives. 
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Figure 4-5 Relationship between baseline central haemodynamics and the 
change in peripheral systolic blood pressure (SBP) at peak dynamic V̇O2 peak 
testing). 
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The data show that there is a positive correlation between pulse wave velocity, 
aortic pulse pressure (PP) and aortic systolic blood pressure (SBP) and the 
change in peripheral SBP during peak dynamic exercise (V̇O2 peak testing). Blue 
dots, normotensives; green dots, treated-controlled hypertensives; red dots, 
treated-uncontrolled hypertensives and black dots, untreated hypertensive 
participants. 
  




Chapter 5 Can dietary nitrates prevent excessive rises in blood pressure 
in people with treated-controlled hypertension?  
5.1 Introduction 
The study in Chapter 3 demonstrated that patients with treatment controlled 
hypertension had an exaggerated rise in systolic blood pressure (SBP) during 
incremental exercise testing which was similar to patients with untreated 
hypertension (Chant et al., 2018). Importantly, both groups had an elevated rise 
in SBP compared to normotensive individuals (Chant et al., 2018). This was, in 
part, due to increased metaboreflex activation during exercise in the patients with 
hypertension (Chant et al., 2018). This finding is concerning because an 
exaggerated blood pressure (BP) response to exercise is independent risk for 
adverse cardiovascular (CV) events (Kjeldsen et al., 2001, Kjeldsen et al., 1997, 
Kurl et al., 2001, Laukkanen et al., 2006, Ren et al., 1985, Mizuno et al., 2016a, 
Mundal et al., 1996, Filipovsky et al., 1992). Therefore, first line treatment for 
hypertension clearly does not target the metaboreflex and alternative therapies 
need to be developed to make exercise safer in hypertension. 
 
The increased sympathetic nerve activity (SNA) that occurs during exercise is 
directed to all vascular beds (active and inactive). Vasoconstriction in non-
metabolically active areas helps to maintain perfusion pressure into the active 
skeletal muscle. In the active skeletal muscle, the increased SNA is offset by 
vasoactive metabolites in a process known as functional sympatholysis (Thomas 
et al., 1994), which helps to ensure adequate perfusion pressure of the active 
muscle. Functional sympatholysis is impaired in patients with untreated 




hypertension (Vongpatanasin et al., 2011, Price et al., 2013). Impaired functional 
sympatholysis is partially mediated by reduced nitric oxide (NO) bioavailability in 
animal models of hypertension (angiotensin II infused rats) (Zhao et al., 2006) 
and spontaneously hypertensive rats (SHRs) (Mizuno et al., 2014a). In 
hypertensive humans nebivolol, a non-specific β adrenoreceptor antagonist with 
NO potentiating abilities (Münzel and Gori, 2009) improves functional 
sympatholysis during dynamic handgrip exercise with lower body negative 
pressure (-20 mmHg) in untreated hypertensives (Price et al., 2013). Research 
indicates that reductions in blood flow to the active skeletal muscle during 
exercise have been shown to increase metaboreflex hyperreflexia (Kaufman et 
al., 1984, Xing et al., 2013). For example, ligation of the femoral artery in rats 
leads to an increased expression of acid sensing ion channel 3 (ASIC3) (Liu et 
al., 2010), purinergic receptor 3 subtype (P2x3) (Xing et al., 2013) and bradykinin 
B2 (Lu et al., 2013) on the group IV (metaboreflex) afferents, which augments 
metaboreflex sensitivity. This suggests that improving blood flow responses to 
exercise, by enhancing NO bioavailability in hypertensive individuals could 
decrease the activation of the metaboreflex during exercise.  
 
Increasing NO bioavailability is possible through dietary nitrates (NO3-) (e.g. 
beetroot, spinach, rocket) (Demoncheaux et al., 2002, Webb et al., 2008b). This 
is known as the NO3--nitrite (NO2-)-NO pathway. NO3- is reduced by symbiotic 
bacteria reduce NO2- on the posterior portion of the tongue (Duncan et al., 1995). 
The reduction of NO2- to NO is endothelial independent and is favoured under 
conditions of hypoxia, acidity and reduced oxygen (O2) tension (Shiva, 2013); 
ideal conditions for the skeletal muscle during exercise (Piknova et al., 2016). 




Consumption of dietary NO3- has been shown to lower BP in placebo controlled, 
double-blind, randomised and crossover design studies in patients with 
hypertension (Kapil et al., 2015, Ghosh et al., 2013). Importantly, in pre-
hypertensive males, dietary NO3- consumption for 15 days increased total 
vascular conductance and decreased the BP response to submaximal cycle 
ergometer testing (Choi et al., 2016). In addition, dietary NO3- have also been 
shown to lower SNA during isometric handgrip exercise (Notay et al., 2017) and 
metaboreflex activity (post-exercise ischemia (PEI)) in healthy individuals 
(Schneider et al., 2018). Currently, it is not understood whether dietary NO3- can 
lower the metaboreflex hyperreflexia and exercise BP in treated controlled 
hypertensive patients. By increasing NO bioavailability and improving functional 
sympatholysis, dietary NO3- could be expected to decrease metaboreflex 
hyperreflexia and the BP response to peak exercise testing (V̇O2 peak testing) in 
treated controlled hypertension.  
 
Therefore, the main aim of this study was to assess whether 4 weeks of dietary 
NO3- can improve the SBP at peak exercise (V̇O2 peak testing) in treated 
controlled hypertension compared to a placebo. The secondary aim was to 
assess whether 4 weeks of dietary NO3- can improve metaboreflex hyperreflexia 
during PEI compared to a placebo. The tertiary aim was to evaluate whether 
dietary NO3- for 4 weeks will change the MSNA (bursts/min) and MSNA 
(bursts/100Hb) during PEI compared to a placebo. The quaternary aim was to 
measure whether the change in MSNA (bursts/min) and MSNA (bursts/100Hb) 
during quiet resting was changed following dietary NO3-compared to a placebo. It 
was hypothesised that 4 weeks of dietary NO3- will cause a change in SBP at 




peak exercise (V̇O2 peak testing) when compared to a placebo (primary 
hypothesis). In addition, 4 weeks of dietary NO3- will cause a change in SBP 
during isolation of the metaboreflex (PEI2). The tertiary hypothesis was that 4 
weeks of dietary NO3- will cause a change in MSNA (bursts/min) and MSNA 
(bursts/100Hb) during metaboreflex isolation (PEI2). The quaternary hypothesis 
was that 4 weeks of dietary NO3- will cause a change in resting MSNA 
(bursts/min) and MSNA (bursts/100Hb) at baseline following 4 weeks of dietary 




5.2.1.1 Beetroot juice study 
36 treated controlled hypertensive participants were screened for this study. 21 
participants were recruited and a further 15 were excluded due to screening failure 
(Figure 5.1, page 309). 12 participants were randomly allocated to the dietary NO3- 
group and 9 participants were allocated to the placebo group. All participants were 
matched for age, body mass index (BMI) and for CV fitness (V̇O2 peak) (Table 5.1, 
page 301). Overall, 11 females (52%) were recruited to this study and all of which 
were postmenopausal (100%). This study was designed as a pilot study for a future 
project grant application to the British Heart Foundation (BHF). Ethical approval 
was granted by the Northern-Ireland proportionate review NHS REC (17/NI/0097) 
and received local R&D approval. Volunteers were recruited from our groups’ 
specialist hypertension clinic at University Hospitals Bristol Trust and Foundation, 
Bristol. The remaining participants were recruited from the surrounding area. The 




study was conducted at the Clinical Research and Imaging Centre (CRiC), Bristol. 
All participants attended the CRiC-Bristol at a similar time of day and all lab 
conditions were controlled to a set temperature (22C). Participants were asked to 
refrain from alcohol and caffeine for 12 hours before the study visits. In addition, 
participants were asked to abstain from high-intensity exercise for at least 24-hours 
prior to participation. The participants were asked to take their anti-hypertensive 
medication as normal. 
 
Inclusion and exclusion criteria: In accordance with the National Institute for 
Health and Care Excellence (NICE) guidelines (NICE, 2011), treated-controlled 
hypertension was defined as taking one or more anti-hypertensive medications 
and adequate BP control on daytime ambulatory blood pressure monitoring 
(ABPM) (<135/85 mmHg). Similar to the study in Chapter 3, exclusion criteria 
included; diabetes mellitus (urine dipstick test and self-reported), BMI (>30 
kg/m2), pregnancy, major illness (such as cancer), overt respiratory-CV disease 
(other than hypertension), and febrile illness with 2 weeks of the study. 
Participants were also asked to avoid the use of painkillers such as aspirin, 
paracetamol or anti-inflammatory drugs (e.g., ibuprofen) for 24 hours prior to the 
study visits. Participants were asked to refrain from these medications due to 
their known inhibitory effects on exercise BP (Drew et al., 2013, Cui et al., 2007, 
Cui et al., 2008b). For this study additional exclusion criteria included: i) current 
use of antibiotics or antibiotic use with the last 3 months, ii) current use of 
antibacterial mouthwash, iii) use of proton pump inhibitors (including 
esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole) and 
xanthine oxidase inhibitors, iv) currently consuming dietary NO3-based products 




(e.g., beetroot juice). Participants currently using antibiotics, antibacterial 
mouthwash and proton pump inhibitors are excluded from this study as these are 
known to alter the bacteria that convert NO3- to NO2-, which is vital for inorganic 
NO3- to have its therapeutic benefit (Woessner et al., 2016, Kapil et al., 2013). 
5.2.1.2 Study design and randomisation 
This was a single-centre, double-blinded, randomised placebo-controlled trial with 
a parallel group design. The researcher remained blinded until the data analysis 
was complete. Volunteers were randomised to receive the active and placebo 
beetroot juice in a 1:1 ratio with concealment using a binary random number 
sequence by a study co-coordinator who was not involved in the data collection, 
analysis or interpretation of data.  
 
5.2.2 Dietary Nitrates 
Participants were randomly allocated to take one x 70 mL/day of active beetroot 
juice (Beet It Sport; James White Drinks Ltd) containing ~6 mmol of NO3- or one x 
70 mL/day of a NO3- depleted placebo beetroot juice (Beet It Sport; James White 
Drinks Ltd) with breakfast for 4-weeks in total. This was a parallel design study; 
participants took the active or the placebo NO3- depleted beetroot juice. 
Importantly, both the active and placebo beetroot juice can produce discolouration 
of the urine and stool. The NO3--depleted placebo control is identical in 
appearance, taste and causes similar side effects which ensured that participants 
remain blinded to the treatment group (active placebo). Following the 4-week 
intervention, participants returned for post-assessment one which involved fitting a 
24-hour ABPM again. The participant then returned for a final visit (post-




assessment two) which was a repeat of pre-assessment two. Participants were 
instructed to take their final supplement on the morning of post-assessment two. A 
flow diagram of pre- and post-assessment two can be found in Figure 5.3 (page 
311). 
 
A 6 mmol/day dose of dietary NO3- was chosen due to a recent study which found 
that the O2 cost (V̇O2) of submaximal exercise was reduced in healthy individuals 
when consuming 6 mmol of NO3- per day for 4-weeks but not 3 mmol of NO3- per 
day (Wylie et al., 2016). Similarly, Kapil et al. (2015) found that 24-hour ambulatory 
BP was reduced in treated and drug-naïve hypertensive patients after consumption 
of 6 mmol/day of dietary NO3- for 4-weeks compared to placebo. A recent meta-
analysis suggested that a longer duration of beetroot juice (>14 days) had a more 
profound effect on lowering resting BP compared to <14 days (Bahadoran et al., 
2017). Therefore, based on this previous evidence we chose one x 70 mL of Beet 
It Sport for 4-weeks which contains ~6 mmol of NO3- per day.  
 
5.2.3 Screening procedures 
Participants attended four visits for this study. Pre-assessment one and two and 
post-assessment one and two. The screening procedures were carried out at pre-
assessment one. A summary of each visit can be found in Table 5.2 (page 303). 
A flow diagram for pre-assessment one can be found in Figure 5.2 (page 310). 
Participants attended a screening visit where resting clinic BP was measured 
using an automated cuff (Omron, The Netherlands). In accordance with the 
European Society of Hypertension (O'Brien et al., 2000, O'Brien et al., 2001, 




O'Brien et al., 2013), the first BP measurement was ignored which was followed 
by a BP reading on both the left and right arm and a final reading was then taken 
on the arm where BP was highest. An average of the final two readings was 
taken as clinic BP. A research nurse then fitted participants with a 12-lead 
electrocardiogram (ECG) to rule out any CV abnormalities. The ECG was 
checked by a cardiologist. Participants were fitted with a 24-hour ABPM to ensure 
that participants were classified as treated controlled hypertension (Spacelabs, 
OSI Systems Company, USA). The 24-hour ABPM assessed BP every 30 
minutes during the daytime and once per hour throughout sleeping hours 
(O'Brien et al., 2000, O'Brien et al., 2013, O'Brien et al., 2001). In addition, 
participants completed a 24-hour BP diary. Participants were asked to avoid any 
exercise during this 24-hour period to avoid post-exercise hypotension (Brito et 
al., 2014). 
 
5.2.4 Study procedures 
An outline of pre- and post-assessment two can be found in Figure 5.3 (page 311). 
Once the daytime ABPM was confirmed as treated controlled hypertension 
(SBP<135/85 mmHg) participants were asked to return for a follow up visit (pre-
assessment two) at least 48 hours after pre-assessment one. Participants were 
asked to follow a low- NO3- diet for 24 hours prior to arrival at the laboratory for 
pre-assessment two for the assessment of baseline plasma NO3- and NO2- levels 
(see section 5.2.4.1, Biological sample collection, page 264). Upon arrival, 
participants were asked to be supine on the bed prior to a venous sample being 
taken for the assessment of baseline plasma NO3- and NO2- levels (see section 




5.2.4.1, Biological sample collection, page 264; Figure 5.3, page 311). Following 
this, clinic BP was assessed using the same protocol from pre-assessment one. 
The maximal voluntary contraction (MVC) was then assessed using a handgrip 
dynamometer on the dominant hand. To assess the MVC, participants performed 
a maximal contraction of the handgrip dynamometer three times with at least 30 
seconds between each attempt. The highest value of the three attempts was 
regarded as the MVC (Delaney et al., 2010). The MVC was assessed to calculate 
40% MVC for the isometric handgrip exercise. An outline of pre-assessment two 
can be found in Figure 5.3 (page 311). Microneurography was then attained in the 
participants prior to isometric handgrip exercise and metaboreflex testing. After a 
15-minute rest, a V̇O2 peak test was then completed on a cycle ergometer (see 
section 5.2.4.4. V̇O2 peak testing, page 267). 
 
5.2.4.1 Biological sample collection: 
To confirm whether participants had been taking the NO3--rich beetroot juice or the 
NO3--depleted beetroot juice supplement, NO3-/NO2- concentrations from venous 
plasma were tested (Kapil et al., 2015). Baseline levels of NO3- and NO2- were 
tested following a 24-hour low NO3- diet to ensure similar baseline levels between 
the NO3--rich and placebo group. During this time participants were asked to keep 
a food diary. Participants then returned after 4-weeks for testing of venous plasma 
levels of NO3- and NO2-. Participants were asked again to follow a low dietary NO3- 
diet for 24-hours prior to this visit (except for the NO3--rich beetroot juice or NO3--
depleted placebo). Dietary NO3- has a half-life of ~6-hours (Webb et al., 2008b). 
NO2- peaks at around 3-hours following ingestion (Webb et al., 2008b). However, 




the plasma NO2- levels will remain elevated for around 6-hours in healthy (Webb 
et al., 2008b) and in hypertensive (Ghosh et al., 2013) individuals. Therefore, in 
the follow up visits following 4-weeks of supplementation we asked both the 
dietary-NO3- rich beetroot juice and NO3--depleted beetroot juice group to take their 
final supplement 1.5 hours prior to attending the laboratory.  
 
Blood sample collection and storage: Participants blood was collected using 
standard venepuncture from the median cubital vein into two paediatric 2mL lithium 
heparin vacutainer tubes and immediately centrifuged (1500g, 4°C, 10 minutes) to 
separate plasma from red blood cells. Using filtration, the samples were 
deproteinated using 3kDa filters (Vivaspin 500, Sartorius Biotech, Aubagne, 
France) (14000g, 4°C, 60 minutes). The resulting filtrate was then stored at -80°C 
until analysis at a later date. This procedure was followed in accordance with Dr. 
Kapil’s (Kapil et al., 2010, Kapil et al., 2013, Kapil et al., 2015) laboratory. 
 
5.2.4.1.1 Nitrate/nitrite concentration:  
Determination of NOx: The total concentration of NO3- and NO2- (NOx) was 
determined using ozone based chemiluminescence (Ignarro et al., 1993, Bush et 
al., 1992) (Figure 5.4, page 312). Total NOx (NO3- and NO2-) concentration was 
determined by adding biological samples to 0.1 mol/L vanadium (III) chloride in 1 
mol/L hydrochloric acid refluxing at 95°C under nitrogen (inert gas) (Kapil et al., 
2015). Both NO3- and NO2- are reduced to NO in acidic vanadium (III) chloride 
(Ignarro et al., 1993). NO present or produced is then carried by an inert gas 
(nitrogen) to the reaction cell. NO that is produced reacts with ozone (O3) in the 




reaction cell to form nitrogen dioxide (NO2) in an excited state (NO2*) (Coneski and 
Schoenfisch, 2012). The subsequent decaying and relaxation of NO2* to NO2 
releases a photon (hY) that is detected by a photomultiplier tube (Coneski and 
Schoenfisch, 2012). This can be summarised by the following equations: 
NO + O3            NO2* + O2 [equation 5.1] 
NO2*           NO2 + hY [equation 5.2] 
* indicates an excited state of the NO2-. 
The signal detected by the chemiluminescence procedure is proportional to the 
level of NO and therefore NOx (Coneski and Schoenfisch, 2012). Samples 
measured were then compared to a standard calibration curve generated from a 
commercially available premixed known concentration of NO gas. 
 
Determination of nitrate and nitrite concentration: NO2- concentrations can be 
directly determined by refluxing 1% potassium iodide in glacial acetic acid (Ignarro 
et al., 1993). Under these conditions NO2- is reduced to NO, however, NO3- 
concentrations cannot be detected as NO3- cannot be directly reduced to NO 
(Ignarro et al., 1993). Therefore, to calculate NO3- concentrations: 
NO3- = NOx – NO2- [equation 5.3] 
 
Levels of NO3- and NO2- (µmol/L) from plasma will be reported as absolute values 
at both baseline and following 4-weeks of supplementation. 
 




This analysis took place in Dr Vikas Kapils laboratory at Queen Mary University of 
London (an expert in NO3- metabolism) where NO3- and NO2- levels are regularly 
measured (Kapil et al., 2013, Kapil et al., 2015, Kapil et al., 2010). 
 
5.2.4.2 Microneurography 
Multiunit efferent muscle sympathetic nerve activity (MSNA) was assessed using 
a tungsten microelectrode positioned in the peroneal nerve at the fibular head. For 
expanded information regarding the microneurography procedure see Chapter 2 
(section 2.7, page 117). 
 
5.2.4.3 Isometric handgrip and Metaboreflex testing 
Following a baseline period of 10 minutes participants were asked to perform 
isometric handgrip at 40% MVC for 1 minute. An occlusion cuff was then pumped 
up to supra-systolic pressures (240) mmHg and this remained inflated following 
isometric handgrip exercise for 2 minutes and was regarded as post-exercise 
ischemia (PEI) (Delaney et al., 2010, Sausen et al., 2009, Greaney et al., 2014, 
Alam and Smirk, 1937). For a more detailed information regarding isometric 
handgrip exercise and metaboreflex testing see Chapter 2 (section 2.6, page 108). 
 
5.2.4.4 V̇O2 peak testing 
Participants were asked to rest for 15 minutes prior to the V̇O2 peak test. BP was 
assessed every 1.5 minute during V̇O2 peak testing on the left arm of the participant 
using an automated sphygmomanometer (Love Medical, Manchester, UK). Heart 




rate (HR) was assessed using a 12-lead ECG (Love Medical, Manchester, UK). 
Breathing frequency, tidal volume, minute ventilation (breathing frequency * tidal 
volume), V̇O2 and volume of carbon dioxide expired (V̇ECO2) were assessed using 
an Ergoflow flow sensor for spirometry (Ergostik CPET system, Love Medical, 
Manchester, UK). The same protocol was used to assess V̇O2 peak that was used 
in Chapter 3 (Chapter 2; section 2.3.1, page 94 and Chapter 3; section 3.2.1, page 
151). See Chapter 3 (section 3.2.1, page 151) for the criteria used to define V̇O2 
peak. 
 
5.2.4.5 Physiological Monitoring During V̇O2 Peak and Metaboreflex Testing 
5.2.4.5.1 V̇O2 peak test 
The methods used for physiological assessment during the V̇O2 peak test can be 
found in chapter 3 (section 3.2.3.1, page 154). 
 
5.2.4.5.2 Handgrip and Metaboreflex isolation 
See Chapter 3 for methods used for physiological assessment during handgrip, 
and metaboreflex isolation (PEI) (section 3.2.4.1, page 155). Additionally, for this 
study the change in MSNA (bursts/min, bursts/100Hb and total MSNA/min and total 
MSNA/Hb) were compared to a baseline period prior to isometric handgrip 
exercise. The change in BP was assessed on a beat-to-beat basis using finger 
plethysmography (Finometer; Finapres Medical Systems, The Netherlands, 
Chapter 2, section 2.6, page 108). The change in HR was measured using a 3-
lead ECG. Finally, the change in stroke volume (SV), cardiac output (CO) and total 




peripheral resistance (TPR) were assessed using modelflow from the Finapres 
(Finometer; Finapres Medical Systems, The Netherlands, Chapter 2, section 2.6.2, 
page 111). 
 
5.2.5 Power calculations 
To test the hypothesis, 20 participants with treated-controlled hypertension in 
each group (n=20 for intervention and n=20 for placebo) will provide the power of 
>80% to find a statistical difference (P≤0.05) in peak SBP during maximal 
exercise testing after 4-weeks intervention period of NO3--rich beetroot juice 
compared to a placebo control (NO3- depleted beetroot juice). This is based on 
previous results (Kapil et al., 2015) indicating that clinic SBP was reduced by 
8.7±8.2 mmHg following NO3- rich beetroot juice (n=32) compared to a 1±8.4 
mmHg reduction following placebo control (n=32) (NO3- depleted beetroot juice) 
in individuals with hypertension. From these previous results a large effect size 
was calculated (d=0.93). See results section for information regarding why 
recruitment was stopped prematurely. 
 
5.2.6 Outcomes 
The primary end point of this study was the difference in SBP at peak exercise 
from pre to post intervention (V̇O2 peak test). Secondary end points were the 
change in SBP and MSNA (bursts/min) and MSNA total activity (arbitrary units 
(au)) from pre to post intervention during metaboreflex isolation (PEI). The 
change in diastolic blood pressure (DBP), pulse pressure (PP), mean arterial 
pressure (MAP), heart rate (HR), tidal volume, breathing frequency, minute 




ventilation and the respiratory efficiency slopes were also considered during V̇O2 
peak testing. Similarly, DBP, PP, MAP, HR, heart rate variability, cardiac 
and sympathetic baroreflex sensitivity and sympathetic transduction were 
considered during metaboreflex isolation (PEI). 
 
5.2.7 Data analysis 
5.2.7.1 V̇O2 peak test 
The methods used to analyse the V̇O2 peak test are described in Chapter 3 (section 
3.2.7.1, page 157). 
 
5.2.7.2 Isometric handgrip, metaboreflex testing and recovery 
The absolute change in SBP, DBP, mean arterial pressure (MAP), pulse pressure 
(PP), HR, SV, CO, TPR and MSNA (bursts/min, bursts/100hb, MSNA area and 
total MSNA) were averaged over 1-minute periods. The change in SBP, DBP, 
MAP, PP, HR, SV, CO, TPR and MSNA (bursts/min, bursts/100hb, MSNA area 
and total MSNA) were assessed by comparing to a baseline period prior to the 
onset of isometric handgrip exercise. PEI was split into 2x1 minute periods which 
accounted for the initial drop in BP following the withdrawal of isometric handgrip 
exercise expected in PEI1 (Delaney et al., 2010). The second minute of post-
exercise ischemia (PEI2) was used for analysis of the metaboreflex. When 
isometric HG stops, there is an initial drop in BP that may activate the baroreflex 
and therefore isolation of the metaboreflex cannot be guaranteed (Delaney et al., 
2010). However, BP rises again and remains stable during the second minute of 




PEI2. Recovery was split into 5x1 minute periods for the assessment of recovery 
SBP, DBP, MAP, PP, HR, SV, CO, TPR and MSNA (bursts/min, bursts/100hb, 
MSNA area and total MSNA). 
 
5.2.7.3 Identifying and quantifying MSNA (bursts/min, bursts/100Hb, MSNA area 
and total MSNA) 
MSNA burst identification was completed using a script written in a data analysis 
program (Spike 2, Cambridge Electronic Designs). More specific details 
regarding MSNA burst identification can be found in Chapter 2 (section 2.7, page 
117). 
 
5.2.7.4 Additional physiological measurements 
5.2.7.4.1 Sympathetic vascular transduction 
Noradrenaline released from the sympathetic nerves leads to vasoconstriction of 
resistance vessels and increased arterial resistance. This transfer of sympathetic 
activity into vascular tone is known as sympathetic vascular transduction (Briant 
et al., 2016). To quantify this the relationship between MSNA and DBP was 
assessed. DBP is used for this analysis because DBP has a stronger correlation 
with MSNA than SBP (Sundlöf and Wallin, 1978). This analysis was performed 
using an automated script in MATLAB (The MathWorks, Natick, MA, USA). First 
the neurogram was normalised. Burst area was calculated by firstly assigning the 
largest burst in the signal as 100 arbitrary units (AU) and a period of no bursts 
was marked as 0 AU (Hart et al., 2017). The start and end of each multiunit 




MSNA burst were then marked and the integral was then assessed between 
‘start’ and ‘end’ (Hart et al., 2017). More specifically, for each DBP the MSNA 
burst area was calculated during a fixed cardiac interval. The slope of MSNA 
burst area (arbitrary units; au) against DBP (mmHg) was then calculated using 
weighted linear regression (Briant et al., 2016). The slope of the line was taken 
as the sympathetic vascular transduction (Briant et al., 2016). To assess the 
optimal cardiac cycle to use for this analysis, the sympathetic vascular 
transduction analysis was performed for each defined cardiac cycle (3–1, 4–2, 5–
3, 6–4, 7–5, 8–6, 9–7 and 10–8) during both baseline and recovery (Figure 5.5, 
page 313). Similar to previous research (Briant et al., 2016) a cardiac cycle of 8-6 
was used for analysis of the sympathetic vascular transduction (Figure 5.5, page 
313). A previous study using this technique found that sympathetic vascular 
transduction increased from young women to older women whereas sympathetic 
vascular transduction decreased in men with age (Briant et al., 2016). As NO 
may influence sympathetic vascular transduction, the pre-dietary NO3- vs post 
dietary NO3- data will be compared. Sympathetic vascular transduction was 
measured during baseline (10 minutes) and recovery from PEI (5 minutes). 
 
5.2.7.4.2 Spontaneous sympathetic baroreflex sensitivity 
The sensitivity of the sympathetic baroreflex can be assessed by quantifying 
spontaneous changes in DBP and whether this triggers changes in MSNA (Hart 
et al., 2010). Changes in DBP are used because increases in MSNA are initiated 
when baroreflex inhibition wears off during diastole (Wallin and Nerhed, 1982). 
More specifically, the DBP was first calculated for each cardiac cycle and put into 




1 mmHg bins.  Next, each DBP that was associated with an MSNA burst was 
calculated. If no MSNA burst occurred during the cardiac cycle, then the burst 
was assigned a value of 0. A weighted linear regression of the % of 1 mmHg 
DBP that were associated with a burst and the total number of cardiac cycles was 
then performed. The slope of the weighted linear regression was then taken as 
the sensitivity of the sympathetic baroreflex (Hart et al., 2010). The sensitivity of 
the baroreflex was calculated during baseline (10 minutes) and during recovery 
(5 minutes) from metaboreflex testing. An example can be found in Figure 5.6 
(page 314). 
 
5.2.7.4.3 Heart Rate Variability 
The methods used to analyse heart rate variability are described in Chapter 3 
(section 3.2.8.1, page 159). 
 
5.2.7.4.4 Spontaneous Cardiac Baroreflex Sensitivity 
The methods used to analyse spontaneous cardiac baroreflex sensitivity are 
described in Chapter 3 (section 3.2.8.2, page 160). 
 
5.2.8 Statistical Analysis 
The difference in baseline parameters (daytime BP, night time BP and clinic BP) 
from pre- to post-treatment was compared between placebo and dietary NO3- 
groups using an unpaired students t-test.  
 




Primary outcome: For this study the main outcome was the difference in the 
absolute SBP at peak exercise (V̇O2 peak testing) from pre- to post-treatment. This 
was compared between placebo and dietary NO3- groups using an unpaired 
students t-test. Magnitude based inferences were carried out to determine the 
effect of the active treatment on the primary outcome. A qualitative inference of 
beneficial, trivial or harmful effect of active treatment was given as follows 0-5% 
(very unlikely), 5-25% (unlikely), 25-75% (possibly), 75-95% (likely), 95-99.5% 
(very likely) and > 99.5% (most likely) (Batterham and Hopkins, 2006).  
 
Secondary outcomes: The difference in the absolute DBP, PP, MAP, HR, tidal 
volume, breathing frequency and minute ventilation at peak exercise from pre- to 
post-treatment were also analysed using an unpaired t-test. 
 
The absolute change and % change in SBP, DBP, PP, MAP, HR, tidal volume, 
breathing frequency and minute ventilation from baseline during the different 
exercise intensities (% V̇O2 peak testing) were tested using a 2-way mixed model 
ANOVA (within-subject (time (exercise intensity)) and between-subject 
(treatment)). A post-hoc Tukey test was used if a significant interaction was found. 
 
The difference in the absolute SBP during metaboreflex isolation (PEI2) from pre- 
to post-treatment was compared using an unpaired students t-test. The difference 
in the absolute DBP, PP, MAP, HR, SV, CO, TPR and MSNA (bursts/min, 
bursts/100hb, MSNA area and total MSNA) during PEI2 from pre- to post-treatment 
were also analysed using an unpaired t-test. 




The group averages for the absolute change in SBP, DBP, MAP, PP, HR, SV, CO, 
TPR and MSNA (bursts/min, bursts/100hb, MSNA area and total MSNA) from 
baseline during isometric handgrip exercise and the two 1-minute periods of PEI 
were compared using a mixed model 2-way ANOVA (within-subject (time 
(isometric handgrip or PEI) and between-subject (treatment)). A post-hoc Tukey 
test was used if a significant interaction was found.  
 
All data from the V̇O2 peak test, isometric handgrip and PEI are reported as 
mean ± standard deviation (SD). The Cohens effect sizes (d) and eta squared 
(Ƞ2) were calculated to assess the magnitude of the differences. The magnitude 
of the d and Ƞ2 were based on the following criteria: <0.2 (trivial), 0.2-0.6 (small 
effect), 0.6-1.2 (moderate effect), 1.2-2 (large effects) and >2 a very large effect. 
Data were tested for normal distribution using a D’Agostino-Pearson omnibus K2 
normality test. The α level was set at 0.05. 
 
5.3 Results 
This study was stopped before the correct number of participants were collected 
to fulfil the sample size due to time constraints in the completion of this thesis. 21 
participants with treated controlled hypertension have completed this study. 12 in 
the active dietary NO3- group and 9 in the placebo group. Recruitment of 
participants with treated-controlled hypertension was much more difficult than 
previously expected (Figure 5.1, page 309). 
 




5.3.1 Pre/post-treatment participant demographics 
Pre-treatment age was similar between the placebo and dietary NO3- group (t(19) 
= 0.19; P=0.85; Table 5.1, page 301). Pre and post treatment BMI scores 
remained similar following dietary NO3- (26.2±3.1 (pre) vs 25.9±2.8 (post) kg/m2) 
and after placebo (26.7±3.2 (pre) vs 26.5 (post) kg/m2) (F(1,19)=3.34; P=0.83; Ƞ2 
= 0.150). 
 
At pre-treatment daytime ambulatory SBP was similar between the placebo 
(124±8 mmHg) and dietary NO3- group (125±8 mmHg) prior to intervention (t(19) 
= 0.15; P=0.87; d=0.125 Table 5.1, page 301). Daytime DBP was also similar 
between placebo and dietary NO3- (79±11 vs 80±7 mmHg, t(19) = 0.03; P=0.97; 
d=0.11). Similar results were found for MAP (t(19) = 0.13; P=0.91; d=0.124), PP 
(t(19) = 0.07; P=0.94; d=0.117) and HR (t(19) = 0.3; P=0.77; d=0.13) prior to 
intervention. Prior to intervention night-time SBP, DBP, MAP, PP and HR were 
also similar prior to intervention (P=>0.05; Table 5.1. page 301). Finally, the clinic 
SBP. DBP, MAP, PP and HR were also similar prior to intervention (P=>0.05; 
Table 5.1. page 301). 
 
5.3.2 Dietary nitrates and nitrites 
5.3.2.1 Plasma nitrate and nitrite concentrations 
5.3.2.1.1 Baseline 
Plasma NO3- and NO2- were measured in 9 out of 9 of the placebo group (100%) 
and 9 out of 12 of the dietary NO3- group (75%). Baseline plasma NO3- were 




similar between the placebo (25.58±7.95 μM/L) and dietary NO3- group 
(31.89±11.47 μM/L) (t(16)=1.301; P=0.21; d=0.64; Figure 5.7; page 315). 
Similarly, baseline plasma NO2- levels were similar between placebo (0.33±0.21 
μM/L) and the dietary NO3- group (0.23±0.16 μM/L) (t(16)=1.105; P=0.29; d=0.54; 
Figure 5.7, page 315). 
 
5.3.2.1.2 Pre-post intervention 
As expected, the change in plasma NO3- from baseline following 4 weeks of 
intervention was increased in the dietary NO3- group (Δ187.5±120.5 μM/L; 95% 
confidence interval (CI) [94.9 to 280.1) compared to the placebo group 
(Δ0.811±11.6 μM/L; 95% CI [-8.1 to 9.7) (t(16)=4.628; P=0.0003; d=2.18; Figure 
5.7; page 315). In addition, the change in plasma NO2- concentrations from 
baseline increased following dietary NO3- intervention (Δ0.24±0.29; 95% CI 
[0.009 to 0.46) compared to the placebo group (Δ-0.1±0.09; 95% CI [-0.18 to -
0.03) (t(16)=3.312; P=0.004; d=1.58; Figure 5.7, page 315). The percentage 
change in plasma NO3- and NO2- were also increased following intervention 
(Figure 5.7, page 315). 
 
5.3.2.2 Resting blood pressure and dietary nitrates 
Following 4 weeks of intervention there was no difference in the change in 
daytime ambulatory SBP between placebo group (3±5 mmHg (95% CI [0 to 6])) 
and in the active treatment group (3±4 mmHg (95% CI [0 to 5])), (t(19) = 0.28; 
P=0.78, d=0.00; Figure 5.8, page 316). There was also no change in daytime 
ambulatory DBP between the placebo group (0±7 mmHg (95% CI [0 to 7])) and 




the active treatment group (0±5 mmHg (95% CI [0 to 5])), (t(19) = 0.22; P=0.98, 
d=0.00, Figure 5.8, page 316). No differences were found for daytime ambulatory 
MAP (F (1,19) = 0.439, P=0.52; d=0.00, Figure 5.8, page 316), daytime 
ambulatory PP (F (1,19) = 3.45, P=0.08; d=0.00 Figure 5.8, page 316) and 
daytime ambulatory HR (F (1,19) = 1.65, P=0.21, d=0.00 ; Figure 5.8, page 316). 
Similar results were found for night-time ABPM for SBP, DBP, MAP, PP and HR 
(Figure 5.9, page 317). 
 
The change in clinic SBP pre-post treatment was not different between the active 
treatment group (-11±8 mmHg; 95% CI [-16 to -5]) and placebo intervention (-6±9 
mmHg; 95% CI [-13 to 1]), (t(19)=1.318, P=0.2; d=0.59; Figure 5.10, page 318). 
There was no difference between the active treatment group (-6±5 mmHg; 95% 
CI [-9 to -3]) and placebo control group (-3±7 mmHg; 95% CI [-9 to 2]) in clinic 
DBP (t(19) = 0.93, P=0.37; d=0.49, Figure 5.10, page 318). Similar results were 
found for clinic MAP and PP (Figure 5.10, page 318). In addition, no difference 
was found in the change in clinic HR between pre and post intervention between 
the active treatment (-3±10 beats/min; 95% CI [-4 to 5]) and the placebo control 
group (1±7 beats/min; 95% CI [-11 to 4]) (t(19)=1.09, P=0.29; d=0.46, Figure 
5.10, page 318). The antihypertensive medications that participants were taking 
are shown in Table 5.1 (page 301) and Table 5.3 (page 305). Antihypertensive 
medication remained the same throughout the study. 
 




5.3.2.3 V̇O2 peak testing 
The change in V̇O2 peak pre-post treatment was not different between the active 
treatment group (0.05±2.34 mmHg; 95% CI [-1.44 to -1.53]) and the placebo 
intervention group (-0.49±3.12 mmHg; 95% CI [-2.89 to 1.91]) (t(19)=0.45., 
P=0.66; d=0.2). Similarly, there were no changes in the anaerobic threshold, the 
peak RER attained, or the peak watts attained during V̇O2 peak testing (P=>0.05, 
Table 5.4, page 306). 
 
The change in absolute SBP from pre to post intervention at peak exercise (V̇O2 
peak testing) was not significantly different between the active treatment group (-
5±11 mmHg; 95% CI [-12 to 2]) and the placebo group (4±9 mmHg; 95% CI [-3 to 
11]) (t(19) = 0.723; P=0.07; d=0.9; Figure 5.11, page 319). The chance of being 
beneficial/trivial/harmful (magnitude based inference) was 13/87/0 suggesting 
that any effect seen for the active group was likely trivial. At peak exercise there 
was no difference between the pre-post difference in DBP between the active 
treatment group (2±21 mmHg; 95% CI [-11 to 16]) and placebo control (-1±10 
mmHg; 95% CI [-9 to 7]) (t(19) = 0.44; P=0.66; d=0.18; Figure 5.11, page 319). 
There was no change in MAP from pre to post intervention (t(19) = 1.37; P=0.19; 
d=0.62) or PP (t(19) = 2.06; P=0.06; d=0.91) at peak exercise (Figure 5.11, page 
319). Furthermore, the change in HR from pre to post intervention was not 
significantly different between the placebo control (-4±6 beats/min; 95% CI [-9 to 
0]) and the active treatment group (-1±4 beats/min; 95% CI [-4 to 2]) at peak 
exercise (V̇O2 peak testing) (t(19) = 1.46; P=0.16; Figure 5.11, page 319). 
 




To assess the absolute and % change from baseline in SBP, DBP, MAP, PP and 
HR during the incremental exercise test (V̇O2 peak test) a 2-way mixed model 
ANOVA (within-subject (time; % V̇O2 peak) and between-subject (treatment)) was 
used. There was not a significant interaction effect for the absolute change in 
SBP from baseline following the active treatment or placebo during any exercise 
intensity of V̇O2 peak testing (F (15,190) = 1.15, P=0.32; Ƞ2 = 0.01, Figure 5.13, 
page 322). Similar to SBP there was no group by time interaction effect for active 
treatment or the placebo intervention on the absolute change in DBP during any 
exercise intensity (% of V̇O2 peak testing) (F (15,190) = 0.6, P=0.87; Ƞ2 = 0.02; 
Figure 5.13, page 322). Similar results were found for the change in MAP, PP or 
HR during the V̇O2 peak test (Figure 5.13 page 322). Similar results were found 
for the % change in SBP, DBP, MAP, PP and HR during V̇O2 peak testing (Figure 
5.14, page 324).  
 
5.3.2.3.1 Respiratory data 
The differences in peak tidal volume, breathing frequency, minute ventilation, 
VEVCO2 (L/min) and the change in RER from pre to post intervention at peak 
exercise (V̇O2 peak testing) were not significantly different following active 
treatment when compared to placebo (Figure 5.15, page 326). 
 
The VE/VEVCO2 slope during V̇O2 peak testing was not different following active 
treatment (29.5±4 (pre; 95% CI [27 to 32.1]) vs. 28.4±3 (post; 95% CI [26.5 to 
30.4])) or following placebo (29.7±3.1 (pre; 95% CI [27.3 to 32.1]) vs. 28.4±3 
(post; 95% CI [28.5 to 33.7]) (F(1,19) = 0.22; P=0.65; Ƞ2 = 0.01). Finally, the rise 




in V̇O2 was plotted against the change in watts during V̇O2 peak testing (Figure 
5.16, page 328). There was no difference in the rise in V̇O2 during the V̇O2 peak 
test following dietary NO3- or placebo control for 4 weeks (F(3,38) = 0.32; P=0.32; 
Ƞ2 = 0.003, Figure 5.16, page 328). The changes from baseline in respiratory 
values were not different following NO3- or placebo control and can be found in 
Figure 5.17 to Figure 5.19 (pages 329-333). 
 
5.3.2.4 Resting neural-haemodynamics, handgrip exercise and metaboreflex 
isolation 
5.3.2.4.1 Baseline 
The absolute values of MSNA at baseline can be found in Figure 5.20 to 5.22 
(pages 335-337). MSNA recordings for baseline, isometric handgrip exercise and 
PEI were made only in 5 out of 9 (56%) of the placebo group and 8 out of 12 of 
the dietary NO3- group (67%). The change in MSNA burst frequency (bursts/min) 
during baseline from pre to post treatment was not different following 4 weeks of 
active treatment (-1±9 bursts/min; 95% CI [-9 to 7]) or placebo (-1±7 bursts/min; 
95% CI [-10 to 7]) (t(11)=0.13;P=0.9;d=0.00; Figure 5.23, page 338). The 
difference in MSNA burst incidence (bursts/100Hb) was also not different 
following 4 weeks of active treatment (2±19 bursts/100Hb; 95% CI [-14 to 18]) or 
placebo (-3±10 bursts/100Hb; 95% CI [-16 to 9]) (t(11)=0.55;P=0.59;d=0.33; 
Figure 5.23, page 338). Total MSNA/time and total MSNA/Hb were assessed in 3 
out 5 (60%) of the placebo group and 7 out of 8 of the active group (88%). This 
was because the active site for MSNA analysis was lost during isometric 
handgrip or PEI but was put back in for MSNA burst frequency and incidence. As 




the distance of the needle from the active site will not be same, the area cannot 
be calculated. The difference in total MSNA/time and MSNA/Hb were not different 
following active treatment or placebo (t(8)=0.63; P=0.55; d=0.46 and t(8)=1.032; 
P=0.33; d=0.73; Figure 5.23, page 338). 
 
Spontaneous sympathetic baroreflex sensitivity was measured in all individuals 
with a baseline MSNA recording. The slope of the spontaneous sympathetic 
baroreflex sensitivity was similar following active treatment (-2.89±1.77 pre; 95% 
CI [-4.25 to -1.53] vs -2.35±1.55 post; 95% CI [-3.54 to -1.15] bursts/mmHg) or 
placebo intervention (-2.45±1.72 pre; 95% CI [-4.59 to -0.31] vs -2.76±1.39 post; 
95% CI [-4.49 to -1.1] bursts/mmHg) (F(1,11) = 0.046; P=0.83; Ƞ2 = 0.004). 
Sympathetic vascular transduction was also similar when measured during 
baseline succeeding active treatment (0.07±0.07 pre; 95% CI [0.02 to 0.12] vs 
0.09±0.07 post; 95% CI [0.04 to 0.14] mmHg/%·s) and the placebo (0.09±0.11 
pre; 95% CI [0 to 0.24] vs 0.1±0.09 post; 95% CI [0 to 0.21] mmHg/%·s) 
(F(1,11)=0.162; P=0.7; Ƞ2 = 0.013). 
 
5.3.2.4.2 Heart rate variability 
All data relating to heart rate variability can be found in Table 5.5 (page 307). 
 




5.3.2.4.2.1 Spectral analysis 
No differences were found for either the LF/HF ratio, LF (nu), HF (nu), LF (ms2) or 
HF (ms2) following dietary NO3- or placebo in treated controlled hypertension 
during baseline (P=>0.05; Table 5.5, page 307). 
 
5.3.2.4.2.2 Time-domain analysis 
No differences were found for either the SDDR (ms), RMSDD (ms) or the pRR50 
(%) following dietary NO3- or placebo in treated controlled hypertension during 
baseline (P=>0.05; Table 5.5, page 307). 
 
5.3.2.4.3 Cardiac baroreflex sensitivity 
No differences were found for either the overall number of ramps (baroreflex 
mediated and non-baroreflex ramps), baroreflex mediated ramps, the gain of the 
cardiac baroreflex or the baroreflex effectiveness index following dietary NO3- or 
placebo in treated controlled hypertension during baseline (P=>0.05; Table 5.6, 
page 308). 
 
5.3.2.5 Isometric handgrip 
The difference in absolute SBP from pre to post active treatment (-3±18 mmHg; 
95% CI [-15 to 8]) or placebo (9±23 mmHg; 95% CI [-8 to 26]) was not different 
(t(19)=1.4; P=0.18; d=0.58; Figure 5.24, page 339). Similarly, there was no 
difference in absolute DBP from pre to post active treatment (2±9 mmHg; 95% CI 
[-4 to 8]) or placebo intervention (8±14 mmHg; 95% CI [-3 to 18]) (t(19)=1.14; 




P=0.27; d=0.51; Figure 5.24, page 339). The change in MAP and PP from pre-
post intervention during isometric handgrip was also similar (t(19)=1.3; P=0.21; 
d=0.58 and t(19)=0.73; P=0.47; d=0.32 Figure 5.24, page 339). The absolute 
difference in HR during isometric handgrip from pre to post intervention also 
remained comparable (active treatment 2±4; 95% CI [-1 to 5] vs placebo -1±4; 
95% CI [-4 to 2] beats/min; t(19)=0.92; P=0.92; d=0.00; Figure 5.25, page 340). 
No differences in SV (t(19)=0.4; P=0.7; d=0.19), CO (t(19)=0.52;P=0.61;d=0.25) 
or TPR (t(19)=0.97; P=0.35; d=0.46) pre to post-intervention (Figure 5.25, page 
340). 
 
The change in absolute MSNA burst frequency from pre to post intervention was 
the same during isometric handgrip exercise following dietary NO3- (1±10 
bursts/min; 95% CI [-8 to 11]) and placebo (3±3 bursts/min; 95% CI [-2 to 5]) 
(t(11)=0.04;P=0.97; d=0.02 Figure 5.26, page 341). In addition, there were no 
differences in MSNA burst incidence (dietary NO3-: 1±17; 95% CI [-15 to 17] vs 
placebo: 1±5; 95% CI [-2 to 9] bursts/100Hb; t(11)= 0.22; P=0.83; d=0.14; Figure 
5.26, page 341). Similar findings were found for total MSNA/min and total 
MSNA/Hb (t(8)=0.59; P=0.57; d=0.43 and t(8)=1.14; P=0.29; d=0.75; Figure 5.26, 
page 341). 
 
The absolute change from baseline in SBP during isometric handgrip exercise 
was similar succeeding active treatment (14±8 pre; 95% CI [9 to 19] vs 12±8 
post; 95% CI [6 to 17] mmHg) or following placebo control (11±6 pre; 95% CI [7 
to 16] vs 18±8 post; 95% CI [12 to 24] mmHg) (Interaction: F(9,108)=0.48; 




P=0.89; ɳ2 = 0.004; Figure 5.29, Page 344). No interaction effect was found for 
the absolute change in DBP from baseline following the active treatment (7±7 
pre; 95% CI [3 to 12] vs 7±5 post; 95% CI [3 to 11] mmHg) or placebo (7±4 pre; 
95% CI [4 to 10] vs 10±5 post; 95% CI [7 to 14] mmHg) (F(9,108)=0.42; P=0.92; 
ɳ2 = 0.009; Figure 5.29, Page 344). Comparable results were attained for the 
absolute change in MAP (F(9,108)=0.36; P=0.95; ɳ2 = 0.005), PP (F(9,108)=0.58; 
P=0.81 ɳ2 =0.006) or HR (F(9,108)=0.68; P=0.72; ɳ2 = 0.02; Figure 5.30, Page 
345) from baseline during isometric handgrip exercise (Figure 5.29, Page 344). In 
addition, no significant interaction was found for the absolute change in SV 
(F(9,108)=0.86; P=0.56 ɳ2 = 0.04), CO (F(9,108)=0.96; P=0.48; ɳ2 = 0.04) or TPR 
(F(9,108)=0.08; P=0.99; ɳ2 = 0.003) following active treatment or placebo (Figure 
5.30, Page 345). No difference was found for the absolute change in respiratory 
rate during isometric handgrip testing from pre to post intervention (P=>0.05). 
Similar results were found for the % change in SBP, DBP, MAP, PP, HR, SV, 
CO, TPR and respiratory rate during isometric handgrip exercise following dietary 
NO3- and placebo intervention (Figure 5.31 and 5.32, Page 346-347). 
 
The change in absolute MSNA burst frequency from baseline during isometric 
handgrip exercise was similar following active treatment (6±9 pre; 95% CI [-2 to 
15] vs 8±7; 95% CI [1 to 14] post bursts/min) and after placebo intervention (7±8 
pre; 95% CI [-3 to 17] vs 8±8 post; 95% CI [-3 to 18] bursts/min) (F(9,60)=0.45; 
P=0.9; ɳ2 = 0.03; Figure 5.21, page 336). The change in MSNA burst incidence 
(bursts/100Hb) from baseline was also similar during isometric handgrip exercise 
following active treatment (3±13 pre; 95% CI [-9 to 14] vs 6±6 post; 95% CI [1 to 
11] bursts/100Hb) and placebo (6±11 pre; 95% CI [-7 to 19] vs 9±10; 95% CI [-4 




to 22] post bursts/100Hb) (F(9,60)=0.75; P=0.66; ɳ2 = 0.04; Figure 5.21, page 
336). The absolute change from baseline during isometric handgrip exercise 
remained similar for total MSNA/min and total MSNA/Hb following dietary NO3- 
and placebo intervention (F(9,48)=0.78;P=0.63; ɳ2 = 0.03; and 
F(9,48)=0.59;P=0.8; ɳ2 = 0.03; Figure 5.21, page 336). 
 
5.3.2.6 Post-exercise ischaemia 
The physiological data collected during PEI1 and PEI2 can be found in Figures 
5.20 to 5.22 (pages 335-337) and Figures 5.27 to 5.32 (pages 342-347).  
 
The change in absolute SBP during PEI2 from pre to post active treatment (-
6±16; 95% CI [-17 to 5] mmHg) or placebo (8±23; 95% CI [-10 to 25] mmHg) was 
not different (t(19)=1.54; P=0.14; d=0.11; Figure 5.33, page 348). In addition, 
there was no change in absolute DBP from pre to post active treatment (-1±8; 
95% CI [-6 to 5] mmHg) or placebo intervention (6±14; 95% CI [-4 to 17] mmHg) 
(t(19)=1.41; P=0.17; d=0.61; Figure 5.33, page 348). The absolute change in 
MAP and PP from pre-post intervention during PEI2 were also not significantly 
different (t(19)=1.36; P=0.19; d=0.66 and t(19)=1.005; P=0.33; d=0.36; Figure 
5.33, page 348). The absolute HR pre to post intervention also remained 
comparable following active treatment (-2±4; 95% CI [-4 to 1] beats/min) and 
placebo (2±3; 95% CI [-1 to 5] beats/min) (t(19)=1.64; P=0.0.12; d=0.81; Figure 
5.34, page 349). There were no differences in SV (t(19)=1.19; P=0.25; d=0.59), 
CO (t(19)=0.04;P=0.97;d=0.02) or TPR (t(19)=0.96; P=0.35; d=0.46) pre to post 
intervention (Figure 5.34, page 349). 




During PEI2, the difference in the absolute MSNA burst frequency from pre to 
post intervention was comparable following active treatment (-4±8; 95% CI [-11 to 
3] bursts/min) and placebo (3±5; 95% CI [-3 to 9] bursts/min) (t(11)=0.53;P=0.61; 
d=0.33; Figure 5.35, page 350). In addition, there were no differences in MSNA 
burst incidence from pre to post intervention (active treatment:-3±6; 95% CI [-16 
to 17] vs placebo: 2±3; 95% CI [-3 to 6] bursts/100Hb; t(11)=0.32; P=0.76; 
d=0.16; Figure 5.35, page 350). Similar findings were found for total MSNA/min 
and total MSNA/Hb (t(8)=0.84; P=0.42; d=0.67 and t(8)=0.03; P=0.98; d=0.02; 
Figure 5.35, page 350). 
 
The absolute change in SBP during PEI2 from baseline was similar following 4 
weeks of active treatment (39±15 pre; 95% CI [29 to 49] vs 35±14 post; 95% CI 
[25 to 44] mmHg) or following placebo control (36±10 pre; 95% CI [29 to 44] vs 
40±15 post; 95% CI [29 to 52] mmHg) (Interaction: F(9,108)=0.48; P=0.89; ɳ2 = 
0.004; Figure 5.29, page 344). There was no interaction effect for the absolute 
change in DBP during PEI2 from baseline succeeding active treatment (15±7 pre; 
95% CI [10 to 19] vs 12±6 post; 95% CI [8 to 16] mmHg) or placebo (13±3 pre; 
95% CI [10 to 15] vs 13±15 post; 95% CI [2 to 24] mmHg) (Interaction: 
F(9,108)=0.42; P=0.92; ɳ2 = 0.009; Figure 5.29, Page 344). Similar results were 
found for the absolute change in MAP (Interaction: F(9,108)=0.36; P=0.95; ɳ2 = 
0.005) and PP (Interaction: F(9,108)=0.58; P=0.81 ɳ2 =0.006) during PEI2 
(Figure 5.29, Page 344). No interaction effect was found for the absolute change 
from baseline in HR during PEI2 after active treatment (2±5 pre; 95% CI [-2 to 5] 
vs -1±6 post; 95% CI [-5 to 3] beats/min) or placebo (-1±6 pre; 95% CI [-6 to 4] vs 
2±5 post; 95% CI [0 to 7] beats/min) (F(9,108)=0.68; P=0.72; ɳ2 = 0.02; Figure 




5.30, page 345). No significant interaction effects were found for the absolute 
change in SV (F(9,108)=0.86; P=0.56 ɳ2 = 0.04), CO (F(9,108)=0.96; P=0.48; ɳ2 
= 0.04) or TPR (F(9,108)=0.08; P=0.99; ɳ2 = 0.003) during PEI2 following dietary 
NO3- or placebo intervention (Figure 5.30, page 345). There were also no 
differences in the absolute change in respiratory rate pre or post intervention 
during PEI2 (P=>0.05). Similar results were found for the % change in SBP, DBP, 
MAP, PP, HR, SV, CO, TPR and the respiratory rate during PEI2 following 
dietary NO3- and placebo intervention (Figures 5.31 and 5.32, page 346-347). 
 
The change in absolute MSNA burst frequency during PEI2 from baseline was 
similar after active treatment (7±7 pre; 95% CI [1 to 14] vs 6±2 post; 95% CI [4 to 
8] bursts/min) and after placebo intervention (8±6 pre; 95% CI [0 to 15] vs 9±7 
post; 95% CI [0 to 17] bursts/min) (F(9,60)=0.45; P=0.9; ɳ2 = 0.03; Figures 5.21, 
page 336). The change in MSNA burst incidence (bursts/100Hb) from baseline 
was comparable during PEI2 following active treatment (9±16 pre; 95% CI [-6 to 
24] vs 11±9 post; 95% CI [3 to 20] bursts/100Hb) and placebo (15±13 pre; 95% 
CI [-1 to 31] vs 18±14 post; 95% CI [0 to 35] bursts/100Hb) (F(9,60)=0.75; 
P=0.66; ɳ2 = 0.04; Figures 5.21, page 336). The absolute change in total 
MSNA/min and total MSNA/Hb from baseline followed a similar pattern following 
active treatment and placebo intervention (F(9,48)=0.78;P=0.63; ɳ2 = 0.03; and 
F(9,48)=0.59;P=0.8; ɳ2 = 0.03; Figure 5.21, page 336). An example MSNA trace 
from baseline to PEI2 can be found in Figure 5.36 (page 351). 
 





There was no effect of active treatment or placebo intervention for 4 weeks on 
the absolute, change or % change in SBP, DBP, MAP, PP, HR, SV, CO, TPR, 
MSNA burst frequency, MSNA burst incidence, MSNA area, total MSNA/min and 
total MSNA/Hb during recovery from PEI (P=>0.05) (Figures 5.37 to 5.45, pages 
352-360). A mixed model ANOVA (within-subject (time) and between-subject 
(treatment)) was used to assess the spontaneous sympathetic baroreflex 
sensitivity and sympathetic vascular transduction during the 5-minute recovery 
period.  The slope of the spontaneous sympathetic baroreflex sensitivity during 
recovery was similar following active treatment (-1.16±1.25 pre; 95% CI [-2.31 to 
-2.71] vs -1.65±1.14 post; 95% CI [-2.71 to -0.6] bursts/mmHg) and placebo 
intervention (-1.19±1.25 pre; 95% CI [-2.74 to 0.36] vs -1.48±1.18 post; 95% CI [-
2.94 to -0.02] bursts/mmHg) (F(1,10) = 1.87; P=0.201; Ƞ2 = 0.158). There were 
also no differences in the spontaneous sympathetic baroreflex sensitivity from 
baseline to recovery pre or post intervention (F(3,30) = 4.25; P=0.013; Ƞ2 = 
0.298). Sympathetic vascular transduction was also similar when measured 
during recovery after active treatment (0.15±0.08 pre; 95% CI [0.08 to 0.23] vs 
0.11±0.12 post; 95% CI [0.004 to 0.23] mmHg/%·s) and placebo (0.11±0.17 pre; 
95% CI [-0.1 to 0.32] vs 0.15±0.15 post; 95% CI [-0.03 to 0.34] mmHg/%·s) 
(F(1,10)=0.00; P=0.98; Ƞ2 = 0.00). Finally, there were no differences from 
baseline to recovery pre or post treatment (F(3,30) = 0.733; P=0.54; Ƞ2 = 0.068). 
 




5.3.2.7.1 Heart rate variability 
5.3.2.7.1.1 Spectral analysis 
No differences were found for either the LF/HF ratio, LF (nu), HF (nu), LF (ms2) or 
HF (ms2) following dietary NO3- or placebo in treated controlled hypertension 
during recovery from metaboreflex testing (P=>0.05; Table 5.4, page 306). 
 
5.3.2.7.1.2 Time-domain analysis 
No differences were found for either the SDDR (ms), RMSDD (ms) or the pRR50 
(%) following dietary NO3- or placebo in treated controlled hypertension during 
recovery from metaboreflex testing (P=>0.05; Table 5.4, page 306). 
 
5.3.2.7.2 Cardiac baroreflex sensitivity 
No differences were found for either the overall number of ramps (baroreflex 
mediated and non-baroreflex ramps), baroreflex mediated ramps, the gain of the 
cardiac baroreflex or the baroreflex effectiveness index following dietary NO3- or 
placebo in treated controlled hypertension during recovery from metaboreflex 
testing (P=>0.05; Table 5.5, page 307). 
 
5.4 Discussion 
This single-centre, double-blinded, randomised placebo-controlled trial with a 
parallel group design was the first study to assess the effect of dietary NO3- on 
the BP and MSNA response to metaboreflex and peak exercise testing. The 




elevation in plasma NO3- and NO2- indicates increased dietary NO3- intake and 
suggests an increased substrate pool for endothelial independent NO production 
is increased in treated controlled hypertensive patients over the intervention 
period. In contrast to the hypotheses, dietary NO3- did not cause a reduction in 
BP or MSNA during metaboreflex isolation, or a reduction in BP during peak 
exercise testing. 
 
5.4.1 Plasma NO3- and NO2- concentrations 
The current study found that dietary NO3- intake for 4 weeks lead to a 667% 
increase in plasma NO3- concentration, which is similar to values reported in 
previous literature (Kapil et al., 2015, Bondonno et al., 2015). Participants were 
asked to maintain a normal diet throughout the study and the placebo group’s 
plasma NO3- levels did not change over the 4-week period. Furthermore, plasma 
NO2- levels were also elevated by 95% following dietary NO3- intervention. This 
confirms previous findings that the entero-salivary tract is still intact and 
functioning normally in treated controlled hypertensives (Kapil et al., 2015). Most 
importantly this suggests that the participants adhered to the beetroot juice over 
the 4-week period. A previous study in treated and untreated hypertensives found 
that 4 weeks of dietary NO3- caused a significant reduction in clinic, home and 
daytime ABPM (Kapil et al., 2015). However, in this study there was no effect of 
dietary NO3- intervention on clinic or daytime ABPM. Interestingly, the participants 
in Kapil et al. (2015) study had treated-uncontrolled BP (daytime ABPM: 139/84 
mmHg), whereas the participants in this study were treatment-controlled 
hypertensives (daytime ABPM: 125/80 mmHg). A previous study assessing 




dietary NO3- in patients with treated controlled hypertension also found no effect 
on daytime ABPM, home or clinic BP (Bondonno et al., 2015). The authors 
postulated that the disparity between their results and those of Kapil et al. (2015) 
were due to the level of resting BP. This fits with the literature because it has 
been shown that the acute effect of an antihypertensive medication is 
proportional to the level of BP at rest (Law et al., 2009). In addition, larger 
reductions in BP were seen following acute dietary NO3- intake when baseline BP 
was higher (Webb et al., 2008b, Kapil et al., 2010, Ghosh et al., 2013). 
Antihypertensive medications may also increase the bioavailability of NO in 
patients with hypertension (Ignarro et al., 2002). Therefore, a change in BP may 
not have been expected in the already well controlled hypertensives in this study. 
The lack of improvement in resting BP was associated with no improvements in 
resting MSNA, or cardiac and sympathetic baroreflex sensitivity following dietary 
NO3- intervention. A similar study, but in healthy individuals found that 
improvement in resting BP was not associated with an improvement in cardiac 
baroreflex sensitivity following dietary NO3-  (Schneider et al., 2018). 
 
5.4.2 V̇O2 peak and the metaboreflex 
It was hypothesised that dietary NO3- would reduce metaboreflex hyperreflexia 
and lower MSNA response to PEI in treated controlled hypertension. It was 
thought that reducing metaboreflex hyperreflexia would help to reduce the blood 
pressure response to dynamic exercise This is important to assess because the 
BP response to exercise is an independent risk factor for adverse CV events in 
the general population (Kurl et al., 2001, Laukkanen et al., 2006). Treated 




controlled hypertensives have an exaggerated rise in BP at submaximal and 
peak exercise (V̇O2 peak testing) similar to untreated and treated uncontrolled 
hypertensives, which is elevated compared to normotensives (Chant et al., 2018). 
Of concern, this may place these treated controlled hypertensives at increased 
CV risk when compared to normotensives (Lawlor et al., 2011). Previous 
research in healthy young humans has shown that dietary NO3- intake dampens 
the increase in BP during 40, 60 and 80% of V̇O2 peak (Bond et al., 2013). In 
addition, following 15 days of dietary NO3- at a similar dose to this study (5.6 
mmol/day) the SBP was reduced at 30 and 60% of V̇O2 peak following compared 
to a placebo in young (age: 23±1) untreated pre-hypertensive individuals. 
However, the data presented in this Chapter highlight that the difference in peak 
SBP following dietary NO3- or placebo intervention was not different. In addition, 
dietary NO3- had no effect on BP measured at any submaximal intensity of V̇O2 
peak testing. The VE/VEVCO2 slope, which is also an independent risk factor for 
adverse CV events is known to be mediated by the peripheral chemoreceptors 
and the metaboreceptors (Ponikowski et al., 2001). It has been shown that NO 
can have an inhibitory effect on the chemoreceptors (Wang et al., 1994). There 
was no effect of dietary NO3- on the VE/VEVCO2 slope during V̇O2 peak testing. 
Previous research has highlighted the importance of the metaboreflex for 
mediating exaggerated rises in SBP during exercise in patients with hypertension 
(Delaney et al., 2010, Sausen et al., 2009). Increases in BP during metaboreflex 
isolation are mostly mediated by the SNS (Delaney et al., 2010). The hypothesis 
for this study was that dietary NO3- would decrease the BP and MSNA response 
during metaboreflex isolation (PEI). Only one study has looked at dietary NO3- 
and the metaboreflex. This study found that in healthy older participants (age: 




67±2 years) that 4 weeks of dietary NO3- reduced the SBP response to PEI 
compared to a placebo (Schneider et al., 2018). Unfortunately, this latter study 
did not assess MSNA and the authors postulated that the reduction in BP during 
PEI was associated with a fall in MSNA (Schneider et al., 2018). One study in 
young healthy individuals found that acute dietary NO3- intervention reduced 
MSNA at rest and during isometric handgrip exercise (Notay et al., 2017). Notay 
et al. (2017) suggested that the reductions in MSNA were due to the central 
effects of NO as the decrease in MSNA was not associated with improvements in 
sympathetic baroreflex sensitivity. These data suggest that dietary NO3- can 
inhibit sympathetic outflow from the brainstem (Notay et al., 2017). This study 
found no effect of dietary NO3- intervention for 4 weeks on MSNA during resting, 
isometric handgrip, PEI or recovery. Interestingly, a recent study found that in 
healthy individuals (aged between 18-48 years) that isolation of the metaboreflex 
only leads to increases in MSNA in the non-contracting limb, not the contracting 
limb (Boulton et al., 2018). MSNA was measured in the non-contracting right leg 
in this study and future research will need to assess the findings of Boulton et al. 
(2018) in individuals with hypertension. SBP also remained the same at baseline 
and during isometric handgrip and PEI following the intervention period. The 
following section focuses on plausible mechanisms for the lack of effect of dietary 
NO3- to improve the neural-haemodynamic response to peak exercise testing 
(V̇O2 peak testing) and metaboreflex isolation (PEI). 
 




5.4.3 Putative mechanisms for the lack of effect of dietary NO3- during exercise 
or metaboreflex isolation 
There are several plausible mechanisms why elevated levels of NO3- and NO2- 
did not suppress the CV reactions during exercise in the treated-controlled 
hypertensives in this study. Firstly, angiotensin II and ROS (such as O2-) increase 
in the skeletal muscle in relation to exercise intensity in healthy individuals 
(Moralez et al., 2018, Bailey et al., 2003). NO is quickly scavenged by O2-, 
forming the oxidant peroxynitrite (Pattwell et al., 2004). O2- and peroxynitrite can 
oxidise guanylyl cyclase making it unresponsive to NO (Stasch et al., 2006). In 
healthy Sprague-Dawley rats the increase in ROS during hindlimb contraction is 
modest, whereas in angiotensin II infused hypertensive rats the increase is 
substantially elevated (Zhao et al., 2006). This increase in O2- decreased 
functional sympatholysis and increased the BP response to exercise in the 
hypertensive rats (Zhao et al., 2006). It could be speculated that irrespective of 
how NO is increased it will have little effect on functional sympatholysis and 
subsequently the metaboreflex in hypertensive individuals, unless ROS levels are 
depressed (Zhao et al., 2006). The improvement in functional sympatholysis and 
the BP response to dynamic handgrip exercise testing following 12 weeks of 
nebivolol may reflect nebivolols antioxidant capabilities (Price et al., 2013). 
Indeed, nebivolol has been shown to reduce the subunits Rac1 and p67phox which 
are necessary for the oxidative activity of nicotinamide-adenine dinucleotide 
phosphate oxidase (NAD(P)H) (Oelze et al., 2006, Whaley-Connell et al., 2009). 
Through this mechanism it is proposed that nebivolol reduces exercise induced 
increases in in O2- (Oelze et al., 2006). Nebivolol also stimulates the release of 
NO by binding to endothelial β2 and β3 adrenergic receptors (Broeders et al., 




2000, Dessy et al., 2005) in addition to the stimulation of purinergic receptors 
(P2Y receptors) by endothelial ATP efflux (Kalinowski et al., 2003). Furthermore, 
tetramethyl-pereride 1-oxyl (Tempol), a known scavenger of O2- improves 
functional sympatholysis and exercise BP in the active hindlimb during 
contraction in angiotensin II treated hypertensive animals (Zhao et al., 2006). As 
β-adrenoceptor antagonists are known to impair exercise capacity (Van Baak, 
1988), drugs that target reactive O2 species and that increase NO, whilst 
improving exercise capacity may be more beneficial in hypertension. 
 
There is considerable evidence that NO plays an important role in functional 
sympatholysis and BP regulation during exercise (Price et al., 2013, Thomas and 
Victor, 1998). However, a significant body of research is overlooked which 
suggests that NO is not obligatory for either functional sympatholysis or BP 
control during exercise (Rosenmeier et al., 2003, Campbell et al., 2011, 
Radegran and Saltin, 1999). Firstly, acute local NO inhibition with N(G)-
monomethyl-L-arginine (L-NMMA) increased BP at rest and during sub-maximal 
exercise, but not at maximal exercise in healthy subjects (Campbell et al., 2011). 
In addition, L-NMMA has no effect on femoral blood flow or BP during 
submaximal or maximal, one-legged, dynamic knee-extensor exercise (Radegran 
and Saltin, 1999). Finally, exogenous NO stimulation does not blunt sympathetic 
vasoconstriction in healthy humans (Rosenmeier et al., 2003). Furthermore, it 
has been shown that NO works in synergy with other substances, such as 
prostacyclin, to mediate functional sympatholysis (Casey and Joyner, 2011, 
Dinenno and Joyner, 2004). However, the above-mentioned studies were 
conducted in healthy individuals and the available data in hypertensive 




individuals does suggest an important role of NO (Price et al., 2013, Thomas and 
Victor, 1998). Nevertheless, the results presented in this Chapter suggest a non-
obligatory role of NO during exercise in treated-controlled hypertension. 
 
5.4.4 Limitations 
Firstly, due to time constraints in completing this thesis the study had to be 
stopped prematurely meaning that the study was potentially left underpowered 
compared to other studies to find any differences in the primary outcome 
variable. The original power calculations suggested that 40 participants were 
needed for this study and only 21 were recruited. Future research will need to 
reconfirm these findings with a larger sample size. Plasma NO3- and NO2- 
concentrations were measured at rest in this study and it was assumed that NO3- 
and NO2- levels remained elevated during exercise in this group. An interesting 
study in healthy adult Wistar rats found that an acute bout of exercise caused a 
reduction in blood NO3- and NO2-, which indicated increased NO formation in the 
skeletal muscle (Piknova et al., 2016). This is important to assess in hypertension 
because maintained levels of NO3- and NO2- during exercise would suggest that 
the reductase mechanisms that reduce NO2- to NO are dysfunctional during 
exercise in hypertension. However, previous research in spontaneous 
hypertensive rats at rest has demonstrated that xanthine oxidoreductase 
expression is increased, suggesting an enhanced ability to reduce NO2- to NO 
(Ghosh et al., 2013). Cyclic guanosine monophosphate (cGMP), the most 
sensitive marker of increase NO activity was not measured in the participants in 
this study (Ghosh et al., 2013, Kapil et al., 2015). Previous research has found 




that plasma cGMP is increased in a temporal pattern following dietary NO3- intake 
at rest (Kapil et al., 2015, Kapil et al., 2010). The previous literature in treated 
hypertensive individuals that has also shown a temporal increase in plasma 
cGMP following dietary NO3- consumption at rest (Kapil et al., 2015). Future 
studies should measure cGMP during exercise in hypertension to confirm the 
adequate reduction of NO2- to NO. In addition, the dose of dietary NO3- used in 
this study was similar to previous research that found that ABPM was reduced 
following dietary NO3- consumption (Kapil et al., 2015). Whether a larger dose of 
dietary NO3- is needed to have an effect during exercise in hypertension is 
unknown and requires further research. Furthermore, it was assumed that 
elevated ROS levels inhibited the effect of elevated NO2- in this study. Future 
research will need to measure the level of superoxide anions during exercise, for 
example using electron spin resonance spectroscopy from venous blood samples 
(Moralez et al., 2018).  
 
Adherence to anti-hypertensive medication is typically poor (Herttua et al., 2013, 
Ong et al., 2007) and it is unclear whether poor adherence to the intervention in 
this study influenced the study results. Although, the plasma NO3- and NO2- 
concentrations were elevated in this following dietary NO3- for 4 weeks, it cannot 
be guaranteed that participants were taking the intervention every day. For 
example, acute dietary NO3- consumption increases plasma NO3- and NO2- (Kapil 
et al., 2010). A large proportion of participants complained of a foul taste and this 
likely would likely influence adherence. However, participants did complete a 
diary which suggested all of them adhered to the interventions. 




In addition, the studies that have assessed functional sympatholysis in 
hypertension have measured BP, MSNA and forearm blood flow response to 
dynamic handgrip testing (Price et al., 2013, Vongpatanasin et al., 2011). During 
isometric handgrip exercise, the arterial BP response is much larger as the BP 
needs to overcome the compressed blood vessels caused by intramuscular 
pressure increases (Kaur and Mann, 2016, Lind et al., 1964). Skeletal muscle 
blood flow was not measured in this study and future studies should measure 
forearm blood flow during dynamic handgrip exercise to assess functional 
sympatholysis (Price et al., 2013, Vongpatanasin et al., 2011). In addition, Kapil 
et al. (2015) found the flow-mediated dilatation (FMD) was increased following 
dietary NO3- consumption. As decreased FMD is related to excessive exercise 
BPs (Stewart et al., 2004), it is important to assess whether improvements in 
FMD associated with dietary NO3- consumption (Kapil et al., 2013, Kapil et al., 
2015) are associated with improvements in exercise BP. Finally, only 1 minute of 
isometric handgrip exercise was used in this study, Delaney et al. (2010) used 
90s of isometric handgrip due to difficulties with getting participants to maintain 
40% of MVC for longer than 90 seconds. In order to maintain adequate quality of 
the MSNA signal 1 minute was chosen instead of 90s. Although BP and MSNA 
did increase, it could be argued that this was not a long enough stimulus to 
stimulate the metaboreceptors (Crisafulli et al., 2006). 
 
5.4.5 Clinical perspectives 
Dietary NO3- consumption has previously been shown to lower clinic, home and 
24-hour ambulatory BP monitoring in treated and untreated hypertension (Kapil et 




al., 2015) This is important as this would be expected to lower CV risk in 
hypertensive individuals (Lewington et al., 2002, Wright et al., 2015). 
Unfortunately, dietary NO3- consumption for 4 weeks is not associated with 
improvements resting BP, the BP response to metaboreflex isolation, 
submaximal exercise (51-75% V̇O2 peak) or peak exercise in treated controlled 
hypertension. Future research needs to consider different therapeutic strategies 
for improving the BP response to exercise as an excessive BP response to 
exercise is an independent risk factor for hypertension (Kurl et al., 2001, 
Laukkanen et al., 2006). 
 
5.5 Conclusions 
This is the first study to assess the effect of consumption of dietary NO3- 
consumption for 4 weeks on the BP and MSNA response to metaboreflex 
isolation and the BP response to peak exercise testing (V̇O2 peak test). Dietary 
NO3- had no effect on BP or MSNA response to metaboreflex isolation. In 
addition, there was no effect on the BP response to peak exercise in treated 
controlled hypertension. 
  





Table 5-1 Participant demographics at pre-treatment 
Participant 
demographics 
Placebo (pre) Dietary nitrates (pre) 
N 9 12 
M/F 4/5 6/6 
Age (Years) 63±8 63±7 
Height (cm) 170±7 171±8 
Weight (kg) 76±11 76±10 
BMI (kg/m2) 26.7±3 26.2±3 
V̇O2 peak (ml/min/kg) 23.8±6.6 25.9±9.9 
AT (%) 67.6±6.9 70.4±6.4 
Daytime ABPM 
SBP (mmHg) 124±8 125±8 
DBP (mmHg) 79±11 80±7 
MAP (mmHg) 94±9 95±7 
PP (mmHg) 45±11 46±5 
HR (beats/min) 64±7 66±10 
Night-time ABPM 
SBP (mmHg) 120±15 118±10 







HR (beats/min) 59±8 62±11 
Clinic BP 
SBP (mmHg) 142±13 136±18 
DBP (mmHg) 81±9 78±11 
MAP (mmHg) 101±8 97±12 
PP (mmHg) 61±12 58±13 
HR (beats/min) 67±10 63±6 
Antihypertensive medications 
Median number of anti-
hypertensive medications 
2 (IQR=1-2.5) 2 (IQR=1-2) 




Percentage of participants taking anti-hypertensives (by class) 
ACEi (%) 44 42 
ARB (%) 22 8 
CCB (%) 67 67 
α-blocker (%) 0 8 
β-blocker (%) 11 17 
Diuretics (%) 22 8 
N; number, M; male, F; female, BMI; body mass index, V̇O2 peak; peak volume of 
oxygen inspired, AT; anaerobic threshold (%), ABPM; ambulatory blood pressure 
monitoring, SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean 
arterial pressure, PP; pulse pressure, HR; heart rate, ACEi; angiotensin converting 
enzyme inhibitor, ARB; angiotensin receptor blocker, CCB; calcium channel blocker, 
IQR; inter-quartile range.  





Table 5-2 Schedule of Assessments and Procedures 








Procedure/Assessment     
Written informed consent X    
Demographics (Medical history, age, 
height, weight, BMI) 
X X  X 
Vital signs (heart rate, blood pressure and 
oxygen saturations). 
X X  X 
Ambulatory blood pressure monitoring 
(ABPM) (24 hours) 
X  X  
ECG (12-lead) for screening at rest and 
exercise testing 
X X  X 
Urine dipstick test X    
Blood sample for nitrate and nitrite 
analysis 
 X  X 
ECG (3-lead), heart rate, oxygen 
saturation, spirometry (tidal volume, 
respiratory frequency), partial pressures 
 X  X 
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of inspired and expired gases (CO2 and 
O2) 
Microneurography  X  X 
Isometric handgrip testing  X  X 
Finapres continuous blood pressure 
measurement (finger cuff) 
 X  X 
Peak exercise testing (V̇O2 peak test)  X  X 
Participant given inorganic nitrate 
supplement or placebo 
 X   






















ACEi; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blocker, CCB; 
calcium channel blocker 
  
 Placebo  
Anti-hypertensive 
class 
Specific drug taken % taking drug 
ARB Losartan 11 
 Candesartan 11 
ACEi Ramipril 44 
CCB Amlodipine 56 
























Table 5-4 Pre- and post-treatment V̇O2 peak data 
 Placebo  Dietary nitrates  
 Pre Post Pre Post 
V̇O2 peak 23.8±6.6 23.3±6.9 25.9±9.9 26±10.8 
AT (%) 67.6±6.9 66.9±9 72.5±5.3 69.2±7.9 
RERMAX 1.36±0.07 1.32±0.06 1.27±0.06 1.26±0.1 
WattMAX 174±50 175±55 200±83 196±82 
V̇O2 peak; peak volume of oxygen inspired, AT; anaerobic threshold, RER; respiratory 
exchange ratio.
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Table 5-5 Heart rate variability (HRV). 
Heart rate variability (HRV) 
Spectral analysis 

























LF/HF ratio 1.25±0.6 1.35±0.9 1.99±2.7 1.63±1.1 1.91±1.17 2.09±1.92 1.59±0.96 1.22±1.13 
LF (nu) 48.32±15.8 47.26±17.9 48.49±24.1 50.62±22.1 58.03±14.75 56.78±18.97 52.92±18.75 43.77±20.76 
HF (nu) 41.88±11.44 43.73±15.45 42.07±20.08 44.7±20.3 37.33±13.04 39.1±16.59 42.51±19.22 48.91±18.29 
LF (ms2) 434.64±257.6 427.48±244.6 499.06±533.2 529.98±509.2 818.8±578.21 674.48±489.16 917.93±907.63 711.81±444.66 
HF (ms2) 607.31±390.7 592.86±395.7 352.86±307.9 352.64±268.6 418.45±276.82 431.78±257.64 551.77±417.56 682.28±747.89 
Time domain 
SDRR (ms) 46.83±15.17 48.83±11.49 0.36±14.84 43.77±18.82 54.61±19.44 53.99±14.8 76.91±47 47.82±16.59 
RMSSD 
(ms) 
34.17±14.32 41.19±14.32 34.24±16.5 37.65±25.08 37.28±15.92 39.47±14.61 47.49±34.27 38.88±21.93 
pRR50 (%) 13.53±12.99 15.8±12.3 11.17±11.61 16.05±19.1 16.05±14.31 16.49±12.14 16.44±11.23 18.66±19.08 
LF/HF; low frequency/high frequency ratio, LF (nu); low frequency, HF (nu); high frequency, SDRR; standard deviation of the R-R interval, RMSSD, 
root mean square of the successive differences, pRR50, percentage of R-R intervals > 50 ms. 
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Table 5-6 Spontaneous cardiac baroreflex sensitivity. 
Spontaneous cardiac baroreflex sensitivity 
Sequence technique 
 Baseline Recovery 
 Placebo Dietary nitrates Placebo Dietary nitrates 
Total with sequences (n) 7/9(78%)  12/12(100%)  7/9(78%)  10/12(83%)  
Up ramps (n) 47±20 43±12 53±26 45±20 27±9 27±10 24±7 25±10 
Down ramps (n) 52±15 54±22 59±22 48±20 29±6 30±7 30±10 28±10 
All ramps (n) 98±35 97±30 112±46 92±39 56±15 57±16 54±15 52±18 
Sequence ramps up (n) 11±11 8±10 7±9 9±9 6±3 3±2 5±5 5±3 
Sequence ramps down (n) 18±16 12±13 7±8 10±10 10±4 8±5 5±4 4±4 
Sequence ramps all (n) 29±27 20±23 14±16 19±19 16±7 11±6 11±9 9±6 
Up ramps (gain) 7.6±3.7 7.6±3.2 10.9±8.1 9.8±5.7 11±8.7 9.7±3 10±6.3 12.16±6.4 
Down ramps (gain) 11.5±3.1 9.6±5.4 9.2±4.9 10.1±5 9.9±4.7 10.3±4.5 9±3.2 10.1±3.6 
All ramps (gain) 10.1±3.2 8.9±3.9 9.9±4.9 10.2±5.3 9.9±5.5 10±3.7 9.1±3.9 10.5±5 
Baroreflex effectiveness index (BEI) 
Total number of participants  7/9(78%) N/A 12/12(100%) N/A 7/9(78%) N/A 10/12(83%) N/A 
BEI (up) 0.23±0.14 0.2±0.22 0.19±0.17 0.23±0.18 0.24±0.07 0.13±0.02* 0.26±0.18 0.19±0.06* 
BEI (down) 0.30±0.26 0.24±0.28 0.15±0.18 0.21±0.18 0.32±0.11 0.24±0.12 0.22±0.16 0.19±0.16 
BEI (all) 0.25±0.18 0.20±0.25 0.15±0.17 0.21±0.17 0.27±0.09 0.18±0.08 0.21±0.17 0.17±0.1 
* denotes a significant difference from pre to post (placebo or dietary nitrates). 




5.7 Figures  
 
Participants recruited for study (n=21): Randomly allocated too: 
• Placebo (n=9) 
• Dietary nitrates (n=12) 
 
Participants completed screening and pre-treatment assessment (n=21) 
• Placebo (n=9) 
• Dietary nitrates (n=12) 
 
Participants completed post-treatment assessment (n=21) 
• Placebo (n=9) 
• Dietary nitrates (n=12) 
No participants withdrew from the study. 
 
Assessed for eligibility (n = 36) 
Excluded (n=15) 
Did not meet exclusion criteria: 
• Cancer diagnosis (n=1) 
• Use of antibiotics (n=2) 
• Personal reasons (n=2) 
• Treated uncontrolled hypertension (daytime ABPM >135/85 mmHg) (n=9) 
• Leg injury (n=1) 
Figure 5-1 Participant screening and recruitment information 








Height, weight, non-invasive oxygen saturations taken, clinic blood 
pressure, and 12-lead ECG. Urine test to assess kidney function and 
markers of diabetes. 
 
1. Consent obtained 
The research team can answer any questions from the participant at 
this point. 
 
2. Medical history taken 10 minutes 
15 minutes 
4. Ambulatory Blood Pressure Monitor Fitted <15 minutes  
Figure 5-2 Flow Chart for pre-assessment one 



















3. Metaboreflex protocol 
• Maximal voluntary contraction assessed 
• Microneurography 
• 10 minutes baseline data collection 
• Exercise and post-exercise blood pressure, heart rate, ventilation 
was monitored. 
• Isometric handgrip (40% MVC) (2 minutes) followed by occlusion 
cuff inflated to initiate post-exercise ischemia (2 minutes). 
 
20 minutes 
1 hour 30 
minutes 
15 minutes 
5. Prior to VO2 max test 
• 12-lead ECG fitted 
• Automatic blood pressure cuff fitted (left arm) and stethoscope 
fitted to participant (right arm). 
• Metabolic cart system mask fitted. 
 
























2. Clinic blood pressure measurement. Measurement of vital signs 
(including height and body mass). 
15 minutes 
7. Participant given active or placebo beetroot juice 
 
4. Participant asked to rest for 20 minutes 
Figure 5-3 Flow chart for pre- and post-assessment. 





Figure 5-4 Basic set-up for Ozone (O3) based chemiluminescence (image from 
Coneski and Schoenfisch (2012)). 
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Figure 5-5 Determination of the optimal lag for transduction analysis. 
To determine the optimal cardiac cycle lag for treated controlled hypertension a 
transduction slope was produced for each participant using 8 windows of 2 
cardiac cycles. Similar to Briant et al. (2016) 8-6 cardiac lags was used for 
transduction analysis.  
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Figure 5-6 An example of the spontaneous baroreflex slope calculated from the 
10-minute baseline period. 
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Figure 5-7 Pre and post plasma dietary nitrates and nitrite concentrations. 
A) plasma nitrates, B) plasma nitrites, C) the change in plasma nitrates from 
baseline, D) the change in plasma nitrites from baseline, E) % change in plasma 
nitrates from baseline and F) % change in plasma nitrites from baseline. 
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Figure 5-8 The effect of dietary nitrate or placebo on the change in ambulatory 
daytime haemodynamic measurements in treated controlled hypertension. 
The change in A) systolic blood pressure (SBP), B) diastolic blood pressure 
(DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) heart 
rate (HR) from pre to post intervention.  
  
Chapter 5 Can dietary nitrates prevent excessive rises in blood pressure in 




Figure 5-9 The effect of dietary nitrate or placebo on the change in ambulatory 
night-time haemodynamic measurements in treated controlled hypertension. 
The change in A) systolic blood pressure (SBP), B) diastolic blood pressure 
(DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) heart 
rate (HR) from pre to post intervention. 
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Figure 5-10 The effect of dietary nitrate or placebo on the change in clinic 
haemodynamic measurements in treated controlled hypertension. 
The change in A) systolic blood pressure (SBP), B) diastolic blood pressure 
(DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) heart 
rate (HR) from pre to post intervention. 
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Figure 5-11 The effect of dietary nitrate or placebo on the change in peak 
haemodynamic measurements during peak cycle ergometer exercise testing  
The change in peak A) systolic blood pressure (SBP), B) diastolic blood pressure 
(DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) heart 
rate (HR) from pre to post intervention from a peak cycle ergometer exercise test 
(V̇O2 peak test). 
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Figure 5-12 The effect of dietary nitrate or placebo on the absolute 
haemodynamic measurements during peak cycle ergometer exercise testing 
(V̇O2 peak test). 
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The absolute A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), 
C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) heart rate (HR) 
during a peak cycle ergometer exercise test (V̇O2 peak test) pre and post 4 
weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), 
post-placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-
dietary nitrates (blue dashed line). 
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Figure 5-13 The effect of dietary nitrate or placebo on the change in 
haemodynamic measurements during peak cycle ergometer exercise testing 
(V̇O2 peak test). 
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The absolute change in A) systolic blood pressure (SBP), B) diastolic blood 
pressure (DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) and E) 
heart rate (HR) from baseline during a peak cycle ergometer exercise test (V̇O2 
peak test) pre and post 4 weeks of dietary nitrates or nitrate depleted placebo. 
Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary nitrates 
(blue solid line) and post-dietary nitrates (blue dashed line). 
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Figure 5-14 The effect of dietary nitrate or placebo on % change in 
haemodynamic measurements during cycle ergometer exercise testing (V̇O2 
peak test). 
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The percentage (%) change in A) systolic blood pressure (SBP), B) diastolic 
blood pressure (DBP), C) mean arterial pressure (MAP), D) pulse pressure (PP) 
and E) heart rate (HR) from baseline during a peak cycle ergometer exercise test 
(V̇O2 peak test) pre and post 4 weeks of dietary nitrates or nitrate depleted 
placebo. Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary 
nitrates (blue solid line) and post-dietary nitrates (blue dashed line). 
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Figure 5-15 The effect of dietary nitrate or placebo on the change in peak 
respiratory measurements during peak cycle ergometer exercise testing. 
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The effect of 4 weeks of dietary nitrate or placebo on the change in peak A) 
minute ventilation (VE), B) breathing frequency (Bf), C) tidal volume, D) volume of 
carbon dioxide expired (VCO2) and E) respiratory exchange ratio (RER) from pre 
to post intervention from a peak cycle ergometer exercise test (V̇O2 peak test). 
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Figure 5-16 The V̇O2 vs watts during a peak cycle ergometer exercise test (V̇O2 
peak test) pre and post 4 weeks of dietary nitrates or nitrate depleted placebo.  
Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary nitrates 
(blue solid line) and post-dietary nitrates (blue dashed line). 
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Figure 5-17 The effect of dietary nitrate or placebo on absolute respiratory 
measurements during cycle ergometer exercise testing (V̇O2 peak test). 
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A) minute ventilation (VE), B) breathing frequency and C) tidal volume D) volume 
of expired carbon dioxide (VCO2) and E) the respiratory exchange ratio (RER) 
during a peak cycle ergometer exercise test (V̇O2 peak test) pre and post 4 
weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), 
post-placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-
dietary nitrates (blue dashed line). 
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Figure 5-18 The effect of dietary nitrate or placebo on absolute change in 
respiratory measurements during cycle ergometer exercise testing (V̇O2 peak 
test). 
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A) minute ventilation (VE), B) breathing frequency and C) tidal volume D) volume 
of expired carbon dioxide (VCO2) and E) the respiratory exchange ratio (RER) 
during a peak cycle ergometer exercise test (V̇O2 peak test) pre and post 4 
weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), 
post-placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-
dietary nitrates (blue dashed line). 
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Figure 5-19 The effect of dietary nitrate or placebo on the % change in 
respiratory measurements during cycle ergometer exercise testing (V̇O2 peak 
test). 
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A) minute ventilation (VE), B) breathing frequency and C) tidal volume D) volume 
of expired carbon dioxide (VCO2) and E) the respiratory exchange ratio (RER) 
during a peak cycle ergometer exercise test (V̇O2 peak test) pre and post 4 
weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), 
post-placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-
dietary nitrates (blue dashed line). 
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Figure 5-20 The effect of dietary nitrate or placebo on absolute muscle 
sympathetic nerve activity (MSNA) measurements during handgrip and 
metaboreflex testing. 
A) MSNA burst frequency (bursts/min), B) MSNA burst incidence 
((bursts/100Hb), C) MSNA area, D) total MSNA/min and E) total MSNA/Hr during 
isometric handgrip exercise at 40% maximal voluntary contraction, the first 
minute of post-exercise ischemia (PEI1) and the second minute of post-exercise 
ischemia (PEI2) pre and post 4 weeks of dietary nitrates or nitrate depleted 
placebo. Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary 
nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-21 The effect of dietary nitrate or placebo on the change in muscle 
sympathetic nerve activity (MSNA) during handgrip and metaboreflex testing. 
A) MSNA burst frequency (bursts/min), B) MSNA burst incidence 
((bursts/100Hb), C) MSNA area, D) total MSNA/min and E) total MSNA/Hr during 
isometric handgrip exercise at 40% maximal voluntary contraction, the first 
minute of post-exercise ischemia (PEI1) and the second minute of post-exercise 
ischemia (PEI2) from baseline pre and post 4 weeks of dietary nitrates or nitrate 
depleted placebo. Pre-placebo (red solid line), post-placebo (red dashed line), 
pre-dietary nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-22 The effect of dietary nitrate or placebo on the % change in muscle 
sympathetic nerve activity (MSNA) during handgrip and metaboreflex testing. 
A) MSNA burst frequency (bursts/min), B) MSNA burst incidence (bursts/100Hb), 
C) MSNA area, D) total MSNA/min and E) total MSNA/Hr during isometric 
handgrip exercise at 40% maximal voluntary contraction, the first minute of post-
exercise ischemia (PEI1) and the second minute of post-exercise ischemia 
(PEI2) from baseline pre and post 4 weeks of dietary nitrates or nitrate depleted 
placebo. Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary 
nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-23 The effect of dietary nitrate or placebo on the change in muscle 
sympathetic nerve activity (MSNA) during 10 minutes of baseline. 
A) muscle sympathetic nerve activity (MSNA) burst frequency (bursts/min), B) 
MSNA burst incidence (bursts/100Hb), C) total MSNA/min and D) total MSNA/Hr 
from pre to post intervention. 
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Figure 5-24 The effect of 4 weeks of dietary nitrate or placebo on the change in 
blood pressure during isometric handgrip testing at 40% MVC for 1 minute. 
A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), C) mean 
arterial pressure (MAP) and D) pulse pressure (PP) from pre to post intervention 
during isometric handgrip exercise. 
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Figure 5-25 The effect of 4 weeks of dietary nitrate or placebo on the change in 
haemodynamics during isometric handgrip testing at 40% MVC for 1 minute. 
The effect of 4 weeks of dietary nitrate or placebo on the change in A) heart rate 
(HR), B) stroke volume (SV), C) cardiac output (CO) and D) total peripheral 
resistance (TPR) from pre to post intervention during isometric handgrip exercise. 
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Figure 5-26 The effect of 4 weeks of dietary nitrate or placebo on the change in 
muscle sympathetic nerve activity (MSNA) during isometric handgrip testing. 
The effect of 4 weeks of dietary nitrate or placebo on the change in A) muscle 
sympathetic nerve activity (MSNA) burst frequency (bursts/min), B) MSNA burst 
incidence (bursts/100Hb), C) total MSNA/min and D) total MSNA/Hr from pre to 
post intervention. 
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Figure 5-27 The effect of dietary nitrate or placebo on the absolute blood 
pressure during baseline, isometric handgrip exercise and metaboreflex testing. 
A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), C) mean 
arterial pressure (MAP) and D) pulse pressure (PP) during isometric handgrip 
exercise at 40% maximal voluntary contraction, the first minute of post-exercise 
ischemia (PEI1) and the second minute of post-exercise ischemia (PEI2) pre and 
post 4 weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red 
solid line), post-placebo (red dashed line), pre-dietary nitrates (blue solid line) 
and post-dietary nitrates (blue dashed line).  
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Figure 5-28 The effect of dietary nitrate or placebo on the absolute 
haemodynamics during baseline, isometric handgrip exercise and metaboreflex. 
A) heart rate (HR), B) stroke volume (SV), C) cardiac output (Q) and D) total 
peripheral resistance (TPR) during isometric handgrip exercise at 40% maximal 
voluntary contraction, the first minute of post-exercise ischemia (PEI1) and the 
second minute of post-exercise ischemia (PEI2) pre and post 4 weeks of dietary 
nitrates or nitrate depleted placebo. Pre-placebo (red solid line), post-placebo 
(red dashed line), pre-dietary nitrates (blue solid line) and post-dietary nitrates 
(blue dashed line).  
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Figure 5-29 The effect of dietary nitrate or placebo on the change in absolute 
blood pressure during baseline, isometric handgrip exercise and metaboreflex. 
A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), C) mean 
arterial pressure (MAP) and D) pulse pressure (PP) from baseline during 
isometric handgrip exercise at 40% maximal voluntary contraction, the first 
minute of post-exercise ischemia (PEI1) and the second minute of post-exercise 
ischemia (PEI2) pre and post 4 weeks of dietary nitrates or nitrate depleted 
placebo. Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary 
nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-30 The effect of dietary nitrate or placebo on the absolute change in 
haemodynamics during baseline, isometric handgrip and metaboreflex testing. 
A) heart rate (HR), B) stroke volume (SV), C) cardiac output (Q) and D) total 
peripheral resistance (TPR) during isometric handgrip exercise at 40% maximal 
voluntary contraction, the first minute of post-exercise ischemia (PEI1) and the 
second minute of post-exercise ischemia (PEI2) pre and post 4 weeks of dietary 
nitrates or nitrate depleted placebo. Pre-placebo (red solid line), post-placebo 
(red dashed line), pre-dietary nitrates (blue solid line) and post-dietary nitrates 
(blue dashed line).  
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Figure 5-31 The effect of dietary nitrate or placebo on the % change in absolute 
blood pressure during baseline, isometric handgrip and metaboreflex testing. 
A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), C) mean 
arterial pressure (MAP) and D) pulse pressure (PP) from baseline during 
isometric handgrip exercise at 40% maximal voluntary contraction, the first 
minute of post-exercise ischemia (PEI1) and the second minute of post-exercise 
ischemia (PEI2) pre and post 4 weeks of dietary nitrates or nitrate depleted 
placebo. Pre-placebo (red solid line), post-placebo (red dashed line), pre-dietary 
nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-32 The effect of dietary nitrate or placebo on the % change in absolute 
haemodynamics during baseline, isometric handgrip and metaboreflex testing. 
A) heart rate (HR), B) stroke volume (SV), C) cardiac output (CO) and D) total 
peripheral resistance (TPR) during isometric handgrip exercise at 40% maximal 
voluntary contraction, the first minute of post-exercise ischemia (PEI1) and the 
second minute of post-exercise ischemia (PEI2) pre and post 4 weeks of dietary 
nitrates or nitrate depleted placebo. Pre-placebo (red solid line), post-placebo 
(red dashed line), pre-dietary nitrates (blue solid line) and post-dietary nitrates 
(blue dashed line).  
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Figure 5-33 The effect of 4 weeks of dietary nitrate or placebo on the change in 
blood pressure during metaboreflex testing (post-exercise ischemia). 
The change in A) systolic blood pressure (SBP), B) diastolic blood pressure 
(DBP), C) mean arterial pressure (MAP) and D) pulse pressure (PP) from pre to 
post intervention during the second minute of post-exercise ischemia (PEI2). 
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Figure 5-34 The effect of 4 weeks of dietary nitrate or placebo on the change in 
haemodynamics during metaboreflex testing (post-exercise ischemia). 
The change in A) heart rate (HR), B) stroke volume (SV), C) cardiac output (CO) 
and D) total peripheral resistance (TPR) from pre to post intervention during the 
second minute of post-exercise ischemia (PEI2). 
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Figure 5-35 The effect of 4 weeks of dietary nitrate or placebo on the change in 
muscle sympathetic nerve activity (MSNA) during metaboreflex testing. 
The change in A) MSNA burst frequency (bursts/min), B) MSNA burst incidence 
(bursts/100Hb), C) total MSNA/min and D) total MSNA/Hr from pre to post 
intervention during the second minute of post-exercise ischemia.




Figure 5-36 An example muscle sympathetic nerve activity (MSNA) trace (as measured by microneurography) at baseline and 
during post-exercise ischemia (PEI). 
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Figure 5-37 The effect of dietary nitrate or placebo on the absolute blood 
pressure during recovery from isometric handgrip and metaboreflex testing. 
The absolute A) systolic blood pressure (SBP), B) diastolic blood pressure (DBP), 
C) mean arterial pressure (MAP) and D) pulse pressure (PP) during the second 
minute of post-exercise ischemia (PEI) and the 5 one-minute epochs of recovery 
(R1, R2, R3, R4 and R5) pre and post 4 weeks of dietary nitrates or nitrate 
depleted placebo. Pre-placebo (red solid line), post-placebo (red dashed line), 
pre-dietary nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-38 The effect of dietary nitrate or placebo on the absolute 
haemodynamic measurements during recovery from isometric handgrip and 
metaboreflex testing. 
The absolute A) heart rate (HR), B) stroke volume (SV), C) cardiac output (CO) 
and D) total peripheral resistance (TPR) during the second minute of post-
exercise ischemia (PEI) and the 5 one-minute epochs of recovery (R1, R2, R3, 
R4 and R5) from baseline pre and post 4 weeks of dietary nitrates or nitrate 
depleted placebo. Pre-placebo (red solid line), post-placebo (red dashed line), 
pre-dietary nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-39 The effect of dietary nitrate or placebo on the absolute change in 
blood pressure during recovery from isometric handgrip and metaboreflex testing. 
The absolute change in A) systolic blood pressure (SBP), B) diastolic blood 
pressure (DBP), C) mean arterial pressure (MAP) and D) pulse pressure (PP) 
from baseline during the second minute of post-exercise ischemia (PEI) and the 5 
one-minute epochs of recovery (R1, R2, R3, R4 and R5) pre and post 4 weeks of 
dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), post-
placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-dietary 
nitrates (blue dashed line).  
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Figure 5-40 The effect of dietary nitrate or placebo on the absolute change in 
haemodynamics during recovery from isometric handgrip and metaboreflex. 
The absolute change in A) heart rate (HR), B) stroke volume (SV), C) cardiac 
output (CO) and D) total peripheral resistance (TPR) during the second minute of 
post-exercise ischemia (PEI) and the 5 one-minute epochs of recovery (R1, R2, 
R3, R4 and R5) from baseline pre and post 4 weeks of dietary nitrates or nitrate 
depleted placebo. Pre-placebo (red solid line), post-placebo (red dashed line), 
pre-dietary nitrates (blue solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-41 The effect of dietary nitrate or placebo on the % change in blood 
pressure during recovery from isometric handgrip and metaboreflex testing. 
The percentage (%) change in A) systolic blood pressure (SBP), B) diastolic 
blood pressure (DBP), C) mean arterial pressure (MAP) and D) pulse pressure 
(PP) from baseline during the second minute of post-exercise ischemia (PEI) and 
the 5 one-minute epochs of recovery (R1, R2, R3, R4 and R5) pre and post 4 
weeks of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), 
post-placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-
dietary nitrates (blue dashed line).  
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Figure 5-42 The effect of dietary nitrate or placebo on the % change in 
haemodynamics during recovery from isometric handgrip and metaboreflex.  
The percentage (%) change in A) heart rate (HR), B) stroke volume (SV), C) 
cardiac output (CO) and D) total peripheral resistance (TPR) during the second 
minute of post-exercise ischemia (PEI) and the 5 one-minute epochs of recovery 
(R1, R2, R3, R4 and R5) from baseline pre and post 4 weeks of dietary nitrates 
or nitrate depleted placebo. Pre-placebo (red solid line), post-placebo (red 
dashed line), pre-dietary nitrates (blue solid line) and post-dietary nitrates (blue 
dashed line).  
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Figure 5-43 The effect of dietary nitrate or placebo on the absolute muscle 
sympathetic nerve activity (MSNA) during recovery from metaboreflex testing.  
The absolute A) muscle sympathetic nerve activity (MSNA) burst frequency 
(bursts/min), B) MSNA burst incidence (bursts/100Hb), C) total MSNA/min and D) 
total MSNA/Hr during the second minute of post-exercise ischemia (PEI) and the 
5 one-minute epochs of recovery (R1, R2, R3, R4 and R5) pre and post 4 weeks 
of dietary nitrates or nitrate depleted placebo. Pre-placebo (red solid line), post-
placebo (red dashed line), pre-dietary nitrates (blue solid line) and post-dietary 
nitrates (blue dashed line).  
Chapter 5 Can dietary nitrates prevent excessive rises in blood pressure in 
people with treated-controlled hypertension? 
359 
 
Figure 5-44 The effect of dietary nitrate or placebo on absolute change in muscle 
sympathetic nerve activity (MSNA) during recovery from metaboreflex testing.  
The absolute change in A) muscle sympathetic nerve activity (MSNA) burst 
frequency (bursts/min), B) MSNA burst incidence (bursts/100Hb), C) total 
MSNA/min and D) total MSNA/Hr during the second minute of post-exercise 
ischemia (PEI) and the 5 one-minute epochs of recovery (R1, R2, R3, R4 and 
R5) pre and post 4 weeks of dietary nitrates or nitrate depleted placebo. Pre-
placebo (red solid line), post-placebo (red dashed line), pre-dietary nitrates (blue 
solid line) and post-dietary nitrates (blue dashed line).  
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Figure 5-45 The effect of dietary nitrate or placebo on the absolute muscle 
sympathetic nerve activity (MSNA) during recovery from metaboreflex testing.  
The percentage change in A) muscle sympathetic nerve activity (MSNA) burst 
frequency (bursts/min), B) MSNA burst incidence (bursts/100Hb), C) total 
MSNA/min and D) total MSNA/Hr during the second minute of post-exercise 
ischemia (PEI) and the 5 one-minute epochs of recovery (R1, R2, R3, R4 and 
R5) pre and post 4 weeks of dietary nitrates or nitrate depleted placebo. Pre-
placebo (red solid line), post-placebo (red dashed line), pre-dietary nitrates (blue 
solid line) and post-dietary nitrates (blue dashed line).  
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Chapter 6 General Discussion 
Prior to the research in this thesis, it was unclear whether adequately controlling 
blood pressure (BP) with antihypertensive medications normalises the BP 
response to exercise and reduces metaboreflex hyperreflexia in human 
hypertension. The main aim of this thesis was to assess whether adequate 
control of BP with anti-hypertensive medication normalises the exaggerated 
pressor response to exercise that is associated with untreated hypertension. The 
overall hypothesis was that anti-hypertensive medication will have no effect on 
the cardiovascular response to exercise in hypertension and that treatments that 
reduce metaboreflex hyperreflexia in hypertension will prove more beneficial. 
 
6.1 Summary of key findings 
6.1.1 Antihypertensive medications fail to normalise the blood pressure 
response to peak exercise and metaboreceptor isolation 
In support of the first hypothesis of this thesis, it was found that first-line 
antihypertensive treatment (as per NICE guidelines) fail to control BP during 
exercise. More specifically, treated controlled, uncontrolled and untreated 
hypertensives had an exaggerated BP response to maximal exercise testing on a 
cycle ergometer (V̇O2 peak test) when compared to normotensive controls. In 
addition, the BP response to metaboreflex isolation using post-exercise ischemia 
(PEI) was increased in treated controlled, uncontrolled and untreated 
hypertensives when compared to normotensives. 
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6.1.2 Aortic blood pressure is related to the exaggerated blood pressure 
response to exercise in hypertension 
In contrast to the hypothesis tested in Chapter 4, only aortic BP was elevated in 
treated controlled and uncontrolled hypertensives. Pulse wave velocity was only 
elevated in untreated hypertensives and was similar among treated controlled, 
uncontrolled and normotensive individuals. A forced entry multiple linear 
regression was used to make a model to assess the contribution of aortic pulse 
pressure (PP), pulse wave velocity, age, daytime ambulatory peripheral SBP and 
the change in peripheral SBP during metaboreflex isolation on the change in SBP 
during submaximal (51-75% of V̇O2 peak) and peak exercise. During submaximal 
(51-75% of V̇O2 peak) exercise the only predictor of the SBP was the SBP 
response to metaboreflex isolation. At peak exercise (V̇O2 peak) only the SBP 
response to metaboreflex isolation and the resting aortic PP were predictive of 
peak SBP. 
 
6.1.3 Dietary NO3- for 4 weeks fails to lower the systolic blood pressure 
response to peak exercise and metaboreflex isolation 
In contrast to the tertiary main hypothesis in this thesis, chronic dietary NO3- 
intake had no effect on the peak SBP to incremental exercise and metaboreflex 
isolation in treated controlled hypertension. This was despite an elevation in both 
plasma NO3- and NO2-. However, group size was very small and the levels of 
plasma NO3- and NO2- following the active intervention were highly variable. 
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6.2 Treating an exaggerated blood pressure response to exercise 
Drawing the results from this thesis together, alternative medications or therapies 
are needed that decrease the BP response to exercise in patients with treated 
controlled hypertension. The data from this thesis has highlighted that the 
metaboreflex and aortic BP are important contributors to an exaggerated BP 
response to exercise.  
 
Elevated aortic BP may indicate reduced aortic compliance. An elevated aortic 
stiffness and aortic characteristic impedance in hypertension would lead to 
exaggerated brachial artery BP because a reduced capacity to expand during 
exercise-induced increases in stroke volume would cause A) an increased 
forward wave from the left ventricle and B) the left ventricle to have to work 
harder to eject blood. Treatments that target elevated aortic stiffness would likely 
reduce the brachial artery BP during exercise and also reduce the work of the left 
ventricle. The current consensus is that angiotensin converting enzyme inhibitors 
(ACEi) are most effective at lowering aortic pressures at rest (Boutouyrie et al., 
2011). However, 44% of treated uncontrolled hypertension and 88% of treated 
controlled hypertension were taking an ACEi in the study in Chapter 4. Further 
research is needed to establish the most effective method for reducing aortic 
stiffness in patients with hypertension. 
 
It is well established that an exaggerated BP response to exercise is an 
integrated response, involving several feedback mechanisms (mechanoreflex 
and metaboreflex), feed-forward mechanisms (central command) and continuous 
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buffering by the arterial baroreflex. Future research will need to further investigate 
these mechanisms in patients with treated controlled and uncontrolled 
hypertension to fully understand the mechanisms that lead to an exaggerated BP 
response to exercise. The importance of excessive metaboreflex drive in 
hypertension has been highlighted in this thesis but the exact location along the 
reflex arc where this occurs is still unclear. Future research will need to answer 
this question as this is likely to influence treatment. There are several positions 
along the reflex arc that could be causing abnormal metaboreflex mediated CV 
responses to exercise: A) impaired functional sympatholysis and thus skeletal 
muscle hypoperfusion, B) hypersensitivity of the metaboreceptors or C) 
processing of the metaboreflex at the dorsal horn or more centrally in the 
brainstem (Figure 6.1, page 369). Much redundancy exists in human physiology 
and it has been demonstrated that blocking one of the metabolites that mediate 
the metaboreflex will have little or no effect (Light et al., 2008, Stone et al., 2015). 
It may be that only complete blockade of all of the metabolites that activate the 
metaboreflex will reduce its effects during exercise in hypertension. This was 
demonstrated by Barbosa et al. (2016) who found that fentanyl, which blocks 
afferent feedback into the dorsal horn, reduces the BP response to exercise in 
untreated hypertensives. Obviously, fentanyl cannot be used as a medication to 
normalise the BP response to exercise every time a patient with hypertension 
exercises. In addition, the BP response to exercise may be essential to maintain 
perfusion to the active skeletal muscle (as well as the vital organs). A better 
approach to normalising the CV response to exercise in patients with 
hypertension would be to target the cause of augmented metaboreflex 
hyperreflexia. An additional issue with inhibiting the metaboreflex is that many of 
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the mechanoreceptors are also polymodal and are sensitized by metabolites 
during contraction (Cui et al., 2008a, Rotto and Kaufman, 1988). The 
metaboreflex was studied in isolation in this study post-exercise, it is likely that 
during exercise the interaction between the mechanoreflex and metaboreflex 
influence the BP response to exercise (Cui et al., 2007, Cui et al., 2008a). 
 
For the study in Chapter 5, the rationale for using dietary NO3- was that improving 
nitric oxide (NO) bioavailability would buffer increased MSNA and improve blood 
flow during exercise, which should theoretically decrease the level of metabolites 
that activate the metaboreflex (Kaufman et al., 1984, Xing et al., 2013). However, 
blood flow was not measured in the study in Chapter 5 due to logistical problems. 
Despite increased levels of plasma nitrates and nitrites, dietary NO3- 
supplementation had no impact on the BP response to exercise compared to a 
placebo. However, there was a large variance for both the change in NO3- and 
NO2- following dietary NO3- supplementation and the sample size was small. 
Indicating that some patients had no increase in NO3- and NO2- following dietary 
NO3- supplementation. Improving the blood flow response to exercise seams a 
more plausible mechanism from the current literature than pharmacologically 
targeting the metaboreflex (Price et al., 2013). An issue with increasing NO 
bioavailability in hypertensive individuals is that elevated reactive oxygen species 
(ROS; which are elevated in patients with hypertension) during exercise will 
cleave the NO whilst also binding to guanylate cyclase, reducing its affinity for 
NO (Zhao et al., 2006). An alternative mechanism for improving vasodilation in 
the skeletal muscle vasculature, which is not reliant on unstable and highly 
reactive NO is direct stimulation of the enzyme guanylate cyclase (Arnold et al., 
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1977). Direct guanylate cyclase activators and stimulators have been shown to 
have therapeutic potential in heart failure (Dubin and Shah, 2016) and in 
pulmonary hypertension (Lian et al., 2017). Guanylate cyclase simulators 
enhance sensitivity to low levels of NO (Evgenov et al., 2006). Importantly, these 
drugs have also been shown to improve exercise performance in pulmonary 
hypertension (Stasch and Evgenov, 2013). Future studies should consider the 
use of these drugs for reducing metaboreflex hyperreflexia in hypertension. 
 
The signalling of the metaboreflex afferents at the dorsal horn in the spinal cord is 
understudied in hypertensive animals and humans. However, one study found 
that TRPv1 receptors were upregulated in the dorsal root ganglion in 
spontaneously hypertensive rats (SHRs) (Mizuno et al., 2011a). Future research 
in animal models of hypertension needs to further assess metaboreflex signalling 
at the dorsal root. Central angiotensin II production is linked to increases in ROS 
and a reduction in NO in the brainstem (Zimmerman et al., 2002, Murphy et al., 
2013). Smith et al. (2006) found that the same level of stimulation of the ventral 
roots led to exaggerated increases in renal sympathetic nerve activity (RSNA) in 
SHRs compared to Wistar Kyoto rats, suggesting central alterations in the 
interpretation of the afferent metaboreflex signal. Furthermore, antihypertensive 
medications that have high lipid solubility and are therefore able to cross the 
blood brain barrier (e.g. the ACEi Perindopril) have been shown to be more 
effective at lowering MSNA and lowering BP during acute and prolonged exercise 
in healthy individuals when compared to peripherally acting ACEi (Moralez et al., 
2018). Future studies will need to confirm these findings in patients with 
hypertension. In addition, the mineralocorticoid receptor antagonist, 
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spironolactone decreased the BP response exercise in SHR’s. The oral 
administration of the drug limited the ability to identify which part of the reflex the 
drug was improving. However, it is known that there are high levels of 
mineralocorticoid receptors at the level of the dorsal horn (González et al., 1992) 
and within the NTS (Sequeira et al., 2006). Future research will need to assess 
the effect of spironolactone on the metaboreflex in patients with hypertension. 
Finally, exercise training may be an important treatment to improve the overall 
CV response to exercise. Despite long term adherence to exercise being typically 
poor, it is evident that chronic dynamic exercise is probably the best protection 
against chronic disease. Indeed, chronic endurance training decreases the 
exercise BP in spontaneously hypertensive rats (SHR) through an increase in NO 
bioavailability (Mizuno et al., 2014a). Three months of wheel running in SHRs 
decreased the BP and RSNA during mechanoreflex and metaboreflex isolation 
(Mizuno et al., 2015b). Future research will need to confirm these results in 
patients with hypertension as this could provide a low-cost solution to excessive 
BP rises during exercise. Furthermore, resistance exercise decreases aortic BP 
in patients with hypertension (Heffernan et al., 2013) as well as reducing 
oxidative stress during exercise (Dantas et al., 2016). Studies will also need to 
assess methods for improving adherence to exercise, especially once patients 
have left structured training programs so that the benefits of exercise can be 
maintained. 
 
Future research in this area will need to repeat the findings of this thesis in multi 
centre studies in larger population numbers. In addition, longitudinal studies will 
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need to assess whether the BP response to exercise in treated-controlled 
hypertension is an independent risk factor for CV events. If this is proven, this 
could change the current management of hypertension, for example the inclusion 




Exercise BP is not controlled by anti-hypertensive medications and this is partially 
due to excessive metaboreflex drive and aortic stiffness.  
There is still much to learn regarding the specific mechanisms that activate the 
metaboreflex and the exaggerated BP response to exercise in treated controlled 
hypertensive individuals. In addition, other mechanisms that are known to 
mediate the BP response to exercise need to be examined in human 
hypertension in more detail. Future research in animal models of hypertension 
and human hypertension is needed to offer the possibility of the metaboreflex as 
a possible novel target for an exaggerated BP response to exercise in 
hypertension. Targeting reactive oxygen species and downstream pathways of 
the NO pathway (such as guanylyl cyclase) may prove more beneficial that 
targeting the metaboreflex with pharmacological interventions. Reducing 
metaboreflex hyperreflexia would decrease MSNA activity and BP during 
exercise.
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Four main mechanisms have been identified: 1. impaired functional sympatholysis, 2. augmented sensitivity of the 
metaboreceptors, 3. altered spinal modulation and 4. altered medulla modulation. Several potential treatment options have been 
implicated for the treatment of metaboreflex hyperreflexia, each targeting a different part of the reflex arc. DRG; dorsal root 
ganglion, NTN; nucleus of solitary tract, RVLM; rostral ventrolateral medulla, IML; intermediolateral cell column, NAD(P)H; 
Figure 6-1 Potential treatment options for metaboreflex hyperreflexia along the reflex arc in patients with hypertension. 
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nicotinamide-adenine dinucleotide phosphate oxidase, O2-; superoxide anions, NO; nitric oxide, MSNA; muscle sympathetic nerve 
activity, and ATP; adenosine triphosphate.  
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